{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "defaultdict(<class 'list'>, {'methods': ['a case report', 'acquisition of evidence', 'action', 'actions', 'activities', 'admission findings', 'ams subject classification', 'analyses', 'analysis', 'analytical approach', 'analytical techniques', 'anatomy', 'anesthesia', 'animal', 'animal or sample population', 'animal population', 'animal studied', 'animal studies', 'animal(s)', 'animals', 'animals and interventions', 'animals and methods', 'animals or sample population', 'animals studied', 'animals, materials and methods', 'animals, methods', 'approach', 'approach and methods', 'area covered', 'area covered in this review', 'areas covered', 'areas covered in the review', 'areas covered in this review', 'article chosen', 'article selection', 'assessment of problem', 'assessment of risk factors', 'assessment tools', 'assessments', 'availability and implementation', 'background & materials and methods', 'background & method', 'background & methods', 'background and design', 'background and method', 'background and methodology', 'background and methods', 'background and procedure', 'background and setting', 'background, material and methods', 'background, materials and methods', 'background/method', 'background/methods', 'baseline data', 'basic design', 'basic methods', 'basic procedure', 'basic procedures', 'basic research design', 'basic research design and participants', 'blinding', 'brief description', 'cadavers', 'calculation', 'calculations', 'case', 'case 1', 'case 2', 'case and methods', 'case characteristics', 'case definition', 'case description', 'case description and methods', 'case descriptions', 'case details', 'case diagnosis/treatment', 'case discussion', 'case histories', 'case history', 'case history and clinical findings', 'case history and diagnosis', 'case history and findings', 'case illustration', 'case material', 'case or series summary', 'case outline', 'case outlines', 'case presentation', 'case presentation & methods', 'case presentation and intervention', 'case presentations', 'case record', 'case report', 'case report and discussion', 'case report and method', 'case report and methods', 'case report/methods', 'case reports', 'case results', 'case review', 'case series', 'case series summary', 'case studies', 'case study', 'case summaries', 'case summary', 'case(s)', 'case-diagnosis/treatment', 'case-report', 'case-reports', 'cases', 'cases & methods', 'cases and method', 'cases and methods', 'cases description', 'cases presentation', 'cases report', 'cases reports', 'casuistic & methods', 'casuistic and method', 'casuistic and methods', 'centers', 'chemotherapy', 'chief outcome measures', 'children and methods', 'choice of solution', 'classification', 'classification of evidence', 'clinic case', 'clinical', 'clinical application', 'clinical applications', 'clinical aspects', 'clinical case', 'clinical cases', 'clinical characteristics', 'clinical context', 'clinical course', 'clinical data', 'clinical description', 'clinical feature', 'clinical features', 'clinical history', 'clinical investigations', 'clinical material', 'clinical material and methods', 'clinical materials and methods', 'clinical observation', 'clinical observations', 'clinical picture', 'clinical presentation', 'clinical presentation and intervention', 'clinical presentations', 'clinical procedure', 'clinical question/level of evidence', 'clinical report', 'clinical scenario', 'clinical setting', 'clinical settings', 'clinical signs', 'clinical studies', 'clinical study', 'clinical symptoms', 'cohort', 'comparators', 'comparison with existing methods', 'concept', 'conceptual framework', 'conference process', 'consensus', 'consensus position', 'consensus process', 'consensus statement', 'content analysis of literature', 'contraindication', 'contraindications', 'control', 'control data', 'control group', 'controls', 'count', 'credibility', 'criteria', 'current data', 'data', 'data & methods', 'data abstraction', 'data acquisition', 'data analyses', 'data analysis', 'data analysis method', 'data and method', 'data and methods', 'data and sources', 'data capture', 'data collected', 'data collection', 'data collection & analysis', 'data collection and analysis', 'data collection method', 'data collection methods', 'data collection/analysis', 'data collection/extraction', 'data collection/extraction method', 'data collection/extraction methods', 'data extraction', 'data extraction and analysis', 'data extraction and data synthesis', 'data extraction and synthesis', 'data extraction methods', 'data extraction/synthesis', 'data identification', 'data identification and selection', 'data quality', 'data resources', 'data retrieval', 'data selection', 'data selection and extraction', 'data set', 'data source', 'data source and methods', 'data source and selection', 'data source and study selection', 'data source/study design', 'data source/study setting', 'data sources', 'data sources & selection', 'data sources & study setting', 'data sources and data extraction', 'data sources and extraction', 'data sources and methods', 'data sources and review methods', 'data sources and selection', 'data sources and selection criteria', 'data sources and setting', 'data sources and study design', 'data sources and study selection', 'data sources and study setting', 'data sources and synthesis', 'data sources, extraction, and synthesis', 'data sources, study selection, and data extraction', 'data sources/data collection', 'data sources/setting', 'data sources/study design', 'data sources/study selection', 'data sources/study setting', 'data sources/study settings', 'data sources/synthesis', 'data summary', 'data syntheses', 'data synthesis/methods', 'database', 'databases', 'databases used', 'date sources', 'demographics', 'dependent measures', 'dependent variable', 'dependent variables', 'description', 'description of case', 'description of cases', 'description of course', 'description of instrumentation', 'description of policy practice', 'description of program', 'description of project', 'description of study', 'description of system', 'description of systems', 'description of technique', 'description of technology/therapy', 'description of the case', 'description of the project', 'description of the project/innovation', 'description of the study', 'description of the system', 'descriptions', 'design', 'design & definition', 'design & intervention', 'design & method', 'design & methodology', 'design & methods', 'design & participants', 'design & setting', 'design & subjects', 'design and analysis', 'design and data sources', 'design and intervention', 'design and interventions', 'design and main outcome measures', 'design and materials', 'design and measurement', 'design and measurements', 'design and measures', 'design and method', 'design and methodology', 'design and methods', 'design and outcome measures', 'design and participants', 'design and patient', 'design and patients', 'design and population', 'design and procedure', 'design and procedures', 'design and sample', 'design and scope', 'design and setting', 'design and settings', 'design and study participants', 'design and study population', 'design and study sample', 'design and study subjects', 'design and subjects', 'design and volunteers', 'design classification', 'design methods', 'design of study', 'design of the study', 'design setting', 'design setting and participants', 'design setting and subjects', 'design study', 'design(s)', 'design, interventions, and main outcome measures', 'design, material and methods', 'design, materials & methods', 'design, materials and methods', 'design, materials, and methods', 'design, participants', 'design, participants and measurements', 'design, participants and setting', 'design, participants, & measurements', 'design, participants, and intervention', 'design, participants, and interventions', 'design, participants, and measures', 'design, participants, and methods', 'design, participants, and setting', 'design, participants, measurements', 'design, patients', 'design, patients and measurements', 'design, patients and methods', 'design, patients and setting', 'design, patients, & setting', 'design, patients, and interventions', 'design, patients, and main outcome measures', 'design, patients, and methods', 'design, patients, and setting', 'design, patients, measurements', 'design, setting', 'design, setting & participants', 'design, setting & patients', 'design, setting and methods', 'design, setting and participants', 'design, setting and patients', 'design, setting and subjects', 'design, setting participants, & measurements', 'design, setting, and methods', 'design, setting, and participants', 'design, setting, and patient', 'design, setting, and patients', 'design, setting, and population', 'design, setting, and subjects', 'design, setting, participants', 'design, setting, participants & measurements', 'design, setting, participants and intervention', 'design, setting, participants and interventions', 'design, setting, participants and measurements', 'design, setting, participants, & measurements', 'design, setting, participants, & methods', 'design, setting, participants, & objectives', 'design, setting, participants, and intervention', 'design, setting, participants, and interventions', 'design, setting, participants, and main outcome measures', 'design, setting, participants, and measurements', 'design, setting, participants, and measures', 'design, setting, participants, measurements', 'design, setting, patients', 'design, setting, patients, and intervention', 'design, setting, patients, and main outcome measure', 'design, setting, patients, interventions', 'design, setting, subjects', 'design, settings and participants', 'design, settings, and participants', 'design, settings, and patients', 'design, settings, and subjects', 'design, settings, participants, & measurements', 'design, settings, participants, & methods', 'design, subjects and intervention', 'design, subjects and measurements', 'design, subjects and methods', 'design, subjects and setting', 'design, subjects, and intervention', 'design, subjects, and setting', 'design/intervention', 'design/interventions', 'design/measurements', 'design/method', 'design/method/approach', 'design/methodology', 'design/methodology/approach', 'design/methods', 'design/outcome measures', 'design/participants', 'design/participants/setting', 'design/patients', 'design/patients/measurements', 'design/sample', 'design/setting', 'design/setting/participants', 'design/setting/participants/measurements', 'design/setting/patients', 'design/setting/subjects', 'design/subjects', 'designs', 'designs and methods', 'developing recommendations', 'development', 'devices', 'diabetes strategy evidence platform', 'diagnosis', 'diagnosis and course', 'diagnosis and management', 'diagnosis and therapy', 'diagnosis and treatment', 'diagnosis, therapy and clinical course', 'diagnosis, therapy and course', 'diagnosis, treatment and clinical course', 'diagnosis, treatment and course', 'diagnostic', 'diagnostic methods', 'diagnostic procedures', 'diagnostic test', 'diagnostic tests', 'diagnostic work-up', 'diagnostics', 'differential diagnosis', 'disease management', 'disease signs', 'disease symptoms', 'donors and methods', 'duration', 'ebm rating', 'economic analysis', 'eligibility criteria', 'eligibility criteria for included studies', 'eligibility criteria for selecting studies', 'emplacement', 'end point', 'end points', 'endpoint', 'endpoints', 'environment', 'equipment', 'equipment and methods', 'ethical issues', 'ethical issues and approval', 'ethics', 'evaluation design', 'evaluation method', 'evaluation methods', 'evaluations', 'evaluations/measurements', 'evidence', 'evidence acquisition', 'evidence acquisition and synthesis', 'evidence acquisitions', 'evidence and consensus process', 'evidence and information sources', 'evidence base', 'evidence level', 'evidence review', 'evidence summary', 'evidence-based analysis methods', 'examinees and methods', 'exclusion criteria', 'exclusions', 'exegese', 'exegesis', 'experiment', 'experiment design', 'experimental', 'experimental animals', 'experimental approach', 'experimental approaches', 'experimental design', 'experimental designs', 'experimental intervention', 'experimental interventions', 'experimental material', 'experimental materials', 'experimental methods', 'experimental procedure', 'experimental procedures', 'experimental protocol', 'experimental studies', 'experimental subjects', 'experimental variable', 'experimental variables', 'experiments', 'exposure', 'exposure measures', 'exposures', 'extraction', 'extraction methods', 'facility', 'factor', 'factors', 'features', 'final diagnosis', 'first case', 'format', 'framework', 'general methods', 'group and methods', 'group of patients and methods', 'history', 'history and admission findings', 'history and clinical data', 'history and clinical finding', 'history and clinical findings', 'history and clinical presentation', 'history and clinically findings', 'history and examination', 'history and findings', 'history and findings on admission', 'history and general investigations', 'history and physical examination', 'history and physical findings', 'history and presenting complaint', 'history and reason for admission', 'history and signs', 'host range', 'identification', 'illustrative case', 'illustrative cases', 'imaging', 'implementation', 'in vitro studies', 'in vivo studies', 'included studies', 'inclusion', 'inclusion & exclusion criteria', 'inclusion & exclusions', 'inclusion and exclusion criteria', 'inclusion criteria', 'independent variable', 'independent variables', 'index test', 'index tests', 'indication', 'indications', 'individuals', 'individuals and methods', 'infants and methods', 'information sources', 'initial assessment', 'injury patterns', 'innovation', 'institution', 'instrument', 'instrumentation', 'instruments', 'instruments and methods', 'intervention', 'intervention & measurements', 'intervention and main outcome measure', 'intervention and main outcome measures', 'intervention and measurements', 'intervention and methods', 'intervention and outcome measures', 'intervention and technique', 'intervention and testing', 'intervention(s)', 'intervention(s) and main outcome measure(s)', 'intervention/methods', 'intervention/technique', 'interventions', 'interventions and main outcome measurements', 'interventions and main outcome measures', 'interventions and measurements', 'interventions and methods', 'interventions and outcome measures', 'interventions(s)', 'interventions/methods', 'introduction and clinical case', 'introduction and clinical cases', 'introduction and method', 'introduction and methodology', 'introduction and methods', 'introduction/methods', 'investigated group', 'investigation', 'investigation and diagnosis', 'investigation(s)', 'investigations', 'investigations and diagnosis', 'investigations and treatment', 'investigations, diagnosis and treatment', 'investigations, treatment and course', 'key exposure/study factor', 'key measures', 'key measures for improvement', 'key risk/study factor', 'key study factor', 'laboratory tests', 'level iii', 'level of clinical evidence', 'level of evidence', 'level of evidence i', 'level of evidence ii', 'level of evidence iii', 'level of evidence iv', 'level of evidence v', 'level of proof', 'levels of evidence', 'literature', 'literature review', 'literature reviewed', 'literature search', 'literature survey', 'local setting', 'location', 'locations', 'main components of program', 'main exposure', 'main exposure measure', 'main exposure measures', 'main exposures', 'main features', 'main independent variables', 'main measure', 'main measurement', 'main measurements', 'main measures', 'main method', 'main methods', 'main observation', 'main observations', 'main observations and results', 'main outcome and measure', 'main outcome and measurements', 'main outcome and measures', 'main outcome criteria', 'main outcome measure', 'main outcome measure(s)', 'main outcome measured', 'main outcome measurement', 'main outcome measurement(s)', 'main outcome measurements', 'main outcome measures', 'main outcome measures and methods', 'main outcome measures(s)', 'main outcome methods', 'main outcome parameters', 'main outcome variable', 'main outcome variables', 'main outcomes and measure', 'main outcomes and measures', 'main outcomes measure', 'main outcomes measure(s)', 'main outcomes measured', 'main outcomes measurements', 'main outcomes measures', 'main research classifications', 'main research variable', 'main research variables', 'main study measures', 'main variables', 'main variables examined', 'main variables of interest', 'main variables studied', 'major outcome measures', 'material', 'material & method', 'material & methods', 'material and method', 'material and methodology', 'material and methods', 'material and patients', 'material and subjects', 'material and surgical technique', 'material and treatment', 'material method', 'material methods', 'material of study', 'material or subjects', 'material, methods', 'material, patients and methods', 'material-method', 'material-methods', 'material/method', 'material/methods', 'material/patients & methods', 'material/subjects and methods', 'materials', 'materials & method', 'materials & methodology', 'materials & methods', 'materials and  methods', 'materials and interventions', 'materials and materials', 'materials and method', 'materials and methodology', 'materials and methods', 'materials and patients', 'materials and subjects', 'materials and surgical technique', 'materials and treatment', 'materials methods', 'materials of study', 'materials or subjects', 'materials, methods', 'materials, setting and methods', 'materials, setting, methods', 'materials-methods', 'materials/method', 'materials/methods', 'materials/patients and methods', 'materials/subjects and methods', 'mean outcome measure', 'mean outcome measure(s)', 'mean outcome measures', 'measure', 'measurement', 'measurement & outcomes', 'measurements', 'measurements & outcomes', 'measurements and analysis', 'measurements and interventions', 'measurements and methods', 'measurements and outcomes', 'measures', 'measures and analysis', 'measures of outcome', 'measurments', 'medical history', 'medical treatment', 'medication', 'method', 'method & material', 'method & materials', 'method & procedures', 'method and analysis', 'method and clinical material', 'method and design', 'method and material', 'method and materials', 'method and participants', 'method and patients', 'method and procedure', 'method and procedures', 'method and sample', 'method and subjects', 'method of approach', 'method of study', 'method of study selection', 'method summary', 'method(s)', 'method/design', 'method/materials', 'method/patients', 'methodical innovations', 'methodologic approach', 'methodological approach', 'methodological design', 'methodological design and justification', 'methodological procedures', 'methodological quality', 'methodologies', 'methodology', 'methodology and patients', 'methodology and sample', 'methodology/approach', 'methods', 'methods & design', 'methods & material', 'methods & materials', 'methods & outcome measures', 'methods & patients', 'methods & procedure', 'methods & procedures', 'methods & study design', 'methods - data sources', 'methods - study selection', 'methods / design', 'methods and analyses', 'methods and analysis', 'methods and approach', 'methods and data', 'methods and design', 'methods and interventions', 'methods and main outcome measures', 'methods and main outcomes', 'methods and material', 'methods and materials', 'methods and measurements', 'methods and measures', 'methods and methods', 'methods and outcome measures', 'methods and outcomes', 'methods and participants', 'methods and patients', 'methods and population', 'methods and procedure', 'methods and procedures', 'methods and sample', 'methods and setting', 'methods and study design', 'methods and subjects', 'methods and technique', 'methods design', 'methods of analysis', 'methods of study', 'methods of study selection', 'methods used', 'methods/description', 'methods/design', 'methods/designs', 'methods/literature reviewed', 'methods/materials', 'methods/patients', 'methods/sample', 'methods/setting', 'methods/study design', 'methods/subjects', 'model', 'model & outcomes', 'model description', 'model, perspective, & time frame', 'model, perspective, & timeframe', 'models', 'new method', 'new methods', 'no level assigned', 'numbers', 'observation', 'observation procedure', 'observation procedures', 'observational procedure', 'observations', 'operations', 'operative procedure', 'operative technique', 'opportunities', 'options', 'options and outcomes', 'organization', 'organizing construct', 'organizing construct and methods', 'organizing framework', 'origins of information', 'other measurements', 'other participants', 'outcome & measurement', 'outcome & measurements', 'outcome & measures', 'outcome assessment', 'outcome measure', 'outcome measure(s)', 'outcome measured', 'outcome measurement', 'outcome measurements', 'outcome measurements and statistical analysis', 'outcome measures', 'outcome parameters', 'outcome variable', 'outcome variables', 'outcomes & measurement', 'outcomes & measurements', 'outcomes & measures', 'outcomes & other measurements', 'outcomes and measurements', 'outcomes assessment', 'outcomes measure', 'outcomes measured', 'outcomes measures', 'outcomes of interest', 'outline of cases', 'overall approach to quality and safety', 'overall strength of evidence', 'parameters', 'participant', 'participant(s)', 'participants', 'participants & setting', 'participants & settings', 'participants and context', 'participants and controls', 'participants and design', 'participants and intervention', 'participants and interventions', 'participants and main outcome measures', 'participants and measurements', 'participants and measures', 'participants and method', 'participants and methods', 'participants and outcome measures', 'participants and patients', 'participants and setting', 'participants and settings', 'participants and/or controls', 'participants or samples', 'participants, design and setting', 'participants, design, and setting', 'participants, setting and methods', 'participants, setting, methods', 'participants/intervention', 'participants/interventions', 'participants/material, setting, methods', 'participants/materials, setting and methods', 'participants/materials, setting, and methods', 'participants/materials, setting, methods', 'participants/materials, settings, methods', 'participants/methods', 'participants/patients', 'participants/setting', 'participants/settings', 'participation', 'pathogenesis', 'pathology', 'pathophysiology', 'patient', 'patient & method', 'patient & methods', 'patient and intervention', 'patient and method', 'patient and methods', 'patient case', 'patient characteristics', 'patient description', 'patient findings', 'patient group', 'patient history', 'patient material', 'patient population', 'patient population and methods', 'patient presentation', 'patient report', 'patient sample', 'patient sample and methodology', 'patient samples', 'patient selection', 'patient(s)', 'patient(s) and animal(s)', 'patient(s) and intervention(s)', 'patient, methods and results', 'patient/method', 'patient/methods', 'patient/participants', 'patients', 'patients & method', 'patients & methods', 'patients & setting', 'patients (or participants)', 'patients and control subjects', 'patients and controls', 'patients and design', 'patients and intervention', 'patients and interventions', 'patients and main outcome measurements', 'patients and main outcome measures', 'patients and material', 'patients and materials', 'patients and measurements', 'patients and method', 'patients and methodology', 'patients and methods', 'patients and other participants', 'patients and others participants', 'patients and outcome measures', 'patients and participants', 'patients and setting', 'patients and settings', 'patients and study design', 'patients and subjects', 'patients and technique', 'patients and techniques', 'patients and treatment', 'patients or materials', 'patients or other participants', 'patients or others participants', 'patients or participants', 'patients participants', 'patients(s)', 'patients, design, and setting', 'patients, material and methods', 'patients, material, methods', 'patients, materials and methods', 'patients, materials, and methods', 'patients, method', 'patients, methods', 'patients, participants', 'patients, subjects and methods', 'patients--methods', 'patients-methods', 'patients/design', 'patients/intervention', 'patients/interventions', 'patients/material and method', 'patients/material and methods', 'patients/materials and methods', 'patients/materials/methods', 'patients/method', 'patients/methods', 'patients/participants', 'patients/setting', 'patients/subjects', 'performance', 'period', 'period covered', 'period of study', 'personal experience', 'persons', 'perspective & time frame', 'perspective (values)', 'phenomena of interest', 'phenomenon of interest', 'physical examination', 'place', 'place and duration', 'place and duration of study', 'population', 'population and method', 'population and methods', 'population and sample', 'population and setting', 'population or sample', 'population studied', 'population, material and methods', 'population, sample, setting', 'population/sample', 'populations', 'populations and methods', 'positioning and anaesthesia', 'possible complications', 'postoperative care', 'postoperative management', 'potential intervention', 'practice description', 'practice innovation', 'practice pattern examined', 'predictor', 'predictor & outcome', 'predictor or factor', 'predictor variable', 'predictor variables', 'predictor, outcomes, & measurements', 'predictors', 'predictors & outcome', 'predictors & outcomes', 'preoperative counseling and informed consent', 'preoperative work up', 'presentation', 'presentation of a case', 'presentation of case', 'presentation of cases', 'presentation of the case', 'primary and secondary outcome measures', 'primary and secondary outcomes', 'primary endpoint', 'primary measurements', 'primary measures', 'primary outcome', 'primary outcome measure', 'primary outcome measures', 'primary outcome variable', 'primary outcome variables', 'primary outcomes', 'primary practice setting', 'primary practice setting(s)', 'primary practice settings', 'primary variables of interest', 'principal measurements', 'principles and methods', 'probands', 'probands and methods', 'procedure', 'procedures', 'process', 'program', 'program description', 'program design', 'programme description', 'project', 'project description', 'projects', 'proposal', 'proposals', 'proposed method', 'prospective study', 'protocol', 'quality assessment', 'quality improvement plan', 'quality of evidence', 'randomisation', 'randomization', 'rationale and design', 'rationale and method', 'rationale and methods', 'recent data', 'recent studies', 'reference test', 'reference test & measurements', 'reference test or outcome', 'reference tests', 'report', 'report of a case', 'report of cases', 'reporting period', 'reporting period covered', 'reports', 'requirements', 'research', 'research and design methods', 'research and methods', 'research approach', 'research design', 'research design & methods', 'research design and method', 'research design and methods', 'research design and participants', 'research design and subjects', 'research design, subjects, and measures', 'research design, subjects, measures', 'research design/methods', 'research designs and methods', 'research method', 'research method and procedures', 'research method/design', 'research methodology', 'research methodology/design', 'research methods', 'research methods & procedures', 'research methods and procedure', 'research methods and procedures', 'research setting', 'research strategy', 'research, design and methods', 'resolution', 'resolutions', 'resource', 'resources', 'respondents', 'review', 'review date', 'review method', 'review methods', 'review of literature', 'review of the literature', 'review process', 'review strategy', 'reviewer', 'reviewers', 'risk factors', 'risk stratification', 'risk-adapted therapy', 'risks', 'sample', 'sample & setting', 'sample and method', 'sample and methodology', 'sample and methods', 'sample and setting', 'sample population', 'sample size', 'sample(s)', 'sample/setting', 'samples', 'samples and methods', 'sampling', 'sampling and method', 'sampling and methods', 'scope', 'scope of review', 'search method', 'search methods', 'search protocol', 'search strategies', 'search strategy', 'search strategy & selection criteria', 'search strategy & sources', 'search strategy and selection criteria', 'second case', 'secondary outcome measure', 'secondary outcome measures', 'selection', 'selection criteria', 'selection criteria for studies', 'selection of studies', 'selection procedure', 'selection procedures', 'series summary', 'setting', 'setting & design', 'setting & participants', 'setting & population', 'setting & sample', 'setting and design', 'setting and intervention', 'setting and interventions', 'setting and method', 'setting and methods', 'setting and participants', 'setting and patient(s)', 'setting and patients', 'setting and population', 'setting and sample', 'setting and sample population', 'setting and study participants', 'setting and study population', 'setting and subject', 'setting and subjects', 'setting and type of participants', 'setting(s)', 'setting, design, and patients', 'setting, participants', 'setting, participants, and measurements', 'setting, patients', 'setting, population, & intervention', 'setting, subjects & interventions', 'setting/ participants', 'setting/design', 'setting/location', 'setting/participants', 'setting/participants/resources', 'setting/patients', 'setting/population', 'setting/sample', 'setting/subjects', 'settings', 'settings & design', 'settings & participants', 'settings and design', 'settings and design & materials and methods', 'settings and designs', 'settings and methods', 'settings and participants', 'settings and patients', 'settings and subjects', 'settings/location', 'settings/participants', 'settings/subjects', 'solution', 'solutions', 'source', 'source of data', 'source of information', 'sources', 'sources of data', 'sources of information', 'sources used', 'special features', 'specialty', 'specimens', 'standard radiological methods', 'standard treatment', 'standards', 'startpoints', 'statistic', 'statistical', 'statistical analyses', 'statistical analyses performed', 'statistical analysis', 'statistical analysis performed', 'statistical analysis used', 'statistical method', 'statistical methods', 'statistical tests', 'statistics', 'statistics analysis', 'strategies', 'strategies for change', 'strategies for improvement', 'strategy', 'strategy for change', 'strength of recommendation', 'strength of recommendation grade', 'studies', 'studies included', 'studies reviewed', 'study', 'study and design', 'study appraisal', 'study appraisal and synthesis', 'study appraisal and synthesis methods', 'study area', 'study design', 'study design & methods', 'study design & setting', 'study design and data collection', 'study design and main outcome measures', 'study design and measurements', 'study design and method', 'study design and methodology', 'study design and methods', 'study design and participants', 'study design and patients', 'study design and setting', 'study design and settings', 'study design and size', 'study design and subjects', 'study design materials and methods', 'study design, materials and methods', 'study design, patients, and methods', 'study design, setting & participants', 'study design, setting and subjects', 'study design, setting, & participants', 'study design, setting, and patients', 'study design, size and duration', 'study design, size duration', 'study design, size, and duration', 'study design, size, duration', 'study design/data collection', 'study design/data collection/extraction methods', 'study design/material and methods', 'study design/materials and methods', 'study design/method', 'study design/methods', 'study design/patients and methods', 'study design/setting', 'study designs', 'study designs and methods', 'study designs/materials and methods', 'study development & implementation', 'study eligibility', 'study eligibility criteria', 'study eligibility criteria, participants and interventions', 'study eligibility criteria, participants, and interventions', 'study factors', 'study group', 'study group and methods', 'study groups', 'study identification', 'study inclusion and exclusion criteria', 'study material', 'study method', 'study methods', 'study participants', 'study participants and methods', 'study patients', 'study period', 'study perspective', 'study population', 'study population and design', 'study population and methods', 'study population and setting', 'study populations', 'study protocol', 'study sample', 'study samples', 'study selection', 'study selection and data abstraction', 'study selection and data extraction', 'study selection and extraction', 'study selection criteria', 'study selection/data extraction', 'study selections', 'study setting', 'study setting/data sources', 'study site', 'study subjects', 'study subjects and methods', 'study type', 'study units', 'study variables', 'study-design', 'subject', 'subject & methods', 'subject and method', 'subject and methods', 'subject(s)', 'subject/methods', 'subjects', 'subjects & method', 'subjects & methods', 'subjects & setting', 'subjects (materials) and methods', 'subjects and design', 'subjects and intervention', 'subjects and interventions', 'subjects and main outcome measures', 'subjects and material', 'subjects and materials', 'subjects and measurements', 'subjects and measures', 'subjects and method', 'subjects and methodology', 'subjects and methods', 'subjects and outcome measures', 'subjects and participants', 'subjects and patients', 'subjects and setting', 'subjects and settings', 'subjects and study design', 'subjects and treatment', 'subjects or participants', 'subjects, main outcome measures', 'subjects, material & methods', 'subjects, material and methods', 'subjects, materials and methods', 'subjects, participants', 'subjects/design', 'subjects/interventions', 'subjects/materials', 'subjects/method', 'subjects/methods', 'subjects/participants', 'subjects/patients', 'subjects/patients and methods', 'subjects/samples', 'subjects/setting', 'subjects/settings', 'suggestions', 'summary of case', 'summary of data', 'summary of evidence', 'summary of report', 'surgery', 'surgical approach', 'surgical method', 'surgical procedure', 'surgical procedures', 'surgical technique', 'surgical treatment', 'survey', 'survey design & setting', 'survey instrument', 'survey sample', 'surveys', 'symptoms', 'system description', 'systematic review methodology', 'target population', 'taxonomy', 'technical considerations', 'technical note', 'technique', 'techniques', 'technology', 'testing', 'testing of the hypothesis', 'testing the hypothesis', 'tests', 'the case', 'the method', 'the solution', 'the technology', 'the technology being reviewed', 'theoretical framework', 'theory and methods', 'therapeutic methods', 'therapy', 'therapy and clinical course', 'time horizon', 'timing', 'tools', 'tools and methods', 'toxicokinetics', 'transmission', 'treatment', 'treatment and clinical course', 'treatment and course', 'treatment and further course', 'treatment and methods', 'treatment innovations', 'treatment protocol', 'treatments', 'trial design', 'trial status', 'trials', 'type of participant', 'type of participants', 'type of review', 'type of studies reviewed', 'type of study', 'type of study/design', 'type of study/level of evidence', 'type of the study', 'types of participants', 'types of studies reviewed', 'validating the recommendations', 'values', 'variables', 'variables measured', 'variables of interest', 'variables studied', 'volunteers', 'volunteers and methods', 'work method', 'work results'], 'background': ['abbreviations', 'access to data', 'accme accreditation', 'acknowledgments', 'aetiology', 'anamnesis', 'anamnesis and clinical findings', 'antecedents', 'approach to the problem', 'article title and bibliographic information', 'audience', 'availability', 'availability and supplementary information', 'background', 'background and context', 'background and importance', 'background and introduction', 'background and motivation', 'background and overview', 'background and significance', 'background content', 'background context', 'background data', 'background information', 'background of the study', 'background to the debate', 'background/introduction', 'background/rationale', 'background/significance', 'backgrounds', 'basic remarks', 'basics', 'basis', 'citation', 'clinical trial', 'clinical trial information', 'clinical trial number', 'clinical trial registration', 'clinical trial registration information', 'clinical trial registration number', 'clinical trial registration url', 'clinical trial registration- url', 'clinical trial registry', 'clinical trial registry number', 'clinical trials identifier', 'clinical trials registration', 'clinical trials registration number', 'clinical trials registry', 'condition', 'conflict of interest', 'conflict-of-interest statement', 'contact', 'contacts', 'content', 'contents', 'context', 'context & background', 'context and rationale', 'context of case', 'context/background', 'current knowledge', 'current knowledge and key points', 'current situation', 'current situation and salient points', 'declaration of interest', 'definition', 'definitions', 'descriptor', 'descriptors', 'developer and funding', 'disclosure', 'disease overview', 'electronic supplementary material', 'endorsement', 'enhanced version', 'epidemiology', 'ethics and dissemination', 'ethno pharmacological relevance', 'ethnopharmacological evidence', 'ethnopharmacological importance', 'ethnopharmacological relevance', 'ethnopharmacological significance', 'ethnopharmacology', 'ethnopharmacology relevance', 'etiology', 'financial disclosure', 'financial disclosure(s)', 'financial disclosures', 'foundation', 'funding', 'funding source', 'funding sources', 'genetics', 'global importance', 'health political background', 'historical aspects', 'historical background', 'historical overview', 'historical perspective', 'history and admission diagnosis', 'importance of the field', 'importance to the field', 'incidence', 'infection', 'instruction', 'intention, goal, scope, background', 'intro', 'introduction', 'introduction & background', 'introduction and background', 'introduction and development', 'introduction and material', 'introduction or background', 'introduction/background', 'introductions', 'jel classification', 'jel codes', 'justification', 'key words', 'keywords', 'linked article', 'linked articles', 'mini summary', 'motivation', 'motivations', 'open peer review', 'organizing constructs', 'overview', 'overview of literature', 'physical properties', 'practical relevance', 'preface', 'preliminary studies', 'prevalence', 'primary argument', 'primary funding source', 'principle', 'principles', 'protocol registration', 'rational', 'rationale', 'rationale and background', 'reason for performing study', 'reason for study', 'reasons for performing study', 'reasons for performing the study', 'recent advances', 'recent developments', 'reference/citation', 'registration', 'registration details', 'registration id in irct', 'registration number', 'review registration', 'scientific background', 'scope and background', 'scope of the problem', 'situation', 'source of funding', 'sponsor', 'sponsors', 'sponsorship', 'sponsorships', 'starting point', 'state of art', 'state of knowledge', 'state of the art', 'statement of problem', 'statement of problem and rationale', 'statement of problems', 'statement of the problem', 'statements of the problem', 'study background', 'study funding', 'study funding/competing interest', 'study funding/competing interest(s)', 'study funding/competing interests', 'study registration', 'summary and background', 'summary and background data', 'summary background', 'summary background data', 'summary of background', 'summary of background data', 'summary of background information', 'summary of the background data', 'supplemental material', 'supplementary information', 'support', 'systematic review registration', 'target audience', 'theoretical background', 'theoretical considerations', 'theories', 'theory', 'title', 'trial number', 'trial register', 'trial registration', 'trial registration isrctn', 'trial registration no', 'trial registration number', 'trial registration numbers', 'trial registrations', 'trial registry', 'trials registration', 'useful websites', 'video abstract available', 'what is already known', 'what is already known about this subject', 'what is known', 'what is known already', 'what is known and background', 'what is known and what this paper adds', 'what will the reader gain'], 'results': ['achievements', 'adverse effects', 'analysis and results', 'analysis of results', 'analytic validity', 'approach and results', 'areas of agreement', 'areas of agreement and controversy', 'areas of controversy', 'assessment', 'background and results', 'baseline results', 'benefits', 'benefits, harm and costs', 'benefits, harms and costs', 'benefits, harms, and costs', 'benefits, harms, costs', 'case management', 'case report and results', 'clinical and pathological findings', 'clinical findings', 'clinical findings and diagnosis', 'clinical manifestations', 'clinical outcome', 'clinical results', 'clinical trials', 'clinical utility', 'clinical validity', 'complications', 'costs', 'course', 'course and treatment', 'critical issues', 'critique', 'current status', 'data synthesis', 'data/results', 'design and results', 'discussion and evaluation', 'discussion and results', 'disease control', 'dissemination', 'effectiveness', 'effects of change', 'efficacy', 'essential results', 'evaluation', 'evaluation results', 'evidence synthesis', 'evolution', 'examination', 'examinations', 'examples', 'expected results', 'experience', 'experience and results', 'experiences', 'experimental approach & key results', 'experimental design and results', 'experiments and results', 'feasibility', 'finding', 'findings', 'findings and outcomes', 'findings and recommendations', 'findings/results', 'follow up', 'follow-up', 'genetic toxicology', 'harms', 'histology', 'histopathology', 'human data synthesis', 'hypertension', 'important findings', 'innovations', 'intervention and outcome', 'intervention and outcomes', 'intervention and results', 'interventions and main results', 'interventions and outcome', 'interventions and outcomes', 'interventions and results', 'interventions, measurements, and main results', 'key finding', 'key findings', 'key findings and implications', 'key issue', 'key issue(s)', 'key issues', 'key results', 'laboratory findings', 'literature findings', 'main contribution', 'main finding', 'main findings', 'main issues', 'main measurements and results', 'main measures and results', 'main message', 'main methods and key findings', 'main outcome', 'main outcome and results', 'main outcome findings', 'main outcome measure and results', 'main outcome measurements and results', 'main outcome measures and results', 'main outcome measures/results', 'main outcome results', 'main outcomes', 'main outcomes and results', 'main points', 'main result', 'main results', 'main results and role of chance', 'main results and the role of chance', 'major findings', 'major points', 'major results', 'management', 'material and discussion', 'material and results', 'material, methods and results', 'materials & results', 'materials and methods and results', 'materials and methods/results', 'materials and results', 'materials, methods and results', 'materials, methods, and results', 'measurement & results', 'measurement and findings', 'measurement and main result', 'measurement and main results', 'measurement and results', 'measurements & results', 'measurements and findings', 'measurements and main findings', 'measurements and main outcomes', 'measurements and main result', 'measurements and main results', 'measurements and results', 'measurements/main results', 'measurements/results', 'measures and main results', 'measures and results', 'mechanism of action', 'mechanisms', 'mechanisms of action', 'method & results', 'method and findings', 'method and result', 'method and results', 'method/principal findings', 'method/result', 'method/results', 'methodologies/principal findings', 'methodology & principal findings', 'methodology & principle findings', 'methodology and findings', 'methodology and principal finding', 'methodology and principal findings', 'methodology and principle findings', 'methodology and results', 'methodology principal findings', 'methodology/ principal findings', 'methodology/findings', 'methodology/main findings', 'methodology/main results', 'methodology/principal', 'methodology/principal finding', 'methodology/principal findings', 'methodology/principle findings', 'methodology/results', 'methods & findings', 'methods & procedures/outcomes & results', 'methods & results', 'methods and discussion', 'methods and finding', 'methods and findings', 'methods and key results', 'methods and main results', 'methods and principal findings', 'methods and result', 'methods and results', 'methods, results', 'methods-results', 'methods/findings', 'methods/principal finding', 'methods/principal findings', 'methods/results', 'methods\\u2004and\\u2004results', 'mortality', 'motivation and results', 'motivations and results', 'observation & results', 'observation and results', 'observations and results', 'outcome', 'outcome & results', 'outcome and results', 'outcome measures & results', 'outcome measures and results', 'outcomes', 'outcomes & results', 'outcomes and results', 'outcomes/results', 'output', 'outputs', 'pathological findings', 'patient and results', 'patient summary', 'patient, intervention, and results', 'patients and results', 'patients, methods and results', 'patients, methods, and results', 'pharmacokinetics', 'preliminary results', 'preventive measures', 'primary findings', 'primary results', 'principal finding', 'principal findings', 'principal findings/methodology', 'principal observations', 'principal results', 'principle findings', 'principle results', 'procedure and results', 'procedures and results', 'program evaluation', 'programme evaluation', 'progress', 'prophylaxis', 'recent finding', 'recent findings', 'recent progress', 'rehabilitation', 'relevant changes', 'relevant findings', 'research design and methods and results', 'research findings', 'research topics', 'response', 'result', 'result(s)', 'results', 'results and analysis', 'results and comments', 'results and comparison with existing methods', 'results and complications', 'results and findings', 'results and methods', 'results and observations', 'results and statistics', 'results of base-case analysis', 'results of data analysis', 'results of data synthesis', 'results of sensitivity analyses', 'results of sensitivity analysis', 'results of studies', 'results of the study', 'results(s)', 'results, discussion', 'results/findings', 'results/interpretation', 'results/outcome', 'results/outcomes', 'results/significance', 'results/statistics', 'results/summary', 'review findings', 'review results', 'review summary', 'safety', 'secondary outcomes', 'setting and results', 'side effects', 'statistical analysis and results', 'study design and results', 'study design/results', 'study findings', 'study outcome', 'study outcomes', 'study results', 'study selection & results', 'subjects and results', 'summary of comment', 'summary of findings', 'summary of important findings', 'summary of results', 'summary of review', 'summary of the findings', 'survival', 'synthesis', 'synthesis of evidence', 'tabulation, integration and results', 'tabulation, integration, and results', 'the results', 'therapy and course', 'therapy and outcome', 'therapy and results', 'tolerability', 'toxicity', 'treatment and follow-up', 'treatment and outcome', 'treatment/outcome', 'uniqueness', 'validation', 'validity', 'validity and coverage', 'veterinary data synthesis', 'viewpoints', 'what the reader will gain', 'what the readers will gain'], 'conclusions': ['actions taken', 'advances in knowledge', 'advances in knowledge and implications for patient care', 'advantages', 'answer', 'application', 'application to clinical practice', 'application/conclusions', 'applications', 'applications/conclusion', 'applications/conclusions', 'areas timely for developing research', 'areas to develop research', \"author's conclusions\", \"authors' conclusion\", \"authors' conclusions\", 'best practices', 'bias, confounding and other reasons for caution', 'bottom line', 'capsule summary', 'challenges', 'challenges and lessons learned', 'clinical advantages', 'clinical implication', 'clinical implications', 'clinical importance', 'clinical potential', 'clinical recommendations', 'clinical rehabilitation impact', 'clinical relevance', 'clinical significance', 'clinical value', 'comment', 'commentaries', 'commentary', 'comments', 'comments and conclusion', 'comments and conclusions', 'comparison with existing method', 'comparison with existing method(s)', 'concluding remarks', 'concluding statement', 'conclusion', 'conclusion & clinical relevance', 'conclusion & discussion', 'conclusion & implications', 'conclusion & inferences', 'conclusion and clinical implications', 'conclusion and clinical importance', 'conclusion and clinical rehabilitation impact', 'conclusion and clinical relevance', 'conclusion and clinical significance', 'conclusion and discussion', 'conclusion and general significance', 'conclusion and impact', 'conclusion and implication', 'conclusion and implications', 'conclusion and implications for practice', 'conclusion and message', 'conclusion and outlook', 'conclusion and perspective', 'conclusion and perspectives', 'conclusion and potential relevance', 'conclusion and practice implications', 'conclusion and recommendation', 'conclusion and recommendations', 'conclusion and relevance', 'conclusion and relevance to clinical practice', 'conclusion and scientific significance', 'conclusion and significance', 'conclusion(s)', 'conclusion-discussion', 'conclusion/clinical relevance', 'conclusion/discussion', 'conclusion/hypothesis', 'conclusion/implications', 'conclusion/implications for practice', 'conclusion/interpretation', 'conclusion/recommendation', 'conclusion/recommendations', 'conclusion/relevance', 'conclusion/significance', 'conclusions', 'conclusions & clinical importance', 'conclusions & clinical relevance', 'conclusions & implication', 'conclusions & implications', 'conclusions & implications for nursing', 'conclusions & inferences', 'conclusions & interpretation', 'conclusions & recommendations', 'conclusions & significance', 'conclusions / implications for practice', 'conclusions and clinical implications', 'conclusions and clinical importance', 'conclusions and clinical relevance', 'conclusions and clinical significance', 'conclusions and discussion', 'conclusions and general significance', 'conclusions and impact', 'conclusions and implication', 'conclusions and implications', 'conclusions and implications for cancer survivors', 'conclusions and implications for nursing management', 'conclusions and implications for practice', 'conclusions and implications of key findings', 'conclusions and inferences', 'conclusions and interpretation', 'conclusions and limitations', 'conclusions and outlook', 'conclusions and perspectives', 'conclusions and potential relevance', 'conclusions and practical implications', 'conclusions and practice implications', 'conclusions and recommendations', 'conclusions and relevance', 'conclusions and relevance to clinical practice', 'conclusions and scientific significance', 'conclusions and significance', 'conclusions significance', 'conclusions(s)', 'conclusions, significance and impact of the study', 'conclusions/ significance', 'conclusions/applications', 'conclusions/clinical relevance', 'conclusions/discussion', 'conclusions/findings', 'conclusions/implications', 'conclusions/implications for practice', 'conclusions/importance', 'conclusions/interpretation', 'conclusions/interpretations', 'conclusions/lessons learned', 'conclusions/level of evidence', 'conclusions/practice implications', 'conclusions/recommendations', 'conclusions/relevance', 'conclusions/significance', 'conclusions/significances', 'conclusions/summary', 'condensation', 'condensed abstract', 'conditions', 'consequence', 'consequences', 'consideration', 'considerations', 'contextual issues', 'critical issues and future directions', 'current & future development', 'data synthesis and conclusion', 'data synthesis and conclusions', 'development and conclusion', 'development and conclusions', 'developments', 'disclaimer', 'discussion', 'discussion & conclusion', 'discussion & summary', 'discussion - conclusion', 'discussion and conclusion', 'discussion and conclusions', 'discussion and implications', 'discussion and implications for practice', 'discussion and limitations', 'discussion and recommendations', 'discussion and summary', 'discussion, conclusion', 'discussion-conclusion', 'discussion/conclusion', 'discussion/conclusions', 'discussions', 'discussions and conclusion', 'discussions and conclusions', 'discussions/conclusions', 'emerging areas for developing research', 'epilogue', 'expert opinion', 'final considerations', 'final remarks', 'findings and conclusion', 'findings and conclusions', 'findings and discussion', 'findings and implications', 'findings and practice implications', 'findings/conclusion', 'findings/conclusions', 'future', 'future and projects', 'future directions', 'future perspectives', 'future prospect and projects', 'future prospects', 'future prospects and projects', 'future research', 'future work', 'general significance', 'generalizability to other populations', 'growing points', 'growing points and areas timely for developing research', 'guidelines', 'highlights', 'impact', 'impact for human medicine', 'impact of the study', 'impact on industry', 'impact on research, practice, and policy', 'impact on the industry', 'impact on traffic safety', 'impacts', 'implication', 'implication for cancer survivors', 'implication for further research', 'implication for nursing management', 'implication for nursing practice', 'implication for practice', 'implication of the hypothesis', 'implication statement', 'implications', 'implications and action', 'implications and conclusions', 'implications for cancer survivors', 'implications for case management', 'implications for case management practice', 'implications for clinical practice', 'implications for cm practice', 'implications for further research', 'implications for future research', 'implications for health care provision', 'implications for health care provision and use', 'implications for health policies', 'implications for health policy', 'implications for nurse managers', 'implications for nursing', 'implications for nursing and health policy', 'implications for nursing management', 'implications for nursing practice', 'implications for nursing research', 'implications for policy', 'implications for practice', 'implications for practice/research', 'implications for practise', 'implications for public health', 'implications for public health practice', 'implications for rehabilitation', 'implications for research', 'implications for research and practice', 'implications for research/practice', 'implications of the hypothesis', 'implications statement', 'implications/conclusions', 'in clinical practice', 'in conclusion', 'in practice', 'in summary', 'inference', 'innovation and conclusion', 'innovation and conclusions', 'innovation and implications', 'integrative significance', 'interpretation', 'interpretation & conclusion', 'interpretation & conclusions', 'interpretation and conclusion', 'interpretation and conclusions', 'interpretation/conclusion', 'interpretation/conclusions', 'interpretations', 'interpretations & conclusion', 'interpretations & conclusions', 'interpretations and conclusions', 'key conclusion', 'key conclusion and implications for practice', 'key conclusions', 'key conclusions and implications', 'key conclusions and implications for practice', 'key learning point', 'key learning points', 'key limitations', 'key message', 'key messages', 'key points', 'key practitioner message', 'key questions and answers', 'key recommendations', 'key results and conclusions', 'keys to success', 'knowledge translation', 'learning points', 'lessons', 'lessons and messages', 'lessons learned', 'lessons learnt', 'limitation', 'limitation, reasons for caution', 'limitations', 'limitations and conclusions', 'limitations and reasons for caution', 'limitations of the study', 'limitations, reason for caution', 'limitations, reasons for caution', 'limitations, reasons for cautions', 'limits', 'linking evidence to action', 'main conclusion', 'main conclusions', 'main messages', 'main recommendations', 'main results and conclusions', 'major conclusion', 'major conclusions', 'management of refractory disease', 'message', 'methods and conclusions', 'methods, results and conclusions', 'mini-abstract', 'new information', 'new or unique information provided', 'next steps', 'nursing implications', 'objective and conclusion', 'observation & discussion', 'ongoing issues', 'originality', 'originality/value', 'originality/value of chapter', 'outcomes summary', 'outlook', 'perspective', 'perspectives', 'perspectives and conclusion', 'perspectives and conclusions', 'perspectives and projects', 'place in therapy', 'plain language summary', 'points of consensus', 'policy implications', 'policy points', 'positions', 'potential clinical relevance', 'potential difficulties', 'potential relevance', 'practical application', 'practical applications', 'practical attitude', 'practical implications', 'practical recommendations', 'practice guideline', 'practice implication', 'practice implications', 'practitioner points', 'precis', 'prevention', 'principal conclusion', 'principal conclusions', 'principal findings and conclusions', 'principal findings/conclusions', 'principle conclusions', 'prognosis', 'prospect', 'prospects', 'prospects and projects', 'public health action', 'public health actions', 'public health implications', 'purpose and clinical relevance', 'purposes and clinical relevance', 'qualifying statements', 'recommendation', 'recommendation 1', 'recommendation 2', 'recommendation 3', 'recommendation and outlook', 'recommendation and perspective', 'recommendation and perspectives', 'recommendations', 'recommendations and conclusions', 'recommendations and outlook', 'recommendations and perspective', 'recommendations and perspectives', 'recommendations for clinical practice', 'reflections', 'relevance', 'relevance for clinical practice', 'relevance to clinical or professional practice', 'relevance to clinical practice', 'relevance to practice', 'relevance/impact', 'remarks', 'research implications', 'research implications/limitations', 'research limitations', 'research limitations/implications', 'research recommendations', 'result & conclusion', 'result & conclusions', 'result and conclusion', 'result and conclusions', 'result and discussion', 'result/conclusion', 'results & conclusion', 'results & conclusions', 'results & discussion', 'results & interpretation', 'results and conclusion', 'results and conclusions', 'results and discussion', 'results and discussions', 'results and implications', 'results and interpretation', 'results and interpretations', 'results and limitations', 'results and major conclusion', 'results and recommendations', 'results and significance', 'results and сonclusion', 'results and/or conclusions', 'results, conclusion', 'results-conclusions', 'results/conclusion', 'results/conclusions', 'results/discussion', \"reviewer's conclusions\", \"reviewers' conclusions\", 'scientific significance', 'scope and conclusions', 'selected highlights', 'significance', 'significance and impact', 'significance and impact of study', 'significance and impact of the study', 'significance and impacts of the study', 'significance and importance of the study', 'significance and the impact of the study', 'significance of research', 'significance of results', 'significance of the research', 'significance of the study', 'significance/conclusion', 'significance/conclusions', 'significances', 'significant and impact of the study', 'significant outcomes', 'social implications', 'speculation', 'state of art and perspectives', 'state of the art and perspectives', 'statement of conclusions', 'study answer', 'study limitation', 'study limitations', 'summary', 'summary and conclusion', 'summary and conclusions', 'summary and discussion', 'summary answer', 'summary of key points', 'summary of recommendations', 'summary points', 'summary statement', 'summary statements', 'summary/conclusions', 'synopsis', 'take home message', 'take home messages', 'take-home message', 'task force recommendations', 'teaching points', 'the conclusion', 'the future', 'therapeutic implications', 'therapeutic management', 'treatment recommendations', 'tweetable abstract', 'unique information provided', 'vaccination recommendations', 'value/originality', 'viewpoint', 'viewpoint and conclusion', 'viewpoint and conclusions', 'what is new and conclusion', 'what is new and conclusions', 'what this paper adds', 'what this study adds', 'where next', 'wider implication of the findings', 'wider implications of the finding', 'wider implications of the findings'], 'objective': ['aim', 'aim & design', 'aim & method', 'aim & objectives', 'aim & purpose', 'aim and background', 'aim and design', 'aim and goals', 'aim and materials & methods', 'aim and method', 'aim and methodology', 'aim and methods', 'aim and objective', 'aim and objectives', 'aim and purpose', 'aim and scope', 'aim and setting', 'aim of investigation', 'aim of paper', 'aim of study', 'aim of the paper', 'aim of the review', 'aim of the study', 'aim of the study and methods', 'aim of the work', 'aim of this study', 'aim of work', 'aim(s)', 'aim(s) of the study', 'aim, patients and methods', 'aim/background', 'aim/hypothesis', 'aim/method', 'aim/methods', 'aim/objective', 'aim/objectives', 'aim/purpose', 'aims', 'aims & background', 'aims & method', 'aims & methods', 'aims & objectives', 'aims & results', 'aims and background', 'aims and design', 'aims and development', 'aims and hypothesis', 'aims and method', 'aims and methodology', 'aims and methods', 'aims and objective', 'aims and objectives', 'aims and purpose', 'aims and scope', 'aims and/or hypothesis', 'aims of study', 'aims of the paper', 'aims of the review', 'aims of the study', 'aims of this study', 'aims/background', 'aims/hypotheses', 'aims/hypothesis', 'aims/introduction', 'aims/methods', 'aims/methods & procedures', 'aims/objective', 'aims/objectives', 'aims/purpose', 'argument', 'arguments', 'background & aim', 'background & aims', 'background & goals', 'background & objective', 'background & objectives', 'background & problems', 'background & purpose', 'background & rationale', 'background aims', 'background and aim', 'background and aim of study', 'background and aim of the study', 'background and aim of the work', 'background and aim of work', 'background and aims', 'background and aims of the study', 'background and goal', 'background and goals', 'background and hypothesis', 'background and object', 'background and objective', 'background and objectives', 'background and purpose', 'background and purpose of study', 'background and purpose of the study', 'background and purposes', 'background and rationale', 'background and research objective', 'background and research objectives', 'background and scope', 'background and study aim', 'background and study aims', 'background and study objective', 'background and study objectives', 'background and study purpose', 'background and the purpose of the study', 'background data and objective', 'background objectives', 'background purpose', 'background, aim and scope', 'background, aim, and scope', 'background, aims', 'background, aims & methods', 'background, aims and scope', 'background, aims, and scope', 'background/aim', 'background/aim of study', 'background/aims', 'background/aims and methods', 'background/aims/methods', 'background/goals', 'background/hypothesis', 'background/objective', 'background/objectives', 'background/purpose', 'background/purpose(s)', 'background/purposes', 'background/study context', 'backgrounds & aims', 'backgrounds and aim', 'backgrounds and aims', 'backgrounds and objective', 'backgrounds and objectives', 'backgrounds and purpose', 'backgrounds/aims', 'basic problem', 'basic problem and aim of study', 'basic problem and objective', 'basic problem and objective of study', 'basic problem and objective of the study', 'basic problems and objective', 'clinical challenges', 'clinical issue', 'clinical need', 'clinical problem', 'clinical question', 'clinical/methodical issue', 'community context', 'context & objective', 'context and aim', 'context and aims', 'context and objective', 'context and objectives', 'context and purpose', 'context of the problem', 'context/objective', 'context/objectives', 'controversial issues', 'definition of the problem', 'design and objective', 'educational objective', 'educational objectives', 'evaluation aims', 'expected outcomes', 'experimental objectives', 'focus', 'focused question', 'fundamentals', 'general question', 'goal', 'goal and methods', 'goal of study', 'goal of surgery', 'goal of the study', 'goal of this study', 'goal of work', 'goal, scope and background', 'goal, scope, and background', 'goals', 'goals and background', 'goals and objectives', 'goals of the study', 'goals of the work', 'goals of this study', 'goals of work', 'goals, scope and background', 'goals/background', 'guideline question', 'guideline questions', 'hypotheses', 'hypothesis', 'hypothesis and aims', 'hypothesis and background', 'hypothesis and objectives', 'hypothesis/background', 'hypothesis/objective', 'hypothesis/objectives', 'hypothesis/problem', 'hypothesis/purpose', 'importance', 'intention', 'intention of the study', 'introduction & aim', 'introduction & objective', 'introduction & objectives', 'introduction & purpose', 'introduction and aim', 'introduction and aim of study', 'introduction and aim of the study', 'introduction and aims', 'introduction and aims of the study', 'introduction and design', 'introduction and goal', 'introduction and goals', 'introduction and hypothesis', 'introduction and object', 'introduction and objective', 'introduction and objectives', 'introduction and potentials of classical radiotherapy', 'introduction and problem', 'introduction and prognosis', 'introduction and proposed study', 'introduction and purpose', 'introduction and rationale', 'introduction/aim', 'introduction/aims', 'introduction/hypothesis', 'introduction/objective', 'introduction/objectives', 'introduction/purpose', 'issue', 'issue addressed', 'issues', 'issues addressed', 'issues and purpose', 'learning objective', 'learning objectives', 'learning outcomes', 'main objective', 'main objectives', 'main problem', 'main purpose', 'main topics', 'methods and aims', 'methods and focus', 'methods and objectives', 'null hypothesis', 'object', 'object & method', 'object and background', 'object and design', 'object and method', 'object and methods', 'object of study', 'object of the study', 'object of work', 'objections', 'objective', 'objective & aims', 'objective & design', 'objective & method', 'objective & methods', 'objective and aim', 'objective and background', 'objective and background data', 'objective and design', 'objective and hypothesis', 'objective and importance', 'objective and method', 'objective and methods', 'objective and motivation', 'objective and participants', 'objective and patients', 'objective and purpose', 'objective and rationale', 'objective and results', 'objective and setting', 'objective and study design', 'objective and subjects', 'objective and summary background data', 'objective of program', 'objective of review', 'objective of study', 'objective of the program', 'objective of the study', 'objective(s)', 'objective, design, and setting', 'objective/aim', 'objective/aims', 'objective/background', 'objective/design', 'objective/design/patients', 'objective/goal', 'objective/hypotheses', 'objective/hypothesis', 'objective/method', 'objective/methods', 'objective/patients', 'objective/purpose', 'objective/setting', 'objectives', 'objectives & methods', 'objectives and aim', 'objectives and aims', 'objectives and background', 'objectives and design', 'objectives and goal', 'objectives and hypothesis', 'objectives and method', 'objectives and methods', 'objectives and patients', 'objectives and rationale', 'objectives and results', 'objectives and setting', 'objectives and study design', 'objectives of study', 'objectives of the review', 'objectives of the study', 'objectives, patients and methods', 'objectives/ hypothesis', 'objectives/aim', 'objectives/aims', 'objectives/background', 'objectives/design', 'objectives/goal', 'objectives/hypotheses', 'objectives/hypothesis', 'objectives/methods', 'objectives/purpose', 'objectives/purposes', 'objectives/study design', 'objects', 'objects and methods', 'outline', 'overall article objective', 'overall article objectives', 'paper aim', 'premise', 'premise of study', 'premise of the study', 'presentation of hypothesis', 'presentation of the hypothesis', 'primary objective', 'primary objectives', 'primary purpose', 'primary study objective', 'problem', 'problem addressed', 'problem and background', 'problem and method', 'problem and method of study', 'problem and objective', 'problem and purpose', 'problem assessed', 'problem being addressed', 'problem considered', 'problem identification', 'problem statement', 'problem statement and background', 'problem statement and purpose', 'problem/condition', 'problem/objective', 'problems', 'problems addressed', 'problems and aims', 'problems/objectives', 'purpose', 'purpose & methods', 'purpose and background', 'purpose and design', 'purpose and experimental design', 'purpose and method', 'purpose and methods', 'purpose and objective', 'purpose and objectives', 'purpose and patients', 'purpose and patients and methods', 'purpose and setting', 'purpose of investigation', 'purpose of research', 'purpose of review', 'purpose of study', 'purpose of the investigation', 'purpose of the report', 'purpose of the research', 'purpose of the review', 'purpose of the study', 'purpose of the work', 'purpose of this review', 'purpose of this study', 'purpose, patients, and methods', 'purpose/aim', 'purpose/aim of the study', 'purpose/aims', 'purpose/background', 'purpose/hypothesis', 'purpose/method', 'purpose/methods', 'purpose/objective', 'purpose/objective(s)', 'purpose/objectives', 'purpose/question', 'purposes', 'purposes of the study', 'purposes/objectives', 'quality problem', 'quality problem or issue', 'question', 'question addressed', 'question of the study', 'question under study', 'question/purposes', 'questioning', 'questions', 'questions under study', 'questions under study / principles', 'questions under study/principles', 'questions/hypotheses', 'questions/purpose', 'questions/purposes', 'rational and objective', 'rational and objectives', 'rational, aims and objectives', 'rationale & objective', 'rationale & objectives', 'rationale aims and objectives', 'rationale and aim', 'rationale and aims', 'rationale and aims of the study', 'rationale and goals', 'rationale and hypothesis', 'rationale and objective', 'rationale and objectives', 'rationale and purpose', 'rationale for study', 'rationale for the study', 'rationale for this study', 'rationale objective', 'rationale of the study', 'rationale, aim & objectives', 'rationale, aim and objective', 'rationale, aims and objective', 'rationale, aims and objectives', 'rationale/objectives', 'rationales and objectives', 'reason for performing the study', 'reasons for performing study and objective', 'research objective', 'research objectives', 'research problem', 'research question', 'research questions', 'scientific question', 'scope and purpose', 'scope of the report', 'scope of the review', 'scope of the study', 'secondary objective', 'secondary objectives', 'setting and objective', 'setting and objectives', 'short introduction', 'short summary', 'specific aim', 'specific aims', 'specific objective', 'specific objectives', 'specific research challenge', 'state of the problem', 'statement of purpose', 'study aim', 'study aims', 'study design and objective', 'study design and objectives', 'study goal', 'study goals', 'study hypothesis', 'study object', 'study objective', 'study objectives', 'study purpose', 'study question', 'study questions', 'study rationale', 'study/principles', 'subject objective', 'summary introduction', 'summary objective', 'summary objectives', 'summary of background data and objectives', 'target', 'the aim', 'the aim of our study', 'the aim of study', 'the aim of the paper', 'the aim of the study', 'the aim of the work', 'the aim of this study', 'the aim of this work', 'the aim of work', 'the aims', 'the aims of our study were', 'the goal', 'the hypothesis', 'the issue', 'the main aim of the study', 'the object', 'the objective', 'the primary objective', 'the problem', 'the purpose', 'the purpose of the research', 'the purpose of the study', 'the purpose of this study', 'the research objective', 'the study objective', 'this retrospective study aims', 'topic', 'topic of the study', 'what is known and objective', 'what is known and objectives', 'working hypothesis']})\n",
      "['methods', 'background', 'results', 'conclusions', 'objective']\n"
     ]
    }
   ],
   "source": [
    "import urllib.request as urllib2\n",
    "import pickle\n",
    "from collections import defaultdict\n",
    "\n",
    "target_url = 'https://lhncbc.nlm.nih.gov/ii/areas/structured-abstracts/downloads/Structured-Abstracts-Labels-102615.txt'\n",
    "normalized_sections = defaultdict(list)\n",
    "with open('structured_headings.txt', 'w') as file:\n",
    "    for line in urllib2.urlopen(target_url):\n",
    "        clean_line = line.decode(\"utf-8\").split('|')\n",
    "        normalized_sections[clean_line[1].lower()].append(clean_line[0].lower())\n",
    "\n",
    "with open('structured_abstract_sections.pkl', 'wb') as file:\n",
    "    pickle.dump(normalized_sections, file)\n",
    "\n",
    "print(normalized_sections)\n",
    "print(list(normalized_sections))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['aim', 'aim & design', 'aim & method', 'aim & objectives', 'aim & purpose', 'aim and background', 'aim and design', 'aim and goals', 'aim and materials & methods', 'aim and method', 'aim and methodology', 'aim and methods', 'aim and objective', 'aim and objectives', 'aim and purpose', 'aim and scope', 'aim and setting', 'aim of investigation', 'aim of paper', 'aim of study', 'aim of the paper', 'aim of the review', 'aim of the study', 'aim of the study and methods', 'aim of the work', 'aim of this study', 'aim of work', 'aim(s)', 'aim(s) of the study', 'aim, patients and methods', 'aim/background', 'aim/hypothesis', 'aim/method', 'aim/methods', 'aim/objective', 'aim/objectives', 'aim/purpose', 'aims', 'aims & background', 'aims & method', 'aims & methods', 'aims & objectives', 'aims & results', 'aims and background', 'aims and design', 'aims and development', 'aims and hypothesis', 'aims and method', 'aims and methodology', 'aims and methods', 'aims and objective', 'aims and objectives', 'aims and purpose', 'aims and scope', 'aims and/or hypothesis', 'aims of study', 'aims of the paper', 'aims of the review', 'aims of the study', 'aims of this study', 'aims/background', 'aims/hypotheses', 'aims/hypothesis', 'aims/introduction', 'aims/methods', 'aims/methods & procedures', 'aims/objective', 'aims/objectives', 'aims/purpose', 'argument', 'arguments', 'background & aim', 'background & aims', 'background & goals', 'background & objective', 'background & objectives', 'background & problems', 'background & purpose', 'background & rationale', 'background aims', 'background and aim', 'background and aim of study', 'background and aim of the study', 'background and aim of the work', 'background and aim of work', 'background and aims', 'background and aims of the study', 'background and goal', 'background and goals', 'background and hypothesis', 'background and object', 'background and objective', 'background and objectives', 'background and purpose', 'background and purpose of study', 'background and purpose of the study', 'background and purposes', 'background and rationale', 'background and research objective', 'background and research objectives', 'background and scope', 'background and study aim', 'background and study aims', 'background and study objective', 'background and study objectives', 'background and study purpose', 'background and the purpose of the study', 'background data and objective', 'background objectives', 'background purpose', 'background, aim and scope', 'background, aim, and scope', 'background, aims', 'background, aims & methods', 'background, aims and scope', 'background, aims, and scope', 'background/aim', 'background/aim of study', 'background/aims', 'background/aims and methods', 'background/aims/methods', 'background/goals', 'background/hypothesis', 'background/objective', 'background/objectives', 'background/purpose', 'background/purpose(s)', 'background/purposes', 'background/study context', 'backgrounds & aims', 'backgrounds and aim', 'backgrounds and aims', 'backgrounds and objective', 'backgrounds and objectives', 'backgrounds and purpose', 'backgrounds/aims', 'basic problem', 'basic problem and aim of study', 'basic problem and objective', 'basic problem and objective of study', 'basic problem and objective of the study', 'basic problems and objective', 'clinical challenges', 'clinical issue', 'clinical need', 'clinical problem', 'clinical question', 'clinical/methodical issue', 'community context', 'context & objective', 'context and aim', 'context and aims', 'context and objective', 'context and objectives', 'context and purpose', 'context of the problem', 'context/objective', 'context/objectives', 'controversial issues', 'definition of the problem', 'design and objective', 'educational objective', 'educational objectives', 'evaluation aims', 'expected outcomes', 'experimental objectives', 'focus', 'focused question', 'fundamentals', 'general question', 'goal', 'goal and methods', 'goal of study', 'goal of surgery', 'goal of the study', 'goal of this study', 'goal of work', 'goal, scope and background', 'goal, scope, and background', 'goals', 'goals and background', 'goals and objectives', 'goals of the study', 'goals of the work', 'goals of this study', 'goals of work', 'goals, scope and background', 'goals/background', 'guideline question', 'guideline questions', 'hypotheses', 'hypothesis', 'hypothesis and aims', 'hypothesis and background', 'hypothesis and objectives', 'hypothesis/background', 'hypothesis/objective', 'hypothesis/objectives', 'hypothesis/problem', 'hypothesis/purpose', 'importance', 'intention', 'intention of the study', 'introduction & aim', 'introduction & objective', 'introduction & objectives', 'introduction & purpose', 'introduction and aim', 'introduction and aim of study', 'introduction and aim of the study', 'introduction and aims', 'introduction and aims of the study', 'introduction and design', 'introduction and goal', 'introduction and goals', 'introduction and hypothesis', 'introduction and object', 'introduction and objective', 'introduction and objectives', 'introduction and potentials of classical radiotherapy', 'introduction and problem', 'introduction and prognosis', 'introduction and proposed study', 'introduction and purpose', 'introduction and rationale', 'introduction/aim', 'introduction/aims', 'introduction/hypothesis', 'introduction/objective', 'introduction/objectives', 'introduction/purpose', 'issue', 'issue addressed', 'issues', 'issues addressed', 'issues and purpose', 'learning objective', 'learning objectives', 'learning outcomes', 'main objective', 'main objectives', 'main problem', 'main purpose', 'main topics', 'methods and aims', 'methods and focus', 'methods and objectives', 'null hypothesis', 'object', 'object & method', 'object and background', 'object and design', 'object and method', 'object and methods', 'object of study', 'object of the study', 'object of work', 'objections', 'objective', 'objective & aims', 'objective & design', 'objective & method', 'objective & methods', 'objective and aim', 'objective and background', 'objective and background data', 'objective and design', 'objective and hypothesis', 'objective and importance', 'objective and method', 'objective and methods', 'objective and motivation', 'objective and participants', 'objective and patients', 'objective and purpose', 'objective and rationale', 'objective and results', 'objective and setting', 'objective and study design', 'objective and subjects', 'objective and summary background data', 'objective of program', 'objective of review', 'objective of study', 'objective of the program', 'objective of the study', 'objective(s)', 'objective, design, and setting', 'objective/aim', 'objective/aims', 'objective/background', 'objective/design', 'objective/design/patients', 'objective/goal', 'objective/hypotheses', 'objective/hypothesis', 'objective/method', 'objective/methods', 'objective/patients', 'objective/purpose', 'objective/setting', 'objectives', 'objectives & methods', 'objectives and aim', 'objectives and aims', 'objectives and background', 'objectives and design', 'objectives and goal', 'objectives and hypothesis', 'objectives and method', 'objectives and methods', 'objectives and patients', 'objectives and rationale', 'objectives and results', 'objectives and setting', 'objectives and study design', 'objectives of study', 'objectives of the review', 'objectives of the study', 'objectives, patients and methods', 'objectives/ hypothesis', 'objectives/aim', 'objectives/aims', 'objectives/background', 'objectives/design', 'objectives/goal', 'objectives/hypotheses', 'objectives/hypothesis', 'objectives/methods', 'objectives/purpose', 'objectives/purposes', 'objectives/study design', 'objects', 'objects and methods', 'outline', 'overall article objective', 'overall article objectives', 'paper aim', 'premise', 'premise of study', 'premise of the study', 'presentation of hypothesis', 'presentation of the hypothesis', 'primary objective', 'primary objectives', 'primary purpose', 'primary study objective', 'problem', 'problem addressed', 'problem and background', 'problem and method', 'problem and method of study', 'problem and objective', 'problem and purpose', 'problem assessed', 'problem being addressed', 'problem considered', 'problem identification', 'problem statement', 'problem statement and background', 'problem statement and purpose', 'problem/condition', 'problem/objective', 'problems', 'problems addressed', 'problems and aims', 'problems/objectives', 'purpose', 'purpose & methods', 'purpose and background', 'purpose and design', 'purpose and experimental design', 'purpose and method', 'purpose and methods', 'purpose and objective', 'purpose and objectives', 'purpose and patients', 'purpose and patients and methods', 'purpose and setting', 'purpose of investigation', 'purpose of research', 'purpose of review', 'purpose of study', 'purpose of the investigation', 'purpose of the report', 'purpose of the research', 'purpose of the review', 'purpose of the study', 'purpose of the work', 'purpose of this review', 'purpose of this study', 'purpose, patients, and methods', 'purpose/aim', 'purpose/aim of the study', 'purpose/aims', 'purpose/background', 'purpose/hypothesis', 'purpose/method', 'purpose/methods', 'purpose/objective', 'purpose/objective(s)', 'purpose/objectives', 'purpose/question', 'purposes', 'purposes of the study', 'purposes/objectives', 'quality problem', 'quality problem or issue', 'question', 'question addressed', 'question of the study', 'question under study', 'question/purposes', 'questioning', 'questions', 'questions under study', 'questions under study / principles', 'questions under study/principles', 'questions/hypotheses', 'questions/purpose', 'questions/purposes', 'rational and objective', 'rational and objectives', 'rational, aims and objectives', 'rationale & objective', 'rationale & objectives', 'rationale aims and objectives', 'rationale and aim', 'rationale and aims', 'rationale and aims of the study', 'rationale and goals', 'rationale and hypothesis', 'rationale and objective', 'rationale and objectives', 'rationale and purpose', 'rationale for study', 'rationale for the study', 'rationale for this study', 'rationale objective', 'rationale of the study', 'rationale, aim & objectives', 'rationale, aim and objective', 'rationale, aims and objective', 'rationale, aims and objectives', 'rationale/objectives', 'rationales and objectives', 'reason for performing the study', 'reasons for performing study and objective', 'research objective', 'research objectives', 'research problem', 'research question', 'research questions', 'scientific question', 'scope and purpose', 'scope of the report', 'scope of the review', 'scope of the study', 'secondary objective', 'secondary objectives', 'setting and objective', 'setting and objectives', 'short introduction', 'short summary', 'specific aim', 'specific aims', 'specific objective', 'specific objectives', 'specific research challenge', 'state of the problem', 'statement of purpose', 'study aim', 'study aims', 'study design and objective', 'study design and objectives', 'study goal', 'study goals', 'study hypothesis', 'study object', 'study objective', 'study objectives', 'study purpose', 'study question', 'study questions', 'study rationale', 'study/principles', 'subject objective', 'summary introduction', 'summary objective', 'summary objectives', 'summary of background data and objectives', 'target', 'the aim', 'the aim of our study', 'the aim of study', 'the aim of the paper', 'the aim of the study', 'the aim of the work', 'the aim of this study', 'the aim of this work', 'the aim of work', 'the aims', 'the aims of our study were', 'the goal', 'the hypothesis', 'the issue', 'the main aim of the study', 'the object', 'the objective', 'the primary objective', 'the problem', 'the purpose', 'the purpose of the research', 'the purpose of the study', 'the purpose of this study', 'the research objective', 'the study objective', 'this retrospective study aims', 'topic', 'topic of the study', 'what is known and objective', 'what is known and objectives', 'working hypothesis']\n"
     ]
    }
   ],
   "source": [
    "import pickle\n",
    "from collections import defaultdict\n",
    "\n",
    "normalized_sections = defaultdict(list)\n",
    "with open('structured_abstract_sections.pkl', 'rb') as f:\n",
    "    normalized_sections = pickle.load(f)\n",
    "\n",
    "print(normalized_sections['objective'])  # 檢視內容\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "defaultdict(<class 'list'>, {})\n",
      "[]\n"
     ]
    }
   ],
   "source": [
    "import urllib.request as urllib2\n",
    "import pickle\n",
    "from collections import defaultdict\n",
    "\n",
    "normalized_sections = defaultdict(list)\n",
    "with open('structured_abstract_sections.pkl', 'wb') as file:\n",
    "    pickle.dump(normalized_sections, file)\n",
    "\n",
    "print(normalized_sections)\n",
    "print(list(normalized_sections))\n",
    "anonymous_mapping_dict = defaultdict(str)\n",
    "for section in normalized_sections:\n",
    "    for anonymous in normalized_sections[section]:\n",
    "        if anonymous in anonymous_mapping_dict:\n",
    "            print('Found_mapping_two')\n",
    "        anonymous_mapping_dict[anonymous] = section"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "defaultdict(str,\n",
       "            {'a case report': 'methods',\n",
       "             'acquisition of evidence': 'methods',\n",
       "             'action': 'methods',\n",
       "             'actions': 'methods',\n",
       "             'activities': 'methods',\n",
       "             'admission findings': 'methods',\n",
       "             'ams subject classification': 'methods',\n",
       "             'analyses': 'methods',\n",
       "             'analysis': 'methods',\n",
       "             'analytical approach': 'methods',\n",
       "             'analytical techniques': 'methods',\n",
       "             'anatomy': 'methods',\n",
       "             'anesthesia': 'methods',\n",
       "             'animal': 'methods',\n",
       "             'animal or sample population': 'methods',\n",
       "             'animal population': 'methods',\n",
       "             'animal studied': 'methods',\n",
       "             'animal studies': 'methods',\n",
       "             'animal(s)': 'methods',\n",
       "             'animals': 'methods',\n",
       "             'animals and interventions': 'methods',\n",
       "             'animals and methods': 'methods',\n",
       "             'animals or sample population': 'methods',\n",
       "             'animals studied': 'methods',\n",
       "             'animals, materials and methods': 'methods',\n",
       "             'animals, methods': 'methods',\n",
       "             'approach': 'methods',\n",
       "             'approach and methods': 'methods',\n",
       "             'area covered': 'methods',\n",
       "             'area covered in this review': 'methods',\n",
       "             'areas covered': 'methods',\n",
       "             'areas covered in the review': 'methods',\n",
       "             'areas covered in this review': 'methods',\n",
       "             'article chosen': 'methods',\n",
       "             'article selection': 'methods',\n",
       "             'assessment of problem': 'methods',\n",
       "             'assessment of risk factors': 'methods',\n",
       "             'assessment tools': 'methods',\n",
       "             'assessments': 'methods',\n",
       "             'availability and implementation': 'methods',\n",
       "             'background & materials and methods': 'methods',\n",
       "             'background & method': 'methods',\n",
       "             'background & methods': 'methods',\n",
       "             'background and design': 'methods',\n",
       "             'background and method': 'methods',\n",
       "             'background and methodology': 'methods',\n",
       "             'background and methods': 'methods',\n",
       "             'background and procedure': 'methods',\n",
       "             'background and setting': 'methods',\n",
       "             'background, material and methods': 'methods',\n",
       "             'background, materials and methods': 'methods',\n",
       "             'background/method': 'methods',\n",
       "             'background/methods': 'methods',\n",
       "             'baseline data': 'methods',\n",
       "             'basic design': 'methods',\n",
       "             'basic methods': 'methods',\n",
       "             'basic procedure': 'methods',\n",
       "             'basic procedures': 'methods',\n",
       "             'basic research design': 'methods',\n",
       "             'basic research design and participants': 'methods',\n",
       "             'blinding': 'methods',\n",
       "             'brief description': 'methods',\n",
       "             'cadavers': 'methods',\n",
       "             'calculation': 'methods',\n",
       "             'calculations': 'methods',\n",
       "             'case': 'methods',\n",
       "             'case 1': 'methods',\n",
       "             'case 2': 'methods',\n",
       "             'case and methods': 'methods',\n",
       "             'case characteristics': 'methods',\n",
       "             'case definition': 'methods',\n",
       "             'case description': 'methods',\n",
       "             'case description and methods': 'methods',\n",
       "             'case descriptions': 'methods',\n",
       "             'case details': 'methods',\n",
       "             'case diagnosis/treatment': 'methods',\n",
       "             'case discussion': 'methods',\n",
       "             'case histories': 'methods',\n",
       "             'case history': 'methods',\n",
       "             'case history and clinical findings': 'methods',\n",
       "             'case history and diagnosis': 'methods',\n",
       "             'case history and findings': 'methods',\n",
       "             'case illustration': 'methods',\n",
       "             'case material': 'methods',\n",
       "             'case or series summary': 'methods',\n",
       "             'case outline': 'methods',\n",
       "             'case outlines': 'methods',\n",
       "             'case presentation': 'methods',\n",
       "             'case presentation & methods': 'methods',\n",
       "             'case presentation and intervention': 'methods',\n",
       "             'case presentations': 'methods',\n",
       "             'case record': 'methods',\n",
       "             'case report': 'methods',\n",
       "             'case report and discussion': 'methods',\n",
       "             'case report and method': 'methods',\n",
       "             'case report and methods': 'methods',\n",
       "             'case report/methods': 'methods',\n",
       "             'case reports': 'methods',\n",
       "             'case results': 'methods',\n",
       "             'case review': 'methods',\n",
       "             'case series': 'methods',\n",
       "             'case series summary': 'methods',\n",
       "             'case studies': 'methods',\n",
       "             'case study': 'methods',\n",
       "             'case summaries': 'methods',\n",
       "             'case summary': 'methods',\n",
       "             'case(s)': 'methods',\n",
       "             'case-diagnosis/treatment': 'methods',\n",
       "             'case-report': 'methods',\n",
       "             'case-reports': 'methods',\n",
       "             'cases': 'methods',\n",
       "             'cases & methods': 'methods',\n",
       "             'cases and method': 'methods',\n",
       "             'cases and methods': 'methods',\n",
       "             'cases description': 'methods',\n",
       "             'cases presentation': 'methods',\n",
       "             'cases report': 'methods',\n",
       "             'cases reports': 'methods',\n",
       "             'casuistic & methods': 'methods',\n",
       "             'casuistic and method': 'methods',\n",
       "             'casuistic and methods': 'methods',\n",
       "             'centers': 'methods',\n",
       "             'chemotherapy': 'methods',\n",
       "             'chief outcome measures': 'methods',\n",
       "             'children and methods': 'methods',\n",
       "             'choice of solution': 'methods',\n",
       "             'classification': 'methods',\n",
       "             'classification of evidence': 'methods',\n",
       "             'clinic case': 'methods',\n",
       "             'clinical': 'methods',\n",
       "             'clinical application': 'methods',\n",
       "             'clinical applications': 'methods',\n",
       "             'clinical aspects': 'methods',\n",
       "             'clinical case': 'methods',\n",
       "             'clinical cases': 'methods',\n",
       "             'clinical characteristics': 'methods',\n",
       "             'clinical context': 'methods',\n",
       "             'clinical course': 'methods',\n",
       "             'clinical data': 'methods',\n",
       "             'clinical description': 'methods',\n",
       "             'clinical feature': 'methods',\n",
       "             'clinical features': 'methods',\n",
       "             'clinical history': 'methods',\n",
       "             'clinical investigations': 'methods',\n",
       "             'clinical material': 'methods',\n",
       "             'clinical material and methods': 'methods',\n",
       "             'clinical materials and methods': 'methods',\n",
       "             'clinical observation': 'methods',\n",
       "             'clinical observations': 'methods',\n",
       "             'clinical picture': 'methods',\n",
       "             'clinical presentation': 'methods',\n",
       "             'clinical presentation and intervention': 'methods',\n",
       "             'clinical presentations': 'methods',\n",
       "             'clinical procedure': 'methods',\n",
       "             'clinical question/level of evidence': 'methods',\n",
       "             'clinical report': 'methods',\n",
       "             'clinical scenario': 'methods',\n",
       "             'clinical setting': 'methods',\n",
       "             'clinical settings': 'methods',\n",
       "             'clinical signs': 'methods',\n",
       "             'clinical studies': 'methods',\n",
       "             'clinical study': 'methods',\n",
       "             'clinical symptoms': 'methods',\n",
       "             'cohort': 'methods',\n",
       "             'comparators': 'methods',\n",
       "             'comparison with existing methods': 'methods',\n",
       "             'concept': 'methods',\n",
       "             'conceptual framework': 'methods',\n",
       "             'conference process': 'methods',\n",
       "             'consensus': 'methods',\n",
       "             'consensus position': 'methods',\n",
       "             'consensus process': 'methods',\n",
       "             'consensus statement': 'methods',\n",
       "             'content analysis of literature': 'methods',\n",
       "             'contraindication': 'methods',\n",
       "             'contraindications': 'methods',\n",
       "             'control': 'methods',\n",
       "             'control data': 'methods',\n",
       "             'control group': 'methods',\n",
       "             'controls': 'methods',\n",
       "             'count': 'methods',\n",
       "             'credibility': 'methods',\n",
       "             'criteria': 'methods',\n",
       "             'current data': 'methods',\n",
       "             'data': 'methods',\n",
       "             'data & methods': 'methods',\n",
       "             'data abstraction': 'methods',\n",
       "             'data acquisition': 'methods',\n",
       "             'data analyses': 'methods',\n",
       "             'data analysis': 'methods',\n",
       "             'data analysis method': 'methods',\n",
       "             'data and method': 'methods',\n",
       "             'data and methods': 'methods',\n",
       "             'data and sources': 'methods',\n",
       "             'data capture': 'methods',\n",
       "             'data collected': 'methods',\n",
       "             'data collection': 'methods',\n",
       "             'data collection & analysis': 'methods',\n",
       "             'data collection and analysis': 'methods',\n",
       "             'data collection method': 'methods',\n",
       "             'data collection methods': 'methods',\n",
       "             'data collection/analysis': 'methods',\n",
       "             'data collection/extraction': 'methods',\n",
       "             'data collection/extraction method': 'methods',\n",
       "             'data collection/extraction methods': 'methods',\n",
       "             'data extraction': 'methods',\n",
       "             'data extraction and analysis': 'methods',\n",
       "             'data extraction and data synthesis': 'methods',\n",
       "             'data extraction and synthesis': 'methods',\n",
       "             'data extraction methods': 'methods',\n",
       "             'data extraction/synthesis': 'methods',\n",
       "             'data identification': 'methods',\n",
       "             'data identification and selection': 'methods',\n",
       "             'data quality': 'methods',\n",
       "             'data resources': 'methods',\n",
       "             'data retrieval': 'methods',\n",
       "             'data selection': 'methods',\n",
       "             'data selection and extraction': 'methods',\n",
       "             'data set': 'methods',\n",
       "             'data source': 'methods',\n",
       "             'data source and methods': 'methods',\n",
       "             'data source and selection': 'methods',\n",
       "             'data source and study selection': 'methods',\n",
       "             'data source/study design': 'methods',\n",
       "             'data source/study setting': 'methods',\n",
       "             'data sources': 'methods',\n",
       "             'data sources & selection': 'methods',\n",
       "             'data sources & study setting': 'methods',\n",
       "             'data sources and data extraction': 'methods',\n",
       "             'data sources and extraction': 'methods',\n",
       "             'data sources and methods': 'methods',\n",
       "             'data sources and review methods': 'methods',\n",
       "             'data sources and selection': 'methods',\n",
       "             'data sources and selection criteria': 'methods',\n",
       "             'data sources and setting': 'methods',\n",
       "             'data sources and study design': 'methods',\n",
       "             'data sources and study selection': 'methods',\n",
       "             'data sources and study setting': 'methods',\n",
       "             'data sources and synthesis': 'methods',\n",
       "             'data sources, extraction, and synthesis': 'methods',\n",
       "             'data sources, study selection, and data extraction': 'methods',\n",
       "             'data sources/data collection': 'methods',\n",
       "             'data sources/setting': 'methods',\n",
       "             'data sources/study design': 'methods',\n",
       "             'data sources/study selection': 'methods',\n",
       "             'data sources/study setting': 'methods',\n",
       "             'data sources/study settings': 'methods',\n",
       "             'data sources/synthesis': 'methods',\n",
       "             'data summary': 'methods',\n",
       "             'data syntheses': 'methods',\n",
       "             'data synthesis/methods': 'methods',\n",
       "             'database': 'methods',\n",
       "             'databases': 'methods',\n",
       "             'databases used': 'methods',\n",
       "             'date sources': 'methods',\n",
       "             'demographics': 'methods',\n",
       "             'dependent measures': 'methods',\n",
       "             'dependent variable': 'methods',\n",
       "             'dependent variables': 'methods',\n",
       "             'description': 'methods',\n",
       "             'description of case': 'methods',\n",
       "             'description of cases': 'methods',\n",
       "             'description of course': 'methods',\n",
       "             'description of instrumentation': 'methods',\n",
       "             'description of policy practice': 'methods',\n",
       "             'description of program': 'methods',\n",
       "             'description of project': 'methods',\n",
       "             'description of study': 'methods',\n",
       "             'description of system': 'methods',\n",
       "             'description of systems': 'methods',\n",
       "             'description of technique': 'methods',\n",
       "             'description of technology/therapy': 'methods',\n",
       "             'description of the case': 'methods',\n",
       "             'description of the project': 'methods',\n",
       "             'description of the project/innovation': 'methods',\n",
       "             'description of the study': 'methods',\n",
       "             'description of the system': 'methods',\n",
       "             'descriptions': 'methods',\n",
       "             'design': 'methods',\n",
       "             'design & definition': 'methods',\n",
       "             'design & intervention': 'methods',\n",
       "             'design & method': 'methods',\n",
       "             'design & methodology': 'methods',\n",
       "             'design & methods': 'methods',\n",
       "             'design & participants': 'methods',\n",
       "             'design & setting': 'methods',\n",
       "             'design & subjects': 'methods',\n",
       "             'design and analysis': 'methods',\n",
       "             'design and data sources': 'methods',\n",
       "             'design and intervention': 'methods',\n",
       "             'design and interventions': 'methods',\n",
       "             'design and main outcome measures': 'methods',\n",
       "             'design and materials': 'methods',\n",
       "             'design and measurement': 'methods',\n",
       "             'design and measurements': 'methods',\n",
       "             'design and measures': 'methods',\n",
       "             'design and method': 'methods',\n",
       "             'design and methodology': 'methods',\n",
       "             'design and methods': 'methods',\n",
       "             'design and outcome measures': 'methods',\n",
       "             'design and participants': 'methods',\n",
       "             'design and patient': 'methods',\n",
       "             'design and patients': 'methods',\n",
       "             'design and population': 'methods',\n",
       "             'design and procedure': 'methods',\n",
       "             'design and procedures': 'methods',\n",
       "             'design and sample': 'methods',\n",
       "             'design and scope': 'methods',\n",
       "             'design and setting': 'methods',\n",
       "             'design and settings': 'methods',\n",
       "             'design and study participants': 'methods',\n",
       "             'design and study population': 'methods',\n",
       "             'design and study sample': 'methods',\n",
       "             'design and study subjects': 'methods',\n",
       "             'design and subjects': 'methods',\n",
       "             'design and volunteers': 'methods',\n",
       "             'design classification': 'methods',\n",
       "             'design methods': 'methods',\n",
       "             'design of study': 'methods',\n",
       "             'design of the study': 'methods',\n",
       "             'design setting': 'methods',\n",
       "             'design setting and participants': 'methods',\n",
       "             'design setting and subjects': 'methods',\n",
       "             'design study': 'methods',\n",
       "             'design(s)': 'methods',\n",
       "             'design, interventions, and main outcome measures': 'methods',\n",
       "             'design, material and methods': 'methods',\n",
       "             'design, materials & methods': 'methods',\n",
       "             'design, materials and methods': 'methods',\n",
       "             'design, materials, and methods': 'methods',\n",
       "             'design, participants': 'methods',\n",
       "             'design, participants and measurements': 'methods',\n",
       "             'design, participants and setting': 'methods',\n",
       "             'design, participants, & measurements': 'methods',\n",
       "             'design, participants, and intervention': 'methods',\n",
       "             'design, participants, and interventions': 'methods',\n",
       "             'design, participants, and measures': 'methods',\n",
       "             'design, participants, and methods': 'methods',\n",
       "             'design, participants, and setting': 'methods',\n",
       "             'design, participants, measurements': 'methods',\n",
       "             'design, patients': 'methods',\n",
       "             'design, patients and measurements': 'methods',\n",
       "             'design, patients and methods': 'methods',\n",
       "             'design, patients and setting': 'methods',\n",
       "             'design, patients, & setting': 'methods',\n",
       "             'design, patients, and interventions': 'methods',\n",
       "             'design, patients, and main outcome measures': 'methods',\n",
       "             'design, patients, and methods': 'methods',\n",
       "             'design, patients, and setting': 'methods',\n",
       "             'design, patients, measurements': 'methods',\n",
       "             'design, setting': 'methods',\n",
       "             'design, setting & participants': 'methods',\n",
       "             'design, setting & patients': 'methods',\n",
       "             'design, setting and methods': 'methods',\n",
       "             'design, setting and participants': 'methods',\n",
       "             'design, setting and patients': 'methods',\n",
       "             'design, setting and subjects': 'methods',\n",
       "             'design, setting participants, & measurements': 'methods',\n",
       "             'design, setting, and methods': 'methods',\n",
       "             'design, setting, and participants': 'methods',\n",
       "             'design, setting, and patient': 'methods',\n",
       "             'design, setting, and patients': 'methods',\n",
       "             'design, setting, and population': 'methods',\n",
       "             'design, setting, and subjects': 'methods',\n",
       "             'design, setting, participants': 'methods',\n",
       "             'design, setting, participants & measurements': 'methods',\n",
       "             'design, setting, participants and intervention': 'methods',\n",
       "             'design, setting, participants and interventions': 'methods',\n",
       "             'design, setting, participants and measurements': 'methods',\n",
       "             'design, setting, participants, & measurements': 'methods',\n",
       "             'design, setting, participants, & methods': 'methods',\n",
       "             'design, setting, participants, & objectives': 'methods',\n",
       "             'design, setting, participants, and intervention': 'methods',\n",
       "             'design, setting, participants, and interventions': 'methods',\n",
       "             'design, setting, participants, and main outcome measures': 'methods',\n",
       "             'design, setting, participants, and measurements': 'methods',\n",
       "             'design, setting, participants, and measures': 'methods',\n",
       "             'design, setting, participants, measurements': 'methods',\n",
       "             'design, setting, patients': 'methods',\n",
       "             'design, setting, patients, and intervention': 'methods',\n",
       "             'design, setting, patients, and main outcome measure': 'methods',\n",
       "             'design, setting, patients, interventions': 'methods',\n",
       "             'design, setting, subjects': 'methods',\n",
       "             'design, settings and participants': 'methods',\n",
       "             'design, settings, and participants': 'methods',\n",
       "             'design, settings, and patients': 'methods',\n",
       "             'design, settings, and subjects': 'methods',\n",
       "             'design, settings, participants, & measurements': 'methods',\n",
       "             'design, settings, participants, & methods': 'methods',\n",
       "             'design, subjects and intervention': 'methods',\n",
       "             'design, subjects and measurements': 'methods',\n",
       "             'design, subjects and methods': 'methods',\n",
       "             'design, subjects and setting': 'methods',\n",
       "             'design, subjects, and intervention': 'methods',\n",
       "             'design, subjects, and setting': 'methods',\n",
       "             'design/intervention': 'methods',\n",
       "             'design/interventions': 'methods',\n",
       "             'design/measurements': 'methods',\n",
       "             'design/method': 'methods',\n",
       "             'design/method/approach': 'methods',\n",
       "             'design/methodology': 'methods',\n",
       "             'design/methodology/approach': 'methods',\n",
       "             'design/methods': 'methods',\n",
       "             'design/outcome measures': 'methods',\n",
       "             'design/participants': 'methods',\n",
       "             'design/participants/setting': 'methods',\n",
       "             'design/patients': 'methods',\n",
       "             'design/patients/measurements': 'methods',\n",
       "             'design/sample': 'methods',\n",
       "             'design/setting': 'methods',\n",
       "             'design/setting/participants': 'methods',\n",
       "             'design/setting/participants/measurements': 'methods',\n",
       "             'design/setting/patients': 'methods',\n",
       "             'design/setting/subjects': 'methods',\n",
       "             'design/subjects': 'methods',\n",
       "             'designs': 'methods',\n",
       "             'designs and methods': 'methods',\n",
       "             'developing recommendations': 'methods',\n",
       "             'development': 'methods',\n",
       "             'devices': 'methods',\n",
       "             'diabetes strategy evidence platform': 'methods',\n",
       "             'diagnosis': 'methods',\n",
       "             'diagnosis and course': 'methods',\n",
       "             'diagnosis and management': 'methods',\n",
       "             'diagnosis and therapy': 'methods',\n",
       "             'diagnosis and treatment': 'methods',\n",
       "             'diagnosis, therapy and clinical course': 'methods',\n",
       "             'diagnosis, therapy and course': 'methods',\n",
       "             'diagnosis, treatment and clinical course': 'methods',\n",
       "             'diagnosis, treatment and course': 'methods',\n",
       "             'diagnostic': 'methods',\n",
       "             'diagnostic methods': 'methods',\n",
       "             'diagnostic procedures': 'methods',\n",
       "             'diagnostic test': 'methods',\n",
       "             'diagnostic tests': 'methods',\n",
       "             'diagnostic work-up': 'methods',\n",
       "             'diagnostics': 'methods',\n",
       "             'differential diagnosis': 'methods',\n",
       "             'disease management': 'methods',\n",
       "             'disease signs': 'methods',\n",
       "             'disease symptoms': 'methods',\n",
       "             'donors and methods': 'methods',\n",
       "             'duration': 'methods',\n",
       "             'ebm rating': 'methods',\n",
       "             'economic analysis': 'methods',\n",
       "             'eligibility criteria': 'methods',\n",
       "             'eligibility criteria for included studies': 'methods',\n",
       "             'eligibility criteria for selecting studies': 'methods',\n",
       "             'emplacement': 'methods',\n",
       "             'end point': 'methods',\n",
       "             'end points': 'methods',\n",
       "             'endpoint': 'methods',\n",
       "             'endpoints': 'methods',\n",
       "             'environment': 'methods',\n",
       "             'equipment': 'methods',\n",
       "             'equipment and methods': 'methods',\n",
       "             'ethical issues': 'methods',\n",
       "             'ethical issues and approval': 'methods',\n",
       "             'ethics': 'methods',\n",
       "             'evaluation design': 'methods',\n",
       "             'evaluation method': 'methods',\n",
       "             'evaluation methods': 'methods',\n",
       "             'evaluations': 'methods',\n",
       "             'evaluations/measurements': 'methods',\n",
       "             'evidence': 'methods',\n",
       "             'evidence acquisition': 'methods',\n",
       "             'evidence acquisition and synthesis': 'methods',\n",
       "             'evidence acquisitions': 'methods',\n",
       "             'evidence and consensus process': 'methods',\n",
       "             'evidence and information sources': 'methods',\n",
       "             'evidence base': 'methods',\n",
       "             'evidence level': 'methods',\n",
       "             'evidence review': 'methods',\n",
       "             'evidence summary': 'methods',\n",
       "             'evidence-based analysis methods': 'methods',\n",
       "             'examinees and methods': 'methods',\n",
       "             'exclusion criteria': 'methods',\n",
       "             'exclusions': 'methods',\n",
       "             'exegese': 'methods',\n",
       "             'exegesis': 'methods',\n",
       "             'experiment': 'methods',\n",
       "             'experiment design': 'methods',\n",
       "             'experimental': 'methods',\n",
       "             'experimental animals': 'methods',\n",
       "             'experimental approach': 'methods',\n",
       "             'experimental approaches': 'methods',\n",
       "             'experimental design': 'methods',\n",
       "             'experimental designs': 'methods',\n",
       "             'experimental intervention': 'methods',\n",
       "             'experimental interventions': 'methods',\n",
       "             'experimental material': 'methods',\n",
       "             'experimental materials': 'methods',\n",
       "             'experimental methods': 'methods',\n",
       "             'experimental procedure': 'methods',\n",
       "             'experimental procedures': 'methods',\n",
       "             'experimental protocol': 'methods',\n",
       "             'experimental studies': 'methods',\n",
       "             'experimental subjects': 'methods',\n",
       "             'experimental variable': 'methods',\n",
       "             'experimental variables': 'methods',\n",
       "             'experiments': 'methods',\n",
       "             'exposure': 'methods',\n",
       "             'exposure measures': 'methods',\n",
       "             'exposures': 'methods',\n",
       "             'extraction': 'methods',\n",
       "             'extraction methods': 'methods',\n",
       "             'facility': 'methods',\n",
       "             'factor': 'methods',\n",
       "             'factors': 'methods',\n",
       "             'features': 'methods',\n",
       "             'final diagnosis': 'methods',\n",
       "             'first case': 'methods',\n",
       "             'format': 'methods',\n",
       "             'framework': 'methods',\n",
       "             'general methods': 'methods',\n",
       "             'group and methods': 'methods',\n",
       "             'group of patients and methods': 'methods',\n",
       "             'history': 'methods',\n",
       "             'history and admission findings': 'methods',\n",
       "             'history and clinical data': 'methods',\n",
       "             'history and clinical finding': 'methods',\n",
       "             'history and clinical findings': 'methods',\n",
       "             'history and clinical presentation': 'methods',\n",
       "             'history and clinically findings': 'methods',\n",
       "             'history and examination': 'methods',\n",
       "             'history and findings': 'methods',\n",
       "             'history and findings on admission': 'methods',\n",
       "             'history and general investigations': 'methods',\n",
       "             'history and physical examination': 'methods',\n",
       "             'history and physical findings': 'methods',\n",
       "             'history and presenting complaint': 'methods',\n",
       "             'history and reason for admission': 'methods',\n",
       "             'history and signs': 'methods',\n",
       "             'host range': 'methods',\n",
       "             'identification': 'methods',\n",
       "             'illustrative case': 'methods',\n",
       "             'illustrative cases': 'methods',\n",
       "             'imaging': 'methods',\n",
       "             'implementation': 'methods',\n",
       "             'in vitro studies': 'methods',\n",
       "             'in vivo studies': 'methods',\n",
       "             'included studies': 'methods',\n",
       "             'inclusion': 'methods',\n",
       "             'inclusion & exclusion criteria': 'methods',\n",
       "             'inclusion & exclusions': 'methods',\n",
       "             'inclusion and exclusion criteria': 'methods',\n",
       "             'inclusion criteria': 'methods',\n",
       "             'independent variable': 'methods',\n",
       "             'independent variables': 'methods',\n",
       "             'index test': 'methods',\n",
       "             'index tests': 'methods',\n",
       "             'indication': 'methods',\n",
       "             'indications': 'methods',\n",
       "             'individuals': 'methods',\n",
       "             'individuals and methods': 'methods',\n",
       "             'infants and methods': 'methods',\n",
       "             'information sources': 'methods',\n",
       "             'initial assessment': 'methods',\n",
       "             'injury patterns': 'methods',\n",
       "             'innovation': 'methods',\n",
       "             'institution': 'methods',\n",
       "             'instrument': 'methods',\n",
       "             'instrumentation': 'methods',\n",
       "             'instruments': 'methods',\n",
       "             'instruments and methods': 'methods',\n",
       "             'intervention': 'methods',\n",
       "             'intervention & measurements': 'methods',\n",
       "             'intervention and main outcome measure': 'methods',\n",
       "             'intervention and main outcome measures': 'methods',\n",
       "             'intervention and measurements': 'methods',\n",
       "             'intervention and methods': 'methods',\n",
       "             'intervention and outcome measures': 'methods',\n",
       "             'intervention and technique': 'methods',\n",
       "             'intervention and testing': 'methods',\n",
       "             'intervention(s)': 'methods',\n",
       "             'intervention(s) and main outcome measure(s)': 'methods',\n",
       "             'intervention/methods': 'methods',\n",
       "             'intervention/technique': 'methods',\n",
       "             'interventions': 'methods',\n",
       "             'interventions and main outcome measurements': 'methods',\n",
       "             'interventions and main outcome measures': 'methods',\n",
       "             'interventions and measurements': 'methods',\n",
       "             'interventions and methods': 'methods',\n",
       "             'interventions and outcome measures': 'methods',\n",
       "             'interventions(s)': 'methods',\n",
       "             'interventions/methods': 'methods',\n",
       "             'introduction and clinical case': 'methods',\n",
       "             'introduction and clinical cases': 'methods',\n",
       "             'introduction and method': 'methods',\n",
       "             'introduction and methodology': 'methods',\n",
       "             'introduction and methods': 'methods',\n",
       "             'introduction/methods': 'methods',\n",
       "             'investigated group': 'methods',\n",
       "             'investigation': 'methods',\n",
       "             'investigation and diagnosis': 'methods',\n",
       "             'investigation(s)': 'methods',\n",
       "             'investigations': 'methods',\n",
       "             'investigations and diagnosis': 'methods',\n",
       "             'investigations and treatment': 'methods',\n",
       "             'investigations, diagnosis and treatment': 'methods',\n",
       "             'investigations, treatment and course': 'methods',\n",
       "             'key exposure/study factor': 'methods',\n",
       "             'key measures': 'methods',\n",
       "             'key measures for improvement': 'methods',\n",
       "             'key risk/study factor': 'methods',\n",
       "             'key study factor': 'methods',\n",
       "             'laboratory tests': 'methods',\n",
       "             'level iii': 'methods',\n",
       "             'level of clinical evidence': 'methods',\n",
       "             'level of evidence': 'methods',\n",
       "             'level of evidence i': 'methods',\n",
       "             'level of evidence ii': 'methods',\n",
       "             'level of evidence iii': 'methods',\n",
       "             'level of evidence iv': 'methods',\n",
       "             'level of evidence v': 'methods',\n",
       "             'level of proof': 'methods',\n",
       "             'levels of evidence': 'methods',\n",
       "             'literature': 'methods',\n",
       "             'literature review': 'methods',\n",
       "             'literature reviewed': 'methods',\n",
       "             'literature search': 'methods',\n",
       "             'literature survey': 'methods',\n",
       "             'local setting': 'methods',\n",
       "             'location': 'methods',\n",
       "             'locations': 'methods',\n",
       "             'main components of program': 'methods',\n",
       "             'main exposure': 'methods',\n",
       "             'main exposure measure': 'methods',\n",
       "             'main exposure measures': 'methods',\n",
       "             'main exposures': 'methods',\n",
       "             'main features': 'methods',\n",
       "             'main independent variables': 'methods',\n",
       "             'main measure': 'methods',\n",
       "             'main measurement': 'methods',\n",
       "             'main measurements': 'methods',\n",
       "             'main measures': 'methods',\n",
       "             'main method': 'methods',\n",
       "             'main methods': 'methods',\n",
       "             'main observation': 'methods',\n",
       "             'main observations': 'methods',\n",
       "             'main observations and results': 'methods',\n",
       "             'main outcome and measure': 'methods',\n",
       "             'main outcome and measurements': 'methods',\n",
       "             'main outcome and measures': 'methods',\n",
       "             'main outcome criteria': 'methods',\n",
       "             'main outcome measure': 'methods',\n",
       "             'main outcome measure(s)': 'methods',\n",
       "             'main outcome measured': 'methods',\n",
       "             'main outcome measurement': 'methods',\n",
       "             'main outcome measurement(s)': 'methods',\n",
       "             'main outcome measurements': 'methods',\n",
       "             'main outcome measures': 'methods',\n",
       "             'main outcome measures and methods': 'methods',\n",
       "             'main outcome measures(s)': 'methods',\n",
       "             'main outcome methods': 'methods',\n",
       "             'main outcome parameters': 'methods',\n",
       "             'main outcome variable': 'methods',\n",
       "             'main outcome variables': 'methods',\n",
       "             'main outcomes and measure': 'methods',\n",
       "             'main outcomes and measures': 'methods',\n",
       "             'main outcomes measure': 'methods',\n",
       "             'main outcomes measure(s)': 'methods',\n",
       "             'main outcomes measured': 'methods',\n",
       "             'main outcomes measurements': 'methods',\n",
       "             'main outcomes measures': 'methods',\n",
       "             'main research classifications': 'methods',\n",
       "             'main research variable': 'methods',\n",
       "             'main research variables': 'methods',\n",
       "             'main study measures': 'methods',\n",
       "             'main variables': 'methods',\n",
       "             'main variables examined': 'methods',\n",
       "             'main variables of interest': 'methods',\n",
       "             'main variables studied': 'methods',\n",
       "             'major outcome measures': 'methods',\n",
       "             'material': 'methods',\n",
       "             'material & method': 'methods',\n",
       "             'material & methods': 'methods',\n",
       "             'material and method': 'methods',\n",
       "             'material and methodology': 'methods',\n",
       "             'material and methods': 'methods',\n",
       "             'material and patients': 'methods',\n",
       "             'material and subjects': 'methods',\n",
       "             'material and surgical technique': 'methods',\n",
       "             'material and treatment': 'methods',\n",
       "             'material method': 'methods',\n",
       "             'material methods': 'methods',\n",
       "             'material of study': 'methods',\n",
       "             'material or subjects': 'methods',\n",
       "             'material, methods': 'methods',\n",
       "             'material, patients and methods': 'methods',\n",
       "             'material-method': 'methods',\n",
       "             'material-methods': 'methods',\n",
       "             'material/method': 'methods',\n",
       "             'material/methods': 'methods',\n",
       "             'material/patients & methods': 'methods',\n",
       "             'material/subjects and methods': 'methods',\n",
       "             'materials': 'methods',\n",
       "             'materials & method': 'methods',\n",
       "             'materials & methodology': 'methods',\n",
       "             'materials & methods': 'methods',\n",
       "             'materials and  methods': 'methods',\n",
       "             'materials and interventions': 'methods',\n",
       "             'materials and materials': 'methods',\n",
       "             'materials and method': 'methods',\n",
       "             'materials and methodology': 'methods',\n",
       "             'materials and methods': 'methods',\n",
       "             'materials and patients': 'methods',\n",
       "             'materials and subjects': 'methods',\n",
       "             'materials and surgical technique': 'methods',\n",
       "             'materials and treatment': 'methods',\n",
       "             'materials methods': 'methods',\n",
       "             'materials of study': 'methods',\n",
       "             'materials or subjects': 'methods',\n",
       "             'materials, methods': 'methods',\n",
       "             'materials, setting and methods': 'methods',\n",
       "             'materials, setting, methods': 'methods',\n",
       "             'materials-methods': 'methods',\n",
       "             'materials/method': 'methods',\n",
       "             'materials/methods': 'methods',\n",
       "             'materials/patients and methods': 'methods',\n",
       "             'materials/subjects and methods': 'methods',\n",
       "             'mean outcome measure': 'methods',\n",
       "             'mean outcome measure(s)': 'methods',\n",
       "             'mean outcome measures': 'methods',\n",
       "             'measure': 'methods',\n",
       "             'measurement': 'methods',\n",
       "             'measurement & outcomes': 'methods',\n",
       "             'measurements': 'methods',\n",
       "             'measurements & outcomes': 'methods',\n",
       "             'measurements and analysis': 'methods',\n",
       "             'measurements and interventions': 'methods',\n",
       "             'measurements and methods': 'methods',\n",
       "             'measurements and outcomes': 'methods',\n",
       "             'measures': 'methods',\n",
       "             'measures and analysis': 'methods',\n",
       "             'measures of outcome': 'methods',\n",
       "             'measurments': 'methods',\n",
       "             'medical history': 'methods',\n",
       "             'medical treatment': 'methods',\n",
       "             'medication': 'methods',\n",
       "             'method': 'methods',\n",
       "             'method & material': 'methods',\n",
       "             'method & materials': 'methods',\n",
       "             'method & procedures': 'methods',\n",
       "             'method and analysis': 'methods',\n",
       "             'method and clinical material': 'methods',\n",
       "             'method and design': 'methods',\n",
       "             'method and material': 'methods',\n",
       "             'method and materials': 'methods',\n",
       "             'method and participants': 'methods',\n",
       "             'method and patients': 'methods',\n",
       "             'method and procedure': 'methods',\n",
       "             'method and procedures': 'methods',\n",
       "             'method and sample': 'methods',\n",
       "             'method and subjects': 'methods',\n",
       "             'method of approach': 'methods',\n",
       "             'method of study': 'methods',\n",
       "             'method of study selection': 'methods',\n",
       "             'method summary': 'methods',\n",
       "             'method(s)': 'methods',\n",
       "             'method/design': 'methods',\n",
       "             'method/materials': 'methods',\n",
       "             'method/patients': 'methods',\n",
       "             'methodical innovations': 'methods',\n",
       "             'methodologic approach': 'methods',\n",
       "             'methodological approach': 'methods',\n",
       "             'methodological design': 'methods',\n",
       "             'methodological design and justification': 'methods',\n",
       "             'methodological procedures': 'methods',\n",
       "             'methodological quality': 'methods',\n",
       "             'methodologies': 'methods',\n",
       "             'methodology': 'methods',\n",
       "             'methodology and patients': 'methods',\n",
       "             'methodology and sample': 'methods',\n",
       "             'methodology/approach': 'methods',\n",
       "             'methods': 'methods',\n",
       "             'methods & design': 'methods',\n",
       "             'methods & material': 'methods',\n",
       "             'methods & materials': 'methods',\n",
       "             'methods & outcome measures': 'methods',\n",
       "             'methods & patients': 'methods',\n",
       "             'methods & procedure': 'methods',\n",
       "             'methods & procedures': 'methods',\n",
       "             'methods & study design': 'methods',\n",
       "             'methods - data sources': 'methods',\n",
       "             'methods - study selection': 'methods',\n",
       "             'methods / design': 'methods',\n",
       "             'methods and analyses': 'methods',\n",
       "             'methods and analysis': 'methods',\n",
       "             'methods and approach': 'methods',\n",
       "             'methods and data': 'methods',\n",
       "             'methods and design': 'methods',\n",
       "             'methods and interventions': 'methods',\n",
       "             'methods and main outcome measures': 'methods',\n",
       "             'methods and main outcomes': 'methods',\n",
       "             'methods and material': 'methods',\n",
       "             'methods and materials': 'methods',\n",
       "             'methods and measurements': 'methods',\n",
       "             'methods and measures': 'methods',\n",
       "             'methods and methods': 'methods',\n",
       "             'methods and outcome measures': 'methods',\n",
       "             'methods and outcomes': 'methods',\n",
       "             'methods and participants': 'methods',\n",
       "             'methods and patients': 'methods',\n",
       "             'methods and population': 'methods',\n",
       "             'methods and procedure': 'methods',\n",
       "             'methods and procedures': 'methods',\n",
       "             'methods and sample': 'methods',\n",
       "             'methods and setting': 'methods',\n",
       "             'methods and study design': 'methods',\n",
       "             'methods and subjects': 'methods',\n",
       "             'methods and technique': 'methods',\n",
       "             'methods design': 'methods',\n",
       "             'methods of analysis': 'methods',\n",
       "             'methods of study': 'methods',\n",
       "             'methods of study selection': 'methods',\n",
       "             'methods used': 'methods',\n",
       "             'methods/description': 'methods',\n",
       "             'methods/design': 'methods',\n",
       "             'methods/designs': 'methods',\n",
       "             'methods/literature reviewed': 'methods',\n",
       "             'methods/materials': 'methods',\n",
       "             'methods/patients': 'methods',\n",
       "             'methods/sample': 'methods',\n",
       "             'methods/setting': 'methods',\n",
       "             'methods/study design': 'methods',\n",
       "             'methods/subjects': 'methods',\n",
       "             'model': 'methods',\n",
       "             'model & outcomes': 'methods',\n",
       "             'model description': 'methods',\n",
       "             'model, perspective, & time frame': 'methods',\n",
       "             'model, perspective, & timeframe': 'methods',\n",
       "             'models': 'methods',\n",
       "             'new method': 'methods',\n",
       "             'new methods': 'methods',\n",
       "             'no level assigned': 'methods',\n",
       "             'numbers': 'methods',\n",
       "             'observation': 'methods',\n",
       "             'observation procedure': 'methods',\n",
       "             'observation procedures': 'methods',\n",
       "             'observational procedure': 'methods',\n",
       "             'observations': 'methods',\n",
       "             'operations': 'methods',\n",
       "             'operative procedure': 'methods',\n",
       "             'operative technique': 'methods',\n",
       "             'opportunities': 'methods',\n",
       "             'options': 'methods',\n",
       "             'options and outcomes': 'methods',\n",
       "             'organization': 'methods',\n",
       "             'organizing construct': 'methods',\n",
       "             'organizing construct and methods': 'methods',\n",
       "             'organizing framework': 'methods',\n",
       "             'origins of information': 'methods',\n",
       "             'other measurements': 'methods',\n",
       "             'other participants': 'methods',\n",
       "             'outcome & measurement': 'methods',\n",
       "             'outcome & measurements': 'methods',\n",
       "             'outcome & measures': 'methods',\n",
       "             'outcome assessment': 'methods',\n",
       "             'outcome measure': 'methods',\n",
       "             'outcome measure(s)': 'methods',\n",
       "             'outcome measured': 'methods',\n",
       "             'outcome measurement': 'methods',\n",
       "             'outcome measurements': 'methods',\n",
       "             'outcome measurements and statistical analysis': 'methods',\n",
       "             'outcome measures': 'methods',\n",
       "             'outcome parameters': 'methods',\n",
       "             'outcome variable': 'methods',\n",
       "             'outcome variables': 'methods',\n",
       "             'outcomes & measurement': 'methods',\n",
       "             'outcomes & measurements': 'methods',\n",
       "             'outcomes & measures': 'methods',\n",
       "             'outcomes & other measurements': 'methods',\n",
       "             'outcomes and measurements': 'methods',\n",
       "             'outcomes assessment': 'methods',\n",
       "             'outcomes measure': 'methods',\n",
       "             'outcomes measured': 'methods',\n",
       "             'outcomes measures': 'methods',\n",
       "             'outcomes of interest': 'methods',\n",
       "             'outline of cases': 'methods',\n",
       "             'overall approach to quality and safety': 'methods',\n",
       "             'overall strength of evidence': 'methods',\n",
       "             'parameters': 'methods',\n",
       "             'participant': 'methods',\n",
       "             'participant(s)': 'methods',\n",
       "             'participants': 'methods',\n",
       "             'participants & setting': 'methods',\n",
       "             'participants & settings': 'methods',\n",
       "             'participants and context': 'methods',\n",
       "             'participants and controls': 'methods',\n",
       "             'participants and design': 'methods',\n",
       "             'participants and intervention': 'methods',\n",
       "             'participants and interventions': 'methods',\n",
       "             'participants and main outcome measures': 'methods',\n",
       "             'participants and measurements': 'methods',\n",
       "             'participants and measures': 'methods',\n",
       "             'participants and method': 'methods',\n",
       "             'participants and methods': 'methods',\n",
       "             'participants and outcome measures': 'methods',\n",
       "             'participants and patients': 'methods',\n",
       "             'participants and setting': 'methods',\n",
       "             'participants and settings': 'methods',\n",
       "             'participants and/or controls': 'methods',\n",
       "             'participants or samples': 'methods',\n",
       "             'participants, design and setting': 'methods',\n",
       "             'participants, design, and setting': 'methods',\n",
       "             'participants, setting and methods': 'methods',\n",
       "             'participants, setting, methods': 'methods',\n",
       "             'participants/intervention': 'methods',\n",
       "             'participants/interventions': 'methods',\n",
       "             'participants/material, setting, methods': 'methods',\n",
       "             'participants/materials, setting and methods': 'methods',\n",
       "             'participants/materials, setting, and methods': 'methods',\n",
       "             'participants/materials, setting, methods': 'methods',\n",
       "             'participants/materials, settings, methods': 'methods',\n",
       "             'participants/methods': 'methods',\n",
       "             'participants/patients': 'methods',\n",
       "             'participants/setting': 'methods',\n",
       "             'participants/settings': 'methods',\n",
       "             'participation': 'methods',\n",
       "             'pathogenesis': 'methods',\n",
       "             'pathology': 'methods',\n",
       "             'pathophysiology': 'methods',\n",
       "             'patient': 'methods',\n",
       "             'patient & method': 'methods',\n",
       "             'patient & methods': 'methods',\n",
       "             'patient and intervention': 'methods',\n",
       "             'patient and method': 'methods',\n",
       "             'patient and methods': 'methods',\n",
       "             'patient case': 'methods',\n",
       "             'patient characteristics': 'methods',\n",
       "             'patient description': 'methods',\n",
       "             'patient findings': 'methods',\n",
       "             'patient group': 'methods',\n",
       "             'patient history': 'methods',\n",
       "             'patient material': 'methods',\n",
       "             'patient population': 'methods',\n",
       "             'patient population and methods': 'methods',\n",
       "             'patient presentation': 'methods',\n",
       "             'patient report': 'methods',\n",
       "             'patient sample': 'methods',\n",
       "             'patient sample and methodology': 'methods',\n",
       "             'patient samples': 'methods',\n",
       "             'patient selection': 'methods',\n",
       "             'patient(s)': 'methods',\n",
       "             'patient(s) and animal(s)': 'methods',\n",
       "             'patient(s) and intervention(s)': 'methods',\n",
       "             'patient, methods and results': 'methods',\n",
       "             'patient/method': 'methods',\n",
       "             'patient/methods': 'methods',\n",
       "             'patient/participants': 'methods',\n",
       "             'patients': 'methods',\n",
       "             'patients & method': 'methods',\n",
       "             'patients & methods': 'methods',\n",
       "             'patients & setting': 'methods',\n",
       "             'patients (or participants)': 'methods',\n",
       "             'patients and control subjects': 'methods',\n",
       "             'patients and controls': 'methods',\n",
       "             'patients and design': 'methods',\n",
       "             'patients and intervention': 'methods',\n",
       "             'patients and interventions': 'methods',\n",
       "             'patients and main outcome measurements': 'methods',\n",
       "             'patients and main outcome measures': 'methods',\n",
       "             'patients and material': 'methods',\n",
       "             'patients and materials': 'methods',\n",
       "             'patients and measurements': 'methods',\n",
       "             'patients and method': 'methods',\n",
       "             'patients and methodology': 'methods',\n",
       "             'patients and methods': 'methods',\n",
       "             'patients and other participants': 'methods',\n",
       "             'patients and others participants': 'methods',\n",
       "             'patients and outcome measures': 'methods',\n",
       "             'patients and participants': 'methods',\n",
       "             'patients and setting': 'methods',\n",
       "             'patients and settings': 'methods',\n",
       "             'patients and study design': 'methods',\n",
       "             'patients and subjects': 'methods',\n",
       "             'patients and technique': 'methods',\n",
       "             'patients and techniques': 'methods',\n",
       "             'patients and treatment': 'methods',\n",
       "             'patients or materials': 'methods',\n",
       "             'patients or other participants': 'methods',\n",
       "             'patients or others participants': 'methods',\n",
       "             'patients or participants': 'methods',\n",
       "             'patients participants': 'methods',\n",
       "             'patients(s)': 'methods',\n",
       "             'patients, design, and setting': 'methods',\n",
       "             'patients, material and methods': 'methods',\n",
       "             'patients, material, methods': 'methods',\n",
       "             'patients, materials and methods': 'methods',\n",
       "             'patients, materials, and methods': 'methods',\n",
       "             'patients, method': 'methods',\n",
       "             'patients, methods': 'methods',\n",
       "             'patients, participants': 'methods',\n",
       "             'patients, subjects and methods': 'methods',\n",
       "             'patients--methods': 'methods',\n",
       "             'patients-methods': 'methods',\n",
       "             'patients/design': 'methods',\n",
       "             'patients/intervention': 'methods',\n",
       "             'patients/interventions': 'methods',\n",
       "             ...})"
      ]
     },
     "execution_count": 1,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from collections import defaultdict\n",
    "import pickle\n",
    "\n",
    "# anonymous_mapping_dict = defaultdict(str)\n",
    "\n",
    "# for section in normalized_sections:\n",
    "#     for anonymous in normalized_sections[section]:\n",
    "#         anonymous_mapping_dict[anonymous] = section\n",
    "\n",
    "# anonymous_mapping_dict\n",
    "\n",
    "# with open('anonymous_mapping_dict.pkl', 'wb') as file:\n",
    "#     pickle.dump(anonymous_mapping_dict, file)\n",
    "\n",
    "with open('anonymous_mapping_dict.pkl', 'rb') as f:\n",
    "    anonymous_mapping_dict = pickle.load(f)\n",
    "anonymous_mapping_dict"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "section_name_to_label = {\n",
    "    '': 0,\n",
    "    'methods': 1, \n",
    "    'background': 2, \n",
    "    'results': 3, \n",
    "    'conclusions': 4, \n",
    "    'objective': 5, \n",
    "}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "''"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# anonymous_mapping_dict['']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'': 89.01367285248133, 'methods': 5.925570035833683, 'conclusions': 2.052596107007253, 'background': 1.8056973555141833, 'results': 1.163760601632201, 'objective': 0.03870304753134614}\n",
      "{'ack': 0.8427922246912097, 'Unlocking the potential of MSCs and exosomes in Dermatology: a promising cell-free therapeutic approach': 0.016015054150901847, 'p': 0.7854049473171448, 'notes': 1.0563262800365676, 'Method': 0.46710574606797056, 'T-TEER': 0.0013345878459084873, 'ETHICS STATEMENTS': 0.0026691756918169746, '3 Results': 0.17349641996810336, 'Therapeutic intervention targeting lipid metabolism in cancer': 0.009342114921359411, '2 Materials and methods': 0.06806398014133286, 'Emerging strategies for delivery across the BBB': 0.026691756918169746, 'Bypassing the BBB': 0.016015054150901847, 'Subjects and methods': 0.08007527075450924, 'Supporting Information': 0.02402258122635277, '2 Methods': 0.052048925990431004, 'Methods and materials': 0.07740609506269228, 'Ethics statement': 0.060056453065881935, 'Pharmacological Routes Attempted and Early Clinical Trial Results': 0.03469928399362067, 'Eosinophilic Asthma': 0.005338351383633949, 'Chronic Rhinosinusitis with Nasal Polyps': 0.005338351383633949, 'Eosinophilic Granulomatosis with Polyangiitis': 0.016015054150901847, 'Patients and Methods': 0.421729759307082, 'Mechanisms of Depolyploidization in PACCs': 0.008007527075450924, 'Materials & methods': 0.009342114921359411, 'Financial & competing interests disclosure': 0.0013345878459084873, 'Experimental Section': 0.021353405534535796, 'Material and methods': 0.31496273163440297, 'PATIENTS AND METHODS': 0.31763190732622, 'PATIENT AND DISEASE CHARACTERISTICS': 0.005338351383633949, '1. Introduction': 0.632594638960623, '2. Method': 0.04937975029861403, 'fn-group': 1.4720503940370615, 'Bacterial infection': 0.005338351383633949, 'A look to the future: new therapy, ongoing studies and precision medicine in bronchiectasis': 0.004003763537725462, 'Research design and methods': 0.037368459685437644, 'Role of cfDNA analysis in gynecologic cancer': 0.02402258122635277, '4. Discussion': 0.6179141726556296, 'ETHICS STATEMENT': 0.06539480444951587, 'FUTURE DIRECTIONS': 0.026691756918169746, 'PRETREATMENT APPROACHES OF MSCS': 0.026691756918169746, '5. Future Perspectives': 0.03469928399362067, '3. Available Attempts at Gene Therapy for Alport Syndrome': 0.0013345878459084873, 'Advantages and disadvantages of cardiac PET': 0.0026691756918169746, 'Gaps between Knowledge and Implementation in Kidney Care': 0.037368459685437644, 'Conclusion': 0.28827097471623325, '3. CAR-T Cell Therapy in AML': 0.021353405534535796, '4. Limitations and Challenges in CAR-T Cell Therapy': 0.0013345878459084873, '3. Discussion': 0.15214301443356756, '4. Anticipated Results': 0.0013345878459084873, 'Results and Discussion': 0.10276326413495353, 'Methods and Materials': 0.08941738567586865, 'DISCUSSION AND FUTURE PERSPECTIVES': 0.0026691756918169746, 'Participants and Methods': 0.026691756918169746, 'Conventional therapeutic interventions associated with DHC': 0.021353405534535796, 'Results from clinical trials': 0.0013345878459084873, 'Ongoing clinical trials': 0.04003763537725462, 'Bispecific Antibodies': 0.012011290613176386, 'Dual Affinity Re-Targeting Molecules and Bispecific T-Cell Engagers': 0.0013345878459084873, 'ANTIVIRAL ACTIVITY OF SALICYLAMIDE DERIVATIVES': 0.0026691756918169746, 'STAR★Methods': 0.4137222322316311, 'Design': 0.005338351383633949, 'Ethics and dissemination': 0.10676702767267898, 'CLINICAL APPLICATION OF IOM STUDIES': 0.0026691756918169746, '2. TAFRO Syndrome': 0.0013345878459084873, '5. Conclusions and Future Research Directions': 0.0013345878459084873, 'Material and Methods': 0.2175378188830834, '2. Material and Methods': 0.09609032490541108, 'Locoregional Therapies and Management of Intermediate Stage HCC': 0.0026691756918169746, 'Systemic therapy': 0.009342114921359411, 'Ethics statements': 0.08007527075450924, 'Clinical Trial Information': 0.026691756918169746, 'Oxidative stress and senescence in cancer therapy': 0.021353405534535796, 'boxed-text': 0.0673966862183786, 'Results and discussion': 0.12945502105312326, '2. Targeting of the PI3K/AKT/mTOR Pathway in Breast Cancer': 0.0026691756918169746, '4. The Future of Targeted Inhibitors of the PI3K/AKT/mTOR Pathway': 0.008007527075450924, '3. Mechanisms of Resistance': 0.005338351383633949, '4. Clinical Evidence of Combination Therapies with PI3K Pathway Inhibitors and Current Trials in Progress': 0.03469928399362067, 'TARGETING THE IGE/FCεRI PATHWAY:': 0.018684229842718822, '3. Major Pathways Involved in the Resistance to Treatment': 0.010676702767267898, '4. Overcoming Therapeutic Resistance': 0.008007527075450924, '2. Liquid Biopsy Markers': 0.0026691756918169746, '2. Methods': 0.624587111885172, 'Glioblastoma': 0.0026691756918169746, 'fig': 0.11143808513335868, '3. Animal Models': 0.0013345878459084873, 'Current evidence for the treatment of JIA associated uveitis with JAKi': 0.0013345878459084873, 'Conclusion & Expert Opinion': 0.0013345878459084873, '5. Role of Vitamin D in Melanoma': 0.010676702767267898, 'CONCLUSIONS': 0.04404139891498008, '3. The Cancer Immunotherapy Strategies': 0.21353405534535796, 'Carrier Technology': 0.005338351383633949, 'MATERIAL AND METHODS': 0.07340233152496681, 'From farm microbes to microbial lysates': 0.0026691756918169746, '4. Challenges in Translation from Bench to Bedside': 0.026691756918169746, 'Clinical implications': 0.0026691756918169746, '3. CD19 as Target': 0.0026691756918169746, '6. Anti-ROR1 Antibody–Drug Conjugate Zilovertamab–Vedotin': 0.0013345878459084873, 'Botulinum toxin for GPPD and CPP': 0.0013345878459084873, 'Ferritin in cancer therapy': 0.008007527075450924, 'Methods:': 0.03336469614771218, 'Dermatomyositis': 0.05872186521997345, 'Anti-synthetase syndrome (ASyS)': 0.02402258122635277, '4. Wnt Signaling in Retinoblastoma': 0.0013345878459084873, '8. Challenges of Wnt/β-Catenin Targeted Therapies in Pediatric Tumors': 0.0013345878459084873, 'Immune-mediated necrotizing myopathy': 0.010676702767267898, 'Sporadic inclusion body myositis': 0.010676702767267898, '2. Targeted Therapies': 0.005338351383633949, 'The IL-1 pathway': 0.0026691756918169746, '4. Clinical Status of ICI in TNBC': 0.0013345878459084873, '6. Identifying Therapies That Will Sensitize Tumors to ICI': 0.17349641996810336, '7. Identifying New Immunotherapy Strategies for TNBC beyond Anti-PD-1/PD-L1': 0.032030108301803695, 'RANDOMIZATION METHODS USED IN STROKENET TRIALS': 0.008007527075450924, 'Conclusion and Perspectives': 0.006672939229542436, '3. Results': 0.8394557550764385, '6. Current and Emerging Therapeutics': 0.037368459685437644, 'The pathobiology of rod CNG channel-related retinopathy': 0.0013345878459084873, 'Advancing the efficacy of': 0.09075197352177714, 'CPs in Clinical Trials': 0.004003763537725462, '2. Neurovascular Unit': 0.06406021660360739, '5. Conclusions and Future Perspectives': 0.008007527075450924, 'Main text': 0.6859781527969625, 'Clinical manifestations': 0.0013345878459084873, '2. Mechanism of oHSV Anti-Tumor Activity': 0.0026691756918169746, '3. oHSV in Preclinical Models and Clinical Trials (': 0.021353405534535796, 'Targeting T': 0.008007527075450924, 'Expert Opinion': 0.018684229842718822, '4. Disease Monitoring at the Time of Increasingly Effective Therapies': 0.008007527075450924, 'CAMs in Phase I or II clinical development': 0.03469928399362067, '8. Conclusions': 0.005338351383633949, '2. Investigator and Sponsor-Initiated Dose Optimization in the Post-Marketing Setting': 0.04003763537725462, '3. FDA Strategies for Managing Dose Optimization in the Post-Marketing Setting': 0.026691756918169746, '4. Shifting Dose Optimization into the Pre-Marketing Setting': 0.010676702767267898, '4. Therapeutic Modalities to Overcome Resistance': 0.20819570396172402, '6. Targeted Therapy': 0.021353405534535796, '7. Gene and Cell Therapy': 0.032030108301803695, '7. Mechanisms of Macrophage-Targeted Therapy for Liver Diseases and Development of Small Molecule Drugs': 0.026691756918169746, '10. Epigenetic Therapy as “Conditioner”': 0.008007527075450924, '5. Discussion': 0.014680466304993362, '4. Conclusions': 0.010676702767267898, 'Current Treatment': 0.008007527075450924, 'Session 3- HPV serology assessments in one dose immunobridging studies and new prophylactic vaccines in development': 0.006672939229542436, 'Emerging molecularly-directed therapies': 0.24556416364716166, 'Clinical Trial Design': 0.0013345878459084873, '4. Effects of a Flavonoid-Rich Diet on Neuroprotection': 0.021353405534535796, '5. Gene Therapies': 0.05872186521997345, '4. Combining Locoregional Treatments with Immune Checkpoint Inhibitors': 0.026691756918169746, '2. Current Treatment Options': 0.010676702767267898, '5. New Therapeutics in Development': 0.14947383874175058, '6. Discussion': 0.02402258122635277, '2. Case Presentation': 0.010676702767267898, '4. Immunotherapeutic Strategies': 0.016015054150901847, '18. Conclusions and Future Perspectives': 0.018684229842718822, '2. Role of protein kinases in chronic lymphocytic leukemia (CLL)': 0.005338351383633949, '4. Materials and Methods': 0.18150394704355427, '3. Suppressing APC/C-CDC20 Sensitizes Cells to KIF18a Inhibition': 0.0026691756918169746, 'ALK': 0.0013345878459084873, 'ROS1': 0.006672939229542436, 'HER2': 0.004003763537725462, 'BRAF': 0.0013345878459084873, 'MET': 0.006672939229542436, '2. Targeting Protein Kinases to Protect Beta-Cell Function and Survival from Inflammation': 0.005338351383633949, '4. Methods': 0.016015054150901847, '3. Biomarker Identification and Validation Criteria': 0.016015054150901847, '4. Material and Methods': 0.021353405534535796, 'app-group': 0.5064760875222709, '5. Reduced-Intensity Chemotherapy': 0.0026691756918169746, 'Discussion and Future Prospects': 0.010676702767267898, '3. Immunotherapy via Diverse Mechanisms': 0.05338351383633949, 'III. Results and Discussion': 0.0026691756918169746, '4. Treatment of C3 Glomerulopathy Recurrence': 0.016015054150901847, '4. Tachyarrhythmias': 0.0026691756918169746, '5. Bradyarrhythmias': 0.010676702767267898, '3. Malignant Disorders': 0.005338351383633949, '4. Clinical Trials on Extracellular Vesicles': 0.04270681106907159, '3. Anti-Fibrotic Therapies': 0.010676702767267898, '7. Ongoing Clinical Trials for NF2 Syndrome': 0.016015054150901847, 'Methods and Procedures': 0.010676702767267898, '6. Therapeutic Strategies for Kidney Aging and CKD': 0.010676702767267898, '6. Structure–Dynamics–Function Correlations': 0.005338351383633949, 'Adaptive RTK upregulation in response to targeted therapies in non-melanoma tumor types': 0.0013345878459084873, 'Online Methods': 0.04804516245270554, '4. Clinical Studies': 0.037368459685437644, 'Design of small-molecule SMAC mimetics as antagonists of IAP proteins': 0.0013345878459084873, 'SMAC mimetics in clinical development for cancer treatment and initial clinical findings': 0.012011290613176386, '3. Migraine': 0.008007527075450924, 'HODGKIN LYMPHOMA': 0.021353405534535796, '3. Clinical Data': 0.21887240672899191, 'Novel Uses for Old Therapies': 0.0026691756918169746, '5. PI3K/Akt Pathway in Ovarian Cancer': 0.005338351383633949, '5. Therapy': 0.010676702767267898, '2. [': 0.04270681106907159, 'DNA Methylation Inhibitors and Histone Deacetylase inhibitors - Clinical Trials': 0.004003763537725462, 'Case Report': 0.029360932609986724, '6. Future Directions': 0.02001881768862731, '4. Other combination approaches in combination with trastuzumab': 0.005338351383633949, 'BACKGROUND': 0.0947557370595026, '3. Therapeutic Strategies after Progression on CDK4/6i Therapy': 0.28293262333259933, '4. Next-Generation Endocrine Agents': 0.05338351383633949, '5. Other Potential Agents Targeting Components of the Cell Cycle': 0.021353405534535796, '6. Final Considerations and Future Perspectives': 0.013345878459084873, 'ONLINE METHODS': 0.16281971720083543, '5. Host-Directed Therapies': 0.0026691756918169746, '4. Regulatory Consideration in Bone Tissue Engineering': 0.010676702767267898, '2. Material and Methods Study Design': 0.0026691756918169746, 'Histone deacetylase': 0.0026691756918169746, 'SDF1/CXCR4': 0.0013345878459084873, 'Kinase Inhibitors': 0.018684229842718822, 'Hedgehog Pathway': 0.0013345878459084873, 'Immunotherapy: Monoclonal and Bispecific Antibodies': 0.0013345878459084873, 'Conclusions': 0.2095302918076325, '5. Therapeutic Potential of Targeted Epigenetic Modifiers and Metabolic Reprogramming in HCC': 0.05338351383633949, '4. Gut Bacteria and CNS Tumors': 0.07473691937087529, 'TLR3': 0.0026691756918169746, '3. Virology': 0.021353405534535796, '9. Conclusions and Future Perspectives': 0.008007527075450924, '2. Patients and Methods': 0.04404139891498008, '3. Advances in Diagnostics and Treatment': 0.005338351383633949, '5. Targeting Complement Pathways in Retinal Disease': 0.10676702767267898, 'Remodeling, Fibrogenesis, and Epithelial Mesenchymal Transition': 0.0013345878459084873, 'F508del-CFTR': 0.0026691756918169746, '5. Discussion and Conclusions': 0.005338351383633949, '3. Nanotechnology in Precision Cancer Therapy': 0.032030108301803695, 'Strategies to normalize tumour vessels': 0.010676702767267898, '12. Application of the mRNA Vaccine for the Influenza Virus': 0.0026691756918169746, '4. Microbicides': 0.09075197352177714, 'STAR METHODS': 0.08274444644632621, 'CLINICAL TRIALS': 0.1668234807385609, 'CLINICAL MANAGEMENT ISSUES': 0.0026691756918169746, '2. Pirfenidone and Nintedanib in ILDs': 0.008007527075450924, '6. Viral Delivery Systems': 0.005338351383633949, '8. Advanced Delivery Strategies': 0.005338351383633949, 'MEDICATION DEVELOPMENT TARGETING MGLUR2/3': 0.0013345878459084873, '5. Progress in the Development of Therapeutic Drugs Targeting Tau Protein': 0.010676702767267898, 'STAR ★ METHODS': 0.005338351383633949, '3. Ongoing Clinical Trials': 0.010676702767267898, '5. Future Directions': 0.046710574606797055, '2. Results': 0.19751900119445612, '4. Pharmacotherapy of Alzheimer’s and Parkinson’s Diseases': 0.12812043320721478, '2 Oligonucleotide Therapeutics': 0.018684229842718822, '11. Clinical Cases': 0.037368459685437644, '3. Material and Methods': 0.005338351383633949, '2. Applications of Sartans in the Treatment of Wounds': 0.005338351383633949, '4. Insights into CXCL12-CXCR4 multitasking from WHIM syndrome immunodeficiency': 0.004003763537725462, '2. Ketamine: the prototype rapid-acting antidepressant': 0.0013345878459084873, '3. IDH Inhibitors in Glioma': 0.04270681106907159, '4. Future Perspectives': 0.017349641996810335, '5. Clinical Trials of Combination': 0.021353405534535796, 'Other TGF-β activation mechanisms in diabetic complications': 0.0013345878459084873, 'MANAGEMENT': 0.052048925990431004, '4. Combination treatment with PARP inhibitors and traditional chemotherapy': 0.028026344764078236, '5. Future directions for PARP inhibitor combination therapies': 0.013345878459084873, '3. SMALL-MOLECULE INHIBITORS FOR COSTIMULATORY AND COINHIBITORY PPIS': 0.010676702767267898, 'References Correction': 0.005338351383633949, 'IVH-INDUCED BRAIN INJURY': 0.005338351383633949, 'EXPERT OPINION': 0.0013345878459084873, '6. Clinical trial data and therapeutic inertia': 0.0013345878459084873, 'Broad Glutamatergic Modulators': 0.008007527075450924, 'Metabotropic Glutamate Receptors (mGluRs)': 0.010676702767267898, '3. Targeted Drug Therapy Designed for the Chronic Wound Microenvironment': 0.19218064981082217, 'Treating SAVI with JAK Inhibitors': 0.0026691756918169746, 'STAR ★METHODS': 0.005338351383633949, 'NOVEL TARGETING TO OVERCOME PCA RADIORESISTANCE': 0.010676702767267898, 'Chymase inhibitors (therapeutic approach in cardiac disease prevention)': 0.0026691756918169746, 'B-CELL DEPLETION': 0.005338351383633949, 'ANTIBODY-INDEPENDENT B-CELL INTERACTIONS': 0.0026691756918169746, 'IMMUNIZATION AND RNA VACCINES': 0.0026691756918169746, 'Integration profile of transgenic epidermis': 0.0013345878459084873, 'Targeting the Achilles’ heel by HIF-2α antagonists': 0.0013345878459084873, 'Clinical studies targeting CTLA4/CD28 and PD-1/PD-L1 pathways in multiple myeloma': 0.013345878459084873, 'Future directions in treatment with immune checkpoint inhibitors': 0.005338351383633949, 'Materials and Methods:': 0.005338351383633949, 'Antibody drug conjugates targeting HER2': 0.2242107581126259, 'Affibodies': 0.037368459685437644, 'Nanobodies': 0.13879713597448268, 'Clinical data supporting the use of dual VEGF/PDGF antagonism in the treatment of wet AMD': 0.005338351383633949, 'Implications in immunotherapy': 0.004003763537725462, 'Trial status': 0.02402258122635277, 'Administrative information': 0.09208656136768563, 'Additional information': 0.012011290613176386, 'Review': 0.2815980354866908, 'CONCLUSION': 0.12144749397767234, 'Patients and methods': 0.7153390854069492, 'Conclusions and Future Directions': 0.012011290613176386, 'TARGETING CXCR4 THERAPEUTICALLY': 0.0013345878459084873, 'Methods and materials of the study': 0.010676702767267898, 'Methods and analysis': 0.2962785017916842, 'Background': 1.2665238657671545, '3. The PI3K/Akt cascade and glucose metabolism in cancer': 0.0026691756918169746, 'STAR Methods': 0.07740609506269228, 'AI techniques in OCT analysis': 0.018684229842718822, 'Material and method': 0.005338351383633949, 'Main': 0.11077079121040445, 'Paternal BMI affects offspring health': 0.0013345878459084873, 'CD45 regions for epitope engineering': 0.0013345878459084873, 'Monotherapy or combination therapy in urogenital tumors': 0.4697749217597876, 'Heated Intraperitoneal Chemotherapy (HIPEC)': 0.04003763537725462, 'METHOD': 0.1267858453613063, 'Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC)': 0.005338351383633949, 'Mouse models of Richter transformation': 0.005338351383633949, 'Methodology': 0.08274444644632621, 'Clinical use of ctDNA in early breast cancer': 0.021353405534535796, 'MG heterogeneity, clinical subgroups and treatments': 0.014680466304993362, 'B cells: key players and therapeutic targets in MG': 0.032030108301803695, 'Antibody recycling by FcRn as physiological mechanism prolonging autoantibody effects': 0.005338351383633949, 'Complement system as key damage mediator and therapeutic target in AChR-MG': 0.008007527075450924, 'Conflict of interest': 0.010676702767267898, '2 Material and methods': 0.018684229842718822, 'Application of ADCs in the treatment of cervical cancer': 0.018684229842718822, 'INTERVENTIONS': 0.008007527075450924, '2. Participants and Materials': 0.0026691756918169746, 'Additional Points': 0.0026691756918169746, 'Ketamine Hydrochloride': 0.005338351383633949, 'Opioid Receptor Modulators': 0.0026691756918169746, 'Low-Field Magnetic Stimulation (LFMS)': 0.0013345878459084873, 'Methods: participants, interventions, and outcomes': 0.05605268952815647, 'DC vaccines (adoptive transfer)': 0.052048925990431004, 'Mechanisms of drug resistance': 0.0026691756918169746, 'Therapeutic strategies to overcome drug resistance': 0.005338351383633949, 'The potential of antitumor therapy on the immune microenvironment of OV': 0.12812043320721478, 'Conclusion and prospectives': 0.0013345878459084873, 'Combined mRNA-based vaccines': 0.010676702767267898, 'Combined subunit vaccines': 0.005338351383633949, 'Improving gut microbiota efficacy': 0.05071433814452252, 'Perspectives': 0.10810161551858748, 'Methods and design': 0.028026344764078236, 'Cancer risk prediction and intervention strategies': 0.13345878459084873, 'mRNA Therapeutics\\\\nin Clinical Trials': 0.006672939229542436, 'Application of immunotherapy in ATC': 0.07740609506269228, '4. Conclusions and future perspectives': 0.004003763537725462, 'Example: ROSSINI-2 selection design': 0.0026691756918169746, '5 Personalized treatments': 0.008007527075450924, 'STAR★METHODS': 0.021353405534535796, 'Adoptive immunotherapy': 0.08541362213814319, 'Mechanism and molecular design of nucleic acid therapeutics': 0.021353405534535796, 'Application of nucleic acid therapeutics to myeloid malignancies': 0.010676702767267898, 'Materials and Method': 0.005338351383633949, 'Drug candidates targeting YAP/TAZ in the liver': 0.0026691756918169746, '1 Introduction': 0.10009408844313655, '2 Experimental': 0.013345878459084873, '3 Results and Discussion': 0.016015054150901847, '2. Essential protocol information': 0.005338351383633949, 'Immunotherapy and other treatments': 0.016015054150901847, 'body': 0.10676702767267898, 'SMALL MOLECULES AND NATURAL PRODUCT INHIBITORS OF THE AR-NTD': 0.0013345878459084873, 'Anti-CTLA-4 mAB combination therapy in BC': 0.010676702767267898, 'Novel immunotherapeutic strategies for targeting CTLA-4': 0.005338351383633949, 'Progress in the research and application of hUMSCs in SCI': 0.0013345878459084873, 'Risk–benefit evaluation of hUMSCs for SCI treatment': 0.016015054150901847, 'Therapeutic implications': 0.014680466304993362, 'Methods/design': 0.16415430504674394, 'STRATEGIES TO IMPROVE FRONTLINE THERAPY IN ELDERLY AML': 0.04270681106907159, 'II. MOLECULAR AND MULTIKINASE INHIBITOR THERAPIES IN THE FRONTLINE AND SALVAGE SETTING': 0.06406021660360739, 'Hypoxia as a therapeutic target in uterine fibroids': 0.005338351383633949, 'Clinical translation of theranostic NPs in cardiovascular disease': 0.016015054150901847, 'Recording patient reported safety events in CKD: a task well-suited for IVRS': 0.0026691756918169746, 'Methods and analysis (including design; selection/treatment of subjects; interventional methods; data analysis)': 0.0026691756918169746, 'Materials and method': 0.012011290613176386, '2. Patients and methods': 0.08808279782996016, 'Subependymal giant cell astrocytomas': 0.0026691756918169746, 'Current gaps in knowledge/disease-modifying effects': 0.0026691756918169746, 'tDCS Special Consideration for Safety in Children': 0.0026691756918169746, 'Before liver transplantation': 0.016015054150901847, 'Artemisinins: Front-line Antimalarials under Threat': 0.0013345878459084873, 'Pharmacological and clinical comparison of IV versus SC trastuzumab': 0.016015054150901847, 'Interleukin-17 inhibitors': 0.016015054150901847, 'Promising molecular-based therapeutical approaches': 0.11343996690222143, 'JAK Inhibitors': 0.008007527075450924, 'Overcoming Resistance to JAK inhibitors': 0.0026691756918169746, 'Histone Deacetylase Inhibitors': 0.0026691756918169746, 'Hypomethylating Agents': 0.0026691756918169746, 'Targeting Additional Signaling Abnormalities': 0.016015054150901847, 'Practical Approaches: Reducing Anemia Associated with JAK-Inhibitors': 0.004003763537725462, 'In Vivo Evidence of Synergy with Combination BRAF Targeted and Immunotherapy': 0.016015054150901847, 'FLT3-ITD AML': 0.010676702767267898, 'DNA methylome modifiers and their roles in FLT3-ITD AML': 0.037368459685437644, 'Designing a regimen to treat MDR-TB': 0.05872186521997345, 'SUBJECTS AND METHODS': 0.05471810168224798, 'Future Directions': 0.2308836973421683, '6. Competitive environment': 0.09609032490541108, 'Immunologically active compounds': 0.046710574606797055, 'Participants and methods': 0.037368459685437644, 'Repurposed drugs': 0.06672939229542436, 'Future perspectives': 0.12278208182358083, 'Targeted immunotherapy': 0.21353405534535796, 'Methods/Design': 0.2535716907226126, 'Evidence Gaps and Future Directions': 0.008007527075450924, '1. Background': 0.013345878459084873, '5. Clinical efficacy': 0.008007527075450924, '6. Combinations': 0.005338351383633949, '9. Expert opinion': 0.005338351383633949, 'MODS diagnostic criteria: past and present': 0.010676702767267898, '1. BLOCKADE OF NERVE GROWTH FACTOR ACTIVITY': 0.0026691756918169746, '2. ION CHANNELS': 0.005338351383633949, '2. METHODS': 0.03603387183952916, 'Outlook': 0.026691756918169746, 'Treatment options – VNS in humans': 0.008007527075450924, 'The anti-lymphangiogenic therapies': 0.02402258122635277, 'Clinical Trials for MPS IIIB Treatment': 0.012011290613176386, 'CLINICAL-TRANSLATIONAL ADVANCES': 0.032030108301803695, 'Treatment': 0.1481392508958421, 'Simultaneous blockade of B7/CD28 and B7/CTLA-4: Confronting the double edge sword of co-stimulation and co-inhibition': 0.0026691756918169746, 'CD40:CD154-directed costimulation blockade: The story of on-target potency being sidelined by an unexpected toxicity': 0.0026691756918169746, 'ICOS/L, a supporting player in germinal center targeting and co-stimulation blockade': 0.005338351383633949, 'Blockade of T cell trafficking to secondary lymph nodes and target organs and tissues: impact on transplant outcomes and interactions with co-signaling blockade': 0.005338351383633949, 'The special role of large animal models in understanding co-signaling in transplantation': 0.021353405534535796, 'Combinations in clinical development: ADCs combined with chemotherapy': 0.010676702767267898, 'Combinations in clinical development: ADCs combined with ICIs': 0.10142867628904503, 'B7-H3': 0.032030108301803695, 'Clinical Development of LAG3 Targeted Immunotherapy': 0.07206774367905831, 'Combinations in clinical development: ADCs combined with targeted therapy (mAbs and small molecules)': 0.06406021660360739, '6. Conclusions': 0.0026691756918169746, 'Combinational therapies': 0.005338351383633949, 'Treatment options': 0.014680466304993362, 'Genetic Alterations as Therapeutic Targets': 0.03469928399362067, 'Targeting Genetic Diversity in PDAs': 0.0026691756918169746, 'Disease targets for neural and glial progenitor cell therapy': 0.016015054150901847, 'Notes': 0.010676702767267898, 'Disease targets of mesenchymal and hematopoietic stem cell-based therapy': 0.0026691756918169746, '4 Discussion': 0.07473691937087529, 'NAD\\xa0+\\xa0as a target to improve vascular health: from bench to bed': 0.041372223223163106, '5. Conclusions and future perspectives': 0.0026691756918169746, 'METHODS AND MATERIALS': 0.018684229842718822, 'V. COMBINATION THERAPY WITH PD-1 PATHWAY BLOCKADE': 0.02402258122635277, 'Administrative Information': 0.0026691756918169746, 'Statistical methods': 0.04537598676088857, '2. Ketamine as a Prototypic Glutamatergic Antidepressant Agent': 0.005338351383633949, 'Challenges': 0.0026691756918169746, 'Aβ modulators': 0.016015054150901847, 'Therapeutic strategies: is protection of renal microvessels feasible?': 0.005338351383633949, 'Patients/material and methods': 0.0026691756918169746, '2. Current therapies for ACC': 0.005338351383633949, '3. Gene Therapeutics for Radiation-Induced Salivary Dysfunction': 0.021353405534535796, 'Study Design and Methods': 0.006672939229542436, 'MARKERS OF INTRINSIC RESISTANCE': 0.008007527075450924, 'PUTATIVE MARKERS OF RESISTANCE AND SENSITIVITY': 0.021353405534535796, 'CELL CYCLE EXIT AND SENESCENCE AS THERAPEUTIC ENDPOINTS': 0.013345878459084873, 'Subjects and Methods': 0.15080842658765908, '8. Therapy for Types A & B NPD': 0.010676702767267898, 'Materials & Methods': 0.05605268952815647, 'Ion channels that mediate volume changes': 0.016015054150901847, 'Stem cell programs in the wrong place': 0.0026691756918169746, '3 Therapies tailored to specific genetic and molecular alterations in neuroblastoma': 0.05872186521997345, 'PRINCIPLES OF ASAP AND CASE EXAMPLE': 0.0026691756918169746, 'TCZ in SSc': 0.0013345878459084873, 'Outcome of DCB therapy with prior debulking': 0.0013345878459084873, 'Summary': 0.05471810168224798, 'Results from Clinical Trials': 0.037368459685437644, 'On the Horizon': 0.005338351383633949, 'Na': 0.0026691756918169746, '2 Patients and methods': 0.010676702767267898, 'Implications for Design of Trials': 0.0026691756918169746, 'METHODS/DESIGN': 0.009342114921359411, 'Clinical Implications': 0.0026691756918169746, '8 Advanced composite biomaterials for osteomyelitis treatment from experimental work': 0.0026691756918169746, 'Neoadjuvant strategies': 0.010676702767267898, 'B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA': 0.06406021660360739, '4. Results': 0.010676702767267898, 'T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (T-ALL)': 0.0026691756918169746, 'RELAPSED ALL': 0.008007527075450924, 'Evidence in clinical populations': 0.19751900119445612, 'Therapeutic approaches': 0.008007527075450924, 'PATIENTS and METHODS': 0.009342114921359411, 'Specific Cell Types Evaluated for HF': 0.021353405534535796, 'Optimal Cell Type': 0.0026691756918169746, 'Engineering strategies': 0.04270681106907159, '5 Targeting the NO-HER family axis in tumors': 0.0026691756918169746, 'Therapeutic interventions targeting the histone code and telomere length in gliomas': 0.0026691756918169746, 'Ethics Statement': 0.030695520455895207, '2. Immunotherapy approaches': 0.1254512575153978, '3. Predictive biomarkers for immunotherapy': 0.008007527075450924, '4 Conclusion': 0.0026691756918169746, '4. Expert opinion': 0.0013345878459084873, 'OVERCOMING RESISTANCE TO IMMUNE CHECKPOINT THERAPY': 0.05471810168224798, 'Circulating Biomarkers': 0.005338351383633949, 'INFLAMMATION IN PANCREATIC CANCER': 0.016015054150901847, 'Universal CAR approaches': 0.0013345878459084873, 'Basic requirements of CAR immune effector cells': 0.0026691756918169746, 'Limitations of CAR T': 0.010676702767267898, 'Clinical experience with adapter CAR technologies': 0.008007527075450924, 'The CAR configurator': 0.004003763537725462, 'Ethical statement': 0.008007527075450924, 'Potential Disease-Modifying Therapies': 0.0026691756918169746, 'Mechanism of action': 0.005338351383633949, 'Potential drugs targeting inflammatory mechanisms in DMD': 0.013345878459084873, 'Future directions': 0.11210537905631295, '4. Choline kinase inhibition': 0.005338351383633949, '6. Methods for ChoKα inhibitor validation': 0.005338351383633949, 'The dual role of extracellular vesicles in drug resistance and therapeutic cargo delivery': 0.0013345878459084873, 'Case presentation': 0.021353405534535796, 'Research Design and Methods': 0.037368459685437644, 'Who should be prescribed sacubitril/valsartan?': 0.0026691756918169746, 'T-cell vaccine design strategies': 0.010676702767267898, 'mAbs': 0.0026691756918169746, 'Therapeutic approaches for DNA repair targeting': 0.010676702767267898, 'PARPi': 0.016015054150901847, 'Current development of other DNA damage-targeted treatments for BC': 0.013345878459084873, 'Other methods of studying tumor': 0.006672939229542436, 'Targeted therapies aiming RTKs': 0.624587111885172, 'EFFICACY OF ADCS IN BREAST CANCER': 0.1174437304399469, 'Case': 0.0013345878459084873, 'PATIENT AND METHODS': 0.005338351383633949, 'SOLUTIONS': 0.05071433814452252, 'Targeted therapies aiming MAPK pathway inhibitors': 0.008007527075450924, 'Targeted therapies aiming poly ADP-ribose polymerase inhibitors': 0.012011290613176386, 'Other targeted therapies': 0.032030108301803695, 'Interventions': 0.018684229842718822, 'TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA': 0.0026691756918169746, 'Emerging and Innovative Lifestyle Change Strategies': 0.0013345878459084873, '2. MATERIAL AND METHODS': 0.009342114921359411, 'Efficacy of Janus-Kinase Inhibitors': 0.05338351383633949, 'Safety of Janus Kinase Inhibitors': 0.0026691756918169746, 'Immune Checkpoint Inhibitors': 0.0026691756918169746, 'INTRODUCTION TO LEVODOPA INHALATION POWDER': 0.029360932609986724, 'CLINICAL EFFICACY': 0.016015054150901847, 'SAFETY AND TOLERABILITY': 0.005338351383633949, 'COMPARISON TO ANTIHYPERTENSIVE DRUGS': 0.0013345878459084873, 'Novel Therapies': 0.021353405534535796, 'Translating immunogenetic observations to novel therapies': 0.0026691756918169746, 'WHIM syndrome': 0.0026691756918169746, '3. Nonsense Suppression as a Treatment for Lysosomal Storage Diseases': 0.010676702767267898, 'To the Editor': 0.032030108301803695, 'Hypochlorous Acid': 0.0013345878459084873, 'CIRCULATING CELL-FREE NUCLEIC ACIDS': 0.018684229842718822, '2. Immunotherapy': 0.02402258122635277, '3. Targeting IDH mutation': 0.005338351383633949, 'Targeting of IDH-mutant tumors': 0.016015054150901847, 'Supplementary materials': 0.04404139891498008, 'NUTRITIONAL FACTORS AND INTERVENTIONS': 0.032030108301803695, 'Strategies for Encapsulating Islet Cells': 0.013345878459084873, 'Approaches to Improve Transplantation Efficacy': 0.02402258122635277, 'Medical Use': 0.010676702767267898, '3. Successful Immunotherapeutic Bacterial Lysates for Infectious Diseases': 0.0026691756918169746, 'TREATMENT': 0.014680466304993362, '5. Bacterial Lysates or Extracts as an Immunotherapy for Cancer': 0.018684229842718822, 'CAFs as Targets in Cancer Immunotherapy': 0.016015054150901847, '1. TARGETING EXTRACELLULAR INDUCERS THAT INITIATE THE EMT PROGRAM': 0.026691756918169746, '2. TARGETING ORCHESTRATORS OF EMT': 0.010676702767267898, 'Tissue engineering and regenerative medicine as kidney replacement therapy': 0.021353405534535796, 'DATA AVAILABILITY STATEMENT': 0.0026691756918169746, 'Idarucizumab (Praxbind)': 0.0013345878459084873, 'ADJUVANT THERAPY TO PREVENT RECURRENCE OF PRIMARY LIVER CANCER': 0.008007527075450924, 'TREATMENTS FOR RECURRENT HCC': 0.008007527075450924, 'ANTIOXIDANT AND ANTI-INFLAMMATORY AGENTS IN NAFLD': 0.0026691756918169746, 'P171. Community health volunteers’ impact on the quality of maternal and newborn health in Kenya': 0.010676702767267898, 'Material & methods': 0.005338351383633949, 'M': 0.12812043320721478, 'C': 0.012011290613176386, 'Participants, materials & methods': 0.0026691756918169746, 'Serotonin receptors (5-HTR)': 0.0026691756918169746, 'Monoamine transporter activity': 0.0026691756918169746, 'Uterine Fibroids': 0.016015054150901847, 'Endometriosis': 0.005338351383633949, 'Hydrogels for cell therapy': 0.04270681106907159, 'Progress and challenges in current clinical applications of hydrogels': 0.03870304753134614, 'Systemic treatments': 0.005338351383633949, 'Clinical applications of extracellular vesicle-derived biomarkers': 0.0013345878459084873, 'Emerging studies': 0.006672939229542436, 'Opportunities of liquid biopsy for cancer predisposition syndromes': 0.010676702767267898, 'HNC molecular pathogenesis': 0.11210537905631295, '5. Dual agonists': 0.0026691756918169746, 'Epigenetic mechanisms': 0.0026691756918169746, 'Feedback': 0.005338351383633949, 'The role of B7-H3 in tumor vasculature and clinical treatment': 0.18150394704355427, '6. Reported clinical trials': 0.026691756918169746, 'Inhibitors for T315I mutant': 0.0026691756918169746, 'New factors besides hypercholesterolemia contribute to vascular foam cell formation, offering avenues for innovative therapies': 0.0026691756918169746, 'The Effects of γT-Rich Tocopherols on PCa and TEs on Other Types of Cancer in Human Clinical Studies': 0.005338351383633949, '3. Ongoing clinical trials on aerosolized siRNA based medicines': 0.008007527075450924, 'NS4B as an antiviral target': 0.0026691756918169746, 'Exploiting Radiation Immunostimulatory Effects against GBM': 0.05338351383633949, 'Somatic pharmacogenomics as a mechanism of drug resistance': 0.018684229842718822, 'Clinical trials of SVV-001': 0.008007527075450924, 'Summary and future development': 0.004003763537725462, 'Tolerability and safety': 0.0013345878459084873, 'METHODS (online-only)': 0.005338351383633949, 'Surgical Treatment': 0.005338351383633949, 'Case Description': 0.004003763537725462, 'Effect of SGLT2 inhibitors on Renal Function': 0.0013345878459084873, 'SGLT2 Inhibitors Versus RAAS-based Agents in Diabetes Therapy': 0.0013345878459084873, 'Author description': 0.0013345878459084873, 'Molecular agents targeting the Wnt pathway': 0.005338351383633949, 'Additional Information and Declarations': 0.013345878459084873, '3. HDACi in MPN': 0.016015054150901847, '5. Expert Opinion': 0.0026691756918169746, 'Clinical Endpoints in Ongoing GA Trials': 0.010676702767267898, 'Alternative or Additional Anti-B-cell Therapies: Obinutuzumab and Belimumab': 0.008007527075450924, 'Targeting Plasma Cells: Proteasome Inhibitors and Anti-CD38 Agents': 0.032030108301803695, 'Targeting Complement System: Beyond Thrombotic Microangiopathy': 0.008007527075450924, 'Molecular hallmarks of aging and immunity': 0.004003763537725462, 'Design strategies for vaccines for elderly individuals': 0.018684229842718822, 'Lymphocyte‐activation gene‐3 and treatment': 0.013345878459084873, 'Clinical trials': 0.15881595366311, 'Lessons from therapeutic targeting as to the hierarchy of pathways and heterogeneity of responses': 0.005338351383633949, 'Declarations': 0.03870304753134614, 'THE CLINICAL USE OF EGFR-TARGETED AGENTS IN NON-SMALL CELL LUNG CANCER': 0.037368459685437644, 'Clinical–Translational Advances': 0.016015054150901847, 'A Shift from Treatment to Prevention Is Driven by Biomarkers Guiding When and How to Intervene': 0.021353405534535796, 'Administrative information\\\\n': 0.0013345878459084873, 'Overview of the Current Landscape of Non‐Cell Therapies': 0.061391040911790415, 'Cell‐Based Therapies: Current and Future Applications': 0.008007527075450924, 'Targeting macrophages in the tumor microenvironment': 0.041372223223163106, 'The ECS as a therapeutic target in IBD': 0.005338351383633949, '3. REPLICATION-COMPETENT, VECTORED VACCINES': 0.04804516245270554, '4. EPLICATION-INCOMPETENT, VECTORED VACCINES': 0.09875950059722806, 'Protection of Human Subjects and Assessment of Safety': 0.0026691756918169746, '9. SUBUNIT VACCINES': 0.0013345878459084873, 'Polo-like kinases': 0.06939856798724134, '3. Methods': 0.12945502105312326, 'Oncological therapeutic value of Nectin-4': 0.07206774367905831, 'Case Studies on Oral Delivery of Bioencapsulated Biopharmaceuticals': 0.0026691756918169746, 'INTRAVESICAL THERAPY': 0.010676702767267898, 'CASE REPORT': 0.008007527075450924, 'Material and Method': 0.005338351383633949, 'Results/Discussion': 0.008007527075450924, 'Novel complement therapeutics in development': 0.037368459685437644, '2. Overview of the market': 0.016015054150901847, '15. Expert Opinion': 0.0026691756918169746, 'Overcoming Resistance to Immunotherapy': 0.013345878459084873, 'PATHOPHYSIOLOGY AND CLINICAL FEATURES OF HEART FAILURE WITH PRESERVED EJECTION FRACTION': 0.0026691756918169746, 'Subjects & methods': 0.0026691756918169746, 'Text': 0.0013345878459084873, 'Methods and Analyses': 0.0026691756918169746, 'Ethics and Dissemination': 0.0013345878459084873, 'AL Cardiac Amyloidosis': 0.021353405534535796, 'RESEARCH DESIGN AND METHODS': 0.05605268952815647, 'Potential future applications of ctDNA within the evolving treatment landscape for LARC': 0.0026691756918169746, 'TREATMENT OF SDB IN HF': 0.005338351383633949, 'Targeting of CAR-T cells for the treatment of thyroid cancer': 0.008007527075450924, 'Emerging role of MHC1/LILRB1 axis as an innate immune checkpoint': 0.0026691756918169746, 'Clinical studies of elotuzumab in multiple myeloma': 0.02402258122635277, 'Combination therapy with lenalidomide': 0.006672939229542436, 'Targeting IR as a therapeutic strategy for AD': 0.005338351383633949, 'Methods and study design': 0.0013345878459084873, 'FUTURE DIRECTION': 0.0013345878459084873, 'NEW TARGETS AND TARGETED THERAPIES': 0.004003763537725462, '4. Driver-dependent genetic vulnerabilities as targets of osteosarcoma therapy': 0.016015054150901847, 'Gene editing tools for CAR-T cell therapy': 0.16015054150901847, 'Gene editing strategies in CAR-T cell therapy': 0.032030108301803695, 'Protein-based ASI': 0.006672939229542436, 'Peptide-based ASI': 0.0013345878459084873, 'NP entrapping antigen alone': 0.0013345878459084873, 'Esophageal cancer': 0.008007527075450924, 'Gastric and gastroesophageal junction cancer': 0.008007527075450924, 'Biliary tract cancer': 0.018684229842718822, '4. Targeting BM elements to control disease (Bone/Niches/Adipose)': 0.032030108301803695, '10. Conclusions and future outlook': 0.0013345878459084873, '2. Neoadjuvant anti-PD-1/PD-L1 therapy according to cancer types': 0.944888194903209, 'Neprilysin inhibitors combined with angiotensin receptor blockers': 0.0026691756918169746, 'Soluble guanylate cyclase stimulators': 0.0026691756918169746, 'Study design': 0.029360932609986724, '1. Tumor immunotherapy development and historical findings on the impact of bacteria on immunotherapy': 0.005338351383633949, '4. Current therapeutics': 0.008007527075450924, '5. Advances in clinics': 0.005338351383633949, '7. Strategy of using mRNA/saRNA approach for GD': 0.0013345878459084873, 'The future perspective and challenges for clinical translation of SFN': 0.02402258122635277, '4. Adverse effects of neoadjuvant immunotherapy': 0.0013345878459084873, 'Clinical investigations': 0.08007527075450924, 'Compliance with Ethical Standards': 0.009342114921359411, 'Androgen signaling': 0.010676702767267898, 'AR co-factors': 0.0013345878459084873, 'Wnt pathway': 0.014680466304993362, 'Cell cycle/proliferation': 0.009342114921359411, 'DNA damage repair/heredity': 0.010676702767267898, '3. Disclosure': 0.005338351383633949, 'The effect of influenza immunization on cardiovascular death and acute coronary syndromes': 0.0013345878459084873, 'The effect of influenza immunization on cerebrovascular events and heart failure': 0.0013345878459084873, 'Influenza immunization as a key element for cardiovascular prevention during the time of COVID-19': 0.0013345878459084873, 'Trials of novel anti-androgen therapy combined with surgical approach': 0.005338351383633949, 'RAVICTI: A SHORT CASE STUDY': 0.012011290613176386, '5.2 Therapeutic implications': 0.0026691756918169746, 'Engineered iPSC-derived NK cells for immunotherapy': 0.018684229842718822, 'NK cellular therapy': 0.07206774367905831, 'E. Emerging pharmacologic agents for NASH': 0.037368459685437644, 'III. Change in Clinical Concepts, Diagnosis and Management in ROP': 0.021353405534535796, 'IV. Current Clinical Trials': 0.04270681106907159, 'ICU CARE': 0.0026691756918169746, '4. Experimental procedures': 0.0026691756918169746, 'Tumor-associated macrophages as a therapeutic target in solid cancers': 0.7527075450923869, 'AF treatment trials: Filling in the gaps': 0.08541362213814319, 'Conclusions & Future Perspectives': 0.017349641996810335, 'Metabolic pathways in fibroblasts and myofibroblasts': 0.0026691756918169746, 'PD-L1: a challenging biomarker': 0.0026691756918169746, 'POTENTIAL APPLICATION OF IMMUNETHERAPY': 0.005338351383633949, '3. Rare disease and current rAAV pre-clinical and clinical studies': 0.005338351383633949, 'Underappreciated clinical advancements': 0.008007527075450924, '2. Spoiled for choice: points of intervention in the complement cascade': 0.08541362213814319, '3. A new diversity in complement inhibition approaches': 0.04804516245270554, '2.0 Vaccine Therapy': 0.07473691937087529, '3.0 Adoptive T cell immunotherapy': 0.04537598676088857, '4.0 Immune Checkpoint Blockade': 0.016015054150901847, '8.0 Expert Opinion': 0.0026691756918169746, 'MET inhibitors': 0.005338351383633949, 'Immunotherapeutics': 0.010676702767267898, 'Treatment options for patients with HRP HGSC': 0.026691756918169746, 'Mosunetuzumab, Results from the Pivotal Studies': 0.0013345878459084873, 'Ongoing Trials and Future Perspectives': 0.02535716907226126, 'Combined targeted therapies': 0.05471810168224798, 'Drug repositioning': 0.0013345878459084873, 'Genotype-specific therapies': 0.008007527075450924, 'Combitherapies and personalized medicine': 0.004003763537725462, '1 EGFR突变可切除的NSCLC术后辅助治疗研究进展': 0.013345878459084873, '2 EGFR突变可切除的NSCLC新辅助治疗研究进展': 0.021353405534535796, 'Soluble epoxide hydrolase inhibitors are under development in humans': 0.0013345878459084873, 'TARGETING THE YAP/TAZ‐TEAD SIGNALLING AXIS IN MPM': 0.010676702767267898, 'Ethical Statement': 0.0026691756918169746, 'Ethics approval': 0.004003763537725462, 'The main treatment for MDSCs': 0.02535716907226126, 'Targeted therapies as milestones in understanding pathogenesis': 0.04003763537725462, '4. Challenges to CAR T cell efficacy in solid tumors': 0.010676702767267898, 'Case Presentation': 0.014680466304993362, 'Ethics Statements': 0.004003763537725462, 'Discussion and conclusions': 0.02001881768862731, 'Procedure and data analysis': 0.0026691756918169746, 'Therapeutic targeting of the Wnt/β-catenin signaling pathway': 0.017349641996810335, 'General data and methods': 0.0026691756918169746, '6. Looking beyond Immune Checkpoint Inhibitors': 0.016015054150901847, '3. Results Obtained to Date': 0.0026691756918169746, '2. SUBJECTS AND METHODS': 0.010676702767267898, '4. Immunotherapeutic Strategies for the Treatment of GBM': 0.14947383874175058, 'Campaign success': 0.0026691756918169746, '5. Combination Therapy': 0.017349641996810335, 'D': 0.026691756918169746, 'Clinical efficacy of immunotherapy in NSCLC with oncogene drivers': 0.005338351383633949, 'Mechanisms for low response rates and possible strategies to improve\\\\nbenefit': 0.005338351383633949, 'Findings': 0.032030108301803695, '4. TNFα Role in ALS: Evidence from Patients and Animal Models': 0.0026691756918169746, '5. Concluding Remarks': 0.004003763537725462, 'CG0070': 0.0013345878459084873, 'Intravesical nadofaragene firadenovec': 0.0013345878459084873, 'Dovitinib': 0.0013345878459084873, 'Oncofid-P-B': 0.0013345878459084873, 'Pembrolizumab': 0.0013345878459084873, '5. Potential Treatment Strategies': 0.0026691756918169746, 'THE CURRENT MARKET STATUS': 0.032030108301803695, 'Ongoing trials': 0.02001881768862731, 'Complement specific therapies for complement mediated kidney diseases': 0.046710574606797055, '4. New Perspectives in HER2 Targeting': 0.018684229842718822, 'Donepezil 23 mg in Clinical Practice': 0.0026691756918169746, '5. Other Developments in HER2 Targeting': 0.006672939229542436, '7. Conclusions': 0.013345878459084873, '6. Plant Extracts in Clinical Trials and Ex Vivo Studies of Preeclampsia': 0.0026691756918169746, '5. Intravesical Therapies': 0.010676702767267898, '6. Intravenous Therapies': 0.026691756918169746, 'ADCs in the Early Setting of Breast Cancer': 0.16015054150901847, '7. Intravesical Delivery Systems': 0.004003763537725462, '8. Radiation Therapy': 0.0026691756918169746, '2. Histopathology of Sarcomas Showing': 0.0013345878459084873, '3. TRK-Inhibitory Therapy': 0.016015054150901847, '3. Future Directions': 0.009342114921359411, '11. Limitations of pHLIP Technology': 0.0013345878459084873, 'LIV1-Targeting ADCs': 0.0026691756918169746, 'Challenges and Strategies to Overcome Resistance Mechanisms in ADCs': 0.0013345878459084873, '5. Future': 0.061391040911790415, 'Future concepts and potential combination therapies': 0.0013345878459084873, 'Ethics approval and trial registration': 0.0013345878459084873, '6. Concluding Remarks': 0.0026691756918169746, 'mRNA as Therapeutics: A Clinical Perspective': 0.1174437304399469, 'Emerging data for adjuvant ICIs': 0.0026691756918169746, 'Combination approaches': 0.004003763537725462, 'Vaccines': 0.046710574606797055, '5. Amyloid- and Tau-PET': 0.0013345878459084873, 'Data Availability': 0.014680466304993362, '3. BAP1': 0.018684229842718822, '4. NF2': 0.0026691756918169746, '6. MTAP': 0.0026691756918169746, '7. AXL': 0.0013345878459084873, '8. ASS1': 0.0026691756918169746, '3. Targeting MUC1–Siglec Axis in Cancer': 0.005338351383633949, '4. Ethics, dissemination, and status': 0.0013345878459084873, '6. Registration details': 0.0013345878459084873, '3. Materials and Microstructures': 0.0026691756918169746, 'Case Presentations': 0.0013345878459084873, '4. Present and Future Challenges': 0.0026691756918169746, 'Clinical Implications: Pharmacological Targets beyond Inflammation': 0.028026344764078236, '4. Molecular Aspects in Metaplastic Breast Carcinoma: Associated Mutations, Involved Pathways, and Transcriptomic Features': 0.0013345878459084873, '5. Tumor Immune Microenvironment': 0.0013345878459084873, 'Experimental Procedures': 0.05338351383633949, '3. Pharmacological and Nutritional Interventions': 0.05605268952815647, 'Targeting Sphingolipids and the Complement System in Glioblastoma': 0.037368459685437644, '6. LGL Leukemia Treatment': 0.0013345878459084873, 'SRK in RA': 0.013345878459084873, 'SRK beyond RA': 0.005338351383633949, 'front': 0.0046710574606797055, '5. Targeting Upstream Kinases: STAT Phosphorylation as a Biomarker for On-Target Effects': 0.004003763537725462, '6. Novel Ways to Identify STAT Transcriptional Inhibitors': 0.005338351383633949, 'Hypoxia in pancreatic cancer': 0.0026691756918169746, '2. Programmatic Collaboration': 0.0026691756918169746, '5. Conclusions': 0.022687993380444284, '4. Breast Cancer': 0.0026691756918169746, '6. NK Cells in Cancer Therapy': 0.008007527075450924, 'Medizinische Versorgung/Therapie von ME/CFS': 0.005338351383633949, 'Insulin Sensitivity Transferred from Donors to Recipients': 0.005338351383633949, 'Applications to Urothelial Carcinoma': 0.004003763537725462, '4. Emerging Therapeutics Targeting OL Dysfunction of Potential Utility for Myelin Regeneration in ALS': 0.016015054150901847, 'BASKET TRIALS: PAST, PRESENT, AND FUTURE': 0.06939856798724134, 'Resolvyx Pharmaceuticals’ semisynthetic resolvins': 0.0013345878459084873, '5. Treatment Strategies and Molecular Targets': 0.026691756918169746, 'DIAGNOSIS AND THERAPY': 0.0026691756918169746, 'Ongoing clinical trials and recent advances in technology': 0.008007527075450924, '4. Diagnostics and Treatment': 0.016015054150901847, 'Endocannabinoid Regulation of Pancreatic': 0.0026691756918169746, '6. RECOVER Clinical Trials': 0.0026691756918169746, '2. Methodology': 0.005338351383633949, 'Work-Up': 0.0026691756918169746, 'Advancing therapies for treating diabetic retinopathy': 0.0013345878459084873, '5. Therapeutic Targets and Emerging Therapies': 0.03469928399362067, '8. The importance of including females in studies of behavioral neuroscience': 0.0013345878459084873, '3. Emerging Proteasome Inhibitors Drug Combinations Targeting Different Molecular Pathways': 0.06406021660360739, '2. Monoclonal antibodies': 0.0013345878459084873, '4. Bispecific T cell Engager (BiTE)': 0.0026691756918169746, '6. Bispecific and Trispecific Killer Cell Engagers': 0.0013345878459084873, '4. Evolving Precision Medicine Using Combinatorial Drug Approach': 0.0013345878459084873, 'HISTOPATHOLOGICAL SURVEILLANCE FOR NASH': 0.0026691756918169746, 'CURRENT PHARMACOLOGIC THERAPIES': 0.0026691756918169746, 'MAGNETIC RESONANCE IMAGING (TABLE 3)': 0.0026691756918169746, 'SURVEILLANCE TOOLS IN PATIENTS WITH NAFLD': 0.0026691756918169746, 'Strategies to optimize cardiovascular outcomes in advanced prostate cancer': 0.016015054150901847, 'STRATEGIES TO REVERSE GBC-SPECIFIC DRUG RESISTANCE': 0.017349641996810335, 'Physico-chemical strategies to increase drug retention in PM': 0.021353405534535796, 'Additional experimental systemic treatments': 0.005338351383633949, 'Linagliptin': 0.004003763537725462, 'Material und Methoden': 0.0026691756918169746, 'SGLT2/DPP‐4 inhibitor STCs': 0.010676702767267898, 'Molecular targeted therapy in gastric cancer': 0.018684229842718822, 'The applications of immune checkpoint inhibitors in gastric cancer': 0.07206774367905831, '3. Practical Aspects of the Use of Combination Therapy with Radiotherapy, Chemotherapy and Immunotherapy in NSCLC Patients': 0.008007527075450924, 'Potential molecular biomarkers in target-based and ICI-based treatment for GC': 0.005338351383633949, 'Summary and future perspective': 0.013345878459084873, '7. Conclusions and Future Perspectives': 0.004003763537725462, '2. Compounds in Clinical Trials': 0.004003763537725462, 'Material & Methods': 0.04937975029861403, 'Other potential treatment targets for personalized therapy': 0.0026691756918169746, 'Adoptive cell therapy': 0.016015054150901847, '3. The Genetic Background of Dystonia': 0.0013345878459084873, 'Results of available trials': 0.28293262333259933, 'Targeting AR in Breast Cancer': 0.013345878459084873, '2. Hit Identification and Lead Optimization': 0.0013345878459084873, 'Inhibitors of oncogenic phosphatases': 0.013345878459084873, '2. Non-Invasive Biomarkers for CKD Detection and Assessment of Risk of Progression': 0.0026691756918169746, '5. Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol': 0.0013345878459084873, 'HA in preclinical and clinical cancer trials: challenges and promises': 0.0026691756918169746, 'Improving Outcomes for Children with Retinoblastoma': 0.004003763537725462, 'Accelerating Discovery in Pediatric Solid Tumors': 0.004003763537725462, '9. Decision Support Tools: Biomolecular Prediction Models': 0.0026691756918169746, 'mRNA vaccines combatting bacterial pathogens transmitted by ticks': 0.0026691756918169746, '2. Oligonucleotides Used in Therapeutics': 0.016015054150901847, 'The review of various delivery platforms': 0.03469928399362067, 'Potential therapeutic approaches beyond the 16p11.2 genes': 0.0013345878459084873, 'Acknowledgments': 0.006672939229542436, '4. Neurological Diseases': 0.04804516245270554, '4. Inhibitors of PRMTs': 0.008007527075450924, '3. Materials and Methods': 0.029360932609986724, '3. Recent Advances in HIV-1 Capsid Inhibitors': 0.004003763537725462, '4. KRAS Mutations': 0.03469928399362067, 'Clinical-Translational Advances': 0.013345878459084873, '16. Future Perspectives': 0.0013345878459084873, '2. Methods of Delivery': 0.026691756918169746, '3. Evolution of the Drugs Used: From Unsophisticated Intra-Abdominal Chemotherapy to Complex Systems': 0.013345878459084873, '4. Evolution of the Clinical Indications of HIPEC': 0.018684229842718822, 'Conclusions and future directions': 0.009342114921359411, '2. Diagnosis of Nosocomial Pneumonia': 0.016015054150901847, '3. Novel Approved Antibiotics for Nosocomial Pneumonia': 0.02402258122635277, 'Intracoronary stem cell delivery': 0.004003763537725462, 'Matrix scaffolds and bioengineered myocardial patches': 0.0013345878459084873, '3. HD Treatment': 0.005338351383633949, '4. Clinical Trials for HD Treatment': 0.032030108301803695, 'Future Directions for Clinical Care': 0.0013345878459084873, 'Clinical trials of stem cell therapy in children': 0.012011290613176386, 'Wharton’s jelly mesenchymal stem cells': 0.0013345878459084873, '4. Next Generation Products: The Middle Years': 0.013345878459084873, '6. The Road Ahead': 0.0026691756918169746, '3. Compounds undergoing phase III clinical development for TRD': 0.33097778578530485, 'Cardiac Safety When Adding Other HER2-Targeted Agents': 0.004003763537725462, '3. Treatment of SARS-CoV-2 with Mesenchymal Stem Cells': 0.0013345878459084873, '9. MSC-Derived Exosomes as a Prospective Treatment for COVID-19': 0.0026691756918169746, 'Case reports': 0.0026691756918169746, '4. Compounds in recent phase II clinical trials': 0.32030108301803695, 'Evaluation of AMT-060': 0.0013345878459084873, 'Evaluation of etranacogene dezaparvovec (AMT-061)': 0.0026691756918169746, 'Ravulizumab, mechanisms of action and clinical trials': 0.010676702767267898, 'Other C5 inhibitors': 0.005338351383633949, 'Proximal complement inhibition': 0.016015054150901847, '3. Type I Inhibitors': 0.04270681106907159, 'Therapeutic interventions': 0.013345878459084873, '9. Type VI Inhibitors': 0.0013345878459084873, '6. Expert commentary': 0.04270681106907159, '6. Closing Remarks and Future Perspectives': 0.005338351383633949, '6. Targeting NETs in Cardiovascular Diseases': 0.026691756918169746, 'Example': 0.0013345878459084873, 'Inhibiting Adhesion and Cell-Cell Interactions': 0.010676702767267898, 'Down-regulating Inflammation': 0.010676702767267898, 'Anticoagulants and Anti-platelet Agents': 0.010676702767267898, 'OVERALL STUDY DESIGN': 0.0013345878459084873, 'Result': 0.4457523405334347, '6. Perspectives for Clinical Trials': 0.02402258122635277, '2. United States Food and Drug Administration (FDA)-Approved Drugs for HIV-1 Treatment': 0.005338351383633949, 'THERAPEUTIC SUCCESSES AND CHALLENGES OF IMMUNE CHECKPOINT BLOCKADE': 0.005338351383633949, 'Early Clinical Findings and Safety': 0.0013345878459084873, 'Translational relevance': 0.0026691756918169746, '3. Critical-Sized Bone Defects': 0.0013345878459084873, '6. Osteonecrosis (ON)': 0.0013345878459084873, 'Non-specific Immunotherapy': 0.0026691756918169746, '5. Future Challenges of ACT': 0.0013345878459084873, 'Candidate Drugs That Affect the Aging Process': 0.0026691756918169746, 'Performance in animal models': 0.0026691756918169746, '3. Benefit-Risk Profile of Insulin Icodec, as Compared to Other Basal Insulins': 0.008007527075450924, '4 PARP inhibitors': 0.008007527075450924, 'PI3K/AKT INHIBITORS IN THE CLINIC': 0.03603387183952916, '5. Challenges and Safety Issues in the Development of mRNA-Based Vaccines against Novel Antigens': 0.013345878459084873, '16. Immuno-oncology in the High-Risk and Metastatic Setting': 0.0013345878459084873, '2. Approved Immune Strategies in MM': 0.04003763537725462, '3. Breakthrough Immune Therapies in MM': 0.07206774367905831, 'PATHOPHYSIOLOGY REVEALED BY CHANGES OF PANCREATIC ISLET‐ASSOCIATED AUTOANTIBODY MEASUREMENT METHOD': 0.0013345878459084873, '4. Future Approaches in MM Treatment': 0.026691756918169746, '4. Concluding Remarks and Future Perspectives': 0.0026691756918169746, '5. Strike Early and Strong': 0.008007527075450924, 'Clinical Trial Design and Methods': 0.0013345878459084873, '7. Perspective': 0.006672939229542436, '4. Metastatic Setting': 0.014680466304993362, '5. A New Entity: HER2low BC': 0.013345878459084873, 'Clinical Trials of CD137': 0.07473691937087529, '5. Targeted Therapy': 0.012011290613176386, 'IMAGING MODALITIES BEYOND US': 0.018684229842718822, '2. The Vaccine Candidates': 0.04404139891498008, 'TARGETING TRANSPORTERS IN THE TREATMENT OF NEUROLOGICAL DISEASES': 0.0013345878459084873, '5. Immunoscore and Immunotherapy': 0.0013345878459084873, 'SECOND-LINE SYSTEMIC AGENTS': 0.010676702767267898, 'COMBINATION OF IMMUNOGENIC IO LOCAL THERAPY AND SYSTEMIC ICI IMMUNOTHERAPY': 0.010676702767267898, 'LOCAL TUMOR TARGETED COMBINATION IO LOCAL THERAPY AND ICI IMMUNOTHERAPY': 0.021353405534535796, 'BIOMECHANICAL CONTRIBUTIONS TO DISEASE PATHOGENESIS AND IMPLICATIONS FOR THERAPY': 0.005338351383633949, '3. Recent developments in SLE therapy': 0.07473691937087529, 'THE ROLE OF MRI IN CHRONIC RHINOSINUSITIS: ADVANTAGES AND LIMITATIONS': 0.0026691756918169746, '3. CTO Revascularization: When? Who?': 0.010676702767267898, 'DC': 0.0026691756918169746, '2. Metformin as an Anticancer Drug: In Vivo and In Vitro Studies': 0.03336469614771218, 'Current Pitfalls and Potential Remedies': 0.016015054150901847, 'Moving Beyond Artisanal T-cell Production': 0.0026691756918169746, 'Targeted therapies: the new kids on the block': 0.013345878459084873, 'Tumor cell intrinsic pathways that modulate the TME and interfere with immunity': 0.0026691756918169746, 'Strategies for prevention and treatment of relapse': 0.06406021660360739, '3. EpCAM': 0.016015054150901847, '4. CD44': 0.016015054150901847, '2. Blood Pressure Variability': 0.008007527075450924, '6. CXCR4': 0.061391040911790415, 'The Next Generation - Enabling Technologies': 0.04804516245270554, '5. Epigenetics of Chondrosarcoma': 0.005338351383633949, '7. CD133': 0.013345878459084873, '9. Notch': 0.10676702767267898, '6.  Effect of Pet and EspC on Fodrin and the Actin Cytoskeleton': 0.0013345878459084873, 'Interactions Between TME and LTICs in Promoting Liver Cancer Stemness': 0.008007527075450924, '10. Wnt/β-Catenin': 0.06672939229542436, '3. Results and Discussion': 0.014680466304993362, 'Ongoing approaches for treating SCI': 0.022687993380444284, '3. Cellular Immunotherapy Targeting CSCs': 0.010676702767267898, 'Materials and Methods.': 0.0046710574606797055, '11. SOX2': 0.032030108301803695, '12. Hedgehog': 0.05605268952815647, '13. Conclusions': 0.17483100781401184, 'Intervention strategies targeting the endothelium': 0.0026691756918169746, '2. Results and Discussion': 0.02535716907226126, '5. The Influence of Anesthetic Drugs on Neutrophils and Their Functions': 0.026691756918169746, 'Other developments and future applications': 0.0026691756918169746, 'The ‘upstream’ therapy of AF and the randomized clinical trials (RCTs)': 0.0026691756918169746, '2. Study Methods, Adaptations for COVID-19, and Their Implications': 0.005338351383633949, '6. Treatment': 0.028026344764078236, '3. Monoaminergic systems in AD': 0.0026691756918169746, 'miRs and potential treatment of bone metastases': 0.0013345878459084873, 'EXPERIMENTAL PROCEDURES': 0.032030108301803695, '3. Molecular Targeted Agents Plus R-CHOP': 0.0026691756918169746, 'Case report': 0.014680466304993362, 'Conclusion and (no) place in therapy': 0.0026691756918169746, '2. Subjects and Methods': 0.009342114921359411, 'Future directions and ongoing clinical trials': 0.02402258122635277, '2. Panretinal Pigmentary Retinopathies': 0.005338351383633949, 'Clinical efficacy': 0.029360932609986724, '5. Conclusions and Future Outlooks': 0.0013345878459084873, 'Safety of elotuzumab treatment': 0.0026691756918169746, 'Immunotherapy': 0.2415604001094362, 'Androgen targeted Therapy': 0.005338351383633949, 'USE OF CSF BIOMARKERS IN CLINICAL TRIALS OF PATIENTS WITH NDs': 0.037368459685437644, '4. Immunotherapy in Adrenocortical Carcinoma: Efficacy': 0.032030108301803695, 'THERAPY': 0.0013345878459084873, '4. Venetoclax Combinations in the Treatment of AML in AYAs': 0.005338351383633949, 'NOVEL THERAPIES': 0.006672939229542436, 'Cancer stem cells and tumor chemotherapy resistance': 0.06939856798724134, '2. Experimental Section': 0.014680466304993362, 'Cancer stem cells and tumor immunotherapy resistance': 0.11210537905631295, 'Safety and Tolerability': 0.010676702767267898, '3. Why Do We Need to Identify Novel Molecular Perturbations?': 0.037368459685437644, 'Cancer stem cells and sensitivity/resistance to radiotherapy': 0.04003763537725462, 'Main Text': 0.2802634476407823, 'Cancer stem cells and targeted therapy': 0.005338351383633949, '4. Efficacy of Direct': 0.004003763537725462, 'Therapeutic strategies targeting CSCs': 0.08541362213814319, '5. Conclusions and Future Perspectives of Combination Therapeutic Approaches': 0.009342114921359411, 'Drug delivery system for targeting CSCs': 0.0013345878459084873, '5. Future Research and Conclusions': 0.004003763537725462, '5. Strategies to Prevent Resistance to Novel Agents': 0.05071433814452252, 'A therapeutic confectionary menu': 0.010676702767267898, 'Other Potential Anti-Inflammatory Targets for Small Molecules': 0.005338351383633949, 'Concluding Remarks': 0.006672939229542436, '4. Anti-Inflammatory Drugs for the Treatment of AD': 0.018684229842718822, '4. DNA VACCINES – MECHANISMS OF RESISTANCE; COMBINATION THERAPIES TO PREVENT TUMOR EVASION': 0.010676702767267898, '6. CLINICAL TRIALS WITH DNA VACCINES FOR PROSTATE CANCER': 0.016015054150901847, '7. SUMMARY AND FUTURE DIRECTIONS – PROSTATE CANCER DNA VACCINES': 0.0026691756918169746, 'Acknowledgements': 0.04537598676088857, 'Methods and Design': 0.02001881768862731, '2. Importance of Supporting Neurotrophic Factors as a Therapeutic Strategy for Neurodegenerative Diseases': 0.0026691756918169746, '5 Innovative strategies in combating antibiotic resistance': 0.026691756918169746, '2 Therapeutical gut-directed approaches in PD': 0.016015054150901847, 'CONFLICT OF INTEREST STATEMENT': 0.008007527075450924, 'TOPCAT TRIAL': 0.0026691756918169746, 'TREATMENT UPDATE ON NAFLD': 0.016015054150901847, 'Recent advances in stem cell research for stroke therapy': 0.005338351383633949, 'HISTONE DEACETYLASES INHIBITORS': 0.037368459685437644, 'NUCLEAR FACTOR-κBp SIGNALING': 0.02402258122635277, 'DEFATTING STRATEGIES': 0.0013345878459084873, '4. Combining mTOR Inhibitors and Immunotherapies in Cancer Therapy': 0.008007527075450924, 'Subjects': 0.010676702767267898, '4. Strategies for targeting eIF4E in AML': 0.0026691756918169746, '4. GPER in Breast and Other Cancers': 0.0026691756918169746, '5. Biomarkers of Brain Dysfunction in Perinatal ID': 0.005338351383633949, '6. Biomarker-Based Iron Supplementation for Optimizing Neurodevelopment': 0.005338351383633949, '6. NK Cells in the Context of Immunotherapies': 0.03469928399362067, 'Clinical efficacy of palbociclib in combination with hormone therapy': 0.005338351383633949, 'IMPAIRMENT OF THE': 0.0013345878459084873, 'THE': 0.008007527075450924, 'Cytotoxic agents': 0.0026691756918169746, 'New agents': 0.005338351383633949, 'Molecular therapies': 0.0026691756918169746, 'Efficacy studies including any relevant case studies and ongoing studies': 0.0026691756918169746, 'HBV': 0.005338351383633949, 'disp-quote': 0.0013345878459084873, '9. Targeting FGF/FGFR': 0.026691756918169746, 'GENE THERAPY': 0.005338351383633949, 'THERAPEUTIC APPROACHES': 0.15881595366311, 'Treatment of Other Malignancies with CAR Modified T Cells': 0.005338351383633949, 'Challenges in Current Clinical Use of CAR T cells': 0.005338351383633949, '2. Whole vs. isolated compound entities': 0.005338351383633949, '5. Looking Forward': 0.037368459685437644, 'CLINICAL EFFICACY OF GEMIGLIPTIN': 0.04270681106907159, '4. New Results': 0.0013345878459084873, '5. Validation of LT as a Standard Treatment Option for Patients with Nonresectable CRLM': 0.004003763537725462, '8. Ongoing Studies': 0.0013345878459084873, '9. New Concepts to Expand the Donor Pool': 0.005338351383633949, 'T-BOX transcription factors in tumor treatment': 0.005338351383633949, '5. Novel Compounds': 0.03469928399362067, 'Common types of RT': 0.005338351383633949, 'Timing and dose considerations for the application of adjuvant RT': 0.0013345878459084873, 'Can RT be avoided': 0.0013345878459084873, 'RT target and dose': 0.0013345878459084873, 'PRECLINICAL TESTING OF NGF BLOCKADE IN ANIMAL MODELS OF OA': 0.005338351383633949, 'Anti-CTLA-4 blockade': 0.0026691756918169746, 'PD1 and PD-L1 blockade': 0.017349641996810335, '2. Materials/Subjects and Methods': 0.0026691756918169746, 'Monoclonal antibodies': 0.0026691756918169746, 'Antibody drug conjugate': 0.008007527075450924, 'Failure to first-line treatment in patients with advanced': 0.005338351383633949, '2. DRD: More Than a Vasculopathy': 0.0026691756918169746, '5. Shared Pathophysiology of DRD and DKD: An Avenue for Further Investigation': 0.0013345878459084873, 'Supplementary Material': 0.012011290613176386, 'Switching to chemotherapy': 0.0026691756918169746, 'Predictive and prognostic biomarkers of modern immunotherapy agents': 0.04804516245270554, 'Molecular alterations of': 0.0013345878459084873, 'Trk inhibitors': 0.017349641996810335, 'Primary liver cancer and liver cirrhosis': 0.010676702767267898, 'Landscape': 0.04537598676088857, 'Oral Treatment Options': 0.037368459685437644, '6. Combining Radiotherapy with Immune Checkpoint Inhibitors': 0.010676702767267898, 'Surgical and Device-Aided Therapies': 0.005338351383633949, 'Expert Opinion and Conclusions': 0.0026691756918169746, '5. Tumoricidal agents': 0.010676702767267898, 'Ethics and funding': 0.0026691756918169746, 'Results of the Consensus Process': 0.005338351383633949, 'Gene therapy applications in the CNS require a dox-sensitive TET-On system': 0.0013345878459084873, '9. Phytocompounds or Phytocompound-Based Products That Reached the Clinical Trials Phase in GBM Research': 0.012011290613176386, 'CONFLICTS OF INTEREST': 0.012011290613176386, 'Harnessing the unique features of NK cells for a functional cure': 0.005338351383633949, '\\\\n': 0.1267858453613063, 'FUTURE PERSPECTIVES': 0.037368459685437644, 'Mechanism of Action': 0.026691756918169746, 'Drugs currently undergoing clinical trials': 0.0026691756918169746, 'Drugs currently in clinical use': 0.010676702767267898, '7. Summary': 0.0013345878459084873, '6. Conclusions and Future Directions': 0.012011290613176386, 'Clinical Activity': 0.0026691756918169746, 'TARGETED THERAPY': 0.38436129962164434, '5. Clinical Trials for the Detection of MSI in Circulating Tumor DNA (ctDNA)': 0.0026691756918169746, '3. Current Available Systemic Therapies for the Treatment of Advanced and Multimetastatic Thyroid Cancer': 0.018684229842718822, '4. Drugs under Evaluation': 0.04270681106907159, 'Disclosure': 0.009342114921359411, 'BEATING RESISTANCE TO TARGETED THERAPY': 0.08274444644632621, '4 CONCLUSION': 0.0013345878459084873, '4. T-VEC Clinical Experience in Combination': 0.004003763537725462, 'Ethics Approval': 0.009342114921359411, 'CYTOTOXICITY': 0.008007527075450924, 'DRUG DELIVERY': 0.0026691756918169746, '3. Isocitrate Dehydrogenase NADP(+) 1 and 2': 0.0026691756918169746, 'Progress in the development of SMA therapeutics': 0.021353405534535796, 'Therapeutic complements to SMN upregulation': 0.004003763537725462, '3) Treatment options in patients with MBM': 0.010676702767267898, '4) The BBB poses a significant challenge to therapies': 0.05338351383633949, 'Facts and numbers': 0.005338351383633949, '2. Study Design': 0.0013345878459084873, 'Second-generation ALK inhibitors': 0.021353405534535796, 'Translational efforts': 0.0013345878459084873, 'DSC-BASED CLINICAL TRIALS FROM PUBLISHED ARTICLES': 0.032030108301803695, 'Vacuolar ATPase': 0.010676702767267898, 'DSC-BASED CLINICAL TRIALS FROM CLINICAL DATABASES': 0.03336469614771218, 'Exercise and its potential to influence pain mechanisms in OA': 0.0026691756918169746, 'Treatment of HCM': 0.032030108301803695, 'CMV vaccines currently in clinical trials': 0.03870304753134614, 'Recombinant gB vaccines': 0.004003763537725462, 'DNA vaccines for CMV': 0.008007527075450924, 'Peptide vaccines': 0.004003763537725462, 'Vectored vaccines': 0.0026691756918169746, 'Attenuated and ‘DISC’ vaccines': 0.0013345878459084873, 'Perspective': 0.009342114921359411, '2. Experimental procedures': 0.005338351383633949, 'Role of ICIs for persistent, recurrent, and metastatic disease following platinum failure': 0.010676702767267898, 'ICIs for persistent, recurrent, and metastatic disease in the frontline setting': 0.006672939229542436, 'Role of ICIs in the locally advanced cervical cancer setting': 0.006672939229542436, 'Novel immunotherapy approaches in cervical cancer': 0.021353405534535796, 'ADVANCE OF THE YEAR: CANCER IMMUNOTHERAPY': 0.03469928399362067, 'Role of neoadjuvant treatment': 0.016015054150901847, 'Role of immunotherapy': 0.0013345878459084873, 'The molecular landscape of pancreatic cancer: new therapeutic opportunities': 0.0026691756918169746, 'SINGLE IMMUNE AGENT THERAPY': 0.06406021660360739, '6. Amyotrophic Lateral Sclerosis': 0.0013345878459084873, 'COMBINATION OF DOUBLE IMMUNE AGENTS THERAPIES': 0.012011290613176386, 'COMBINATION OF IMMUNE AGENTS AND ANTI-ANGIOGENIC DRUG THERAPIES': 0.09342114921359411, '3. Cell-based therapeutic strategies for RDDs': 0.18150394704355427, 'T-antigen–reactive T cells in patients treated with pembrolizumab': 0.0013345878459084873, '2. Dexibuprofen Main Pharmacological Properties': 0.008007527075450924, 'Pembrolizumab (lambrolizumab, MK-3475)': 0.0026691756918169746, 'Clinical trial of antiprogrammed death ligand-1 therapies in gastric cancer': 0.005338351383633949, 'COMBINATION OF IMMUNE AGENTS AND LOCOREGIONAL THERAPIES': 0.021353405534535796, 'ADOPTIVE CELL TRANSFER': 0.03469928399362067, 'Safety, dosing and tolerability': 0.0013345878459084873, 'TUMOR VACCINE': 0.032030108301803695, 'Alemtuzumab in multiple sclerosis': 0.008007527075450924, '4. Repurposed Drugs for Pancreatic Cancer in Clinical Trials': 0.14947383874175058, 'Tackling tumor heterogeneity': 0.037368459685437644, 'HBOT clinical trials': 0.026691756918169746, 'Improving CAR-T cell safety': 0.12812043320721478, 'Does HBOT improve TBI and PTSD symptoms?': 0.004003763537725462, 'Purified Recombinant Circumsporozoite Protein Vaccine, RTS,S/AS01': 0.06939856798724134, 'Optimizing CAR-T cell functionality': 0.010676702767267898, 'Novel Developments: Dual LABA/LAMA Fixed Combinations': 0.0013345878459084873, 'Current outcomes of pancreatic islet transplantation': 0.0013345878459084873, 'β-cell replacement options: stem cells and porcine islets': 0.008007527075450924, 'Ongoing challenges of islet transplantation immunosuppression': 0.008007527075450924, 'Heterologous Prime Boost with DNA, Recombinant Viruses and Bacteria and Recombinant Protein with Adjuvant': 0.0013345878459084873, 'Ethics Committee Approval': 0.0013345878459084873, 'New Drugs Synthesized for Antimalarial Treatment under Phase Trials': 0.029360932609986724, 'What were the “highlights” in your recent development of vaccines/immunotherapeutics?': 0.0013345878459084873, '3. Results, Ethics and Dissemination': 0.0026691756918169746, '4. DISCUSSION': 0.013345878459084873, 'Primary Prevention: Prophylactic HPV Vaccination': 0.0026691756918169746, 'IMMUNOTHERAPY UPDATE: ANTI-PD-1/PD-L1 ANTIBODY IN OVARIAN CANCER': 0.0013345878459084873, 'HORMONE THERAPIES AND ENDOMETRIAL CANCER RISK': 0.0013345878459084873, 'TRABECTEDIN: ANOTHER FDA-APPROVED OPTION FOR LEIOMYOSARCOMA': 0.0013345878459084873, 'TARGETED THERAPY UPDATE IN GYNECOLOGIC CANCER': 0.0026691756918169746, '3. Therapeutic Approaches Redirecting Immuno-Suppressive Microenvironment': 0.05071433814452252, '3. Immune Checkpoint Inhibitors': 0.021353405534535796, '6. Sequencing and Combinations of BRAF/MEK Inhibitors and Immune Checkpoint Inhibitors': 0.010676702767267898, 'Major concerns': 0.0013345878459084873, 'Efficacy and comparative studies': 0.10676702767267898, 'FUTURE DIRECTIONS FOR THERAPY': 0.08674820998405168, 'Chronic Viral Infections': 0.010676702767267898, '6. Clinical Implications of Endoglin': 0.010676702767267898, 'Considerations of 5-HT': 0.0026691756918169746, 'Oxytocin administration studies in individuals with ASD': 0.021353405534535796, 'Outstanding issues with oxytocin administration, and further studies': 0.0026691756918169746, 'METHODS AND ANALYSIS': 0.032030108301803695, 'NNMT and NAD': 0.010676702767267898, 'Concluding Remarks and Future Perspectives': 0.005338351383633949, 'Trial design': 0.006672939229542436, '5. Current Areas of Research': 0.022687993380444284, 'Circadian Biology in Today’s Clinical Trials': 0.030695520455895207, '5. Anticancer Effects and Mechanisms': 0.005338351383633949, 'Genes that Promote Cervical Cancer Development': 0.005338351383633949, '6. Concluding Remarks JME': 0.0013345878459084873, 'HIPPO SIGNALLING PATHWAY IN EYE DISEASES': 0.005338351383633949, 'Neurotrophins and Parkinson’s Disease': 0.0026691756918169746, 'Treatment of RRMM in Europe: The Current Therapeutic Landscape': 0.14146631166629967, 'Research registration number': 0.006672939229542436, 'Therapeutic status of endocrine resistant breast cancer and new choices': 0.026691756918169746, '6. Heparanase inhibitors in cancer therapy': 0.010676702767267898, 'New therapeutic options for advanced HR': 0.0013345878459084873, 'DCV DDIs and Dosing Guidance with Other Antiviral Agents': 0.010676702767267898, 'TRANSLATIONAL THERAPEUTICS': 0.008007527075450924, '2. TMR for the Upper Extremity': 0.005338351383633949, 'CONCLUSIONS AND PROSPECTIVE': 0.0013345878459084873, 'Blockade of CTLA-4/CD80/86': 0.0013345878459084873, 'Targeted therapy': 0.3229702587098539, 'IMPLICATIONS AND ONGOING CLINICAL TRIALS': 0.013345878459084873, 'Heparanase Inhibitors as Novel Cancer Therapeutics': 0.005338351383633949, 'Genetically engineered oncolytic viruses': 0.010676702767267898, 'Naturally occurring oncolytic viruses': 0.0026691756918169746, 'Oncolytic virus as immunotherapy': 0.004003763537725462, 'Rationale for combination therapy': 0.008007527075450924, 'Emerging strategies to target cancer cells in GBM': 0.029360932609986724, 'Combination therapies in GBM': 0.0013345878459084873, 'Implications': 0.0026691756918169746, 'Clinical mapping methods for the rotor: pros and cons': 0.010676702767267898, 'Opportunities for ASD clinical trial improvements': 0.005338351383633949, 'OVERVIEW OF TISOTUMAB VEDOTIN': 0.0013345878459084873, 'CLINICAL MANAGEMENT OF OCULAR ADVERSE EVENTS': 0.0013345878459084873, 'FUTURE PLANS AND CONSIDERATIONS': 0.0013345878459084873, 'Drug resistance and cancer cell plasticity': 0.026691756918169746, 'Targeting B7-H3 in CRC': 0.0026691756918169746, '5. Unresolved Key Issues in the Pharmacological Management of Non-IPF F-ILD: Where We Would Like to Be': 0.018684229842718822, '2. Single immunotherapies for glioma': 0.010676702767267898, '3. Combination immunotherapeutic strategies for glioma': 0.16015054150901847, 'Preoperative Risk Assessment': 0.0026691756918169746, '2. Cell Therapeutics: The Past, the Present and the Future': 0.10409785198086201, 'Behavioral Economic Approaches to Reducing Smoking in SMI': 0.004003763537725462, 'Drug Delivery Pathways': 0.0026691756918169746, 'Locoregional Approaches to Therapeutic Delivery': 0.05071433814452252, 'Clinical Trials and Future Directions': 0.0026691756918169746, 'Future perspectives on Sam68-targeting drug discovery': 0.0013345878459084873, 'Data Availability Statement': 0.0026691756918169746, 'Statement of Ethics': 0.012011290613176386, 'APPLICATIONS OF iPSCs': 0.005338351383633949, '3. Immunotherapy Approaches in Treatment of ALK-Rearranged NSCLC': 0.016015054150901847, 'Contributions': 0.0013345878459084873, 'Overcoming KRAS(G12C) OFF resistance': 0.0013345878459084873, 'Modulation of gut microbiota': 0.0026691756918169746, 'SGLT2 inhibitors and BP control': 0.008007527075450924, '2. Ion Channel Targets': 0.016015054150901847, '3. TMEM16A': 0.0013345878459084873, '5. BK Channels': 0.0013345878459084873, 'Development of CFTR potentiators for COPD with chronic bronchitis': 0.004003763537725462, 'Septins and neurological disorders': 0.0013345878459084873, 'Patient and methods': 0.0013345878459084873, 'supplementary material': 0.021353405534535796, '2. Research design and study population': 0.010676702767267898, '8. Discussion': 0.022687993380444284, 'THE LSD1 LYSINE DEMETHYLASE IN CANCER': 0.005338351383633949, '5. Immunotherapeutic Options and Conventional Radiotherapy': 0.032030108301803695, 'Background about SCOTS': 0.0013345878459084873, 'Literature Description': 0.016015054150901847, '2. Design and methods': 0.005338351383633949, 'FLAVIVIRIDAE': 0.0026691756918169746, 'SURGICAL IMMUNE INTERVENTIONS': 0.005338351383633949, 'MULTIMODALITY IMMUNOTHERAPY': 0.0026691756918169746, 'Mandatory Factors in an Optimized Therapeutic Strategy Using MSCs for ALS': 0.016015054150901847, 'Iron metabolism as a therapeutic target': 0.010676702767267898, 'TEXT': 0.008007527075450924, 'PDE4': 0.021353405534535796, 'PDE10': 0.018684229842718822, '2. Small Molecule Drugs and Potential Synergy with Immune Checkpoint Inhibition': 0.018684229842718822, 'Clinical trials of ICIs in CRC': 0.005338351383633949, 'The limitation of ICI therapy in CRC': 0.04804516245270554, 'A. Gene therapy historical development': 0.005338351383633949, 'Combination of ICIs with other therapies': 0.005338351383633949, 'Chemotherapy': 0.021353405534535796, '5. Effects of Currently Available Therapies on GI Symptoms': 0.0026691756918169746, '3. Functional components of the Breast Milk Fat Globule (MFG)': 0.0026691756918169746, 'Effective adjuvants and vaccine delivery system': 0.0013345878459084873, 'CLINICAL APPLICATION OF RIC IN STROKE': 0.03336469614771218, 'ARGININE DEIMINASE': 0.016015054150901847, 'Examples of research': 0.0013345878459084873, 'PI3K/AKT/mTOR Pathway and Their Inhibitors': 0.04804516245270554, 'PI3K/AKT/mTOR Pathway Induces Drug Resistance in Breast Cancer': 0.09075197352177714, 'Potential Predictive Biomarkers of Response or Resistance to PI3K Inhibitors': 0.0026691756918169746, 'Discussion and Conclusion': 0.018684229842718822, 'Potential strategies, research gaps, and future directions': 0.010676702767267898, 'A Repair-Cell Therapy Approach for Parkinson’s Disease: A Summary of Safety,\\\\nFeasibility, and Clinical Data for 68 Participants': 0.0026691756918169746, 'METHODS AND RESOURCES': 0.005338351383633949, 'Ion channels define activity pattern and Ca': 0.005338351383633949, 'Discussion and conclusion': 0.013345878459084873, 'Targeting NETs as Therapy in AAV': 0.005338351383633949, 'Is targeting ROS for MDS therapy feasible?': 0.016015054150901847, 'Clinical trials of CAR-T therapy for solid tumors': 0.33765072501484733, '3. Mechanisms of immune escape in HNSCC and implications for therapeutic targets': 0.05338351383633949, 'Methods for the detection of EGFR ex20ins': 0.0013345878459084873, 'Treatment of EGFR ex20ins': 0.5124817328288591, '4. Future directions': 0.018684229842718822, 'Clinical and pathogenic description of the Mendelian (monogenic) autoinflammatory interferonopathies CANDLE and SAVI': 0.005338351383633949, 'Immunotherapeutic Strategies in HCC': 0.09609032490541108, 'Using CRISPR-Cas to make therapeutics': 0.037368459685437644, 'Rationale for Combination Therapy of ICIs and Molecular Targeted Agents': 0.0026691756918169746, 'The Role of Tyrosine Kinase Inhibitors Post-ICI': 0.04270681106907159, 'Clinical Trials on Therapeutic Small Extracellular Vesicles': 0.012011290613176386, 'Details of ethics approval': 0.0026691756918169746, 'THE ROLE OF NONCANONICAL WNT PATHWAYS IN PROSTATE CANCER': 0.0013345878459084873, 'Study selection': 0.021353405534535796, 'PROSTATE CANCER GENETICS AND THE RESPONSE TO IMMUNOTHERAPY': 0.03469928399362067, 'ANTIANDROGEN AND THE TME': 0.013345878459084873, '4. Management and Treatment': 0.005338351383633949, '2. Experimental methods': 0.0026691756918169746, 'Therapies for TNBC': 0.13879713597448268, '4. Conclusion': 0.010676702767267898, 'Trial organization and administration': 0.0026691756918169746, '5. Importance and Future Perspectives': 0.005338351383633949, 'The immune system and TNBC': 0.016015054150901847, 'Targeting TMPRSS6 for Iron-Restrictive Therapy in Hematologic Disorders': 0.008007527075450924, 'Pipeline of HA Drugs': 0.018684229842718822, '4. Clinical Investigations of Immunocytokines': 0.0026691756918169746, 'Gene Therapy and Virotherapy in Glioma': 0.021353405534535796, 'Medulloblastoma': 0.0026691756918169746, 'Exploration of CAR-T-cell therapy targets in T-cell malignancies': 0.0840790342922347, 'Approaches to Gene Therapy': 0.09075197352177714, 'R': 0.028026344764078236, 'Immune Stimulatory Gene Therapy': 0.016015054150901847, 'Oncolytic Virotherapy': 0.016015054150901847, 'Combination Therapies': 0.012011290613176386, 'Phagocytosis Checkpoint Blockade': 0.03870304753134614, 'Current Studies of CAR-Macrophages': 0.0013345878459084873, 'Future therapeutic prospects of NGPs': 0.009342114921359411, 'Oral Testosterone Undecanoate Formulations': 0.021353405534535796, 'INPs under clinical trials for breast cancer diagnosis and treatment': 0.032030108301803695, 'Therapeutic Potential of Placenta and Umbilical Cord-Derived Stem Cells in Bronchopulmonary Dysplasia': 0.04270681106907159, 'Exercise in Prostate Cancer Patients on ADT': 0.006672939229542436, 'Expanding Accessibility and Enrollment to Precision-Oncology Studies': 0.018684229842718822, 'TRAIL-R Agonistic Antibodies': 0.05338351383633949, 'Combination Strategies': 0.016015054150901847, 'Malignant melanoma therapy': 0.0013345878459084873, 'Application of Nanomedicines in Treating Cold Tumors': 0.010676702767267898, 'Role of immunotherapy in thymic tumors with or without co-morbidities with ADs': 0.02402258122635277, 'Therapeutic options for cancer-chemotherapy-related anemia': 0.021353405534535796, 'Treatments to Restore the Intestinal Microbiome': 0.0026691756918169746, 'Database and Methods': 0.005338351383633949, 'Clinical Trials of MSCs Therapy in KD': 0.052048925990431004, 'SLE': 0.0013345878459084873, 'Different mechanisms involved in the development of SLE': 0.0013345878459084873, 'Retinal Gene Therapy Clinical Trials': 0.09609032490541108, 'Clinical trial for PTSD prevention by omega-3 fatty acids': 0.0013345878459084873, 'Targeted therapies': 0.021353405534535796, 'Novel therapies': 0.0026691756918169746, 'MITOCHONDRIAL MEDICINE AND ALZHEIMER’S DISEASE': 0.21353405534535796, 'ACKNOWLEDGEMENTS': 0.0026691756918169746, 'Statistical Design and Methods': 0.0026691756918169746, 'Targeting PDE Isoforms in\\\\nthe CNS': 0.0026691756918169746, 'MITOCHONDRIAL MEDICINE IN ALS': 0.06406021660360739, 'Clinical Trials': 0.12812043320721478, 'Therapeutic Strategies Targeting Mitochondrial Dysfunction': 0.021353405534535796, 'Infections and Neurodegenerative Diseases': 0.0013345878459084873, 'APPROVED DAA-BASED TREATMENTS IN PATIENTS WITH COMPENSATED CIRRHOSIS': 0.037368459685437644, 'PRECISION MEDICINE AND ITS POTENTIAL BENEFITS IN ALLEVIATING RACIAL DISPARITIES': 0.03870304753134614, 'Limitations': 0.02535716907226126, 'SUBJECTS, MATERIALS AND METHODS': 0.0026691756918169746, 'The TME’s Role in PDAC Development and Progression': 0.032030108301803695, 'Cellular Immunotherapy': 0.04270681106907159, 'Vaccine Immunotherapy Strategies for PDAC Treatment': 0.08541362213814319, 'Approaches to treatment': 0.005338351383633949, 'Does serotonin modulate TRPV1 channels?': 0.0026691756918169746, 'MAIN TEXT': 0.012011290613176386, '3. Vaccinal Approaches Based on the Structure of Anti-HIV Antibodies': 0.008007527075450924, 'Engineered TCRs': 0.0013345878459084873, 'Multispecific engagers binding NK cells in cancer and infectious diseases': 0.005338351383633949, 'CREST-2: Two Parallel Trials, Three Methods of Stroke Prevention': 0.005338351383633949, 'Milvexian': 0.005338351383633949, 'THERAPEUTIC POTENTIAL OF SEROTONERGIC PATHWAY IN CANCER': 0.04270681106907159, 'Research registration unique identifying number (UIN)': 0.04937975029861403, 'Ethics approval and registration': 0.0013345878459084873, 'PSMA-Directed Chemotherapy': 0.005338351383633949, 'EFFICACY AND SAFETY OF G‐POEM': 0.0026691756918169746, 'miRNAs as diagnostic and prognostic biomarkers for pancreatic cancer': 0.04003763537725462, 'Inhibitors of p21-Activated Kinases': 0.004003763537725462, 'miRNAs as therapeutic targets in pancreatic cancer': 0.0013345878459084873, 'Therapeutic Targeting of TGF-β Signaling Pathway': 0.008007527075450924, 'Engineering Mesenchymal Stromal Cells for Enhancing Their Therapeutical Properties': 0.02535716907226126, 'Protein Modification by Acetylation of Lysine Residues: The Acetylosome': 0.013345878459084873, 'Integrated Brain, Body, and Social (IBBS) Intervention': 0.0013345878459084873, 'Early clinical data of RAF inhibitors in melanoma patients': 0.006672939229542436, 'Rationally designed combination drug therapy': 0.0026691756918169746, 'Adoptive transfer clinical trials': 0.016015054150901847, 'Rabbits: The': 0.0013345878459084873, 'IgE pathway targets': 0.005338351383633949, 'The Clinical Perspective: Concluded and Ongoing Trials': 0.008007527075450924, 'Methods: Participants, interventions and outcomes': 0.0026691756918169746, 'MATERIAL & METHODS': 0.0026691756918169746, 'EXPERIENCES ON ANTI-HCV THERAPIES IN POPULATIONS AT RENAL RISK': 0.0026691756918169746, 'Treatment of LSECs in liver diseases': 0.0013345878459084873, 'Risk factors of subfertility in SpA women of childbearing age': 0.0026691756918169746, 'Introduction and background': 0.004003763537725462, '9 Conclusion': 0.004003763537725462, 'UPS': 0.021353405534535796, 'Conclusions and prospects': 0.009342114921359411, 'CAR-T cell therapy in multiple myeloma': 0.13345878459084873, '2. Experimental': 0.010676702767267898, 'Approaches to Address Ibrutinib Intolerance': 0.12278208182358083, 'CTLA-4': 0.016015054150901847, 'PD-1': 0.06406021660360739, 'PD-L1': 0.018684229842718822, 'Antibody-Based Therapeutics in Metastatic RCC: Early Lessons From the Clinic': 0.0026691756918169746, '3. Oncolytic Viruses': 0.0026691756918169746, 'TREATMENT STRATEGIES FOR MN': 0.005338351383633949, 'Development of PARP inhibitors in prostate cancer used alone or in combination': 0.13078960889903174, 'PARP inhibitors in 2021: Where are we? What will be the future challenges?': 0.0026691756918169746, '2. Avibactam': 0.005338351383633949, '3. Vaborbactam': 0.016015054150901847, '5. Proposed Roles in Therapy': 0.0026691756918169746, 'back': 0.003336469614771218, 'Clinically relevant drug-target biomarkers': 0.0026691756918169746, 'Recent advances in endovascular treatment': 0.016015054150901847, 'Endovascular treatment in specific locations': 0.005338351383633949, 'Selexipag and ACT-333679': 0.0026691756918169746, 'Materials and methods animals and vaccines': 0.009342114921359411, 'Clinical studies': 0.005338351383633949, 'Cardiovascular Outcome Trials': 0.04270681106907159, 'Reported Outcomes With Low-Dose Ponatinib': 0.0013345878459084873, 'Advances in the treatment of cardiac amyloidosis': 0.021353405534535796, 'Supporting information': 0.02535716907226126, 'Methods and subjects': 0.0026691756918169746, 'Precision medicine prescriptions': 0.008007527075450924, 'FLT-3': 0.0013345878459084873, 'CD123': 0.004003763537725462, 'e-PROMs and Digital Narrative Medicine: A Novel Person-Based Framework for Integrative Oncology': 0.0013345878459084873, 'CLINICAL TRIALS USING MSCS': 0.11877831828585537, 'Molecularly targeted therapy in pediatric ALL': 0.029360932609986724, 'Immunotherapy in pediatric ALL': 0.016015054150901847, 'MANAGEMENT OF RESECTABLE GC': 0.026691756918169746, 'Conclusions and Future Perspectives': 0.014680466304993362, 'IMPACT OF OBESITY TREATMENT ON IBD OUTCOMES': 0.0026691756918169746, 'History of Immunotherapy for Prostate Cancer': 0.026691756918169746, 'Likelihood of Success': 0.009342114921359411, 'Experimental procedures': 0.010676702767267898, 'Allergic Rhinitis/Asthma': 0.05338351383633949, 'Other Allergy/Immunology': 0.04270681106907159, 'Supplementary Materials': 0.0013345878459084873, 'Stimulators of Pathogenic Tau Formation': 0.032030108301803695, 'Cancer clinical trials': 0.006672939229542436, 'P': 0.006672939229542436, '2 Potential candidates for repositioning in the treatment of bacterial infections': 0.13879713597448268, 'Treatment landscape': 0.005338351383633949, 'Emerging treatments and approaches': 0.018684229842718822, 'Persistence of Sequential Effects Under Cognitive Load': 0.005338351383633949, 'Clinical data for single-agent CDK 4/6 inhibitors': 0.032030108301803695, 'Combination approaches with CDK 4/6 inhibitors': 0.5765419494324665, 'Introduction and Background': 0.04804516245270554, 'POTENTIAL FOR NEOEPITOPE BIOMARKERS IN EXISTING AND EMERGING THERAPIES': 0.008007527075450924, 'Sipuleucel-T': 0.018684229842718822, 'Complement Inhibitors': 0.010676702767267898, 'FcRn Blockers': 0.010676702767267898, 'B Cell Depleting Therapies': 0.008007527075450924, 'Cytokine and Chemokine Targeting Therapies': 0.008007527075450924, 'Chimeric Antigen Receptor (CAR) and Chimeric Autoantibody Receptor (CAAR) T Cell Therapy': 0.0026691756918169746, 'CAR T therapy': 0.006672939229542436, '2 DPSCs extraction': 0.005338351383633949, 'Medical Therapies': 0.008007527075450924, 'PREOPERATIVE FACTORS AND INFLUENCES': 0.004003763537725462, 'Novel Therapeutics and Future Directions': 0.005338351383633949, 'INTRAOPERATIVE FACTORS AND INFLUENCES': 0.0026691756918169746, 'Heart Failure': 0.017349641996810335, 'Combination with targeted signaling pathway inhibitors': 0.008007527075450924, 'Combination with chemotherapy': 0.0026691756918169746, 'Anticoagulation for atrial fibrillation': 0.004003763537725462, 'Biomarkers in ACS': 0.0013345878459084873, 'Arrhythmia and Devices': 0.009342114921359411, 'Imaging': 0.0026691756918169746, 'Gene Therapy in the Retina and Cochlea': 0.008007527075450924, '3. Mechanisms of resistance': 0.010676702767267898, '3 Potential of targeting CAMKK2 and ATM for cancer treatment': 0.009342114921359411, '1.0: Agents that target protein homeostasis': 0.0026691756918169746, '4.0: Agents that target the bone marrow microenvironment': 0.026691756918169746, 'Screening yield and risk for stroke and adverse outcomes': 0.008007527075450924, 'Underpowered phase 2 trial': 0.0026691756918169746, 'METHODS & PROCEDURES': 0.0013345878459084873, 'Emerging therapeutic directions': 0.021353405534535796, 'Clinical Interventions and Value of the Intestinal Microbiota in aGVHD': 0.032030108301803695, 'Major determinants of venetoclax resistance: MCL-1 and BCL-X': 0.037368459685437644, 'pCR as a surrogate for survival': 0.0026691756918169746, 'TREATMENT OF': 0.04804516245270554, 'CHALLENGES OF': 0.021353405534535796, 'Discussion and Conclusions': 0.005338351383633949, 'Hypoxia in critically ill patients': 0.0026691756918169746, '2. Immunotherapy for GBM': 0.016015054150901847, '6. Loading DCs with antigen': 0.013345878459084873, 'Epi-therapy in cancer: a new frontier for the emergence of precision medicine advanced therapies': 0.061391040911790415, 'Repurposed drugs and epitherapy in CVDs: network medicine can improve the current reductionist approach to reach the goal of personalized treatments': 0.037368459685437644, 'CONJUGATIVE PILI AND PILUS BIOGENESIS': 0.0026691756918169746, 'Clinical data of studies targeting PI3K pathway in TNBC': 0.11210537905631295, 'ETHICS AND Dissemination': 0.0013345878459084873, 'Therapeutics for regulating metabolic reprogramming in DKD': 0.008007527075450924, 'CTC singlets, clusters and survival strategies; safety with friends or potential therapeutic targets?': 0.004003763537725462, 'Disegno dello studio': 0.0026691756918169746, 'State of the art and unmet needs in ovarian cancer clinical management': 0.06672939229542436, 'Targeting Macrophage Recruitment, Survival and Polarization': 0.021353405534535796, 'Bridging preclinical studies to clinical outcomes in lymphatic anomalies': 0.0013345878459084873, 'Potential role of Wnt/β catenin signaling pathway in HCC targeted therapy': 0.008007527075450924, 'CRF in Psychopathology; From Bench to Bedside': 0.0026691756918169746, 'CAR T cell and other therapies in breast cancer': 0.0026691756918169746, 'What are we missing?': 0.005338351383633949, 'The Role of JAKi in in vivo Studies': 0.008007527075450924, 'Management': 0.014680466304993362, 'CLINICAL TRANSLATION OF MRNA‐BASED CANCER IMMUNOTHERAPY': 0.032030108301803695, 'MT dysfunction in Alzheimer’s disease and related tauopathies: the potential therapeutic utility of MT-stabilizing agents': 0.005338351383633949, 'Therapy of renal fibrosis': 0.005338351383633949, 'PD Approaches: Nanomedicines for Treating Anesthesia‐Related Complications': 0.021353405534535796, 'Triple combination therapy': 0.004003763537725462, 'Ethics': 0.010676702767267898, 'Registration': 0.0026691756918169746, 'Study registration number': 0.0013345878459084873, 'The state of clinical trials in precision oncology': 0.0026691756918169746, 'Case description': 0.005338351383633949, 'Discussion/conclusion': 0.0026691756918169746, 'Exercise modulation of tumour perfusion and hypoxia': 0.010676702767267898, 'Discussion—remote monitoring tools for inflammatory arthritis': 0.0026691756918169746, 'Technique': 0.0026691756918169746, 'Immune-focused therapies': 0.005338351383633949, 'Do-it-yourself closed-loop systems': 0.0013345878459084873, 'Clinical application of the combined therapy': 0.06672939229542436, 'TIP 1. DO NOT PRESCRIBE IMMUNOSUPPRESSIVE TREATMENT (IST) TO PATIENTS WITHOUT NEPHROTIC SYNDROME (NS)': 0.0026691756918169746, 'TIP 4. PRESCRIBE CYC-BASED IMMUNOSUPPRESSION IN PATIENTS AT HIGH RISK FOR DISEASE PROGRESSION': 0.0013345878459084873, 'TIP 7. MONITOR AND PERSONALIZE IST BY CLOSELY MEASURING KIDNEY FUNCTION, PROTEINURIA, SERUM ALBUMIN AND ANTI-PLA2R LEVELS': 0.0013345878459084873, '2 Monoclonal antibodies': 0.008007527075450924, 'Strategies for NEC prevention': 0.005338351383633949, 'Current treatment landscape': 0.005338351383633949, 'Future directions in HER2 targeting': 0.008007527075450924, 'Combined Therapy of Anti-COVID-19 Antibodies and Ang (1-7) Agonist for the Treatment of COVID-19 Patients': 0.004003763537725462, 'The GH/IGF-1 System and Cancer Risk': 0.005338351383633949, 'Angiotensin system inhibitors in renal cell carcinoma': 0.004003763537725462, 'Strategies to Target T Cell Trafficking': 0.0013345878459084873, 'Ongoing Clinical Trials for FT': 0.005338351383633949, '2. Immunotherapy strategies with emphasis on CAR-T cell therapies for the most common adenocarcinomas': 0.10676702767267898, 'SAFETY': 0.0026691756918169746, 'KAPPA‐OPIOID RECEPTORS': 0.018684229842718822, 'Choice of Intra-arterial Therapy': 0.004003763537725462, 'Evolution of Embolic Materials': 0.0026691756918169746, 'Combined Loco-regional And Systemic Therapies': 0.008007527075450924, 'Optimizing treatment regimens in hormone-sensitive PCa': 0.010676702767267898, 'THE USE OF BBMS IN CLINICAL TRIALS': 0.005338351383633949, 'HCC Subtypes According to Molecular and Immune Classifications': 0.32030108301803695, '4. ER as a therapeutic target for preventing β cell death in type 1 diabetes': 0.0013345878459084873, 'Methods / Design': 0.0026691756918169746, 'CD20-directed BsAbs': 0.026691756918169746, 'CONFLICT OF INTEREST': 0.008007527075450924, 'CD20-directed CAR-T cells': 0.0013345878459084873, 'Combination therapies with CD20 immunotherapeutics': 0.0026691756918169746, 'V. POTENTIAL NEW THERAPEUTIC OPTIONS': 0.010676702767267898, 'r/r\\u2009B-NHL treated with PD1-19bbz cells': 0.0013345878459084873, 'Challenges in systemic treatment': 0.0026691756918169746, '4 Application of organoids in GI tumors': 0.10676702767267898, 'Case 2': 0.0026691756918169746, 'Management of coagulopathy': 0.006672939229542436, 'Case 6': 0.0026691756918169746, 'Case 6, treatment summary': 0.005338351383633949, 'ETHICS APPROVAL': 0.008007527075450924, 'Sudden cardiac death': 0.008007527075450924, 'Principles of Management in PCNSL': 0.0026691756918169746, 'Management of oligoprogression': 0.028026344764078236, 'Interleukin-21 exploitation in preclinical studies': 0.0013345878459084873, 'Interleukin-21-candidate for adoptive cell therapies': 0.005338351383633949, 'Interleukin-21 implementation in clinical trials': 0.07340233152496681, 'Management of systemic progression': 0.010676702767267898, 'LBs as Biomarkers for Prognosis': 0.0013345878459084873, 'Combination targeted therapies': 0.021353405534535796, 'ADCs': 0.0026691756918169746, 'Other potential strategies to maximize response to ALK TKI therapy': 0.008007527075450924, 'RIOM Epidemiology': 0.0026691756918169746, 'ctDNA': 0.009342114921359411, 'Netrin-1 in other clinical diseases': 0.0013345878459084873, 'POTENTIAL MECHANISMS OF ACTIONS OF TIRZEPATIDE': 0.0026691756918169746, 'INITIAL EVIDENCE ON CARDIOVASCULAR AND RENAL SAFETY': 0.0013345878459084873, 'Human PSC and Cardiovascular Cell Therapy Session': 0.0026691756918169746, 'AUTHOR CONTRIBUTIONS': 0.0013345878459084873, 'Previous preclinical and clinical stroke neuroprotection studies': 0.005338351383633949, 'Conclusion and discussion': 0.0013345878459084873, 'Bronchodilator therapy': 0.021353405534535796, '2. Antioxidants in HL': 0.06406021660360739, '3. Anti-inflammatory agents in HL': 0.016015054150901847, '4. Biological agents': 0.016015054150901847, '5. Transport inhibitors': 0.013345878459084873, '6. Proton pump inhibitors': 0.005338351383633949, 'Neurosurgical implantation of the BSI': 0.0026691756918169746, 'Conclusion and outlook': 0.005338351383633949, 'Peptide-protein-based vaccines': 0.010676702767267898, 'Nucleic acid-based vaccines': 0.021353405534535796, 'Live vector-based vaccines': 0.005338351383633949, 'Current clinical trials': 0.005338351383633949, 'Gentherapien für die Huntington-Erkrankung': 0.04270681106907159, '3. Questioning the impact of the gut microbiota on cancer treatment': 0.0026691756918169746, 'Radiotheranostics': 0.05071433814452252, 'TRIAL DESIGN CONSIDERATIONS': 0.005338351383633949, 'Nanotechnology-assisted inflammation diagnosis': 0.0026691756918169746, 'ATR, ATM,\\\\nand DNA-PKcs Inhibitors': 0.05338351383633949, 'CDK12 Inhibitors': 0.005338351383633949, '3. RESULTS and DISSCUSSION': 0.0026691756918169746, 'Potential therapeutic intervention of PCa metastasis': 0.018684229842718822, 'Clinical Trials on DPP4 Inhibitors and Heart Failure': 0.0026691756918169746, 'Study phases': 0.005338351383633949, 'Guillain-Barré Syndrome': 0.0013345878459084873, 'TARGETING THE GUT': 0.010676702767267898, 'ANTIFIBROTICS': 0.021353405534535796, '3. Adoptive cell therapy (ACT) of effector cells': 0.026691756918169746, 'Inhibiting the RdRp': 0.03469928399362067, \"The A4 Study (The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease)\": 0.0013345878459084873, 'Pharmaco-therapeutic Options in NASH': 0.037368459685437644, 'Blocking the Virus-Cell Membrane Fusion': 0.008007527075450924, 'Modulators of the Innate Immune System': 0.021353405534535796, 'Mitigation of Inflammatory Immune Response': 0.026691756918169746, 'Contemporary Vaccines': 0.018684229842718822, 'New Generation Vaccines': 0.005338351383633949, 'What are the potential harmful effects of BP reduction, which was indeed very effectively accomplished in ATACH-2?': 0.0013345878459084873, 'ADMINISTRATIVE INFORMATION': 0.0026691756918169746, 'Understanding Response to Immunotherapy': 0.010676702767267898, 'Safety summary of second-generation BTK inhibitors in MS': 0.08808279782996016, 'High priority topics for LMICs': 0.0026691756918169746, 'Clinical qualification of AR-V7: A Treatment-Selection Biomarker?': 0.005338351383633949, 'Therapeutic Targeting of AR-V7': 0.008007527075450924, 'Unresolved Questions and Future Research': 0.0026691756918169746, 'Immune Checkpoint Blockade Therapy': 0.0013345878459084873, 'Tumour evolution under immunotherapy': 0.0013345878459084873, 'RESULTS AND DISCUSSION': 0.041372223223163106, 'DEVELOPING INTERVENTIONS TO RESTORE LIPIDOME HOMEOSTASIS': 0.0026691756918169746, '5. Further Development of Camptothecins in Treatment of Ewing Sarcoma': 0.0013345878459084873, '6. Combination Strategies': 0.010676702767267898, 'COMPARATIVE EFFECTIVENESS STUDIES USING RWD AND SINGLE‐ARM TRIALS': 0.0026691756918169746, 'Animal models to test anti-COVID-19 therapies': 0.0013345878459084873, 'Clinical trials in the pandemic': 0.03469928399362067, 'Challenges in planning clinical trials in a pandemic': 0.013345878459084873, 'REVIEW': 0.013345878459084873, 'COMPLEMENT FACTOR D AS A DRUG TARGET': 0.10943620336449596, 'COMPLEMENT FACTOR B': 0.010676702767267898, 'Lumacaftor and Ivacaftor': 0.021353405534535796, 'Lumacaftor/Ivacaftor Combination Therapy for Phe508del-CFTR': 0.026691756918169746, 'Scale-up systemic AAV delivery in large mammals': 0.0013345878459084873, 'TARGETING FGF‐FGFR AND VEGF‐VEGFR SIGNALLING IN CANCER': 0.22954910949625984, '1.0 Introduction': 0.008007527075450924, 'III. ESTROGEN RECEPTOR-β IN TRIPLE-NEGATIVE BREAST CANCER': 0.0026691756918169746, 'Immunologic Barriers to Effective Onc.Ad Anti-Tumor Effect in Solid Tumors': 0.0026691756918169746, 'Therapeutic efficacy': 0.005338351383633949, 'EMERGING TREATMENTS': 0.008007527075450924, 'TRIAL STATUS': 0.0013345878459084873, '2. Current development of miRNA therapeutics that may impact CVD': 0.021353405534535796, 'STUDY DESIGN AND PROCEDURES': 0.0013345878459084873, 'Ethics and dissemination plan': 0.0013345878459084873, 'Design/methods': 0.0026691756918169746, '2. Ionic anti-AF targets': 0.0026691756918169746, 'Evidence review': 0.005338351383633949, '4. Upstream therapy approaches': 0.005338351383633949, 'Surgical aspects affecting recurrence': 0.016015054150901847, 'Potential perioperative interventions': 0.010676702767267898, 'Original Research Abstracts': 0.013345878459084873, 'iRT in NSCLC': 0.026691756918169746, 'Cardiovascular Risk Reduction in CKD': 0.0026691756918169746, 'HF and CKD': 0.013345878459084873, 'THERAPEUTIC IMPLICATIONS': 0.0026691756918169746, 'Drugs, inflammation and cancer prevention': 0.0026691756918169746, 'Targeting recruitment and polarization of tumor-associated macrophages (TAMs)': 0.0013345878459084873, 'Targeting pro-inflammatory pathways': 0.005338351383633949, 'NEOADJUVANT ENDOCRINE THERAPY AS A PLATFORM FOR DRUG DEVELOPMENT': 0.021353405534535796, 'LIMITATIONS OF NEOADJUVANT ENDOCRINE THERAPY': 0.016015054150901847, 'Coronary artery calcium': 0.0026691756918169746, 'Overview': 0.005338351383633949, 'Clinical Assessment and Care of Women With MS': 0.0026691756918169746, 'Novel challenges for the treatment of advanced SQCLC': 0.013345878459084873, 'Drug repurposing: candidates for the therapeutic targeting of hallmarks of cancer': 0.09609032490541108, 'MR-Guidance in Head and Neck Radiotherapy: Current State of Research': 0.006672939229542436, 'Drug repurposing: candidates for TME-targeting therapy': 0.010676702767267898, 'Conclusion and future perspectives': 0.2762596841030569, 'CURRENT TRIALS': 0.017349641996810335, 'Data and Methods': 0.005338351383633949, \"NEW DEVELOPMENTS IN ANTIHERPESVIRUS TREATMENT: WHAT'S THE NEXT STEP?\": 0.08541362213814319, 'Circadian clock genes and immunotherapies': 0.0026691756918169746, 'PDT and anti-cancer immunity': 0.032030108301803695, 'COMPLEMENT‐TARGETING GENE AND': 0.061391040911790415, 'Ethical considerations and dissemination': 0.0013345878459084873, 'TARGETING ANGIOGENESIS WITH BEVACIZUMAB': 0.11477455474812992, 'GENE THERAPIES AND': 0.0026691756918169746, 'Clinical applications of MUC1': 0.010676702767267898, 'SMALL-MOLECULE, ANTIANGIOGENIC TYROSINE KINASE INHIBITORS (TKIs)': 0.05338351383633949, 'Efficacy and safety of immunotherapy for NSCLC': 0.04270681106907159, 'Pyroptosis: lessons learned from non-cardiac pathologies': 0.005338351383633949, 'TWO PROTOTYPICAL COMPLEMENT‐MEDIATED KIDNEY DISEASES': 0.17616559565992032, 'Funding support and author disclosures': 0.0013345878459084873, 'Clinical Studies': 0.0013345878459084873, 'Active Immunization targeting Aβ': 0.018684229842718822, 'Passive Immunization targeting Aβ': 0.021353405534535796, 'Tau Active and Passive immunization': 0.0026691756918169746, 'Ongoing and future clinical studies': 0.0013345878459084873, 'Application of chronic-plus-binge ethanol model in testing therapeutic targets in preclinical studies': 0.005338351383633949, 'Breast cancer screening including supplemental screening of dense breasts': 0.0013345878459084873, 'ENDOTHELIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NON‐DIABETIC CHRONIC KIDNEY DISEASE?': 0.006672939229542436, 'New Therapies': 0.0013345878459084873, '4 DISCUSSION': 0.004003763537725462, '2. Molecular markers': 0.026691756918169746, 'BACKGROUND/CONTEXT': 0.005338351383633949, '5. The Outcome of Some LSD1 Inhibitors in Clinical Trials': 0.02402258122635277, 'Scenario a): The medical context (the patient)': 0.0013345878459084873, 'Therapeutic targeting of FRCs': 0.013345878459084873, 'Novel CAR T-cell therapy targeting ROR-1, CD70\\xa0and dual antigens': 0.014680466304993362, 'Current Therapeutics': 0.0013345878459084873, '3. BEHAVIORAL TREATMENTS FOR POSTTRAUMATIC NIGHTAMRES': 0.029360932609986724, '4. BEHAVIORAL TREATMENTS FOR POSTTRAUMATIC INSOMNIA': 0.006672939229542436, '5. PHARMACOLOGICAL TREATMENT FOR POSTTRAUMATIC NIGHTMARES AND INSOMNIA': 0.07206774367905831, 'Neoadjuvant Therapy as a Platform for Drug Development': 0.005338351383633949, 'Registration details': 0.0013345878459084873, 'FXR ACTIVATION: POTENTIAL THERAPEUTIC STRATEGY FOR NAFLD': 0.0013345878459084873, 'The therapeutic perspective of complement inhibitors in SARS-CoV-2': 0.013345878459084873, 'Strategies to suppress oxidative stress': 0.0026691756918169746, '2. CARs in Practice: Clinical Applications': 0.0026691756918169746, 'METHODS:': 0.0026691756918169746, 'IGF-I intervention in prevention of ROP': 0.0013345878459084873, 'Current Treatment Guidelines': 0.021353405534535796, 'Immune Checkpoint Inhibitor Therapy': 0.07340233152496681, 'Adoptive Cellular Immunotherapy': 0.04270681106907159, 'IV. Active targeting': 0.037368459685437644, 'The role of BTK in myeloid-derived suppressor cells (MDSC)': 0.02001881768862731, 'Looking Forward: Opportunities to Further Expand the Role of Pediatric Endocrinologists in Treating Skeletal Dysplasias': 0.013345878459084873, 'Management of Chemotherapy-Associated TMA': 0.005338351383633949, \"Potential of HDAC Inhibitors in Parkinson's Disease\": 0.0013345878459084873, 'IGF as a Target of Therapy': 0.010676702767267898, 'Association of Cardiovascular Diseases and Mitochondrial Dysfunction and Future Treatment Strategies': 0.005338351383633949, 'HIV in prisons': 0.005338351383633949, '9. Interactions of Aβ with Inhibitors': 0.0026691756918169746, 'PTHrP as a Therapeutic Target': 0.006672939229542436, 'Clinical outcomes over follow-up': 0.0013345878459084873, 'Competing interests': 0.005338351383633949, 'Approaches to Immune Tolerance and Lessons Learned': 0.013345878459084873, 'DEVELOPMENT OF S1P': 0.09075197352177714, 'Molecular Subgroups of Endometrial Cancer': 0.0026691756918169746, 'Targeted Therapy': 0.016015054150901847, 'DEFINITIONS': 0.04270681106907159, 'Patients and method': 0.004003763537725462, 'The race for vaccine development': 0.07874068290860074, 'Clinical use of ceramide for cancer therapy': 0.008007527075450924, 'Worldwide initiatives on vaccine development': 0.0026691756918169746, 'Brazilian initiatives on vaccine development': 0.016015054150901847, 'Disclosures': 0.006672939229542436, 'STOPSTORM consortium': 0.013345878459084873, 'FUTURE DIRECTIONS AND LONG-TERM RECOMMENDATIONS': 0.0026691756918169746, 'THERAPEUTIC STRATEGIES BASED ON PATIENT RESPONSE DATA': 0.0026691756918169746, 'Managing MS in older individuals': 0.032030108301803695, 'Immune Cells Armed with CARs Utilized in Leukemia and Lymphoma': 0.0013345878459084873, 'Engineer iPSC-Derived Cells to Express CAR': 0.014680466304993362, 'Drugs tested in RTT trials': 0.02535716907226126, 'Outcome measures and biomarkers in RTT trials': 0.04404139891498008, 'METHODOLOGY': 0.009342114921359411, 'Overview of CAR T Therapy in Hematological Malignancies': 0.0013345878459084873, 'Clinical Statuses of bsAbs in Lung Cancer': 1.048986046884071, 'Application of CAR-T therapy in patients with gastrointestinal cancer and hepatic carcinoma': 0.05338351383633949, 'Adoptive cellular therapy': 0.012011290613176386, 'Shedding a new light on cardiovascular diagnostics and therapeutics': 0.016015054150901847, 'Erratum to: Adv Ther (2016) 33:747–759 DOI 10.1007/s12325-016-0327-4': 0.0026691756918169746, '2. Power of pre-clinical studies in successful clinical trials for ALS': 0.0013345878459084873, 'Pharmacological Treatment of Chorea in HD': 0.021353405534535796, 'Where do we go from here?': 0.0013345878459084873, '3 Renal Mitochondrial Targeting': 0.029360932609986724, 'Clinical Relevance of Mucosal Healing and Therapeutic Approaches': 0.0026691756918169746, 'Compounds being developed for the treatment of NASH by targeting the gut immune system': 0.005338351383633949, 'Potential Candidates': 0.03336469614771218, 'Institutional Review Board Statement': 0.0026691756918169746, 'Treatment strategies after acquisition of resistance to gefitinib/erlotinib': 0.0013345878459084873, 'Engineering solutions': 0.005338351383633949, 'Treating Depression and Other Neuropsychiatric Disorders by Targeted HPA Axis Modulation': 0.0013345878459084873, 'Therapeutic Applicability of IL-1 Inhibition and Future Perspectives': 0.0026691756918169746, 'Clinical data': 0.013345878459084873, 'Anti-PD-L1 drugs': 0.029360932609986724, 'Predictive factors of response to anti-PD-1/PD-L1 antibodies': 0.010676702767267898, 'Future strategies': 0.037368459685437644, 'Approved ALK inhibitors': 0.029360932609986724, 'Additional ALK inhibitors currently in clinical development': 0.0026691756918169746, 'Idiopathic interstitial pneumonias': 0.0026691756918169746, 'MAMMALIAN TARGET OF RAPAMYCIN INHIBITORS ARE OUTLIERS': 0.0026691756918169746, 'IMMUNOTHERAPY (Table': 0.004003763537725462, 'TUMOR‐INFILTRATING LYMPHOCYTES': 0.0013345878459084873, 'FROM THE BREAKOUT SESSIONS': 0.04270681106907159, 'What relevant clinical trials are ongoing?': 0.0026691756918169746, 'mHEALTH TECHNOLOGIES': 0.010676702767267898, 'Potential Applications of Gerontechnologies for Older Adults With Heart Failure': 0.005338351383633949, 'SPECIFIC CLINICAL SETTINGS': 0.0026691756918169746, '2. Progress in Delivery of Retinoblastoma Therapeutics': 0.032030108301803695, 'Increasing Arginine Availability': 0.005338351383633949, 'Clinical trial: phase 1b clinical trial of ARQ761 treatment with gemcitabine/nab-paclitaxel chemotherapy in pancreatic cancer': 0.0026691756918169746, 'Cellular therapeutic strategies in transplantation patients': 0.008007527075450924, '4. Challenges and opportunities': 0.008007527075450924, 'PPIs involving WT-MLL1': 0.021353405534535796, 'OPEN‐FIELD IMAGING STRATEGY': 0.0026691756918169746, 'Innovations in bio-engineering and cell-based approaches for cell replacement therapy to address immunological issues': 0.02402258122635277, 'Safety and tolerability': 0.0026691756918169746, 'IMPLICATIONS FOR DISEASE AND NEURODEGENERATION': 0.0013345878459084873, 'Agents in clinical development to target the TGF-β pathway in oncology': 0.14547007520402513, 'CLINICAL LIMITATIONS OF PPIs': 0.005338351383633949, 'Novel immunotherapeutic strategies targeting neoantigens in cancer treatment': 0.016015054150901847, 'Clinical application of neoantigen vaccine': 0.1788347713517373, 'NON‐COVALENT': 0.02402258122635277, 'Role of iPlasticity in drug responses': 0.005338351383633949, 'MATERIAL AND METHOD': 0.0026691756918169746, 'NON-PHARMACOLOGIC MANAGEMENT OF OVERALL HAND IMPAIRMENT IN SSc': 0.004003763537725462, 'Sources of Natural History and RWD': 0.013345878459084873, '5 Imaging-Based Pharmacodynamic and Pharmacokinetic Markers': 0.005338351383633949, '6 Early Response Assessment': 0.005338351383633949, 'Alemtuzumab': 0.0013345878459084873, 'NET components as biomarkers for COVID‐19 early diagnosis': 0.004003763537725462, 'Study Design': 0.004003763537725462, 'IFN-free DAA combination therapy': 0.0026691756918169746, 'Treatment Based on Genetic Testing Altering Outcomes': 0.0013345878459084873, 'TREATMENT OF CFRD': 0.010676702767267898, 'ALARMINS AND INFLAMMATORY BIOMARKERS': 0.032030108301803695, 'Patients, Materials, and Methods': 0.0026691756918169746, 'Future perspective and clinical implications': 0.0013345878459084873, 'Clinical Trial Investigating Therapeutic De-escalation': 0.02402258122635277, 'Viral mediated gene addition and gene editing approaches for IEIs': 0.09075197352177714, 'Future perspectives and conclusion': 0.0026691756918169746, 'Therapeutic effects of MSCs on COVID-19-related ARDS': 0.02535716907226126, 'MSC-exosomes-based therapies for COVID-19-related ARDS': 0.006672939229542436, 'Patients, methods, and materials': 0.0026691756918169746, 'Postnatal management': 0.0026691756918169746, 'New “old” techniques for PSP treatment': 0.0013345878459084873, 'MONOCLONAL ANTIBODIES': 0.021353405534535796, 'NANOBODIES': 0.0013345878459084873, '4. Novel approaches to track disease burden': 0.005338351383633949, 'Patients with comorbidities': 0.008007527075450924, 'Ethics, registration, data sharing plan, funding, potential conflicts of interests, and dissemination': 0.0013345878459084873, 'CT-P13 POST-MARKETING STUDIES IN ADULT IBD': 0.0026691756918169746, '4. CD4': 0.06406021660360739, 'Phase I and Phase IIa Study of RP-1127 (Glyburide for injection) in Human Stroke': 0.0026691756918169746, 'Phase II Randomized Trial': 0.0013345878459084873, 'Other Therapies to Modify Stroke Risk': 0.008007527075450924, 'Investigational Therapies': 0.04270681106907159, 'Targeting LFA-1/ICAM-1 Interaction in DED': 0.0013345878459084873, 'Lymphangiogenesis': 0.005338351383633949, '3. Bacterial Flagellin Fusion Proteins: Bridging the Gap between Mice and Humans?': 0.0026691756918169746, 'PERSPECTIVES ON TARGETING BILE ACID-RELATED PATHWAYS FOR THE TREATMENT OF NAFLD': 0.013345878459084873, 'Anti-Complement Treatment Options': 0.09342114921359411, 'Future directions and translation': 0.005338351383633949, 'Perioperative systemic therapy': 0.008007527075450924, 'Supplemental Information': 0.0013345878459084873, 'Limitations of CAR-T cell therapy': 0.010676702767267898, 'New strategies for prevention and combating immunotherapy resistance': 0.10676702767267898, 'CD138-based therapeutic strategies in MM': 0.12812043320721478, '2. Enzyme/Prodrug Systems': 0.016015054150901847, 'Possible clinical challenges of PRP as new agents': 0.06672939229542436, 'Ongoing trials and translational opportunities': 0.0026691756918169746, '3. Macrophage and adipocyte dysfunction in obese adipose tissue': 0.016015054150901847, '4. Therapeutic implications of macrophage biology': 0.005338351383633949, '3. Evidence synthesis': 0.013345878459084873, '5. Therapeutic strategies for HGPS': 0.0026691756918169746, 'Looking to the future: ongoing phase III trials of IO combination therapy in advanced RCC': 0.021353405534535796, 'Treatment of WD': 0.0026691756918169746, 'CSCs as a Target of Therapy – Still a Big Challenge?': 0.004003763537725462, 'Potential Treatment Targeting HH Pathway in Esophageal Cancer': 0.008007527075450924, '4. Menin Inhibitors: Ongoing Clinical Trials in AML': 0.016015054150901847, 'Experimental Attempts to Use Mesenchymal Stem Cells in the Treatment of Central Nervous System Diseases': 0.016015054150901847, 'Therapy': 0.021353405534535796, 'RFA in Combination with Additional Immunotherapeutic Strategies in the Treatment of HCC': 0.0013345878459084873, 'PDAC‐Tailored Nanomaterials for Therapeutic Strategies': 0.05338351383633949, 'Vascular MR in Cardiovascular Pathologies': 0.005338351383633949, 'NEP inhibition: unaddressed issues': 0.0013345878459084873, 'Sacubitril/valsartan in HF: looking ahead': 0.010676702767267898, 'Study methods': 0.008007527075450924, '3. Material and methods': 0.032030108301803695, 'INSTITUTIONAL REVIEW BOARD STATEMENT': 0.0013345878459084873, 'Study registration': 0.0013345878459084873, 'Human studies enabled by AMS': 0.005338351383633949, 'Metastatic disease': 0.10943620336449596, 'Primary Sclerosing Cholangitis': 0.0013345878459084873, 'Epigenetic strategies for the treatment of blood–brain barrier damage': 0.017349641996810335, 'MSC therapy of azoospermia patients': 0.03469928399362067, 'Future Perspectives on Lung Regeneration Therapy in COPD': 0.0013345878459084873, 'Translational approaches to tackle epigenetic dysregulation in pancreatic cancer': 0.05605268952815647, 'Conclusion and perspective': 0.004003763537725462, 'Therapies modulating high-density lipoprotein': 0.0013345878459084873, 'PART II. NOVEL TARGET FOR ALI WARRANTED': 0.026691756918169746, 'PART III. NEW STRATEGY FOR M6A TARGETING THERAPY OF ALI': 0.0026691756918169746, 'DENV and antiviral therapeutics': 0.009342114921359411, '5. Therapeutic Strategies': 0.005338351383633949, 'Controversial issues': 0.008007527075450924, '3. NK Cells in Cancer Immunotherapy': 0.04537598676088857, 'Safety in completed Phase II trials': 0.005338351383633949, 'Current therapy for SCLC': 0.016015054150901847, 'Molecular targeted therapy': 0.05071433814452252, 'Conflict of Interests': 0.012011290613176386, 'DC immunotherapy': 0.005338351383633949, 'In vivo amplification of DC subsets with Flt3L administration': 0.005338351383633949, 'An overview of the cGAS-MITA/STING signaling pathway': 0.04804516245270554, 'Radiotherapy for LD-SCLC': 0.0026691756918169746, 'Novel Treatment Strategies of SCLC': 0.018684229842718822, 'Clinical applications of MSCs in anticancer therapies': 0.0013345878459084873, 'Therapeutic potential and conclusions': 0.0013345878459084873, 'HER2-positive disease': 0.010676702767267898, 'Targeting angiogenesis': 0.0026691756918169746, '2. Introduction': 0.0026691756918169746, 'Online Methods:': 0.005338351383633949, 'Disease-modifying therapies currently available for cardiac amyloidosis': 0.013345878459084873, '4. Animal models of': 0.0013345878459084873, 'Monoclonal antibodies in the treatment of amyloidosis': 0.11210537905631295, 'Pan-amyloid antibodies?': 0.005338351383633949, 'Meta-analysis': 0.0013345878459084873, 'Indications': 0.005338351383633949, '5. Concluding remarks': 0.0026691756918169746, 'Bempedoic acid': 0.0013345878459084873, 'Current evidence': 0.0026691756918169746, 'Clinical Development of PARP Inhibitors (PARPi)': 0.08007527075450924, 'Combination Strategies and Trials for PARP Inhibitors': 0.03469928399362067, '1. Targeting T Cells in MS': 0.005338351383633949, 'PEMBROLIZUMAB IN MELANOMA: CLINICAL OVERVIEW': 0.0013345878459084873, 'Disease-modifying drugs for rare genetic disorders': 0.10142867628904503, 'Other Immune-Based Therapies': 0.0026691756918169746, 'The rate-limiting endosomal escape problem': 0.0013345878459084873, 'Management and Therapy': 0.0013345878459084873, '6. Whole Proteins': 0.016015054150901847, 'Duke University': 0.005338351383633949, '9. DNA Plasmids': 0.0013345878459084873, 'Murine Models of DMD': 0.0026691756918169746, 'The post-docetaxel space': 0.010676702767267898, 'What actions were implemented?': 0.06406021660360739, 'Ongoing Neoadjuvant Studies': 0.032030108301803695, 'The Effect of Conventional Chemotherapy on': 0.014680466304993362, 'Current Treatment Strategies for': 0.014680466304993362, 'Future Perspectives': 0.06672939229542436, 'Ethics and means of dissemination': 0.0013345878459084873, 'Available Therapies and Current Standard of Care for AL and ATTR Amyloidoses': 0.005338351383633949, '2. Genetic abnormalities in HNSCCs': 0.17082724427628637, '3. A new perspective in cancer treatment: targeting the tumor microenvironment': 0.06406021660360739, 'Immune checkpoint inhibitors and clinical trials': 0.04270681106907159, 'Limitations of immune checkpoint inhibitors': 0.005338351383633949, 'S': 0.013345878459084873, 'Experiment 2': 0.010676702767267898, '4 Discussions': 0.0013345878459084873, 'Non-BMS small molecules PD-1/PD-L1 inhibitors': 0.0013345878459084873, 'CRF in CeA': 0.0013345878459084873, 'Outlook: new indications, new combinations and new challenges': 0.018684229842718822, 'Tumour treating fields': 0.0013345878459084873, 'Accelerated Approval Sotorasib (AMG-510) Based on CodeBreaK 100 (NCT03600883)': 0.0013345878459084873, 'Pending Questions About Sotorasib Dosing': 0.0013345878459084873, 'Other Confirmatory Randomized Trials of': 0.004003763537725462, 'Overcoming Multiple Simultaneous on-Target and off-Target Resistances': 0.005338351383633949, 'The neuroimmune interface and pain control': 0.010676702767267898, '4. Simulation Studies': 0.0026691756918169746, 'I': 0.14947383874175058, 'N': 0.04003763537725462, 'EV tropism is demonstrated by recent examples': 0.02402258122635277, 'BCMA-targeting bispecific antibodies': 0.09875950059722806, 'GPRC5d-directed bispecific antibodies': 0.04003763537725462, 'Antibodies as Antivirals and Development of Antibody-Dependent Enhancement': 0.013345878459084873, 'FcRH5-directed bispecific antibodies': 0.018684229842718822, 'Bispecific and trispecific antibodies targeting other immune effector cells and plasma cell targets': 0.037368459685437644, \"5. Clinical Experience with IGF-1R Targeted Treatments in Ewing's Sarcoma\": 0.013345878459084873, 'Antifungals\\\\nunder Development': 0.004003763537725462, 'Mechanisms of resistance to bispecific antibodies and potential mechanisms to overcome resistance': 0.0013345878459084873, 'Discussion and future directions': 0.008007527075450924, 'Small molecules inhibiting TGF-': 0.022687993380444284, 'Vaccinations strategies': 0.004003763537725462, 'Diskussion': 0.0026691756918169746, 'Substrate and Cofactor Requirements of 2-OGDDs': 0.0026691756918169746, 'Pilot studies in heart failure': 0.0013345878459084873, 'Newer Treatment Strategies on the Horizon': 0.005338351383633949, 'Study Registration': 0.0013345878459084873, 'Stool Microbiota and Microbiome-Controlling Anal Incontinence by Performing Anal Exercises with Biofeedback or Loperamide (SMM-CAPABLe) Study': 0.0013345878459084873, 'What should be the control arm in CER randomized studies?': 0.0013345878459084873, 'Passive Immunization': 0.029360932609986724, 'Active Immunization': 0.030695520455895207, 'CONCLUSIONS AND FUTURE CONSIDERATIONS': 0.014680466304993362, '4. Clinical relevance of Epigenetic Modifiers': 0.005338351383633949, 'MNK Inhibitors': 0.06672939229542436, '4. The Case for Lumping': 0.0026691756918169746, 'Applications of LBNPs in cancer therapy': 0.016015054150901847, 'Clinical Studies Using MNK Inhibitors': 0.004003763537725462, 'HER2-Targeted Therapies': 0.08541362213814319, 'Early ALS: exercise and adaptive equipment': 0.0026691756918169746, 'Symptom management as ALS progresses: medications and assistive technology': 0.005338351383633949, 'Design features of CAR constructs': 0.0026691756918169746, 'CD19-targeted CAR T-cells in the clinic': 0.032030108301803695, 'Novel targets in haematological cancer': 0.03336469614771218, 'Novel targets for solid malignancies': 0.06406021660360739, 'Trial designs for interpatient heterogeneity': 0.010676702767267898, 'Current methodologies for drug delivery across the BBB': 0.006672939229542436, 'Approaches to improve CAR T-cells': 0.016015054150901847, 'Improving safety of CAR-T-cell therapy': 0.018684229842718822, 'Aggressive lipid-lowering and cardiovascular and all-cause mortality': 0.0013345878459084873, 'Drugs that Induce PANoptosis or Ferroptosis in Cancers': 0.04804516245270554, 'Therapeutic prospects and clinical transformation of PD-1/PD-L1 PTMs': 0.05471810168224798, 'Locoregional treatments': 0.004003763537725462, 'Current adaptive T cells clinical trials combined with PD-1/PD-L1 blockades in lung cancer': 0.05338351383633949, 'Historical Aspects': 0.0013345878459084873, 'PARTICIPANTS AND METHODS': 0.012011290613176386, 'Classification and clinical therapeutic results of the main kinds of cells according to cellular functions or bio-proprieties': 0.005338351383633949, 'Role of EVs in NB progression': 0.0026691756918169746, '4 Therapeutic strategies to attenuate reactive astrogliosis and associated cerebrovascular diseases': 0.06406021660360739, '5 Therapeutic challenges and future directions': 0.0013345878459084873, 'Therapeutics for Kidney disease in Alport Syndrome': 0.012011290613176386, 'Antibodies that may enter regulatory review in late 2016 or 2017': 0.021353405534535796, 'Antibodies in Phase 3 studies with completion dates in late 2016 or during 2017: Cancer indications': 0.013345878459084873, 'Antibodies in Phase 3 studies with completion dates in 2017: Non-cancer indications': 0.052048925990431004, 'ETHICS APPROVAL STATEMENT': 0.0013345878459084873, '3. Traditional Pharmacological Therapies for Angina': 0.010676702767267898, '4. Investigational/Ongoing Investigational Pharmacological Therapies for Angina': 0.021353405534535796, '6. Herbal Medications': 0.0026691756918169746, 'Bispecific antibodies with a symmetric architecture': 0.0026691756918169746, '2. Investigational PIs': 0.005338351383633949, '4. Novel pharmacokinetic enhancers for PIs': 0.0026691756918169746, 'miRNA-based targeted therapy for the treatment of CLL': 0.0026691756918169746, 'Adjuvant therapy': 0.0026691756918169746, 'PD-1 and PD-L1 checkpoint inhibitors in GC: clinical data': 0.08541362213814319, 'Combination therapy': 0.04270681106907159, 'Fitusiran': 0.005338351383633949, 'Stage III: adverse remodelling': 0.0013345878459084873, 'Stage IV: overt systolic dysfunction': 0.0013345878459084873, 'Sodium zirconium cyclosilicate (ZS-9)': 0.0013345878459084873, 'Timing and completeness of revascularization in patients with NSTEACS': 0.0026691756918169746, 'Abnormalities in the gut–microbiota–brain axis': 0.037368459685437644, 'Novel strategies for HER2-positive cancers': 0.0026691756918169746, 'Measures for clinical trial integrity': 0.0013345878459084873, 'Clinical Trial Registration Code:': 0.026691756918169746, 'BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM': 0.005338351383633949, 'PREDICTIVE FACTORS ASSOCIATED WITH TFR': 0.0013345878459084873, 'POTENTIAL TARGET THERAPY': 0.0013345878459084873, 'ICANS': 0.005338351383633949, '3D structure of the B-like complex': 0.0013345878459084873, 'Therapeutic approach for targeting PTM in NSCLC': 0.0026691756918169746, 'NET des Pankreas': 0.004003763537725462, 'ONCOLYTIC VIRUSES': 0.03603387183952916, 'STROMA TARGETS': 0.026691756918169746, 'CSCs': 0.016015054150901847, 'OTHER TARGETS': 0.004003763537725462, 'DISCLOSURES': 0.0013345878459084873, 'PATENT FORAMEN OVALE (PFO)': 0.004003763537725462, \"'Tailoring' maintenance therapy: which agent to which patient and future perspectives\": 0.017349641996810335, 'IMMUNOTHERAPY BASED APPROACHES IN THE FIRST-LINE SETTING': 0.008007527075450924, 'IMMUNOTHERAPY BASED APPROACHES IN SECOND-LINE SETTING': 0.005338351383633949, 'Resistance to therapy in FLT3-ITD AML': 0.005338351383633949, 'CKD Anemia Treatment': 0.03469928399362067, '6. Clinical Trials': 0.0026691756918169746, 'Place of SGLT2 Inhibitors in Clinical Guidelines': 0.005338351383633949, 'EMERGENCE OF DRUG-RESISTANT TUBERCULOSIS AND THE EVOLUTION OF TREATMENT': 0.013345878459084873, 'EXPLOITING SENESCENCE FOR CANCER THERAPY': 0.08007527075450924, 'Type I IFNs: Preclinical and Clinical Studies': 0.05605268952815647, '3. Lymphangiogenesis': 0.005338351383633949, 'Required modifications for automated and closed manufacturing of non-viral CAR-T cells': 0.013345878459084873, 'P4: Participatory Medicine Catered to Individual KTRs': 0.0026691756918169746, 'Use of venetoclax in further hematologic malignancies and solid tumors': 0.008007527075450924, 'Model systems for oligonucleotide development': 0.005338351383633949, 'Concluding comments and future perspectives': 0.0013345878459084873, '4 Developments in siRNA therapeutics for cancer': 0.03336469614771218, 'RESEARCH RESULTS': 0.029360932609986724, 'BODY': 0.018684229842718822, '5 Therapeutics siRNA for microbial infections': 0.08541362213814319, 'Antiviral\\\\nStudies of HSV-1 in the Elderly': 0.0026691756918169746, '10 Non-viral vectors': 0.0026691756918169746, 'RAS targeting therapeutic strategies': 0.008007527075450924, 'miR-21 as a therapeutic target in lung cancer': 0.0013345878459084873, 'MET alterations testing and future directions of MET-targeting therapies': 0.010676702767267898, 'Traditional ICIs': 0.14947383874175058, 'Emerging immune checkpoint inhibitors': 0.037368459685437644, 'Study BA058-05-028: A Retrospective, Observational Cohort Study Evaluating the Effectiveness of Cardiovascular Safety of Abaloparatide in Postmenopausal Women New to Anabolic Therapies': 0.0013345878459084873, '3. Current and planned HIV vaccine efficacy trials': 0.006672939229542436, '5. T-cell based vaccine concepts': 0.0013345878459084873, 'Therapeutic strategies to overcome acquired resistance': 0.009342114921359411, 'Sequential ALK inhibition and combination strategies': 0.0026691756918169746, 'SALVAGE THERAPY FOR REFRACTORY OR RECURRENT GCTs': 0.0013345878459084873, 'ONGOING PROSPECTIVE REGISTRIES': 0.0026691756918169746, '6. The Application of NDV in Vaccine Vector and Tumor Therapy': 0.010676702767267898, 'Discussions and expectations': 0.006672939229542436, 'Materials/subjects and methods': 0.0026691756918169746, 'Vaccination Types': 0.037368459685437644, 'Developmental Therapeutics in MF': 0.06406021660360739, 'Combination Immunotherapy': 0.005338351383633949, 'Potential Future Treatments': 0.005338351383633949, '3 Marketing Tweet Classifier': 0.0013345878459084873, 'Systemic Therapy for Metastatic Gist': 0.016015054150901847, '7. Clinical Trials of NK Cell-Based Ovarian Cancer Therapeutics': 0.0026691756918169746, 'New Directions': 0.02402258122635277, '2 MATERIALS AND METHODS': 0.0026691756918169746, 'Impact of treatment approaches for secondary MR on exercise dynamics': 0.005338351383633949, 'Matrix-assisted rigidification': 0.0026691756918169746, 'Opportunity and Hurdles in Targeting Macrophages for Therapy': 0.037368459685437644, '3. Findings from Clinical Trial Studies': 0.0026691756918169746, 'Eribulin in clinical practice': 0.026691756918169746, 'Targeting Hepatic Stellate Cells': 0.012011290613176386, 'Stress-alleviation strategies to improve drug delivery and enhance cancer therapy': 0.0013345878459084873, 'Phase II Trial- Study Design': 0.0013345878459084873, 'Treatment schedule/follow-up': 0.0026691756918169746, '2 Research on the antidepressant effects of (': 0.0026691756918169746, '7. CRISPR/Cas-Based Gene Therapies and Therapeutic Applications': 0.0026691756918169746, 'Pravastatin trials in pregnancy': 0.0026691756918169746, '5. Stem cell therapies in age-related central nervous system diseases': 0.010676702767267898, 'Challenges in the clinical translation of nanoparticle-incorporated hydrogels': 0.005338351383633949, '2. The Ongoing Challenges of Glioblastoma Treatment': 0.0026691756918169746, '3. Vaccine Therapy': 0.09075197352177714, '4. Vaccine Platforms Utilising Various PNPs': 0.09609032490541108, 'Emerging Therapy Options for Atopic Dermatitis': 0.010676702767267898, 'AXL as therapeutic target': 0.013345878459084873, 'Immuno-prophylaxis': 0.021353405534535796, 'Live-attenuated vaccines': 0.016015054150901847, 'Agents targeting CD47 with chemotherapy': 0.09342114921359411, 'CAR cells generated from various T cell subtypes': 0.11210537905631295, 'Agents targeting CD47 with radiotherapy': 0.0013345878459084873, 'Agents targeting CD47 with targeted therapy': 0.02402258122635277, 'Agents targeting CD47 with immunotherapy': 0.013345878459084873, 'Discussion and future perspectives': 0.0013345878459084873, 'IDH1 inhibitors': 0.07607150721678378, 'CAR cells generated from innate immune cells': 0.032030108301803695, '2. Protein-Based COVID-19 Vaccines': 0.005338351383633949, '4. Impact of Adjunctive Antibody Therapies on COVID-19 Immunity': 0.005338351383633949, 'Current chemical drug-developing strategies for NASH': 0.09075197352177714, 'Oligonucleotide drug-development strategies for liver diseases': 0.032030108301803695, 'Current status of research in oligonucleotide drug developments for NASH': 0.10276326413495353, 'Nanoparticle-mediated mRNA delivery for cancer treatments': 0.013345878459084873, 'Trop2-targeted therapies': 0.04537598676088857, '4 Base Flipping in the Recognition of Modified Bases': 0.0026691756918169746, 'Are Cancer Clinical Trials Specific for Persons with HIV infection Still Necessary?': 0.013345878459084873, 'Part II': 0.026691756918169746, 'Discussions': 0.08007527075450924, '5.0 Conclusions': 0.0013345878459084873, 'IMMUNE CHECKPOINT INHIBITION FOR EPITHELIAL OVARIAN CANCER (EOC)': 0.05872186521997345, 'IMMUNE CHECKPOINT INHIBITORS FOR CERVICAL CANCER': 0.0026691756918169746, 'CHECKPOINT INHIBITORS FOR GYNECOLOGICAL CANCER: FUTURE PERSPECTIVES': 0.0026691756918169746, 'Trial Coordination Board (TCB)': 0.004003763537725462, 'Potential strategies to target quality control pathways': 0.005338351383633949, 'THERAPEUTIC STRATEGIES TARGETING SIGNALING PATHWAYS': 0.06939856798724134, 'THERAPEUTIC STRATEGIES TARGETING MECHANISMS OTHER THAN SIGNALING PATHWAYS': 0.02402258122635277, 'DEVELOPMENT DILEMMAS FOR DRUGS TARGETING SPECIFIC TARGETS AND COPING STRATEGIES': 0.005338351383633949, 'SUMMARY AND PROSPECTS': 0.005338351383633949, 'Behavioral Health': 0.021353405534535796, 'Clinical Care Settings: System-level Interventions': 0.04270681106907159, 'Promoting Health Equity and Eliminating Disparities': 0.021353405534535796, 'V. Building Smarter Redirected T Cells': 0.0026691756918169746, 'Patients, materials, methods': 0.0013345878459084873, 'Stages of vaccine development': 0.010676702767267898, 'Innovative COVID-19 vaccination strategies': 0.02402258122635277, 'NEW DEVELOPMENTS': 0.010676702767267898, 'Search strategy': 0.005338351383633949, 'Unravelling the potential of tACS in neurostimulation: mechanisms and insights': 0.04003763537725462, 'Current knowledge of gamma tACS for the treatment of AD': 0.04003763537725462, 'Liver Development and Regeneration': 0.005338351383633949, 'Genetic modifiers in the context of novel drug development': 0.006672939229542436, 'Combining': 0.0026691756918169746, 'Construction of islet organoid': 0.04804516245270554, 'METABOTROPIC GLUTAMATE RECEPTOR MODULATORS': 0.010676702767267898, 'Current Treatment Challenges': 0.0013345878459084873, 'Therapeutic Options for AML': 0.05738727737406496, 'Mechanisms of TAM-mediated drug resistance': 0.005338351383633949, 'Therapeutic potential of targeting TAMs': 0.1788347713517373, 'Candidate Targets for New AML Therapies': 0.11477455474812992, 'Clinical management and new directions in aCML and CNL': 0.0013345878459084873, 'Gene Replacement Therapy': 0.008007527075450924, 'Cell-Based Therapies for Retinal Pigment Epithelium Replacement': 0.0013345878459084873, '3. Cell-Free DNA': 0.02402258122635277, '9. The Electronic Nose': 0.0013345878459084873, 'Ad26.ZEBOV/MVA-BN-Filo clinical development': 0.0026691756918169746, 'Current management strategies': 0.005338351383633949, '2. Immunological Based Therapies in HCC': 0.026691756918169746, '2. Current Insights into the Diagnosis and Management of LGGs': 0.0013345878459084873, 'ANALYSIS, DATA GAPS, AND FUTURE DIRECTIONS': 0.0026691756918169746, 'Current technologies/approaches and commercial platforms for ctDNA-based MRD analysis in solid tumors': 0.0026691756918169746, 'Evidence supporting ctDNA MRD in solid tumors': 0.008007527075450924, '2. Trastuzumab, the ToGA Trial and Resistance Mechanisms': 0.0013345878459084873, '3. Trastuzumab Deruxtecan': 0.006672939229542436, '5. ZW25, Tucatinib, and Other HER2-Targeted Agents': 0.0026691756918169746, 'DISEASES AMENABLE TO CELL‐BASED THERAPIES': 0.018684229842718822, 'Author Contribution Statement': 0.0013345878459084873, 'CD8': 0.04804516245270554, 'ANTI‐TUMOUR IMMUNITY OF CD8': 0.04804516245270554, 'Lymphoid Cancers': 0.0026691756918169746, 'FDA APPROVAL STATUS OF PCSK9 INHIBITORS': 0.05872186521997345, 'Rational and evaluation of CGRP targeted therapies': 0.17082724427628637, 'Are We Ready for Customizing Exercise Prescriptions?': 0.0026691756918169746, 'ADVERSE EFFECTS AND CONTRAINDICATIONS': 0.0026691756918169746, '2. Current Knowledge': 0.005338351383633949, '3. Clinical Trials for Oligonucleotide Therapeutics in Oncology': 0.312293555942586, '2. Participants and methods': 0.005338351383633949, 'PDTOS IN CLINICAL APPLICATION': 0.08274444644632621, 'Question 2. What might next-generation malaria vaccines look like?': 0.03469928399362067, 'Combination Therapy': 0.018684229842718822, 'Overview of copper-based compounds': 0.005338351383633949, 'Copper nanoparticles in cancer therapy': 0.0026691756918169746, '2. The Implication of AMs in Lung Diseases': 0.005338351383633949, 'Human Thymic Stromal Lymphopoietin: Two Isoforms to Explain the Paradox?': 0.0026691756918169746, '4. Epigenetic States in Testicular Germ Cell Tumors Associated with Tumorigenicity and Chemosensitivity': 0.0026691756918169746, 'Increased memory T cell polyfunctionality during treatment discriminate responding from non-responding patients': 0.004003763537725462, '1. INTRODUCTION': 0.004003763537725462, '4. GBM-Associated Astrocytes': 0.0026691756918169746, 'Lessons for Potential Future Approaches': 0.0013345878459084873, '2. RAS/RAF/MEK/ERK-Pathway Directed Therapies': 0.008007527075450924, '3. PI3K/AKT-Pathway-Directed Therapies': 0.010676702767267898, '4. PIM-Directed Therapies': 0.0013345878459084873, '5. Transcription Factor-Directed Therapies': 0.008007527075450924, 'Mesenchymal Stem Cell Therapy for Alzheimer’s Disease': 0.06672939229542436, '4. CAR-NK: A Compelling Platform for AML Immunotherapy?': 0.03469928399362067, 'Mesenchymal Stem Cell-Derived Extracellular Vesicle Therapy for Alzheimer’s Disease': 0.0013345878459084873, '4. OA Treatment by IA Injection of Protein Therapeutics': 0.013345878459084873, '5. Gene Therapy for OA Treatment by IA': 0.010676702767267898, 'FcRn Inhibitors': 0.14680466304993361, 'Immune Checkpoints and PD1/PDL1 Signaling': 0.004003763537725462, 'Potential for intrinsic modulation of PD-L1 by oncogenic pathways': 0.010676702767267898, 'HPV and PD-L1': 0.006672939229542436, 'STUDY DESIGN AND METHODS': 0.0026691756918169746, 'Mechanisms Common to Cancer and Cardiovascular Disease': 0.005338351383633949, 'Cardiac Risk Factors and Cancer Outcomes': 0.018684229842718822, '3. Treatment Algorithm for MDS': 0.04003763537725462, 'ONGOING RANDOMIZED CONTROLLED TRIALS (RCTS)': 0.0026691756918169746, 'TREATING CANCER BY GETTING ON ITS NERVES: FUTURE DIRECTIONS': 0.0026691756918169746, 'Conclusions and future perspectives': 0.2615792177980635, 'Iron Chelation and Survival': 0.0013345878459084873, '5. Clinical Implications': 0.008007527075450924, '2. Design and Methods': 0.0026691756918169746, 'Atrial cardiomyopathies, systemic biomarkers, and atrial thrombogenesis': 0.005338351383633949, 'Blocking and Reverting Tumor Mesenchymalization': 0.06672939229542436, 'The sequence options': 0.010676702767267898, 'Proposition of therapeutic sequences': 0.016015054150901847, 'Toxic effects and limitations of CAR-T therapy in breast cancer': 0.0013345878459084873, 'Clinical studies on CAR-based immunotherapy for breast cancer': 0.016015054150901847, 'Practical Aspects in the Management of Potentially Resectable PDAC': 0.018684229842718822, '5 Future therapeutic approaches for NDs': 0.005338351383633949, 'Insights from COVID-19 studies': 0.0013345878459084873, 'The potential of 3D cultured ASCs for diabetic therapy': 0.030695520455895207, '2. Cytokines and Chemokines': 0.04537598676088857, '5 Discussion': 0.0013345878459084873, '9. Promising molecular targeting agents as radiosensitizers in pancreatic cancer therapy': 0.0013345878459084873, '2. Discussion': 0.06406021660360739, 'FUTURE PROSPECTS': 0.0026691756918169746, 'Precision medicine for respiratory diseases': 0.0026691756918169746, '4. Gene Therapy': 0.004003763537725462, '6. Adenosine (ADO) in the TME: Potent Mediator of Immunosuppression': 0.0026691756918169746, '7. The Economic Analysis of CNT Production': 0.0013345878459084873, 'Postnatal steroids for prevention, moderation, or treatment': 0.0013345878459084873, 'Clinical pharmacology of eteplirsen': 0.005338351383633949, 'Efficacy of eteplirsen': 0.09742491275131956, '5. Targeting AURKB in Cancer': 0.016015054150901847, 'Safety and tolerability of eteplirsen': 0.013345878459084873, 'Profile of olaparib': 0.013345878459084873, 'Design/Methods': 0.008007527075450924, 'Treatment and Future Directions': 0.08007527075450924, '2. MESENCHYMAL STEM CELLS SECRETOME FOR ACUTE LUNG INJURY AND OTHER INFLAMMATORY LUNG DISEASES': 0.0013345878459084873, '4. CONCLUSIONS': 0.0013345878459084873, '3. Anti-CD38 Monoclonal Antibodies': 0.02402258122635277, 'Necrosis/Necroptosis': 0.0026691756918169746, '3. Treatment and Prognosis of Acute Lymphoblastic Leukemia': 0.041372223223163106, '5. Myeloid Cells': 0.0026691756918169746, '2. Research Design and Study Population': 0.005338351383633949, 'A4: Mitoprotection': 0.0026691756918169746, 'ONGOING RANDOMIZED TRIALS': 0.008007527075450924, 'A': 0.005338351383633949, 'TIRZEPATIDE': 0.02535716907226126, 'WHAT IS NEW ABOUT TIRZEPATIDE?': 0.022687993380444284, 'Factors affecting LF concentration in breast milk': 0.0026691756918169746, '4. Adjuvant Chemotherapy': 0.010676702767267898, '5. Neoadjuvant Chemotherapy': 0.0013345878459084873, '3. Recent Advances in PI3K Inhibitor-Based Therapies': 0.35233119131984064, 'Methods and Patients': 0.004003763537725462, 'Aspirin Interaction': 0.0026691756918169746, 'ICIs/monoclonal antibody drugs-enhanced ACT': 0.0026691756918169746, 'Small molecule inhibitors-enhanced ACT': 0.0013345878459084873, 'Cytokines-enhanced ACT': 0.0026691756918169746, 'A brief history of saponin-based adjuvants': 0.03870304753134614, 'Immune modulation with monoclonal antibodies': 0.005338351383633949, 'CAR-T-cell therapy': 0.004003763537725462, 'mAbs, CAR T cells, or combined therapy?': 0.0026691756918169746, 'Case Reports': 0.0026691756918169746, '5. Dual PI3K/mTOR Inhibitors': 0.06939856798724134, 'Novel combinations': 0.004003763537725462, '2. The Glutamatergic System': 0.02402258122635277, 'Phase II trials': 0.006672939229542436, '4. The Glucocorticoid System': 0.0013345878459084873, '5. Ongoing CardioMEMS Projects': 0.0026691756918169746, '6. Potential Use of Hybrid Constructions of Current Therapies with CardioMEMS Monitoring': 0.0013345878459084873, 'Results\\\\nand Discussion': 0.005338351383633949, '3. Clinical Application of MSCs for Immune-Associated Disorders': 0.013345878459084873, 'INCREASED CHLOROPHYLL ACCUMULATION': 0.0013345878459084873, '4. Management of Kidney Involvement in AAV': 0.016015054150901847, 'CONCLUSIONS AND OUTLOOK': 0.0013345878459084873, 'Conclusions and Prospects': 0.026691756918169746, '2. Biomarkers of Response to Immunotherapy in Gastric Cancer': 0.021353405534535796, '3. Immunotherapy: From Landmark Trials to Clinical Practice and Future Perspectives': 0.021353405534535796, '2.1 Integrated Exercise Intervention': 0.0013345878459084873, '2 Subsections': 0.04270681106907159, '2. Current GBM Vaccine Immunotherapy': 0.0013345878459084873, 'New developments and future therapies': 0.09609032490541108, 'Experience with T Cell Therapy: Lessons Learned': 0.0026691756918169746, '2. Study Design and Aims': 0.0013345878459084873, 'DISCLOSURE': 0.0013345878459084873, 'PART 2: MECHANISM OF ACTION: FROM SELECTIVITY TO TARGETING MITOCHONDRIA': 0.004003763537725462, '5. Immunotherapy for Platinum-Resistant or Refractory OC': 0.005338351383633949, '6. Future Directions for Immune Checkpoint Inhibitor Combinations in Platinum-Resistant or Refractory OC': 0.005338351383633949, '3. Pharmacological Targeting of the PI3K Pathway': 0.013345878459084873, '5. Poly-ADP-Ribose Polymerase Inhibitors in Combination with Cytotoxic Agents': 0.0013345878459084873, '7. Histone Deacetylase Inhibitors': 0.0013345878459084873, '8. Novel Cytotoxic Agents: PLX038': 0.0026691756918169746, '9. Novel Cytotoxic Agents: Eribulin': 0.0026691756918169746, '10. Other Targeted Agents': 0.0013345878459084873, '7. Conclusions and Future Perspective': 0.004003763537725462, '5. Treatment Strategies and Future Perspective': 0.0013345878459084873, '2. History of ATP-Competitive Inhibitors of CK2': 0.0026691756918169746, '5. Antioxidative Therapies': 0.05071433814452252, '3. Current Treatments': 0.004003763537725462, '5. Future potential of stem cell models for drug discovery efforts': 0.0013345878459084873, 'Potential Research Concepts by Study Population': 0.005338351383633949, '2. Adjuvant Anti-PD-1 Therapy: Efficacy and Potential Drawbacks': 0.004003763537725462, '5. Namodenoson for the Treatment of HCC': 0.0026691756918169746, '4. Overview of Delivery Systems': 0.005338351383633949, '5. Cell and/or Tissue Specificity': 0.008007527075450924, '7. miRNA Drugs in Clinical Trials': 0.018684229842718822, 'PEDIATRIC ADVERSE EVENTS: GLOBAL NEED FOR TERMINOLOGY DEVELOPMENT': 0.0026691756918169746, '5. BRAF Mutations as Pharmacological Targets in Melanoma': 0.008007527075450924, '6. From the Past to the Future of BRAF-Mutant Melanoma Treatment': 0.04804516245270554, 'NON-SYNDROMIC RETINITIS PIGMENTOSA': 0.016015054150901847, 'CONVENTIONAL CURATIVE STRATEGIES': 0.0026691756918169746, '4. Role of IDO in Immunomodulation': 0.012011290613176386, '11. The Clinical Use of EPO May Not Be So Benign after All: Development of Neutralizing Antibody and Acceleration of Disease Progression in Patients Treated with EPO': 0.005338351383633949, 'Examples Of Drug Combination Strategies Based On The Cancer Cell-Intrinsic Roles Of PI3K': 0.013345878459084873, 'APPLICATIONS OF NGS IN CLINICAL TRIALS AND CLINICAL PRACTICE': 0.005338351383633949, '2. Material and methods': 0.030695520455895207, '3. The Immunological Key and the Clinical Trials': 0.02402258122635277, 'SAFETY AND TOLERABILITY CONSIDERATIONS FOR CANCER IMMUNOTHERAPY COMBINATIONS': 0.005338351383633949, 'Prognostic importance of chromatin modifiers and therapeutic intervention': 0.0026691756918169746, 'CLINICAL DEVELOPMENT OF CRIZOTINIB': 0.004003763537725462, 'PROFILE 1001: PHASE I STUDY IN ALK‐POSITIVE NSCLC': 0.004003763537725462, 'Non-JAK2 targets in MPNs': 0.018684229842718822, '2 DNA methylation': 0.12278208182358083, 'Statins used in the elderly': 0.0013345878459084873, '3 Histone modification': 0.032030108301803695, 'Future work': 0.021353405534535796, '2. Highly Desmoplastic Tumor Microenvironment in PDAC': 0.037368459685437644, '3. Profound Immunosuppressive TME and Immunotherapy in PDAC': 0.12812043320721478, '4. Preventative New Gepants': 0.010676702767267898, '5. Acute New Gepants': 0.10676702767267898, 'TARGETING ONCOGENIC ALK': 0.0013345878459084873, 'DEVELOPING STRATEGIES TO OVERCOME RESISTANCE': 0.04003763537725462, '3. Direct Targeting of KRAS': 0.032030108301803695, '5. Indirect Inhibition of KRAS': 0.04270681106907159, '9. Other Emerging Therapies': 0.012011290613176386, '4. Engaging the Antitumor Immune Response': 0.010676702767267898, '5. Remaining Hurdles and Future Directions': 0.0013345878459084873, 'Efficacy in spleen size reduction and symptom improvement': 0.0026691756918169746, '4.0 Dabigatran': 0.005338351383633949, '5.0 Anti-Xa Agents': 0.005338351383633949, '5. Methods for Enhancing the Effects of MSCs': 0.0026691756918169746, '6. Therapeutic Strategies': 0.0026691756918169746, 'Management of Dry Eye Disease Associated with Meibomian Gland Dysfunction': 0.04270681106907159, '3. Targeting IGF-1R Signaling in Head and Neck Cancers': 0.0026691756918169746, '4. A Role for Met/HGF Signaling in Head and Neck Cancers': 0.004003763537725462, '5. Understanding Resistance to EGFR-Targeted Therapies in HNSCC': 0.0026691756918169746, '6. Atopic Dermatitis Therapy': 0.004003763537725462, 'HCC Treatment': 0.010676702767267898, 'ILD in Patients with SSc': 0.008007527075450924, 'Role of ibrutinib in the management of WM': 0.005338351383633949, '9. Conclusions': 0.0026691756918169746, '4. Therapeutic Strategies Based on Endothelial Reprogramming in AS': 0.010676702767267898, '2. RTK Activation and Alterations in Melanoma': 0.04537598676088857, 'Study aim': 0.0013345878459084873, 'Current Perspectives on the Role of Radiation Therapy in Early Stage Breast Cancer—More vs. Less': 0.010676702767267898, '10. Ovarian Cancer': 0.005338351383633949, '11. Endometrial Cancer': 0.0026691756918169746, '2. mTOR Pathway: Relevance in NETs': 0.016015054150901847, 'Adjuvant and neoadjuvant targeted therapies': 0.028026344764078236, '3. Role of Angiogenesis in NETs': 0.021353405534535796, '4. Somatostatin Receptors and Other Unique Targets in NETs': 0.005338351383633949, '5. Immunotherapy and Antibody-Drug Conjugates': 0.0026691756918169746, 'Home and School-Based Interventions': 0.0013345878459084873, '3. Cardiovascular Interventions in the Armamentarium of Cancer Therapy': 0.018684229842718822, 'IRE for HCC': 0.0026691756918169746, 'Human SLE': 0.0013345878459084873, 'B cell therapies in SLE': 0.0026691756918169746, 'Current portfolio of BAFF (and APRIL) inhibitors': 0.0026691756918169746, 'Clinical trials with blisibimod': 0.018684229842718822, 'Mechanistic Insights into Therapy Response': 0.010676702767267898, '4. Modelling RTT with hiPSCs': 0.005338351383633949, '5. Future Clinical Translation of hPSC Technology in RTT': 0.008007527075450924, '4. Parkinson’s Disease': 0.010676702767267898, 'Targeting of DNA Damage Signalling Proteins': 0.013345878459084873, 'Therapeutic consideration': 0.03469928399362067, 'Revisiting AR in Breast Cancer': 0.12011290613176387, '4. Immunotherapy for the Treatment of Breast Cancer': 0.037368459685437644, 'CLINICAL TRIAL DESIGN FOR MITIGATORS AND TREATMENT OF RIF': 0.008007527075450924, 'Potential Treatments for': 0.016015054150901847, 'Tumor Microenvironment': 0.005338351383633949, 'Checkpoint Inhibitor Therapy in Soft Tissue Sarcomas': 0.05071433814452252, 'Sarcoma Antigen-Based and Cell Therapy': 0.010676702767267898, 'Future Management/Directions': 0.0026691756918169746, 'Deucravacitinib': 0.008007527075450924, 'Registration of research studies': 0.0013345878459084873, 'Histone deacetylase inhibitors': 0.006672939229542436, 'Immune checkpoint inhibitors': 0.009342114921359411, '2. Immunotherapy Trials in Gastroesophageal Cancer': 0.0026691756918169746, 'Therapeutic potential of ixekizumab': 0.0013345878459084873, '5. The Potential Use of Other Therapeutic Strategies Targeting Cancer Cells and Impacting Angiogenesis': 0.010676702767267898, '5. Clinical Trials Using Vascular-Targeting Agents': 0.0013345878459084873, 'Oral vs IV arsenic': 0.0013345878459084873, 'Pediatric patients': 0.0026691756918169746, '2. Clinical Experience': 0.0026691756918169746, '4. Heart Failure': 0.010676702767267898, '4. Status of Targeted Notch Therapy': 0.02402258122635277, '2. Molecular Pathways Involved in SCLC Development and Progression': 0.018684229842718822, 'ANTIVIRAL AGENTS': 0.1174437304399469, 'IMMUNE-BASED THERAPIES': 0.09609032490541108, 'Perspectives of therapeutic treatment of retinal degenerative diseases': 0.006672939229542436, '9. Gr-MDSCs—The ‘Bad Guys’ in Anti-Tumor Immune Response': 0.0013345878459084873, '4. Currently Approved TCE Therapies in Hematology (November 2023)': 0.04537598676088857, '5. Challenges and Perspectives': 0.016015054150901847, 'Vaccine approaches to contend with HIV‐1 diversity': 0.0013345878459084873, 'T‐cell vaccine design strategies': 0.005338351383633949, 'How do glioma cells migrate?': 0.0026691756918169746, 'Invading glioma cells disrupt brain function': 0.0026691756918169746, 'CURRENT STATUS OF NONSENSE SUPPRESSION THERAPY': 0.005338351383633949, '7. Conclusion and outlook': 0.0026691756918169746, 'Senescence in the pipeline': 0.061391040911790415, '2. Monoclonal Antibodies': 0.014680466304993362, '3. Antibody–Drug Conjugates': 0.0026691756918169746, 'Janus-Kinase Inhibition as a Strategy for the Treatment of Vasculitis': 0.010676702767267898, 'Neuroinflammation in Neurological Disorders': 0.005338351383633949, 'Medications': 0.09075197352177714, 'Method and analysis': 0.0026691756918169746, 'Intravenous Fluids - Colloids': 0.0026691756918169746, 'The Art of War: γδ T Cell-Based Therapeutic Strategies': 0.02402258122635277, 'Therapeutic Strategies Against COVID-19': 0.013345878459084873, 'Lopinavir/Ritonavir': 0.0013345878459084873, 'Convalescent Plasma Therapy': 0.0013345878459084873, 'Repurposing Anticancer Medications for COVID-19 Treatment': 0.016015054150901847, '6. Higher-Risk Disease': 0.013345878459084873, 'Statement of ethics': 0.0026691756918169746, 'Methode': 0.004003763537725462, 'Anti-Angiogenic Therapies': 0.013345878459084873, 'Immunotherapy for HCC': 0.018684229842718822, 'Efforts to Enhance Immunotherapy for HCC': 0.008007527075450924, 'Dendritic Cell Vaccination in PCa': 0.029360932609986724, 'Overcoming Tumor Escape': 0.021353405534535796, 'Tolerogenic Vaccines for the Induction of Antigen-Specific Tolerance': 0.08007527075450924, 'T Cell Therapy': 0.026691756918169746, 'IL2-Mediated Therapy': 0.029360932609986724, 'Selected ongoing Cb NACT studies in TNBC': 0.006672939229542436, '5. Breast Cancer and Systemic Therapy Updates': 0.008007527075450924, '7. Multidisciplinary Management of DCIS': 0.005338351383633949, '9. Optimization Strategies for Individual-Based Prognostic Factors': 0.005338351383633949, '4. Common Therapeutic Approaches in Prediabetes and Colorectal Cancer': 0.013345878459084873, 'Design and methods': 0.0026691756918169746, 'Angiotensin Receptor Blockers in COVID-19': 0.05605268952815647, 'Treatments in pediatric-onset multiple sclerosis': 0.0013345878459084873, '5. Conclusions and Future Directions': 0.0013345878459084873, 'Chronic Pain': 0.0013345878459084873, 'Alcohol Dependence': 0.0013345878459084873, 'Future Avenues of Somatostatin-Based Therapy in PPGLs': 0.016015054150901847, '3 Results and discussion': 0.005338351383633949, '3. Potentially Targetable Genomic Alterations': 0.05338351383633949, '4. Approved CAR T-Cell Products': 0.03469928399362067, 'IgG Fc and FcγRs': 0.0026691756918169746, 'Sialylated IgG in autoimmune diseases': 0.005338351383633949, 'Therapeutic approaches to increase the number of antigen-specific T cells': 0.0026691756918169746, 'Future Directions and Clinical Implications': 0.006672939229542436, 'DISCUSSSION': 0.0013345878459084873, '4. Clinical Trials and Outcomes': 0.09609032490541108, '5. Adverse Events': 0.0013345878459084873, 'IMMUNE THERAPY': 0.008007527075450924, 'CONCLUSIONS AND FUTURE DIRECTIONS': 0.004003763537725462, '5. Therapeutic Potential to Treat mGluR1-Driven Melanoma and Other Cancers with Riluzole': 0.0026691756918169746, 'Epigenetics tools for cancer therapy in cancer': 0.9795874788968296, 'Therapy to Prevent Cardioembolic Stroke': 0.026691756918169746, 'Discussion and review of literature': 0.013345878459084873, 'DISEASE OVERVIEW': 0.10676702767267898, 'HIF INHIBITORS FOR CANCER THERAPY': 0.032030108301803695, 'USEFULNESS OF PSMA PET AS DIAGNOSTIC MODALITY FOR PROSTATE CANCER RECURRENCE AND METASTASIS': 0.0013345878459084873, 'PULSED FIELD ABLATION SYSTEMS': 0.018684229842718822, 'PULSED FIELD ABLATION: EFFICACY, SAFETY, AND FIELDS OF APPLICATION IN CLINICAL STUDIES': 0.0026691756918169746, 'CAUSES FOR THE GAP BETWEEN GUIDELINES AND REAL-WORLD PRACTICE': 0.0026691756918169746, '3. Targeting HER2: Antibodies, Drug positivity conjugates, and tyrosine kinase inhibitors in clinical practice': 0.013345878459084873, 'Vaccines in clinical development': 0.014680466304993362, 'TYPE I INTERFERONOPATHIES': 0.0026691756918169746, 'Epigenetic therapy and immunotherapy': 0.0013345878459084873, 'Enterobacteriaceae that produce extended spectrum β-lactamases': 0.0013345878459084873, 'Implications for future studies': 0.0026691756918169746, 'Cell therapeutic strategies for the treatment of PMD': 0.0026691756918169746, 'EGFR/PI3K/AKT/mTOR pathway might be potentially targeted to HPV-associated HNSCC': 0.0026691756918169746, 'HPV-associated disease trend to obtain more benefit from immunotherapy': 0.0026691756918169746, 'Epidrugs have a long way to go in NHSCC': 0.0013345878459084873, '8. Endocrine therapy': 0.0013345878459084873, 'Antitumour immune responses in glioma microenvironment': 0.008007527075450924, 'Is there an optimal glucocorticoid dose in SLE?': 0.0013345878459084873, 'Biological components of exosomes': 0.010676702767267898, 'Combination therapy for clinical benefits against cancer': 0.008007527075450924, 'Ethics approval and trial status': 0.0026691756918169746, '3. Anti-Prostatic-Specific Membrane Antigen-Based Radioimmunotherapy': 0.0013345878459084873, '2. The Role of the NLRP3 Inflammasome in Acute Liver Injury (ALI)': 0.005338351383633949, 'Modes of Application': 0.005338351383633949, 'Study organization': 0.0013345878459084873, 'The biology of NK cells versus T cells in the context of cancer therapy': 0.0026691756918169746, 'Leveraging the CD16A/Fc-gamma receptor IIIA to engage NK cells': 0.0026691756918169746, 'Therapies leveraging the NKG2D-ligand axis for cancer therapy': 0.010676702767267898, 'Treatment of Metastatic Disease': 0.005338351383633949, 'Targeting heparan sulfate-protein interactions': 0.0026691756918169746, 'Treatment-induced prostate lineages': 0.0026691756918169746, 'Effect of Fingolimod on BVL in Patients with RMS': 0.018684229842718822, 'ORAL DISEASES AND FUNCTIONAL UNIT REGENERATION': 0.005338351383633949, '4. Emerging Treatment Approaches': 0.02402258122635277, 'State of the Art': 0.04003763537725462, 'Future Perspectives and Outlook': 0.0026691756918169746, 'EXPLOITING MICROENVIRONMENTAL CUES FOR THERAPY': 0.06672939229542436, 'TARGETING SIGNALING IN THE TME': 0.008007527075450924, 'IMMUNOTHERAPY AND IMMUNOSUPPRESSIVE SIGNALING IN TME': 0.09075197352177714, '9. Treatment of ILD in ASyS': 0.0026691756918169746, '5. Pharmacological Interventions for PD': 0.026691756918169746, 'How to Improve CAR T-cell Efficacy and Increase Access to Personalized Therapy': 0.0026691756918169746, '8. Novel Treatment Options': 0.04537598676088857, '2. Resistance to Anti-Angiogenesis Therapies in Renal Cell Carcinoma': 0.005338351383633949, '4. Immunotherapy for Renal Cell Carcinoma: Resistance and Novel Therapeutic Approaches': 0.016015054150901847, 'Growth factor receptors': 0.0026691756918169746, 'CURRENT ADVANCES IN CANCER NANOTECHNOLOGY FOR DETECTION AND THERAPY of PANCREATIC\\\\nCANCER': 0.0026691756918169746, '6. Pre-clinical development, in-vitro and biodistribution studies of polymeric micelles': 0.0026691756918169746, 'HER-2 positive ABC': 0.0026691756918169746, 'Replacements for bacille Calmette–Guérin': 0.005338351383633949, 'Bacille Calmette–Guérin booster vaccines': 0.04804516245270554, 'Specific Etiological Management': 0.0026691756918169746, '4. Present and Potential Therapy': 0.026691756918169746, '3. Androgen Receptor, the Great Player': 0.005338351383633949, '6. MYC, a Master Regulator of Transcription': 0.010676702767267898, 'PROTEIN SYNTHESIS IN MUSCLE': 0.0026691756918169746, 'Approaches to overcoming drug resistance': 0.016015054150901847, '4. Immunotherapy in AML with Adverse Genetics': 0.0013345878459084873, '8. Novel Investigational Strategies Combining Immunotherapy and Target Therapy in AML with Adverse Genetics': 0.06939856798724134, 'Data availability statement': 0.004003763537725462, 'Emerging therapeutic targets': 0.02535716907226126, 'Exploration the Best Mode of Radiotherapy and PD-1/PD-L1 Inhibitors': 0.09075197352177714, '6. Prevention and Therapeutic Perspective of IRI': 0.004003763537725462, 'Biological Response Modifiers to Boost the Effect of Combinational Therapy': 0.009342114921359411, 'Diagnosis of M-HLH': 0.0026691756918169746, 'Therapy of M-HLH': 0.008007527075450924, 'PROs in End of Life (EOL)': 0.0013345878459084873, 'Single-Agent Immunotherapy': 0.0013345878459084873, 'Combination Strategies for Immunotherapy': 0.021353405534535796, 'Immunotherapy in a (Neo) Adjuvant Setting': 0.010676702767267898, 'TCRs Side-Effects': 0.028026344764078236, 'COVID-19 Therapeutics': 0.09609032490541108, 'TUMOR NECROSIS FACTOR INHIBITORS': 0.005338351383633949, '5. Material and Methods': 0.0026691756918169746, 'COVID-19 Vaccines': 0.03603387183952916, 'Therapeutic hypothermia': 0.0013345878459084873, 'Ongoing Trials': 0.0026691756918169746, 'Experiment procedures': 0.0026691756918169746, '8. Perspectives': 0.0013345878459084873, 'Adjuvants': 0.0026691756918169746, 'Delivery Systems': 0.013345878459084873, 'Genetic Vaccines': 0.0026691756918169746, 'Viral Vector Vaccines': 0.005338351383633949, 'ANTICOAGULATION IN CIRRHOSIS': 0.005338351383633949, 'Cell therapy for COVID-19': 0.04804516245270554, 'Clinical development of Spinraza™ for the treatment of SMA': 0.0013345878459084873, 'MESENCHYMAL STEM CELLS TO TREAT DIABETES': 0.0026691756918169746, 'MANAGEMENT OF NEWLY DIAGNOSED GLIOMAS AFTER SURGERY': 0.0026691756918169746, '2. Methods/design': 0.005338351383633949, 'SCLC histologic transformation': 0.016015054150901847, 'Current strategies and future perspectives for TIME-targeting treatment': 0.02402258122635277, '8. Considerations on Medical Therapy': 0.0026691756918169746, '5. Ivabradine Use in Sepsis': 0.0013345878459084873, 'TO THE EDITOR': 0.005338351383633949, 'LTCCs as novel drug targets': 0.005338351383633949, 'Definition and progress of neoadjuvant therapy for esophageal cancer': 0.0026691756918169746, 'Therapeutic efficacy of rapastinel in clinical trials': 0.0026691756918169746, 'Normative value analysis': 0.0013345878459084873, 'Criterion validity assessment of the patient scores compared to provider scores demonstrated variable agreement': 0.0013345878459084873, 'mTOR inhibitors': 0.0026691756918169746, 'Future perspectives and challenges': 0.012011290613176386, 'Imaging of tumour tissue': 0.0026691756918169746, 'Clinical Experiences': 0.07073315583314983, 'Combining TILs with ICIs': 0.005338351383633949, '4. TAM-Targeting Therapy': 0.010676702767267898, 'Prophylaxis': 0.09075197352177714, 'Future Changes and Technologies': 0.008007527075450924, 'Prospects and Challenges for Clinical Translation of NOS-Targeted Therapy in Oncology': 0.004003763537725462, 'TARGETED THERAPIES IN BREAST CANCER': 0.008007527075450924, 'IMMUNOTHERAPEUTIC MODALITIES EVALUATED IN SARCOMAS': 0.013345878459084873, 'PERSPECTIVE': 0.0026691756918169746, 'COVID-19 Detection from Exhaled Breath': 0.0013345878459084873, '5. Sarcomatoid Histology Assessment': 0.0026691756918169746, '3. Risk Factors for POR': 0.021353405534535796, 'Definition of Terms': 0.005338351383633949, 'Patient Evaluation': 0.013345878459084873, 'Fibroblast growth factor receptor in GEA: Role and inhibitors': 0.006672939229542436, 'Claudin 18.2 in GEA: Role, inhibitors and CAR-T cell': 0.032030108301803695, 'New anti-HER2 agents': 0.006672939229542436, 'Open issues in TAVI': 0.016015054150901847, 'DMOADs targeting cartilage': 0.07073315583314983, 'DMOADs targeting inflammatory signaling': 0.06806398014133286, 'DMOADs targeting subchondral bone': 0.03603387183952916, '2. The Current State of the Art – Pathophysiology and Tools for Prevention and Treatment of Cerebral Vasospasm and Delayed Cerebral Ischemia': 0.005338351383633949, 'Possible therapy implication': 0.004003763537725462, '8.': 0.0013345878459084873, 'Therapeutic Development Landscape': 0.0026691756918169746, 'Current Clinical Studies': 0.04270681106907159, '5. Therapeutic implication': 0.0013345878459084873, '2. Material and Method': 0.0026691756918169746, '2. Biologic Use across Nasal Polyp Subtypes': 0.013345878459084873, 'Components and function of the intestinal epithelium in the setting of GVHD (': 0.009342114921359411, 'Commensal aspects of the intestinal mucosa in GVHD': 0.010676702767267898, 'II. Targetable and commonly dysregulated pathways in head and neck cancer': 0.009342114921359411, 'The disc is complex in structure, composition, and function. What are we aiming to repair/regenerate?': 0.026691756918169746, 'IMMUNE CHECKPOINT INHIBITORS': 0.08541362213814319, 'THERAPEUTIC VACCINES': 0.10676702767267898, 'CELL‐BASED THERAPIES': 0.029360932609986724, 'Tailoring SERPIN Efficacy and Specificity': 0.0026691756918169746, '2 PD-L1': 0.052048925990431004, \"Blood‐based neuronal and astrocyte extracellular vesicles biomarkers identify treatment responders for Alzheimer's disease in Down Syndrome\": 0.0026691756918169746, 'Rivaroxaban in combination with low‐dose aspirin is associated with a reduction in pro‐inflammatory and pro‐thrombotic circulating vesicle signatures in patients with cardiovascular disease': 0.0013345878459084873, 'Metabolites of human sweat evs are associated with blood glucose levels': 0.0013345878459084873, 'Screening of potential biomarkers for mucopolysaccharidosis III in neuronal extracellular vesicles': 0.0013345878459084873, 'Overview of Exosome': 0.008007527075450924, 'Review of Clinical Reports': 0.013345878459084873, 'Alpha-1-Antitrypsin: A Promiscuous Serpin With Potent Therapeutic Properties': 0.0013345878459084873, 'State of the science': 0.0013345878459084873, 'THE LIKELY EFFICIENCY OF IRCTS MATTERS ETHICALLY': 0.013345878459084873, 'IRCTS AND THE ALTERNATE DESIGNS SHARE SOME PARTIAL JUSTIFICATIONS': 0.004003763537725462, 'IN AN IRCT, ALL PARTICIPANTS’ ACCESS TO THE EXPERIMENTAL VACCINE MAY IMPROVE RELATIVE TO NO TRIAL PARTICIPATION, NO LESS THAN UNDER ALTERNATIVE DESIGNS': 0.009342114921359411, 'IN AN IRCT, ALL PARTICIPANTS’ PROSPECTS PRIOR TO RANDOMISATION MAY IMPROVE RELATIVE TO NO TRIAL PARTICIPATION, NO LESS THAN UNDER ALTERNATIVE DESIGNS': 0.009342114921359411, 'REQUIRING EQUIPOISE WOULD THWART BOTH IRCTS AND THE ALTERNATE STUDY DESIGNS': 0.004003763537725462, 'Insight of Native Exosomes for Stroke': 0.0026691756918169746, 'front-stub': 0.037368459685437644, 'Therapeutic Value of FH and Derivatives in Complement-Mediated Diseases': 0.0013345878459084873, 'Types of RNA Vaccines and State of the Art Technologies': 0.016015054150901847, 'Representative RNA Vaccines for COVID-19 Undergoing Clinical Trials': 0.06406021660360739, 'ILC–IEC Interactions as Therapeutic Target': 0.0013345878459084873, 'ETHICS': 0.0013345878459084873, 'Emerging Clinical Perspectives': 0.0013345878459084873, 'Development': 0.11477455474812992, 'Future Perspective: Ongoing Therapeutic Strategies': 0.022687993380444284, '2. Study One': 0.0013345878459084873, 'Methods and Analysis': 0.0026691756918169746, 'Biomarkers': 0.010676702767267898, 'Cardiac Imaging Evaluation': 0.0026691756918169746, 'Checkpoint inhibitors': 0.08007527075450924, '3. Interventions to reduce SNAEs in HIV infection': 0.021353405534535796, '4. Genetic and Epigenetic Modulation to Impact HIV Transcription': 0.0026691756918169746, 'Literature review': 0.16015054150901847, '2. Genomic Alterations of Clinical Interest in UC': 0.029360932609986724, '4. Third-generation ADCs': 0.008007527075450924, 'Clinical studies using NKT cell based therapies': 0.0026691756918169746, '6. Clinical trials of IL-36 antibody in IBD': 0.009342114921359411, 'Androgen receptor as a therapeutic target in triple negative breast cancer': 0.032030108301803695, 'COVID-19': 0.021353405534535796, 'Hypercalcemic Effect of VDR Ligands': 0.032030108301803695, 'Methods and results': 0.0026691756918169746, 'NEUROBIOLOGY AND MANAGEMENT OF DISEASE-ASSOCIATED COGNITIVE DYSFUNCTION AND DEMENTIA': 0.061391040911790415, 'Novel therapies that target extrinsic and intrinsic factors of heart failure': 0.0013345878459084873, 'Cellular Senescence': 0.0026691756918169746, 'POTENTIAL PERIOPERATIVE INTERVENTIONS': 0.010676702767267898, '7. Trastuzumab in Endometrial Cancer': 0.0013345878459084873, 'The state of treatment for clear cell RCC': 0.016015054150901847, 'Adjuvant/Neoadjuvant Therapy': 0.0013345878459084873, 'Therapie': 0.010676702767267898, 'MOLECULAR MECHANISMS OF FIBROSIS': 0.005338351383633949, 'Pharmacotherapy for DKD': 0.03469928399362067, 'iPSC-based cell therapy': 0.028026344764078236, 'Structural components of HF networking—Development scheme of the RUHR‐HF network': 0.0026691756918169746, 'Strategy Combining the New Anticancer Agents': 0.0013345878459084873, '8. DiaPort – intraperitoneal insulin delivery with externally worn pump': 0.0013345878459084873, '9. Implantable pump and artificial pancreas': 0.0013345878459084873, 'Treatment of ROP': 0.0026691756918169746, 'IGF-1 supplementation: a preventative treatment for ROP in preterm infants': 0.0013345878459084873, '6 Perspectives on TAM-targeted therapeutics': 0.0013345878459084873, 'TARGET ANTIGENS FOR CARS': 0.02001881768862731, 'CHALLENGES FOR CARS TO OVERCOME SOLID TUMOR BARRIER': 0.0026691756918169746, 'COMBINATION STRATEGIES': 0.0013345878459084873, 'Biomarkers of Spinal Cord Injury': 0.0013345878459084873, 'Uncovering Therapeutic Targets—A Proposed Roadmap Forward': 0.04537598676088857, '8. Pathological Alteration of Bile Acid Recirculation': 0.009342114921359411, 'New systems explored': 0.016015054150901847, 'Future tools and targets for drug development': 0.0026691756918169746, '3. Procedure': 0.0026691756918169746, '14. Challenges and Future Perspectives': 0.005338351383633949, 'STUDY DESIGN': 0.0026691756918169746, '2. Sensor-Based HF Monitoring': 0.021353405534535796, 'Method and Materials': 0.0026691756918169746, '4. Clinical Efficacy': 0.009342114921359411, '6. Expert Opinion': 0.004003763537725462, 'Pilot Studies and Clinical Trials': 0.016015054150901847, 'CLINICAL CASES': 0.0026691756918169746, 'Liver MRgRT Clinical Indications': 0.0026691756918169746, 'Phase I, Phase II, and Phase III trials of romosozumab': 0.005338351383633949, '5. Limitations of the Study': 0.0013345878459084873, 'Strategies for Overcoming Tumor Relapse': 0.0013345878459084873, 'mRNA-based cancer vaccines': 0.265582981335789, '2. Adeno-Associated Virus-Based Gene Therapy': 0.032030108301803695, 'Trials': 0.0013345878459084873, 'Recent Developments in HAE Therapy': 0.021353405534535796, 'EMERGING THERAPIES FOR LONG TERM PROPHYLAXIS': 0.07473691937087529, 'mRNA-encoded antigen receptors': 0.04804516245270554, 'Botulinum Toxin Type A: Alleviating Hypertonicity to Lessen Myofascial Pelvic Pain Associated with Endometriosis': 0.0013345878459084873, 'mRNA-encoded antibodies': 0.010676702767267898, 'mRNA-encoded immunomodulators': 0.013345878459084873, 'MAPK/PI3K': 0.0013345878459084873, 'Immunometabolism therapeutic targets and SLE': 0.0013345878459084873, '2. Subjects and methodology': 0.0026691756918169746, 'Systemic therapy of advanced disease': 0.0026691756918169746, 'Current genetic landscape and actionable signatures': 0.005338351383633949, 'Emerging therapies': 0.12812043320721478, 'Complex clinical scenarios': 0.008007527075450924, 'ALTERNATIVE miRNA STRAND USAGE IN HUMAN DISEASE': 0.0026691756918169746, 'CROSS TALK BETWEEN MOLECULAR SIGNALING AND METABOLIC PATHWAYS': 0.20285735257809007, 'Case Series': 0.0026691756918169746, '5. Clinical Trials of miR drugs for Neurological Disorders': 0.005338351383633949, '2. PATIENTS AND METHODS': 0.0026691756918169746, 'IV. Complex Spin Textures Induced by Interfaces': 0.005338351383633949, 'Recombinant TRAIL and TRAIL Receptor Agonists in Human Clinical Trials': 0.04804516245270554, 'HALLMARK CLINICAL TRIALS': 0.008007527075450924, 'META-ANALYSIS': 0.0026691756918169746, 'Oncolytic Viruses': 0.014680466304993362, 'The Problem': 0.026691756918169746, 'CLINICAL RELEVANCE AND IMPLICATIONS': 0.013345878459084873, 'Design of the NOR-COR questionnaire': 0.0026691756918169746, '5. Nucleic-Acid-Based Therapy': 0.05338351383633949, '3. Trial Design': 0.0013345878459084873, 'The potential of engineered binding scaffolds as alternatives to scFvs in CARs': 0.032030108301803695, 'Methods—patients': 0.0026691756918169746, 'PARP inhibitors in combination with anti-angiogenic agents': 0.008007527075450924, 'PARP inhibitors in combination with checkpoint blockade': 0.006672939229542436, 'PARP inhibitors in combination with other small molecule inhibitors': 0.04804516245270554, 'Microbiota and Pca therapy: Interaction of microbiota with Pca treatment': 0.0013345878459084873, '7. Human Epidermal Growth Factor Receptors Inhibitors: HER2 and EGFR (HER1)': 0.005338351383633949, 'Blocking STAT3 activation: targeting upstream receptors': 0.06406021660360739, 'Experimental Design, Materials and Methods': 0.0026691756918169746, 'Blocking STAT3 dimerization: SH2 domain inhibition': 0.010676702767267898, 'Decreasing total STAT3 expression': 0.005338351383633949, '6. Rapid Reversal of COVID-19 Hypoxia by Competitive Binding to SARS-CoV-2 SP': 0.0013345878459084873, '12. Current Approaches in the Therapeutics for Targeting TGF-β in Cancer': 0.21353405534535796, 'Treatment Optimization': 0.016015054150901847, '3. Biological Therapies to Target the CD28/CTLA-4 Pathway: The Benefits': 0.005338351383633949, 'Immunomodulation to Facilitate rAAV Gene Therapy Delivery': 0.010676702767267898, '2. Recent Advances in the Development of Non-Viral Nanomedicine for RNA-Based GBM Gene Therapy': 0.029360932609986724, '3. Conclusions and Future Perspectives': 0.0013345878459084873, 'CHALLENGES TO THE CLINICAL USE OF CDK4/6 INHIBITORS': 0.018684229842718822, '6. Clinical trials incorporating SMAC mimetic therapy in HNSCC and other solid cancers': 0.0013345878459084873, 'Physical activity and breast cancer risk and outcome': 0.0026691756918169746, '3. Oral Protein Degraders: Progress and Limitations': 0.0026691756918169746, '5. Potential Novel Therapeutic Approaches to Targeting Leukemia and Endothelial Cell Interactions': 0.0013345878459084873, 'DISCUSSION AND FUTURE PERSPECTIVE': 0.02001881768862731, 'FIRST-LINE SYSTEMIC THERAPIES': 0.016015054150901847, 'SECOND-LINE SYSTEMIC THERAPIES AND IMMUNOTHERAPY': 0.008007527075450924, 'IMMUNOTHERAPY': 0.022687993380444284, 'ONGOING CLINICAL TRIALS USING ONCOLOGY AND NON-ONCOLOGY DRUGS': 0.05738727737406496, 'THERAPEUTIC STRATEGIES – PI3K/AKT/mTOR PATHWAY INHIBITORS': 0.016015054150901847, 'Novel agents on the horizon: the evolving treatment landscape of FL': 0.006672939229542436, '4. IL-7 in Tumour Therapy': 0.021353405534535796, '4. Induction of Remission': 0.005338351383633949, '5. Maintenance of Remission Therapy': 0.010676702767267898, '3. Design and application of CTA-based tumor vaccines': 0.010676702767267898, '8. Rice Breeding with Marker Assistance for Salt Tolerance': 0.004003763537725462, 'Therapeutics at the development stage': 0.0026691756918169746, '5. Materials and Methods': 0.004003763537725462, 'Cardiovascular Benefits of SGLT2 Inhibitors': 0.008007527075450924, 'Renal Effects of SGLT2 Inhibitors': 0.004003763537725462, 'MATERIALS & METHODS': 0.005338351383633949, '4. Influenza Immunization and Nonspecific Effects': 0.004003763537725462, 'THE CLINICAL RELEVANCE OF TAU': 0.005338351383633949, 'AMYLOID AND TAU PLASMA BIOMARKERS': 0.010676702767267898, '5. The Switch from Steroidal to Nonsteroidal Mineralocorticoid Receptor Antagonists': 0.021353405534535796, 'TAU TARGETED STRATEGIES FOR AD AND PRIMARY TAUOPATHIES': 0.010676702767267898, 'Study selection and grading of the evidence': 0.0013345878459084873, 'Consolidative Allogeneic SCT after CAR T-cell Therapy in ALL': 0.0013345878459084873, '5. ZIKV Therapy in GBM': 0.0026691756918169746, 'Therapeutic Inhibition of GSNOR': 0.006672939229542436, '[': 0.010676702767267898, 'HER2-PET in breast cancer': 0.0013345878459084873, '6. Considerations for PRE-Targeting Strategies in HBV Therapy': 0.032030108301803695, 'Methods and analyses': 0.013345878459084873, 'Relugolix combination therapy in women’s health': 0.0013345878459084873, '5. LAGGING STRAND REPLICATION': 0.0026691756918169746, 'Advances in the covalent inhibitors of KRas': 0.032030108301803695, 'Challenges in the development of covalent inhibitors of KRas': 0.005338351383633949, 'Future perspective': 0.005338351383633949, 'Heterotypic cell signaling in the neurovascular unit': 0.0026691756918169746, 'Declaration of Competing Interest and Funding': 0.0013345878459084873, 'Exon skipping with antisense oligonucleotides': 0.005338351383633949, 'Stop codon readthrough compounds': 0.0013345878459084873, 'IV. Experimental Results': 0.0026691756918169746, 'Genetic basis': 0.026691756918169746, 'EXTERNAL BEAM RADIATION THERAPY': 0.0013345878459084873, 'Macrophage-Targeted Therapeutic Approaches in Liver Disease': 0.008007527075450924, 'RECENTLY APPROVED AND NOVEL THERAPEUTIC AGENTS FOR PSORIASIS': 0.008007527075450924, 'Treatment and clinical trials': 0.19751900119445612, 'Discussion and outlook': 0.021353405534535796, '4. Neuropharmacology of imidazoline I': 0.0026691756918169746, 'Results/discussion': 0.016015054150901847, '5. Prophylactic cancer vaccines': 0.0013345878459084873, 'Translational Relevance': 0.0013345878459084873, 'Locoregional Ablation, Brachytherapy, Chemotherapy, and Immunotherapy': 0.005338351383633949, 'Organic Nanocarriers': 0.008007527075450924, 'Clinical Translation of Nanomedicines': 0.008007527075450924, 'FLT3 INHIBITORS': 0.08007527075450924, 'Preclinical CCA immunotherapy': 0.15214301443356756, 'Cost analysis of current medication regimes': 0.0013345878459084873, 'FLT3 INHIBITOR RESISTANCE': 0.013345878459084873, 'The complement system, a key serum protease system': 0.004003763537725462, '2. Specificity and safety of CAR T cell therapy': 0.02402258122635277, '3. Armored CARs to improve T cell function': 0.010676702767267898, 'CASE STUDIES: BiTE ANTIBODY CONSTRUCTS': 0.005338351383633949, 'Small Molecule Wild-type p53 Activators': 0.037368459685437644, 'Small Molecules Targeting Mutant p53': 0.0026691756918169746, 'Treatment methods': 0.0026691756918169746, 'Motor neuron disorders': 0.06939856798724134, '3. Management of Cryptococcal Meningitis': 0.0026691756918169746, 'Muscular dystrophies': 0.06939856798724134, 'CHECKPOINT INHIBITORS RESULTS IN GI CANCERS': 0.0026691756918169746, 'Critical signaling pathways involved in the stimulation or prevention of BCSC propagation and metastasis': 0.0026691756918169746, 'Congenital myopathies (CM)': 0.013345878459084873, 'Author disclosures': 0.0026691756918169746, 'STAR METHOD': 0.02402258122635277, 'MET as a primary driver in NSCLC': 0.005338351383633949, 'Natural History Studies in Geographic Atrophy': 0.009342114921359411, 'Clinical Development of Potential Pharmacotherapies': 0.010676702767267898, 'Clinical study of neoadjuvant chemoimmunotherapy in LAG/GEJA': 0.04804516245270554, 'Antibody Drug Conjugates': 0.0026691756918169746, 'Conclusion\\\\nand Outlook': 0.0013345878459084873, 'What may explain the differences between Horizon, TAMRAD and BOLERO-2?': 0.0013345878459084873, 'Immune checkpoints': 0.026691756918169746, 'Options for prevention and treatment': 0.04270681106907159, 'Multidisciplinary care of patients in the chemotherapy-naïve mCRPC setting with a focus on treatment with abiraterone acetate plus prednisone': 0.0026691756918169746, 'Key ongoing trials of abiraterone acetate plus prednisone and other regimens in the chemotherapy-naïve prostate cancer setting': 0.028026344764078236, 'Nanodrug delivery for breast cancer treatment': 0.010676702767267898, 'Current Scenario on Cell-based Therapy for Retinal Degeneration in India': 0.0013345878459084873, 'NK cell based': 0.0013345878459084873, '5. CONCLUSION': 0.0013345878459084873, 'PORTAL VEIN THROMBOSIS': 0.0013345878459084873, 'Toward EV-Based Therapeutic Angiogenesis': 0.0026691756918169746, 'Familial Neuroblastoma': 0.0013345878459084873, 'ADCs Advancing into Pivotal Trials for Treating Solid Tumors': 0.013345878459084873, 'The Place of ADCs in the Treatment of Solid Tumors': 0.0026691756918169746, 'Targeting Schlemm’s Canal to Reduce IOP': 0.017349641996810335, 'Phase I–III Clinical Trials on Novel IOP-Lowering Compounds': 0.02402258122635277, 'Immunosuppressive microenvironment of HCC': 0.013345878459084873, 'Clinically established immunotherapies': 0.0026691756918169746, 'The roles of immunotherapy-based perioperative treatment in HCC': 0.016015054150901847, 'Emerging immunotherapies': 0.05605268952815647, 'Anaemia': 0.0026691756918169746, 'Stem Cell Transplantation': 0.0013345878459084873, 'Opportunities to overcome the challenges': 0.005338351383633949, '6. Application of the': 0.0013345878459084873, 'Circadian System and Treatment Developments in Stroke': 0.026691756918169746, 'Study Methods': 0.0026691756918169746, 'Adoptive cellular therapies': 0.021353405534535796, 'Oncolytic virotherapy': 0.032030108301803695, 'CLINICAL THERAPY INVOLVING TLRS': 0.07740609506269228, 'Molecular therapy': 0.016015054150901847, 'Scientific Summary': 0.20285735257809007, 'Repurposed Drug Candidates against Tuberculosis': 0.14413548735811663, 'Promising advancements in clinical trials': 0.04003763537725462, 'Treatment of cardiac amyloidosis': 0.005338351383633949, 'Prevention and therapy of RIHD': 0.06406021660360739, '2 METHODS': 0.005338351383633949, 'Microbiome-targeted investigational therapies for IBD': 0.010676702767267898, 'CLINICAL TRIAL': 0.0013345878459084873, 'ORAL COMMUNICATIONS': 0.0013345878459084873, 'Targeting the TCA cycle enzymes and the associated lncRNAs': 0.029360932609986724, 'Materıals and Methods': 0.0026691756918169746, 'CHIP and personalised cardiovascular management': 0.0013345878459084873, 'FUTURE DEVELOPMENTS': 0.013345878459084873, 'AESTHETIC DEVELOPMENTS': 0.032030108301803695, 'MEDICAL DEVELOPMENTS': 0.017349641996810335, 'Hintergrund und Fragestellung': 0.0026691756918169746, '\\u206f': 0.010676702767267898, 'Yeast-based brachyury vaccine': 0.0013345878459084873, 'Poxvirus-based brachyury-TRICOM vaccine': 0.0013345878459084873, 'Extra-nodal NK/T-cell lymphoma, nasal type': 0.0026691756918169746, 'Patient information': 0.0013345878459084873, 'Issues': 0.0026691756918169746, 'Therapies mainly targeting LDL-cholesterol': 0.016015054150901847, 'Method/design': 0.0013345878459084873, 'Therapies mainly targeting triglycerides/HDL-cholesterol': 0.05338351383633949, 'Immunoproteasome as an emerging target in cancer': 0.0026691756918169746, 'Where to from here?': 0.0013345878459084873, 'Clinical advances of immunomodulatory cellular nanovesicles for disease management': 0.008007527075450924, 'Case 1: adult young patient with': 0.0026691756918169746, 'Targeting Altered Glycosylation in Cancer Cells and CSCs': 0.004003763537725462, '5. Anti-VEGF Agents in Ovarian Cancer: Previous and Current Studies': 0.021353405534535796, 'Therapeutic acute intermittent hypoxia (tAIH)': 0.0026691756918169746, 'Novel mobilizing platforms': 0.0026691756918169746, 'Main body': 0.06939856798724134, '2 The clinical regimens for the treatment of HMs': 0.19751900119445612, 'Study design and methods': 0.004003763537725462, '3 The application of nanocarriers-mediated drug delivery': 0.04270681106907159, 'B-cell receptor signalling inhibitors': 0.0026691756918169746, 'JAK/STAT pathway inhibitors': 0.0026691756918169746, 'Epigenetic-modifying drugs': 0.0026691756918169746, 'Novel agents': 0.018684229842718822, 'Summary of protocol': 0.0026691756918169746, 'Results: systematic review of the evidence for (prefrontal, fast rTMS) TMS therapy': 0.0026691756918169746, 'Exosomes as promising delivery systems for anticancer drugs and future perspectives': 0.02402258122635277, 'Other PD-1 blocking agents, pembrolizumab': 0.0013345878459084873, 'Ongoing developments in treatment of lung SqCC': 0.029360932609986724, 'Current Treatment Options and Therapeutic Approach': 0.010676702767267898, '2. Case report': 0.0026691756918169746, 'An overview of oxidative stress in cancer treatments': 0.004003763537725462, 'Representative drugs that induce oxidative stress in cancer treatments': 0.09075197352177714, 'Biological Treatments': 0.005338351383633949, 'Next-generation magnetic nanoparticles in MRI: translating research to clinical trials': 0.016015054150901847, 'Strategies for enhancing antitumor effects of drug-induced oxidative stress while mitigating toxicity in cancer therapy': 0.0026691756918169746, 'Structural properties of biodegradable polymers': 0.021353405534535796, 'VacA as a candidate for molecular therapy': 0.0026691756918169746, 'Can miRNAs be used as therapeutic agents in cancer?': 0.004003763537725462, '6. Clinical efficacy': 0.008007527075450924, 'New patches': 0.0026691756918169746, 'Immunotherapy and Newer Therapeutic Approaches': 0.0013345878459084873, 'CRISPR screens in lymphoma': 0.04537598676088857, 'Case reports: methods and results': 0.0026691756918169746, 'Drug Repositioning': 0.09075197352177714, 'Future Considerations': 0.0026691756918169746, 'Treatment of advanced disease': 0.012011290613176386, '2. Cholesterol fuels': 0.0026691756918169746, 'Anti-inflammatory agents for mood disorders': 0.0013345878459084873, 'OP17: Novel Surgical Approach for Lumbar Spine Pathologies': 0.0026691756918169746, 'Clinical trial': 0.0026691756918169746, 'Disclosure of Potential Conflicts of Interest': 0.0013345878459084873, 'Current Status of Development of HDP-CDV (CMX001)': 0.004003763537725462, 'The State of Clinical Cardiovascular Gene Therapy': 0.008007527075450924, 'Mitochondrial Delivery Strategies': 0.004003763537725462, 'Therapeutic Vaccination': 0.0013345878459084873, 'IV. Assessing RNAi delivery for GBM treatment': 0.016015054150901847, 'Improving Immunity': 0.005338351383633949, 'Prostate cancer immunotherapy': 0.021353405534535796, 'Urothelial carcinoma immunotherapy': 0.016015054150901847, 'RCC immunotherapy': 0.021353405534535796, 'The BEYOND Trial': 0.0013345878459084873, 'Regenerating CNS tissues': 0.014680466304993362, 'Clinical trials of EV therapy': 0.004003763537725462, 'Diagnosis and Treatment of BV': 0.0026691756918169746, 'Selecting targets for therapeutic vaccines for herpesviruses': 0.0013345878459084873, 'Therapeutic vaccines for HSV': 0.005338351383633949, 'Therapeutic vaccines for CMV': 0.013345878459084873, 'Doxapram': 0.0013345878459084873, 'Complement targets in atrophic AMD': 0.0026691756918169746, 'Agents targeting the FGFR pathway': 0.0013345878459084873, 'Procedural Issues Faced by the MSF ERB during the West African EVD Epidemic': 0.010676702767267898, 'Antimetastatic potential of Wnt and Hedgehog targeting': 0.005338351383633949, 'Pipeline Agents with Activity Against AB': 0.0026691756918169746, 'Motion #5: ‘Future randomized trials should be double blind’': 0.0013345878459084873, 'Data availability': 0.006672939229542436, 'THERAPIES AGAINST HD': 0.04270681106907159, 'LAG3 as a target for cancer immunotherapy': 0.05605268952815647, 'NNT in MS Clinical Trials': 0.008007527075450924, 'Current Status of the Clinical Application of iPSCs in Regenerative Medicine': 0.013345878459084873, 'Targeting Wnt Signaling Inside the Nucleus': 0.0013345878459084873, 'Other TNIK Inhibitors': 0.0026691756918169746, '3. Tumor & Matrix Factors': 0.005338351383633949, '3 Limitations of CAR-T cell therapy in AML': 0.02402258122635277, '4 New approaches for CAR-T cell therapy in AML': 0.005338351383633949, '5 Positioning CAR-T cell therapy in AML: novel solutions for distinct obstacles': 0.0013345878459084873, 'WHAT IS THE CURRENT DEFINITION OF RENAL RESPONSE IN AAV AND WHAT IMPORTANT POINTS ARE MISSED?': 0.008007527075450924, 'Present and Future of GA Treatment': 0.037368459685437644, 'TRIAL STATUS AND PUBLICATIONS': 0.0013345878459084873, 'Methods: participants, interventions and outcomes': 0.008007527075450924, 'Further clinical development of pembrolizumab': 0.022687993380444284, 'Armed TCR-T': 0.05071433814452252, 'NEW DEVELOPMENTS FOR CONVENTIONAL ADJUVANTS': 0.04270681106907159, 'CLINICAL TRIALS OF BIOABSORBABLE POLYMER-COATED DES': 0.05071433814452252, 'EMERGING VACCINE ADJUVANTS': 0.05605268952815647, 'Uveitis': 0.010676702767267898, 'Current Study': 0.0013345878459084873, 'NUCLEUS PULPOSUS REGENERATION AND REPLACEMENT': 0.010676702767267898, 'Treatment of': 0.0026691756918169746, 'Therapeutic advances in the setting of resistance': 0.010676702767267898, '5. Questions and prospects': 0.0013345878459084873, 'The immunotherapy landscape in pediatric CNS tumors': 0.08808279782996016, 'Combination therapy and future studies': 0.008007527075450924, 'CARDIAC PHYSIOLOGIC PACING': 0.005338351383633949, 'The mechanical approach': 0.0026691756918169746, 'The lipid approach': 0.008007527075450924, 'Therapeutic Potential of Gut Microbiota for T2D': 0.04804516245270554, 'Clinical development of pembrolizumab': 0.0013345878459084873, 'Immunotherapies beside pembrolizumab in cervical cancer': 0.02535716907226126, 'FOXO1 improves human CAR T cell stemness': 0.0013345878459084873, '2 HCMV Vaccine Technologies': 0.05872186521997345, '8. Data with': 0.0026691756918169746, 'Types of treatment': 0.021353405534535796, 'IDO1 inhibitors and peptide vaccines in clinical trials': 0.20152276473218161, 'NEW DRUGS': 0.010676702767267898, 'Medicinal chemistry strategies for the development of IDO1 inhibitors in clinical trials': 0.010676702767267898, '4. Nonsurgical, Non-Liver-Directed Therapies': 0.037368459685437644, 'Emerging Treatments': 0.008007527075450924, 'Updates in PRRT': 0.04804516245270554, 'Complications': 0.004003763537725462, 'CLINICAL TRIALS USING ONCOLYTIC MEASLES VIRUS STRAINS': 0.009342114921359411, 'CLINICAL CHALLENGES AND FUTURE PERSPECTIVES': 0.0013345878459084873, 'Challenges and future prospects': 0.02402258122635277, 'CELL TRANSPLANTS IN THE FUTURE': 0.0013345878459084873, 'KNOWLEDGE GAPS IN THE USE OF EXTRACORPOREAL UF IN HEART FAILURE': 0.0026691756918169746, 'Therapeutic Interventions': 0.14146631166629967, '2 Celiac disease novel therapies': 0.0627256287576989, 'Tofacitinib': 0.05071433814452252, 'The Prospect of STAT inhibitors': 0.0026691756918169746, '3. Whole': 0.03469928399362067, '4. Heterologous prime boost with DNA, recombinant viruses and bacteria and recombinant protein with adjuvant': 0.0013345878459084873, 'CONCLUSION AND RESULTS': 0.008007527075450924, 'MOLECULAR PROFILING GUIDING CUSTOMIZED N-OF-1 DESIGN': 0.0013345878459084873, 'Role of epigenetic drugs in B- and T-cell lymphoma': 0.18417312273537126, 'Current pharmacological approaches': 0.0026691756918169746, 'Role in hepatic encephalopathy': 0.0013345878459084873, 'CSL112: a novel investigational pharmacotherapy designed to improve high-density lipoprotein function': 0.017349641996810335, 'Safety, tolerability, and pharmacokinetics/pharmacodynamics of ApoA-I-based intravenous infusions and CSL112': 0.0026691756918169746, 'SECOND (TARGETING IMMUNOSUPPRESSIVE MICROENVIRONMENT)': 0.010676702767267898, 'Clinical applications of IL-20 in liver disease': 0.005338351383633949, '5. Monitoring': 0.0013345878459084873, '1.0. Introduction': 0.005338351383633949, 'β-HYDROXY-β-METHYLBUTYRATE SUPPLEMENTATION': 0.0013345878459084873, 'From lung microbiome alterations to treatment strategies in ILD': 0.0026691756918169746, 'Clinical studies of stem cell-derived EVs': 0.032030108301803695, 'Targeting EMT-inducing signals in the tumor microenvironment for cancer therapy': 0.013345878459084873, '2. Islet Transplantation': 0.05872186521997345, 'Types of adoptive cell therapy': 0.15214301443356756, 'Challenges and strategies of ACT in solid tumors': 0.04270681106907159, 'Overview of therapeutic strategies used in cancer to treat PAH': 0.0026691756918169746, 'Matrix components as therapeutic targets for cancer': 0.013345878459084873, 'NONAUGMENTED BLADDERS': 0.0013345878459084873, '3: Clinical Implications': 0.0013345878459084873, 'Clinical Trial Designs of Approved Targeted Agents for NSCLC': 0.005338351383633949, 'Recent Immunotherapy Approvals in NSCLC': 0.006672939229542436, 'EGFRVIII CAR-T CELLS FOR GBM IMMUNOTHERAPY': 0.0026691756918169746, 'Declaration of competing interest': 0.0013345878459084873, 'Clinical Trials Using AAVs for Retinal Diseases': 0.14280089951220815, 'INHIBITION OF ANTIOXIDANT DEFENSE AND OTHER REACTIVE OXYGEN SPECIES-INDUCING THERAPEUTIC STRATEGIES: PRECLINICAL AND CLINICAL STUDIES': 0.004003763537725462, 'Pimavanserin': 0.10409785198086201, 'Non-Hodgkin Lymphoma (NHL)': 0.0026691756918169746, 'Hodgkin Lymphoma (HL)': 0.0013345878459084873, 'Ongoing studies – Phase III': 0.0026691756918169746, 'Other information': 0.005338351383633949, 'Future prospects': 0.004003763537725462, 'Case Presentation 1': 0.0013345878459084873, 'Clinical reports of CD19-targeted CAR-T therapy in autoimmune rheumatic diseases': 0.02535716907226126, 'Potentials of CAR-based therapy and ongoing clinical trials': 0.006672939229542436, 'Novel Strategies for Stem Cell-Based Therapies': 0.005338351383633949, 'ADDITIONAL INFORMATION': 0.005338351383633949, 'Augmenting B Memory Cell Function can Worsen MS': 0.0026691756918169746, 'TOFACITINIB: A PAN JAK INHIBITOR': 0.016015054150901847, 'Significance and Progression of Personalized Medicine': 0.0013345878459084873, 'Recent Update on Personalized Therapeutics in Perspective of Various Targeted Strategies': 0.005338351383633949, 'Ongoing clinical studies': 0.12945502105312326, 'Clinical applications in oncology': 0.0013345878459084873, 'ANNOUNCEMENT': 0.0013345878459084873, 'V-Wave device': 0.0013345878459084873, '2. Drug Repurposing for COVID-19': 0.0026691756918169746, 'Therapeutic applications of MSC-EVs in bone-related diseases': 0.018684229842718822, 'Mechanisms of resistance': 0.005338351383633949, '9. GSK-3 and GSK-3-Phosphorylated Tau as Therapeutic Targets in AD': 0.006672939229542436, 'Potential Expanded/Future Indications of ARNI use in HFrEF': 0.018684229842718822, 'Potential Therapeutic Strategies Beyond Systolic Heart Failure': 0.005338351383633949, 'Potential Non-Cardiac Indications': 0.010676702767267898, 'Cancer immunotherapy resistance': 0.005338351383633949, 'Current Drug Treatment for Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus: Clinical Practice Guideline Recommendations': 0.010676702767267898, 'Body composition in children with cancer': 0.0026691756918169746, 'Designing Acellular Injectable Biomaterial Therapies for MI': 0.008007527075450924, 'Molecular imaging strategies': 0.0026691756918169746, 'Platform integration to guide selection of novel tracers': 0.0026691756918169746, 'Pharmacological targeting of PTP1B and TCPTP': 0.010676702767267898, 'Clinical Trials of CD19‐CAR‐T Therapy Against B‐NHLs (Including B‐cell Chronic Lymphocytic Leukemia; B‐CLL)': 0.005338351383633949, 'Unsolved Problems in CAR‐T Therapy': 0.006672939229542436, '4. Novel Androgen Receptor Inhibitors in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer': 0.009342114921359411, '5. Androgen Receptor Inhibition in Metastatic Hormone-Sensitive Prostate Cancer': 0.005338351383633949, '6. Selective Androgen Receptor Degraders and Proteolysis Targeting Chimeras': 0.0013345878459084873, 'Co-delivery of chemotherapeutics/siRNA and autophagy inducers/inhibitors': 0.0013345878459084873, 'LNP-Based Strategy in Liver Metastasis Treatment': 0.037368459685437644, 'Pi3K-mTor and Gator1 Gene Variants Resulting in Malformation of Cortical Development and Epilepsy': 0.0013345878459084873, 'The Road to Pembrolizumab': 0.0013345878459084873, 'Pembrolizumab: Hopes for the Future?': 0.03469928399362067, '9.0 Alternative Approaches to RAAS Blockade': 0.0026691756918169746, 'Novel Treatments and Clinical Trials': 0.029360932609986724, 'Previous Clinical Trials for IDH-mutant Gliomas': 0.021353405534535796, 'Current Multicenter Clinical Trials': 0.060056453065881935, 'iRECIST': 0.0026691756918169746, 'Discovery of Dordaviprone (ONC201) for the Treatment of DMG': 0.04537598676088857, 'Potential for Combination Treatment Strategies Including Dordaviprone in DMG': 0.005338351383633949, 'STRATEGY II: RECRUITMENT OF FUNCTIONAL CARDIOMYOCYTES BY PROMOTING THEIR PROLIFERATION OR DIFFERENTIATION': 0.008007527075450924, 'FUTURE THERAPEUTICS AND MOTS-c': 0.0013345878459084873, 'Addressing the Need for Contraception During Elagolix Use': 0.0013345878459084873, 'Managing Endometriosis as a Chronic Disease: Long-Term Treatment Considerations': 0.0013345878459084873, '2.': 0.0026691756918169746, '3. Targeted cytotoxic therapy': 0.008007527075450924, '4. Immunotherapy': 0.037368459685437644, '5. Biologic agents': 0.008007527075450924, '6. Molecularly targeted agents': 0.08808279782996016, 'Translational therapeutics: bringing findings from experimental MPE to clinical investigation': 0.017349641996810335, 'Reprogrammed CAFs and Stellate Cells Sustain Tumor Growth': 0.0013345878459084873, 'Modulation of B cell function': 0.016015054150901847, 'Modulation of autoantibody (IgG) Half‐Life': 0.013345878459084873, 'Avastin for ROP': 0.0013345878459084873, 'Inhibition of inflammatory markers': 0.0026691756918169746, 'Immunological checkpoint receptors and agonists': 0.0013345878459084873, 'Institutional review board statement': 0.0026691756918169746, 'HDAC inhibitors in HNSCC treatment': 0.016015054150901847, 'ANGPLT3 inhibition in HoFH': 0.0013345878459084873, 'BIOMARKERS OF ISCHEMIA-REPERFUSION SYNDROME AND DGF': 0.0026691756918169746, 'CELL GRAFTING IN PD: THE PIONEERING STUDIES (1979-1990)': 0.018684229842718822, 'Materials and methodology': 0.004003763537725462, 'Possible solutions (and their potential shortcomings)': 0.004003763537725462, 'Precision Medicine: Advances in Oncologic, Cardiovascular, and Addiction Medicine': 0.005338351383633949, '2. Oncogenic lncRNAs in breast cancer': 0.04270681106907159, 'COLCHICINE': 0.0013345878459084873, 'IMMUNOSUPPRESSION WITH STEROIDS': 0.0013345878459084873, '6. Declaration': 0.0013345878459084873, 'MOLECULARLY TARGETED THERAPY': 0.004003763537725462, '4. Perspective': 0.0013345878459084873, '6. Other Aspects': 0.004003763537725462, 'Repurposing antifungal drugs for cancer therapy based on original targets': 0.0026691756918169746, 'Repurposing antifungal drugs for cancer therapy based on off-site targets': 0.03469928399362067, 'DISCUSSION OF SELECTED TREATMENT ISSUES': 0.010676702767267898, '5. Targeting RNA Binding Proteins, Oxidative Stress and Mitochondrial Dysfunction in ALS': 0.0013345878459084873, 'VACCINES': 0.0026691756918169746, 'Efficacy': 0.013345878459084873, '5. CD24 as Target for COVID-19 Therapy: An Opportunity for Discovering Novel Cardiac Therapies?': 0.0013345878459084873, 'Apoptosis, fibrosis, and impaired healing': 0.0026691756918169746, '9. Tryptophan Metabolism and Bacterial Indoles as Therapeutic Targets': 0.005338351383633949, 'AI in clinical trials': 0.030695520455895207, '9. Discussion': 0.0026691756918169746, 'Methods: design, participants, interventions and outcomes/design': 0.0013345878459084873, 'FUTURE THERAPIES': 0.010676702767267898, 'Exploring the Clinical Potential of Exosomes': 0.0013345878459084873, '5. Pharmacotherapies with Putative Effects on HSCs': 0.010676702767267898, '3. S100A4 in the Pathology of the Nervous System': 0.008007527075450924, '7. Multimodality Imaging for CRT Optimization': 0.0013345878459084873, '3. Methodology': 0.0026691756918169746, 'Case (': 0.0013345878459084873, '3. Characterization of TM Biology': 0.0026691756918169746, '4. Characterization of TC Biology': 0.005338351383633949, '6. Future Perspectives': 0.02535716907226126, 'Tissue-agnostic indications for immunotherapy in the treatment of GI cancer': 0.04270681106907159, 'Esophageal/Gastroesophageal junction/gastric cancer': 0.04804516245270554, 'Biliary tract cancers': 0.005338351383633949, 'Immunotherapy for the treatment of colorectal and anal cancer': 0.03469928399362067, 'Method and materials': 0.005338351383633949, 'HUMAN DISEASE MODELS OF IMAGING TO STUDY VASCULAR INFLAMMATION': 0.013345878459084873, 'FUSION PROTEINS: THE PARADIGM FOR TARGETED THERAPY IN MYELOID MALIGNANCIES': 0.0013345878459084873, 'GENETIC TARGETS RESULTING FROM SOMATIC MUTATION AND OTHER ABERRANTLY ACTIVE TARGETS': 0.009342114921359411, 'Epidermal growth factor receptor (': 0.05738727737406496, 'Mesenchymal-epithelial transition (': 0.060056453065881935, 'V-Raf murine sarcoma viral oncogene homolog (': 0.0013345878459084873, 'Rearrangement during transfection (': 0.026691756918169746, 'Human epidermal growth factor receptor 2 (HER-2)': 0.04404139891498008, 'Fibroblast growth factor receptor (FGFR)': 0.006672939229542436, 'miRNA targeting of IBD-associated genes': 0.0013345878459084873, 'Strategies to improve immunostimulation': 0.010676702767267898, 'Tumor DNA Repair Deficiencies Impact Response to Immunotherapy': 0.0013345878459084873, 'Enhancing the GVL effect after Treg infusion for GVHD suppression': 0.0013345878459084873, '4. Treatment of ABPA with Approved Therapies': 0.0026691756918169746, '6. PUR1900: Inhaled Itraconazole': 0.009342114921359411, 'ENDOCRINE THERAPY': 0.009342114921359411, 'Applications of nanotechnology-based drug-delivery systems in oral cancer therapy': 0.010676702767267898, 'B-cell non-Hodgkin lymphoma': 0.15080842658765908, 'Classical Hodgkin lymphoma': 0.05071433814452252, 'Therapeutics for COVID-19 and beyond': 0.14413548735811663, 'T-cell lymphoma': 0.013345878459084873, 'Tumor-agnostic CAR': 0.0026691756918169746, 'Neo-adjuvant systemic treatment': 0.005338351383633949, 'Ongoing Trials on Immunoradiotherapy for Sarcomas': 0.012011290613176386, 'The Role of MRD in Older Adult AML Patients': 0.0026691756918169746, 'Side effects': 0.016015054150901847, '7 Clinical strategies to overcome resistance': 0.0013345878459084873, 'Targeting upstream effectors of': 0.03870304753134614, 'Targeting downstream effectors of': 0.03469928399362067, 'ROS1-Targeted Therapies in Lung Cancer': 0.026691756918169746, 'Therapeutic approaches to TNBC': 0.2615792177980635, '3. Novel Emerging Therapies': 0.029360932609986724, '3. Targeting T2 Cytokines': 0.0026691756918169746, '4. Targeting Specific Receptors on Eosinophils': 0.0026691756918169746, '5. Targeting Upstream Pathways of T2 Cytokines': 0.005338351383633949, 'TREATMENT OPTIONS': 0.0026691756918169746, 'FUTURE DIRECTIONS FOR RIPRETINIB': 0.0026691756918169746, 'Ceritinib: overcoming crizotinib resistance': 0.0026691756918169746, 'Clinical development': 0.010676702767267898, '3. Targeted Therapies for Prostate Cancer': 0.08007527075450924, 'Diagnostic Assessment': 0.0013345878459084873, 'AA in the Footsteps of Psoriasis': 0.013345878459084873, 'Broad T Cell Antagonism': 0.029360932609986724, 'Advances in Cardiovascular Prevention': 0.016015054150901847, 'Advances in Heart Failure': 0.014680466304993362, 'Advances in Arrhythmia and Electrophysiology': 0.018684229842718822, 'Types of adjuvant therapy in adrenocortical carcinoma': 0.008007527075450924, '5. Plant-Derived Vesicles for Human Health: From Cell Uptake to Therapeutic Potential': 0.005338351383633949, '5. Immunogenicity': 0.008007527075450924, '5. Treating Metastatic Malignant Melanoma': 0.0026691756918169746, '5. Mesenchymal Stem Cells': 0.0026691756918169746, 'Emerging Therapies': 0.03469928399362067, 'New challenges': 0.004003763537725462, '2. Clinical Trials': 0.008007527075450924, '3. Evaluation of SARS-CoV-2 nAbs in the Treatment and Prophylaxis Settings': 0.032030108301803695, 'Clinical Practice Involving Vessel Regulation': 0.08007527075450924, '4. Susceptibility to Currently Circulating Variants': 0.0013345878459084873, '5. Approaches to Improve nAb Access and Availability': 0.0013345878459084873, 'MPH-LA clinical trial: design and analysis': 0.0013345878459084873, '6. Clinical Studies': 0.0013345878459084873, 'Non-targeted therapies and/or agents': 0.0026691756918169746, 'DRUG REPURPOSING AND DRUG REPOSITIONING': 0.0013345878459084873, 'Section II: Identification of liver-tropic AAV vectors': 0.0026691756918169746, 'Pathogenesis': 0.0026691756918169746, '4. Dysregulation of miRNAs in Rare Gynecological Cancers': 0.005338351383633949, 'Induction of Immune Checkpoint Inhibitors Combined with Chemotherapy': 0.0013345878459084873, 'Induction of Chemo-Free Therapy': 0.005338351383633949, 'Conclusions and Future Prospects': 0.013345878459084873, 'Well-Being Promotion': 0.0026691756918169746, 'Surveillance for Recurrences': 0.04537598676088857, 'Discussion and Future Perspectives': 0.0026691756918169746, '3. Treatment of MRSA Infections': 0.0013345878459084873, '3. Optimizing HER2-targeted therapy for early breast cancer': 0.010676702767267898, 'Current Controversies and Future Outlook': 0.008007527075450924, 'Amlexanox improves metabolic parameters in an open label clinical study': 0.0013345878459084873, 'Amlexanox improves metabolic parameters in a placebo-controlled double blind study': 0.0013345878459084873, 'Star Methods': 0.005338351383633949, 'ROLE OF SEX STEROIDS IN LYMPHANGIOLEIOMYOMATOSIS PATHOGENESIS': 0.0013345878459084873, '6. Targeting C5': 0.017349641996810335, 'HER2-low: An actionable target': 0.05338351383633949, 'Impact of DESTINY-Breast04 on treatment of HER2-low mBC': 0.005338351383633949, 'Mechanisms of resistance to [': 0.014680466304993362, '8 Role in Hereditary and Acquired Diseases': 0.0013345878459084873, 'Gut microbial dysbiosis as a major contributor for the initiation, growth, and metastatic progression of breast carcinoma: the mischiefs of anarchy': 0.005338351383633949, 'Alterations in the gut microbiota impact therapeutic response in breast cancer patients': 0.008007527075450924, 'Restoring the gut microbiota as an effective therapeutic strategy for the management of breast cancer: good health starts in the gut': 0.013345878459084873, 'ANTIBODY-DRUG CONJUGATES': 0.005338351383633949, 'BISPECIFIC ANTIBODIES': 0.008007527075450924, 'CAR-T CELL THERAPIES': 0.006672939229542436, 'Competing Interests': 0.005338351383633949, 'Potential Benefit of Immunostimulant Microbial Exposures': 0.0013345878459084873, '4. Therapeutic Strategies for OCCC Based on the Phenotypes of ARID1A Deficiency': 0.02402258122635277, 'Potential for Cardiometabolic Benefits With Incretins and SGLT2 Inhibitors': 0.006672939229542436, 'NOVEL DRUGS FOR THE TREATMENT OF DIABETIC KIDNEY DISEASE': 0.005338351383633949, 'Ongoing studies (discussion)': 0.004003763537725462, '3. Predictive Biomarkers in the Targeted Therapy Era: Something Old, Something New, Something Borrowed and Something Blue': 0.005338351383633949, 'Prevention of late effects including t-MDS/t-AML': 0.0026691756918169746, '4. Clinical Trials Evaluating the Diagnostic and Therapeutic Potential of Monoclonal Antibodies in Pancreatic Cancer': 0.06406021660360739, '5. Challenges and Future Opportunities with Antibody Therapeutics in Pancreatic Cancer': 0.009342114921359411, '7. VBR through intracellular gene delivery iBTE strategy': 0.0026691756918169746, '6. Summary and Concluding Remarks': 0.008007527075450924, 'Development of GLP-1R/GcgR unimolecular dual-agonists': 0.05872186521997345, 'Head and neck cancer – basic information': 0.026691756918169746, 'Drugs to inhibit EMT': 0.013345878459084873, 'Clinical experiences with elotuzumab': 0.016015054150901847, 'Other trials': 0.0013345878459084873, 'Targeted agents for the treatment of HER2-positive early-stage breast cancer': 0.010676702767267898, 'Neratinib in HER2-positive early-stage breast cancer': 0.005338351383633949, 'ROLE OF STATINS IN ANTI‐CANCER TREATMENT AND POSSIBLE MOLECULAR MECHANISMS': 0.03469928399362067, '4. A theranostic approach with 177Lu-PSMA-617 therapy': 0.010676702767267898, '5. New PSMA-associated radionuclides': 0.0026691756918169746, 'METASTATIC SETTING': 0.0026691756918169746, 'B. CLINICAL-TRANSLATIONAL ADVANCES': 0.026691756918169746, 'mTOR, cognition and brain aging': 0.0026691756918169746, 'Ethics declaration': 0.0026691756918169746, '4. OTHER COMMERCIALLY AVAILABLE AGENTS: HYDROXYUREA, INTERFERON AND HYPOMETHYLATING AGENTS': 0.010676702767267898, '5. NEW JAK INHIBITORS IN PHASE III TRIALS: PACRITINIB AND MOMELOTINIB': 0.008007527075450924, '6. NEW AGENTS IN EARLIER STAGES OF DEVELOPMENT (preclinical, phase I/II)': 0.0026691756918169746, '8. EXPERT OPINION': 0.010676702767267898, 'TA-TMA-diagnosis, Risk Factors, and Treatment': 0.013345878459084873, 'Off-the-shelf CAR-T cell therapies based on gene editing': 0.02402258122635277, 'Programmed death pathway and lung cancer': 0.026691756918169746, 'A review of atezolizumab pharmacology': 0.08808279782996016, 'GPC3-Targeted Therapy': 0.0013345878459084873, '8. Precision Targets from ATLL Genomic Studies': 0.005338351383633949, 'II) Tolerance mechanisms associated with transient mixed chimerism': 0.010676702767267898, 'Data and method': 0.005338351383633949, 'Types of androgen deprivation therapies used in the treatment of prostate cancer': 0.0013345878459084873, 'Androgen deprivation combined with immune-based treatments – clinical trials for prostate cancer': 0.004003763537725462, '3. Putative Strategies Exploiting NK Cell Therapy to Treat PTLDs': 0.018684229842718822, '13. Combination Therapies for Pancreatic Cancer: Combining Immunotherapeutic Approaches with IRE': 0.0026691756918169746, '5. Future Research and Directions in Personalized Medicine and Rehabilitation in Stroke Recovery—Discussion': 0.0013345878459084873, 'Methods of siRNA Delivery': 0.005338351383633949, 'Concomitant treatment of HIV and tuberculosis': 0.0026691756918169746, 'Treatment for specific populations: women, children, adolescent, older people and acutely infected individuals': 0.02402258122635277, 'Small Molecule Inhibitors of WEE1 Kinase': 0.19218064981082217, 'Safety, tolerability and convenience': 0.0026691756918169746, 'Material & method': 0.0026691756918169746, 'Affordability and global access for all PLWH': 0.005338351383633949, '4. Candidate Gene Studies': 0.005338351383633949, 'Clinical experience': 0.016015054150901847, 'Upregulation of coinhibitory receptors also occurs during T cell activation': 0.013345878459084873, 'SURGERY': 0.0026691756918169746, 'Adverse Events of Existing Clinical Candidates': 0.005338351383633949, 'Recent clinical advances in breast cancer immunotherapy': 0.12278208182358083, '2. Historic Overview': 0.0026691756918169746, 'Therapeutic strategies to overcome immunotherapy resistance': 0.005338351383633949, 'Targeting AMPK': 0.0013345878459084873, 'Oral anticoagulants': 0.010676702767267898, '5. Smad7 in Colon Cancer': 0.0013345878459084873, '4. Peptide-Based Caspase-3 Probes': 0.005338351383633949, '3. The Role of Non-Protein-Coding Transcripts and Their Role in the Development of Ovarian Cancer Metastasis': 0.0026691756918169746, 'DIFFERENT TARGETS OF': 0.08007527075450924, 'Hallmarks of response to immune checkpoint blockade': 0.013345878459084873, '2. Herpes Simplex Virus-1': 0.010676702767267898, '4. Adenovirus': 0.018684229842718822, 'Funding and disclosure': 0.0013345878459084873, '5. Molecular Imaging': 0.005338351383633949, '3. Lipid-Based Nanoparticles for Drug Delivery': 0.010676702767267898, '4. Lipid-Based Nanoparticles for Gene Therapy': 0.018684229842718822, 'FUNDING INFORMATION': 0.006672939229542436, 'Conclusions and perspectives': 0.009342114921359411, 'Decipher': 0.0013345878459084873, '2. Current standards of treatment and outcomes': 0.0026691756918169746, '3. Emerging Targeted Therapy for Malignant Glioma': 0.11477455474812992, '3. Clinical Relevance Of Minimal Residual Disease': 0.006672939229542436, '4. MRD Status Interaction with Other Genetic High Risk Groups': 0.02402258122635277, '5. MRD Prognostic Value Peri-Stem Cell Transplant': 0.0013345878459084873, '4. Immunotherapy in malignant glioma': 0.07206774367905831, 'MOLECULAR IMAGING': 0.010676702767267898, 'P2Y(12) receptor antagonists(Table': 0.0013345878459084873, 'Questioning the Vulnerable Plaque Hypothesis': 0.0013345878459084873, 'Gene delivery methods': 0.005338351383633949, 'Existing issues and future directions': 0.016015054150901847, '6. Poly(ADP-Ribose) Polymerase Inhibitors': 0.008007527075450924, '7. Akt Inhibitors': 0.008007527075450924, 'Author contributions': 0.0026691756918169746, '4. SDF-1α/CXCR4 Targeted Therapy in MM': 0.005338351383633949, 'Standard housing temperature': 0.005338351383633949, 'Pazopanib': 0.0013345878459084873, '2. Targeting oncogenic translation with DEAD/H box RNA helicase inhibitors': 0.005338351383633949, '5. Therapeutic Strategies to Block Treg Recruitment and Expansion or Limit Their Stability': 0.11477455474812992, '4. Translational applications of EVs in cancer': 0.010676702767267898, '3. Current Challenges to Optimize Antibiotic Prophylaxis in Proximal Femur Fractures Requiring Hip Hemiarthroplasty': 0.0013345878459084873, '4. Future Scenarios to Optimize Prosthetic Joint Infection Prophylaxis in Proximal Femur Fractures Requiring Hip Hemiarthroplasty': 0.0013345878459084873, '3. Extrinsic and Common Pathway Aptamers': 0.0026691756918169746, 'During cancer treatment': 0.018684229842718822, 'Exosomes as an innovative therapeutic tools for diabetes: current status and promising directions': 0.013345878459084873, '3. Lipid-Based Nanoparticles in Cancer Chemoimmunotherapy': 0.016015054150901847, '3. Pro-inflammatory cytokines and chemokines': 0.005338351383633949, '4. Anti-inflammatory and hepatoprotective cytokines': 0.0013345878459084873, 'TKIs AND BIOLOGICAL THERAPY IN GISTs': 0.03603387183952916, '3. Clinical Efficacy': 0.013345878459084873, '2. Rationale for Hydroxyurea Dose Individualization': 0.0013345878459084873, '4. Application of Bayesian Approach in Hydroxyurea Dosing Individualization': 0.0013345878459084873, '3. Clinical Relevance of Liquid Biopsies in Solid Cancers': 0.0026691756918169746, '2 Method': 0.0013345878459084873, '7. Competitive environment': 0.21887240672899191, 'EFFICACY OF': 0.032030108301803695, '9. Targeted Therapy for DNA Methylation': 0.0013345878459084873, 'CTCs as a marker of micrometastatic spread in early BC': 0.0026691756918169746, 'CTC as a dynamic prognostic factor in metastatic BC': 0.005338351383633949, 'Quantitative aspects of CTC detection': 0.0026691756918169746, 'CTCs as a tool for liquid biopsy': 0.005338351383633949, 'Direct-Acting Antivirals': 0.0026691756918169746, 'Host-Targeting Agents': 0.021353405534535796, '3. Treatment': 0.021353405534535796, '3. Results-Glioblastoma Targeted Therapies': 0.5018050300615912, 'SURVEY OF CURRENT TARGETS OF PAIN THERAPEUTICS': 0.010676702767267898, 'Prediction of Stroke Risk Based on Electrocardiographic Markers': 0.0026691756918169746, '4. Discussion-Guidance towards Future GBM Targeted Therapies': 0.008007527075450924, 'Gene Therapy': 0.026691756918169746, 'COMBINATION THERAPY STRATEGIES FOR NEOANTIGEN IMMUNOTHERAPIES': 0.0013345878459084873, 'Detection and resection of SLs': 0.005338351383633949, '3. What Is the Current Available Treatment?': 0.0013345878459084873, 'Compounds Under Clinical and Preclinical Evaluation': 0.008007527075450924, 'O-glycosylation and immunotherapy': 0.004003763537725462, 'Sialylation and immunotherapy': 0.0013345878459084873, '4. Immunotherapy Trials in ACC': 0.013345878459084873, '2. NK Cell Cancer Immunotherapy Clinical Trials': 0.004003763537725462, '3. Treatment of Bone Metastases': 0.008007527075450924, 'Proinflammatory cytokines and chemokines': 0.0026691756918169746, 'Oxidative stress and antioxidants': 0.0013345878459084873, 'CLINICAL TRIAL INFORMATION': 0.0013345878459084873, 'Immunotherapy biomarkers for gynecologic cancer': 0.018684229842718822, 'Immunotherapy for the treatment of cervical cancer': 0.06939856798724134, 'Immunotherapy for the treatment of endometrial cancer': 0.04270681106907159, 'Emerging immunotherapy strategies for the treatment of ovarian cancer': 0.06406021660360739, 'Emerging immunotherapy strategies for the treatment of rare gynecologic cancers': 0.026691756918169746, '5. Strategies for Management of COVID-19: Current Status, Pitfalls and Obstacles': 0.010676702767267898, '2. Blood-Based Liquid Biopsy Marker Candidates': 0.05071433814452252, '7. PCI Timing in Stabile Patients with AS': 0.0026691756918169746, '3. Experiments': 0.0026691756918169746, 'MANAGEMENT OF CCA': 0.0026691756918169746, 'MOLECULAR CHARACTERISATION AND POTENTIAL FOR TARGETED THERAPIES': 0.03469928399362067, 'OUTCOME AND FOLLOW-UP': 0.0026691756918169746, 'The clinical trials of TCR-T, the United States outshines others': 0.006672939229542436, 'CURRENT TREATMENT REGIME': 0.03870304753134614, 'The multidimensional interaction: tumor, TAA and normal tissue': 0.0013345878459084873, 'The GE-T cancer immunotherapy was followed by fatal serious adverse events': 0.0013345878459084873, 'Current chemotherapy': 0.0013345878459084873, 'Current treatment strategies and progress of glioblastoma': 1.1103770877958614, '5. Systemic Biomarkers': 0.0026691756918169746, 'Patients & Methods': 0.0026691756918169746, '6. Conclusions and future directions': 0.0013345878459084873, '3. Applying nanomedicine in inflammation dynamics': 0.0026691756918169746, '3. Mechanisms of HSC activation': 0.10142867628904503, '4. Vaccines': 0.005338351383633949, 'METHODS AND RESULTS': 0.0026691756918169746, 'SCREENING OPTIONS': 0.010676702767267898, 'The CTRU eConsent approach': 0.010676702767267898, 'Clinical trial details': 0.05071433814452252, '4. Future Directions': 0.0013345878459084873, 'Small backbone benefit: Reduced vector inactivation and improved transfection efficiency with Nanoplasmid vectors': 0.0026691756918169746, 'Approved fluorophores for cancer imaging': 0.021353405534535796, 'Targeted fluorophore development': 0.06939856798724134, '5. Study Design and Methods': 0.0013345878459084873, 'DRUG CANDIDATE TARGETS BASED ON VIRAL STRUCTURE AND LIFE CYCLE': 0.022687993380444284, 'APPROVED DRUGS FOR INFLUENZA': 0.005338351383633949, 'DRUGS IN THE CLINICAL TRIALS': 0.13879713597448268, '2. PARTICIPANTS AND METHODS': 0.0026691756918169746, 'Diagnosis': 0.005338351383633949, 'Physical microenvironment of the tumour': 0.010676702767267898, 'Drug delivery': 0.016015054150901847, 'Complement': 0.010676702767267898, 'Neovascular age-related macular degeneration': 0.008007527075450924, 'Desarrollo': 0.03469928399362067, 'STAR Methods text': 0.010676702767267898, 'IMMUNE CHECKPOINT INHIBITOR PD-1/PD-L1 IN OC': 0.0013345878459084873, 'COMBINED IMMUNOTHERAPIES FOR OC': 0.008007527075450924, '5. Additional Targets and Strategies in Late-Stage Development': 0.010676702767267898, '4. Discussion and Conclusions': 0.0013345878459084873, '12. Targeting Subclonal TAMs for Cancer Therapy': 0.006672939229542436, '2. Epidrugs: toward epigenetic regulation of antitumor immunity': 0.018684229842718822, '4. The renaissance of natural compounds in cancer therapy: an update': 0.013345878459084873, '4. Systemic Therapy': 0.016015054150901847, 'Types of Stem Cells': 0.005338351383633949, '4. Autophagy-Related Therapeutic Targets for COVID-19 Management': 0.1174437304399469, 'SYSTEMIC THERAPIES FOR SDC': 0.026691756918169746, 'Ethics and Trial registration numbers': 0.0026691756918169746, 'The IMPACT trial and its future implications': 0.0013345878459084873, '4. Pharmacologically Induced Epigenetic Control of MMPs': 0.005338351383633949, 'MDSC and colitis-associated colorectal cancer': 0.05338351383633949, 'Targeting MDSC-related therapeutic strategies': 0.05738727737406496, 'New study from Vicinanza et al changes formula for cardiogenic cKit': 0.0013345878459084873, '6. The S1R as a Therapeutic Target for the Treatment of Neurodegenerative Diseases': 0.006672939229542436, 'Neoadjuvant Use of Immune Checkpoint Inhibitors for cSCC': 0.004003763537725462, '7. Inhibitors of SphK': 0.013345878459084873, 'Overcoming the barriers: Are the efforts good enough?': 0.0013345878459084873, 'Oral lipid prodrugs of RDV': 0.0013345878459084873, '5. Studying Influenza in the Extreme Aged with the Aged Ferret': 0.0026691756918169746, 'MOLECULAR TARGETED THERAPY': 0.016015054150901847, 'IMPACT OF DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS AND BIOLOGICS ON CARDIOVASCULAR OUTCOMES?': 0.005338351383633949, 'FIBROBLAST GROWTH FACTOR RECEPTOR IN BLADDER CANCER': 0.004003763537725462, '3. COVID-19 and Immune Checkpoint Inhibitors: Different Considerations': 0.005338351383633949, 'Components of liquid biopsies and their use in solid tumours': 0.08007527075450924, '4. Potential of Targeting Epigenetic Alterations in HBV-Associated HCC': 0.004003763537725462, '3. Patient Preparation for': 0.0026691756918169746, 'PSMA as an antigen target': 0.005338351383633949, 'Integrating PSMA into adoptive cellular therapy': 0.07473691937087529, '3. Fast-Acting Antibiotics': 0.008007527075450924, 'Perspectives and Needs': 0.0026691756918169746, 'CRISPR usage in clinical cancer studies': 0.02001881768862731, '4. Nuclear Medicine: Peptide Receptor Ligand Therapy': 0.0026691756918169746, '5. Evidence-Based Support for Combination of ICIs and PRLT': 0.0013345878459084873, 'Treg-targeted treatment for COVID-19: promising results from case reports': 0.008007527075450924, 'Upregulation of Treg activity by COVID-19 therapeutic agents used in clinic': 0.013345878459084873, 'PD-L1 AS A PROGNOSTIC BIOMARKER IN HNSCCs': 0.0013345878459084873, 'PD-L1 blockade': 0.004003763537725462, 'Use of tofacitinib based on a patient’s baseline characteristics': 0.026691756918169746, 'Usability and UX evaluation of the resulting system': 0.0013345878459084873, 'Features and Status of Different COVID-19 Vaccine Platforms': 0.0026691756918169746, 'Summary and Future Perspectives': 0.005338351383633949, 'Experimental prostate cancer vaccines': 0.04270681106907159, 'Untangling Potency of Gut ILC3 Modulation for MS Therapy': 0.004003763537725462, 'Potential Therapeutic Targets Based on the Virus-Host Interaction': 0.0013345878459084873, 'Future Questions and Implications': 0.004003763537725462, 'Application of MSCs for the Attenuation of Typical Toxicities After Particle Radiation': 0.005338351383633949, 'Completed and Ongoing Clinical Trials': 0.05605268952815647, 'Research methods and design': 0.0026691756918169746, 'Perspectives for Future Clinical Use': 0.0026691756918169746, 'Delivery Strategies for Recombinant AAV Therapeutics and Clinical Candidates': 0.04537598676088857, 'Combinations of coinhibitory checkpoints': 0.026691756918169746, 'Combinations with costimulatory checkpoints': 0.021353405534535796, 'Combinations with other molecules in the tumour microenvironment': 0.0026691756918169746, 'Other anticancer treatment modalities in combination with T-cell checkpoint blockade': 0.06939856798724134, 'Devices and technical details for CDTh': 0.005338351383633949, '7. Conclusion': 0.0013345878459084873, 'Patients & methods': 0.008007527075450924, '2. Treatment': 0.008007527075450924, '2. Current Approaches': 0.010676702767267898, 'Strategies to tackle challenges in CAR-NK cell therapy': 0.02402258122635277, 'Are Reentrant AF Driver Fingerprints within the 3D Atrial Wall Hidden from clinical': 0.0026691756918169746, 'BCIs for specific populations/applications': 0.013345878459084873, 'Management of': 0.026691756918169746, 'Urate elevation therapy': 0.0013345878459084873, 'Urate and other neurological conditions': 0.0013345878459084873, 'Life Span and Immature Form of Neutrophils': 0.005338351383633949, 'Monoclonal Antibodies': 0.010676702767267898, 'ROBUST': 0.005338351383633949, 'Chloroquine Toxicity': 0.0026691756918169746, 'Results of Clinical Trials Done so far With Chloroquine Against COVID-19': 0.022687993380444284, 'Adoptive Cellular Therapy': 0.013345878459084873, 'Diagnostic, Prognostic, and Therapeutic Applications of Exosomal ncRNAs in Cancer': 0.005338351383633949, 'Conclusion and Perspective': 0.0013345878459084873, '8. Epigenome-Targeted Therapy': 0.0026691756918169746, '8. Lymphomas': 0.0026691756918169746, '4. The UPS as a Therapeutic Target': 0.008007527075450924, 'Therapeutic targets of the cGAS-STING pathway in CVDs': 0.0013345878459084873, 'SIRT1 as a therapeutic target for fatty liver diseases': 0.009342114921359411, 'New Targets (Non-VEGF) in Clinical Trials: Links to Inflammation': 0.010676702767267898, 'New Targets in Development': 0.0026691756918169746, 'O': 0.0026691756918169746, 'Opportunities and challenges for effective cure strategies in paediatric infection': 0.021353405534535796, 'Patients': 0.0026691756918169746, 'Future neurostimulation heart failure trials': 0.0013345878459084873, 'Educating and Advising Patients': 0.004003763537725462, 'Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs)': 0.008007527075450924, 'CAR-T and TCR-based therapy in EOC': 0.013345878459084873, 'Natural killer cells (NK)-based immunotherapy': 0.017349641996810335, 'Antibody-Drug Conjugates (ADCs)': 0.0026691756918169746, 'Alnuctamab (CC-93269)': 0.0013345878459084873, 'ABBV-383': 0.009342114921359411, 'CAR-T Therapy': 0.046710574606797055, '2. Enhanced Persistence and Antitumor Properties of CAR-T Therapy': 0.021353405534535796, 'Phase III clinical trial results': 0.008007527075450924, '3. Novel Treatment Possibilities': 0.008007527075450924, 'Switching therapy from natalizumab': 0.0013345878459084873, 'Postmarketing safety and effectiveness studies': 0.005338351383633949, 'Emerging Therapeutic Approaches': 0.02402258122635277, 'The Latest Therapeutic Targets and Representative Drugs of NAFLD': 0.008007527075450924, '8. Bladder Cancer Therapies': 0.0013345878459084873, '4. BP1001: Liposomal P-Ethoxy-Grb2 ASO': 0.010676702767267898, 'Preclinical and clinical studies on ADEVS in ischemic stroke': 0.005338351383633949, 'Biological Roles of Microglia in TBM': 0.030695520455895207, 'PDE inhibitors': 0.0013345878459084873, 'Statins': 0.0013345878459084873, 'PI3K': 0.004003763537725462, 'Other oncogenic drivers': 0.004003763537725462, 'Targeted immunotherapy and future direction': 0.006672939229542436, '2. Primary Biliary Cholangitis': 0.05872186521997345, 'MICROENVIRONMENT': 0.0013345878459084873, 'IMMUNE RESPONSE': 0.0013345878459084873, 'Key pathways and selected studies': 0.06406021660360739, '3. Primary Sclerosing Cholangitis': 0.06406021660360739, '8. Device-Based Approaches': 0.0013345878459084873, '4. Perspectives': 0.0026691756918169746, '2. Oncolytic Virotherapy for Ovarian Cancer - Current Clinical Testing': 0.017349641996810335, 'Methodology: Participants, interventions and outcomes': 0.004003763537725462, 'Ethics, registrati': 0.004003763537725462, 'PARP Inhibitors': 0.010676702767267898, 'Randomized Second-Line Trials of Next-Generation ALK TKI in Crizotinib-Refractory Settings': 0.016015054150901847, 'STAR Methods Text': 0.010676702767267898, '2. Classical Activation of Mitogen-Activated Protein Kinases (MAPK)': 0.005338351383633949, '6. Pathophysiological Implications of Atypical p38 Signaling': 0.0013345878459084873, '8. Therapeutic Perspectives': 0.0013345878459084873, '2 Materials and Methods': 0.0026691756918169746, '4. Targeting TAMs for Cancer Therapy': 0.05071433814452252, 'Tumor angiogenesis and anti-angiogenesis therapy in osteosarcoma': 0.005338351383633949, '4. Ethics': 0.0026691756918169746, '2. Systemic Treatment in the First- and Second-Line for Advanced HCC': 0.016015054150901847, '3. Systemic Treatment for Intermediate HCC': 0.006672939229542436, '5. Neoadjuvant Systemic Treatment': 0.005338351383633949, '6. Systemic Treatment beyond Immune Checkpoint Inhibition': 0.016015054150901847, '6. Immunotherapy': 0.0026691756918169746, '1 INTRODUCTION': 0.005338351383633949, 'I. INTRODUCTION': 0.0013345878459084873, 'IV. DISCUSSION': 0.0013345878459084873, 'Clinical development of aptamer-based therapeutics': 0.07473691937087529, '4. PET Molecular Imaging: The Promising Clinical Perspective of Radioligand Molecular Imaging and Therapy': 0.0026691756918169746, '*Yes, subcutaneous injections of personal DC-ATA vaccines are associated with clinical benefit in some patients': 0.009342114921359411, 'Modern resurgence and future outlook': 0.0013345878459084873, '2. Current Treatment and Therapies': 0.24022581226352774, 'New treatment options for ADT': 0.018684229842718822, 'Evolocumab': 0.009342114921359411, 'Actionable Driver Mutation in NSCLC Associated with Never-Smokers': 0.013345878459084873, '3. Developing Research': 0.032030108301803695, 'Emerging treatments:\\xa0amyloid-directed therapies': 0.013345878459084873, 'Treatment strategies': 0.032030108301803695, '11. Summary': 0.0013345878459084873, 'Immune Checkpoint Blockade Therapy for Breast Cancers': 0.0013345878459084873, 'Limitations of the study': 0.0026691756918169746, '6. Results of PD-1 Blocking Based Combination Therapy on CD8': 0.013345878459084873, 'The tumor microenvironment and VISTA': 0.0013345878459084873, 'Targeting VISTA in the context of contemporary antibody combination therapy in immuno-oncology': 0.013345878459084873, 'STUDY approach and design': 0.005338351383633949, 'Nanosystems for NSCLC treatment with/without image guidance': 0.08007527075450924, 'Assessing\\\\nCatalyst Performance: Benchmarking\\\\nand Best Practices': 0.010676702767267898, '5. Concluding Remarks and Future Perspectives': 0.006672939229542436, 'Main lessons to learn': 0.0026691756918169746, 'Top ten studies/trials to be done in the next 10\\xa0years': 0.09075197352177714, '3. Cell Therapy for Age-Related Macular Degeneration Using Pluripotent Stem Cell-Derived RPE Cells': 0.013345878459084873, '4. Therapy for Mycosis Fungoides/Sézary Syndrome': 0.032030108301803695, 'Clinical manifestations and diagnosis of LQTS': 0.0013345878459084873, '5. Potential of Polyphenol Compounds in Endometriosis Management': 0.016015054150901847, 'Clinical data to date on NK3R antagonists': 0.009342114921359411, 'Current application in liquid biopsy for pan-cancer': 0.037368459685437644, '3. γδ. T Cells': 0.0026691756918169746, '4. NK Cells': 0.0013345878459084873, '5. Invariant NK T Cells': 0.0026691756918169746, '6. Genome Editing of αβ T Cells': 0.005338351383633949, '2. Unresectable or Inoperable CCA': 0.0013345878459084873, 'New Drug Approvals in Relapsed and/or Refractory Multiple Myeloma': 0.0026691756918169746, 'Decision to treat': 0.0026691756918169746, 'Current treatment strategies': 0.12278208182358083, 'Vasovagal Syncope': 0.013345878459084873, 'Neurogenic Orthostatic Hypotension': 0.008007527075450924, 'Development of the drug': 0.005338351383633949, 'Cell-free ctDNA genotyping for EGFR T790M mutation': 0.016015054150901847, 'Future treatment strategies': 0.12812043320721478, 'Growth hormone stimulation tests': 0.0026691756918169746, '4. Current and Future Molecular-Directed Therapeutic Agents in CCA': 0.27759427194896535, '2. In Vitro Haematopoietic Stem Cell Gene Therapy': 0.016015054150901847, '3. In Vivo Gene Therapy': 0.07473691937087529, 'Clinical efficacy in patients with MM': 0.008007527075450924, 'Ongoing phase 3 trials in MM': 0.005338351383633949, '8. Targeting TAMs': 0.016015054150901847, '4. JAK inhibitors': 0.029360932609986724, '8. Targeting the NF-kB pathway': 0.0026691756918169746, '9. Targeting the MAPK pathway': 0.004003763537725462, '10. Targeting the PI3K pathway': 0.02001881768862731, '11. Targeting transcription factors: The new frontier?': 0.013345878459084873, '4. Clinical Investigations with Implications for Relapsed/Metastatic Medulloblastoma': 0.05605268952815647, '6. Emerging Pharmacotherapeutics for NAFLD Targeting Immune or Inflammatory Signaling': 0.005338351383633949, '5. Discussion and Future Ideas': 0.004003763537725462, '2. Canonical Neo-Epitopes': 0.010676702767267898, '3. Noncanonical Neo-Epitopes': 0.010676702767267898, '4. Viral Neo-Epitopes': 0.06672939229542436, 'Funding Support and Author Disclosures': 0.004003763537725462, 'Current Practice and Future Perspectives': 0.004003763537725462, 'How Does This Article Fit Into the Current Landscape?': 0.0026691756918169746, '3. Current Advances in NK Cell Targeted Therapy': 0.005338351383633949, 'The emergence of antiviral PROTACs': 0.0026691756918169746, 'FUTURE PERSPECTIVES OF AI IN ECHOCARDIOGRAPHY': 0.0013345878459084873, '2. Stargardt Disease': 0.0013345878459084873, 'FUTURE STRATEGIES': 0.02402258122635277, 'ESOPHAGOGASTRIC CANCERS (EGC)': 0.0013345878459084873, 'SMALL MOLECULE TKIS': 0.05872186521997345, 'Clinical Benefits of Corticosteroid and Vitamin D Analog Fixed-Dose Combination Treatment': 0.010676702767267898, '10. Pharmacological Modulation of Novel RCD Pathways in Leukemia: Unlocking Therapeutic Strategies': 0.005338351383633949, 'INHIBITING VEGFRS': 0.029360932609986724, 'SMALL MOLECULES': 0.018684229842718822, 'Current role of LCZ696 in heart failure and the future of LCZ696': 0.0026691756918169746, 'CAUSES OF SLEEP DISTURBANCE IN THE CRITICALLY ILL': 0.0026691756918169746, 'PHARMACOLOGICAL MANAGEMENT OF SLEEP DISTURBANCES': 0.0026691756918169746, 'AE-ILD': 0.005338351383633949, '3. ICI therapy for the treatment of cancer': 0.018684229842718822, '8. Targeting Macrophages to Potentiate Anti-Cancer Therapy': 0.008007527075450924, '6. Combination of ICIs with other therapeutic strategies': 0.0013345878459084873, '8. Ongoing Trials with PARPis in Metastatic PC': 0.05338351383633949, 'Patient and Methods': 0.0013345878459084873, 'Diagnostic applications of DNA methylation assays': 0.0026691756918169746, 'Study Registration:': 0.0013345878459084873, 'Therapies targeting the Wnt/β-catenin signaling pathway': 0.017349641996810335, '2. Trastuzumab': 0.0026691756918169746, '4. Zanidatamab': 0.0013345878459084873, '5. Margetuximab': 0.0013345878459084873, '6. Tucatinib': 0.0013345878459084873, 'Reported clinical trials': 0.0026691756918169746, '5. Clinical Implications and Future Directions': 0.004003763537725462, '2. Clinical Trials for CAR-T-Cell Therapy in Adult Patients with GBM': 0.014680466304993362, '4. Tumor Microenvironment': 0.026691756918169746, '5. Mitigating T Cell Exhaustion': 0.005338351383633949, '6. Antigen Heterogeneity and Off-Target Toxicity': 0.008007527075450924, '3. Transient Receptor Potential (TRP) Channels': 0.005338351383633949, '2. PSMA-Targeted Therapies: From the Origins to Our Days': 0.0026691756918169746, '3. Trials Investigating Combination Therapies in Prostate Cancer': 0.04537598676088857, 'CLINICAL DEVELOPMENT OF AGENTS TARGETING GLIOBLASTOMA MULTIFORME': 0.0026691756918169746, 'NEW COMPLIMENTARY TOOLS AND CLINICAL METHODS IN MANAGEMENT OF GBM': 0.0026691756918169746, '5. Non-Clinical and Clinical Trials of CTGF-Targeted and Inhibitory Therapy': 0.029360932609986724, '3. BRAF and MEK Inhibitors in Lung Cancer': 0.05338351383633949, '5. Novel Agents—New Horizon in Near Sight': 0.013345878459084873, 'miRNAs, lncRNAs, and circRNAs in Pregnancy-associated Diseases': 0.005338351383633949, 'VIRAL KERATITIS': 0.0026691756918169746, '3. Challenges and Limitations of CAR-T Cell Therapy in Solid Tumors': 0.04270681106907159, '4. CAR-T Cell Targets in Solid Tumors': 0.13879713597448268, 'Targeting polyamine metabolism as an anticancer strategy': 0.010676702767267898, 'Targeting polyamine metabolism as a strategy for cancer prevention': 0.005338351383633949, 'Treatment of pemphigus': 0.0013345878459084873, '7. Summary and Perspectives': 0.016015054150901847, 'BAFF AND APRIL': 0.004003763537725462, 'COMPLEMENT': 0.0013345878459084873, 'Ovarian Cancer Scenario': 0.0013345878459084873, 'Anterior Versus Posterior or Combined': 0.0013345878459084873, 'Methods of detection': 0.010676702767267898, 'How to overcome resistance against anti-PD-1/PD-L1 immunotherapy?': 0.012011290613176386, 'Targeting PD-1/PD-L1 in TNBC – the clinical perspectives': 0.08941738567586865, 'SAFETY ISSUES OF ADSC CELLS': 0.004003763537725462, 'Exploiting DDR alterations for PCa treatment': 0.06939856798724134, 'CAR-T cell in TNBC immunotherapy': 0.010676702767267898, '4. Spinal Muscular Atrophy (SMA)': 0.0026691756918169746, '5. Amyotrophic Lateral Sclerosis (ALS)': 0.026691756918169746, 'PARP-1: the new target': 0.008007527075450924, 'EGFR TKI-based combination strategy': 0.04270681106907159, 'Novel therapeutic strategy beyond osimertinib': 0.21353405534535796, '2. Aurora kinase inhibition': 0.005338351383633949, '3. Wee1 kinase inhibition': 0.005338351383633949, '4. Kinesin spindle protein inhibition': 0.0026691756918169746, 'Small molecule inhibitors of BET proteins': 0.005338351383633949, 'Integrated therapies for NSCLC': 0.005338351383633949, 'To the editor': 0.0026691756918169746, 'New medication delivery approaches for treating OUD': 0.008007527075450924, 'MyVal-1 First-in-human Study': 0.010676702767267898, 'The LANDMARK Trial': 0.0013345878459084873, 'Correspondence': 0.02535716907226126, '8. NON-ANTICOAGULANT THERAPEUTIC APPROACHES': 0.0026691756918169746, 'Is Killing Cancer Cells Enough? Impact of Minnelide on Tumor Stroma': 0.0013345878459084873, 'The Promise of Technology': 0.0026691756918169746, '5. Clinical Implications and Future Advances': 0.013345878459084873, 'Motivating example': 0.0013345878459084873, 'Indirect Effects on Cytoskeleton of PTCLs Approved Drugs': 0.032030108301803695, '11. Conclusions and Future Perspectives': 0.004003763537725462, 'T-Cell Receptor Transduced T Cell Therapy in Ovarian Cancer: Current Therapeutic Landscape': 0.008007527075450924, 'Historical overview': 0.008007527075450924, 'Copper Complexes as UPS Inhibitors in Cancer Treatment': 0.016015054150901847, 'Subject and Methods': 0.0026691756918169746, 'P2X3 Receptor Ligands': 0.016015054150901847, 'LDL: The Bad': 0.0026691756918169746, 'GTX for treatment of infection: Review of Recent Studies (post G-CSF availability)': 0.005338351383633949, '6. Clinical Trials and Endothelial Function': 0.008007527075450924, 'From immune response to vaccines against COVID-19': 0.04804516245270554, 'Repurposing drugs for COVID-19': 0.013345878459084873, '2. Biomarkers for Personalized Targeted Therapy': 0.010676702767267898, '3. Advances in Immunotherapy': 0.018684229842718822, 'Place in therapy in head and neck cancers': 0.037368459685437644, 'Advanced disease': 0.0026691756918169746, 'METHODS (See also Methods section of the online': 0.0026691756918169746, 'Blocking IGF-1R may allow therapeutic alternatives to attenuate TSHR-mediated events': 0.0013345878459084873, 'Clinical Management of Therapy Resistance in the Precision Oncology Era': 0.0013345878459084873, '4. Paediatric Brain Tumour Immune Microenvironment Modulation by OVs': 0.021353405534535796, 'An Example of Multi-Dimensional Data Sharing: TRACK-TBI': 0.0026691756918169746, 'What is the current evidence on pharmacological interventions?': 0.014680466304993362, 'Drug Repurposing Principles of Network Pharmacology for GI Cancer': 0.0013345878459084873, '3. The Challenges and Opportunities for Developing Novel Strategies to Prevent and Treat': 0.0026691756918169746, 'Immune checkpoint inhibitors (ICIs)': 0.09609032490541108, 'Adoptive cell therapy (ACT)': 0.032030108301803695, 'Cancer vaccines': 0.018684229842718822, '4. Evidence of MIF and DDT in Cancer': 0.0026691756918169746, '5. Current Therapeutic Applications and Clinical Trials': 0.008007527075450924, 'T-cell depletion and CD34+ cell selection in HLA-matched HSCT': 0.0013345878459084873, 'T-cell depletion with T-cell add-back': 0.0026691756918169746, '3. Biologic Treatments': 0.032030108301803695, 'Alternative interventions against MDR pathogens': 0.021353405534535796, 'Novel Combination Therapy': 0.010676702767267898, 'Supplementary material': 0.005338351383633949, 'VEGF AND MTOR INHIBITORS': 0.010676702767267898, '3. PUFA and Mental Illness': 0.1267858453613063, 'Physical Activity and Breast Cancer Risk and Outcome': 0.0026691756918169746, 'SUPPLEMENTARY MATERIALS': 0.0026691756918169746, 'THE CURRENT VACCINE LANDSCAPE': 0.004003763537725462, 'TYPES OF VACCINE DELIVERY SYSTEMS': 0.013345878459084873, 'CURRENT THEMES COVID‐19 VACCINES': 0.021353405534535796, 'Discusssion': 0.0026691756918169746, 'Anti-inflammatory agents': 0.013345878459084873, 'Antioxidants': 0.008007527075450924, 'Vasodilators': 0.008007527075450924, 'Repair agents': 0.018684229842718822, 'Targeted Treatments For Dcm': 0.005338351383633949, 'Emerging Immunomodulator Therapeutic Strategies': 0.008007527075450924, 'Mechanism of action of drugs and targeted therapeutic options': 0.016015054150901847, 'Antigen Presenting Cells and Immune Activating Strategies': 0.005338351383633949, 'Therapeutic Perspectives': 0.02001881768862731, '3. Results and Discussions': 0.0026691756918169746, 'Future Perspective': 0.0026691756918169746, 'Inhibition of Recruitment and Activation of the Inflammatory Cells': 0.10943620336449596, 'Reversibility of Immunoparalysis': 0.005338351383633949, 'Targeting the Products of the Cellular Components of Inflammation': 0.021353405534535796, 'Current developments': 0.0026691756918169746, 'Azithromycin Effectiveness in COVID-19 Management': 0.041372223223163106, 'EMBOLIC OCCLUSION IN PC-LVO': 0.0013345878459084873, 'Constipation and Constipation-Predominant IBS (IBS-C)': 0.010676702767267898, 'Cluster of Differentiation 147 (CD147) and COVID-2019 Treatment: Possible Effects of Azithromycin and Stem Cell Engagement': 0.0013345878459084873, 'PHARMACOTHERAPEUTICS OF BILE ACIDS AND RECEPTORS': 0.026691756918169746, 'FGFRs as Therapeutic Target in NENs': 0.009342114921359411, 'TREATMENT OF RCC AND HCC WITH MTOR INHIBITORS': 0.0013345878459084873, 'Materiales y métodos': 0.0026691756918169746, 'CAR‐NK cells in the clinic': 0.02535716907226126, 'Tissue Overgrowth and Hamartoma Syndromes': 0.0026691756918169746, 'Drug Screening for Neuromuscular and Motor Neuron Disorders in a Dish, From Research Efforts to Clinical Application': 0.0013345878459084873, 'iPSCs for Gene Therapy, a Focus on Antisense Oligonucleotides': 0.005338351383633949, 'Tissue engineering applications': 0.0026691756918169746, 'Clinical evidence for combining anti-angiogenic agents and ICIs in cancer treatment': 0.022687993380444284, 'Therapeutic perspective and conclusion': 0.009342114921359411, 'FDA-approved PARPi': 0.008007527075450924, '5. Leptin and TNBC': 0.0026691756918169746, '4. Potential Therapeutic Targets for TNBC': 0.005338351383633949, 'ALK-001 (Deuterated Vitamin A) Corrects the Aberrant Dimerization of Vitamin A and Prevents Loss of Visual Function in Mouse Models': 0.0013345878459084873, 'Emixustat Hydrochloride for Macular Atrophy in AMD and Stargardt Disease: Lessons Learned from a Phase 2 Efficacy Trial of GA in AMD': 0.0026691756918169746, '2. Glioblastoma Tumor Microenvironment': 0.07473691937087529, 'Work Package B': 0.0026691756918169746, 'Neoadjuvant Anti–PD-1 plus Chemo: The New Standard of Care in 2022': 0.0013345878459084873, 'Ongoing (Neo)adjuvant Immunotherapy Research in Early TNBC Patients': 0.05071433814452252, 'Clinical Experience With': 0.005338351383633949, 'Identifying sensitive tumor types and likely responders': 0.0026691756918169746, '4. Cediranib': 0.0013345878459084873, '4. Role of Trastuzumab in Adjuvant Treatment for Early Breast Cancer': 0.005338351383633949, 'Promoting regeneration after SCI': 0.06939856798724134, 'The patient’s music experience': 0.0013345878459084873, '5. The Interface between NK Cells and Oncolytic Viral Therapy': 0.0026691756918169746, 'Inhibiting Fyn kinase in AD': 0.0026691756918169746, 'Preliminary results from a first in human safety study': 0.004003763537725462, 'Clinical guidelines': 0.0026691756918169746, 'Minimizing Sedation': 0.0013345878459084873, 'Triple-Negative Breast Cancer': 0.0026691756918169746, 'Independent ERG Review': 0.0026691756918169746, 'CANCER THERAPEUTICS WITH': 0.11077079121040445, '4. Clinical Trials with Active Immunotherapy': 0.05071433814452252, '2. Physical and biological properties of polarized agents': 0.021353405534535796, '5. Applications of hyperpolarized': 0.04804516245270554, '5. Clinical Trials with Passive Immunotherapy': 0.08541362213814319, 'Application prospects of sEVs in GC': 0.021353405534535796, 'Role of Adjuvant Chemotherapy in Anaplastic Astrocytoma': 0.0026691756918169746, 'Clinical therapeutic trials addressing PTOA': 0.005338351383633949, 'ADOPTIVE T CELL THERAPY': 0.05605268952815647, '5. Oncolytic Virotherapy for Hematological Malignancies': 0.0013345878459084873, 'ENHANCEMENT OF CAR T CELL FUNCTION': 0.005338351383633949, 'ADOPTIVE NK CELL THERAPY': 0.008007527075450924, 'COMBINATION THERAPY': 0.005338351383633949, '6. Targeted Therapies': 0.032030108301803695, 'Heterogeneous Responses on Immunotherapy': 0.0026691756918169746, 'Clinical and epidemiological heterogeneity in TNBC': 0.032030108301803695, 'Comment and evidence synthesis': 0.013345878459084873, 'Concluding Remarks and Future Outlook': 0.0026691756918169746, 'Neoadjuvant treatment': 0.05605268952815647, 'Strategies to mitigate the development of intraprocedural atelectasis': 0.0026691756918169746, 'Summary and Future Perspective': 0.005338351383633949, 'Background & Summary': 0.0013345878459084873, 'Novel Antibiotics': 0.0026691756918169746, 'Perspectives for the Future': 0.02535716907226126, 'Targeting the CXCL12/CXCR4/CXCR7 Axis in Combination Therapy': 0.03603387183952916, 'Viral Vectors as a Promising Platform for Some of the Deadliest Diseases': 0.0026691756918169746, 'History of Viral Vector–Based Vaccines Development Against SARS and MERS-CoV': 0.006672939229542436, 'COVID-19 and Viral Vector–Based Vaccine Platform': 0.17616559565992032, 'Advanced HCC: the field of molecular target therapies': 0.013345878459084873, 'STEM CELL MARKERS AS THERAPEUTIC TARGETS FOR THE TREATMENT OF LUNG CANCER': 0.0026691756918169746, 'KINDS OF NANODRUG DELIVERY SYSTEMS': 0.0026691756918169746, 'Design and Methods': 0.0026691756918169746, 'The Landscape of Cancer Vaccines': 0.061391040911790415, 'MAIN SUBJECTS': 0.010676702767267898, 'Processing (Cryo-)Em Images From Native Extracts With a Focus on Machine Learning': 0.0013345878459084873, 'ALTERATION OF THE TA- p73 ΔN-p73 RATIO': 0.0026691756918169746, 'Conclusions and outlook': 0.005338351383633949, 'Molecular glue degraders': 0.016015054150901847, 'The trends of next-generation HDACi': 0.21353405534535796, 'The benefits of mild ketosis': 0.016015054150901847, 'Potential Biosimilars to Bevacizumab: Considerations and Challenges': 0.02402258122635277, 'Rationale for Combination Studies Using IGF-Targeted Agents': 0.026691756918169746, 'Manufacturing': 0.0026691756918169746, 'Mechanistic Insights into SCLC Chemotherapy Resistance and Overcoming Strategy': 0.0026691756918169746, 'Emerging Therapeutic Strategies Targeting the PCa TME': 0.27759427194896535, 'Prospectives': 0.012011290613176386, 'Gene Mutations Related to Pancreatic Cancer Development and Maintenance': 0.0026691756918169746, 'Lipid Metabolism Reprogramming in Pancreatic Cancer and its Effect': 0.008007527075450924, 'Conclusions and Perspectives': 0.0013345878459084873, 'Lysosomal Storage Diseases': 0.009342114921359411, 'Muscular System Diseases': 0.0013345878459084873, '2. TLR3 agonist therapies': 0.005338351383633949, 'Echocardiography': 0.005338351383633949, 'Leadless Cardiac Resynchronisation Therapy': 0.0013345878459084873, 'Technology': 0.005338351383633949, 'Thyromimetics That Reached Clinical Testing': 0.013345878459084873, 'Algorithmic, Multiparametric Heart Failure Remote Monitoring Tools': 0.0026691756918169746, 'Approaches to Reduce Risk of Relapse Post Stem Cell Transplant': 0.026691756918169746, 'Direct translation of fibroblast research to clinical trials': 0.03469928399362067, 'FIRST-IN-HUMAN STUDY': 0.0026691756918169746, 'Dosing in renal, hepatic, and cardiac disease': 0.004003763537725462, 'Types of Clinical Studies': 0.02402258122635277, 'Alternatives to FMT': 0.0026691756918169746, 'Future directions for cabozantinib in mRCC': 0.004003763537725462, 'Results & Discussion': 0.0013345878459084873, 'Insights from clinical trials and practice for solid tumors': 0.016015054150901847, 'Research methods': 0.0026691756918169746, 'LESSONS LEARNED FROM PRIOR IMMUNOTHERAPY COMBINATIONS': 0.0026691756918169746, 'Online-only Methods': 0.010676702767267898, 'GOALS AND CHALLENGES OF IMMUNOTHERAPY COMBINATIONS': 0.008007527075450924, 'Place in therapy': 0.005338351383633949, 'Current development of axitinib and future directions': 0.008007527075450924, 'Lasmiditan: Design and Development': 0.016015054150901847, 'Combinatorial Strategies using Epigenetically directed therapies': 0.005338351383633949, 'Phase II Studies': 0.0026691756918169746, 'Pivotal Trials': 0.005338351383633949, 'Phase III Randomized Control Trials': 0.0026691756918169746, 'Androgen receptor targeting': 0.03469928399362067, 'Clinical Experience of CAR T-Cell Immunotherapy of Lung Cancer': 0.05738727737406496, 'DIGITALIS': 0.0013345878459084873, '4. Chemotherapy': 0.005338351383633949, '6. Novel Targeted Strategies: Small Molecule Inhibitors': 0.0026691756918169746, 'Difamilast': 0.04003763537725462, 'Therapeutic Potentials of MSC in COVID-19 Treatment': 0.09609032490541108, 'The Case': 0.0013345878459084873, 'The Effects of MSC-EVs on COVID-19': 0.012011290613176386, '4 Discussion and conclusion': 0.0013345878459084873, 'Clinical significance and research implications': 0.008007527075450924, 'Small molecules for cardiac treatments': 0.013345878459084873, 'Genetic therapies': 0.04270681106907159, 'Primary prophylaxis of VTE': 0.010676702767267898, 'Phase II trial': 0.0026691756918169746, 'Supplementary Information': 0.0026691756918169746, 'Use of Reversal Agents in Patients with GI Bleeding': 0.0013345878459084873, 'CMV-CMI': 0.013345878459084873, 'CAR T-cell therapy in MM': 0.052048925990431004, 'Non-BCMA CAR T cells': 0.04003763537725462, 'Technological advances of CAR T-cell manufacturing in myeloma': 0.012011290613176386, 'Ibrutinib combinations': 0.026691756918169746, 'ATTR cardiac amyloidosis': 0.013345878459084873, '3 Research methods': 0.0026691756918169746, 'Application of Fundamental Theory of Biomarker Utility To Current Melanoma Biomarkers': 0.0026691756918169746, 'Added Value of Animal Models': 0.008007527075450924, 'THERAPEUTIC IMPLICATIONS OF MELANOMA METABOLISM': 0.010676702767267898, 'Advances in the Study of Neoantigens': 0.0013345878459084873, 'Lesinurad Phase 3 randomized clinical trials': 0.004003763537725462, 'Evidence for the role of complement in the TMAs': 0.029360932609986724, 'The Role of the Gut-Liver Axis in Liver Disease': 0.05872186521997345, '2 | RESEARCH DESIGN AND METHODS': 0.0026691756918169746, 'ADCs currently approved for BC treatment': 0.02001881768862731, 'Investigational Drugs Targeting Inflammatory Mechanisms': 0.026691756918169746, 'HER2-targeted ADCs in clinical development for the treatment of BC': 0.014680466304993362, 'Beyond HER2: investigational ADCs exploring other targets for the treatment of BC': 0.02001881768862731, 'Small Molecule Inhibitors: Direct Intracellular Inhibition of EBOV': 0.005338351383633949, 'Investigational Drugs Targeting the Subchondral Bone': 0.010676702767267898, 'Predictive biomarkers for ADCs': 0.004003763537725462, 'EVD Immunotherapy': 0.008007527075450924, 'Investigational Drugs to Relieve Pain': 0.016015054150901847, 'IL-15-granzyme-ILC1 axis': 0.061391040911790415, 'Conclusion and Future Perspectives': 0.0026691756918169746, 'LYMPHOTROPIC NANOPARTICLE MRI': 0.004003763537725462, 'EXISTING ISSUES AND FUTURE RESEARCH': 0.0026691756918169746, 'Clinical trials of CDK4/6 inhibitors': 0.030695520455895207, 'ADOPTIVE T CELL THERAPY FOR POLYOMAVIRUS DISEASES': 0.005338351383633949, 'BROADENING APPLICABILITY TO HIV': 0.010676702767267898, 'Rationale for combining radiotherapy and immunotherapy in GI malignancies': 0.0026691756918169746, 'Current status and ongoing efforts for immunotherapy in gastrointestinal cancers': 0.19484982550263913, '5. Advanced LXR therapeutics': 0.004003763537725462, 'Registration of Research Studies': 0.0013345878459084873, 'Pregnancy after breast cancer': 0.0013345878459084873, 'Results of clinical studies': 0.021353405534535796, 'State of the art of DC therapy and future plans for CMN-001 deployment in mRCC': 0.0026691756918169746, 'Cardiovascular Outcomes Data': 0.004003763537725462, 'Function of SGLTs and Drugs for SGLT Inhibition': 0.008007527075450924, 'II. Materials and methods': 0.0026691756918169746, 'Combination studies with pembrolizumab': 0.0013345878459084873, 'Financial disclosures': 0.0013345878459084873, 'Summary and perspective': 0.0026691756918169746, 'ctDNA and breast cancer prognosis': 0.0026691756918169746, 'ctDNA and breast cancer treatment': 0.04003763537725462, 'HEREDITARY COLORECTAL CANCER': 0.0026691756918169746, 'HEREDITARY/FAMILIAL PANCREATIC CANCER': 0.026691756918169746, 'ctDNA and breast cancer follow-up': 0.0013345878459084873, 'Can we design drugs that are ‘resistance proof’?': 0.0026691756918169746, 'Potential for clinical intervention': 0.0026691756918169746, 'CARCINOID-SYNDROME: ADVANCES, RECENT INSIGHTS, CONTROVERSIES': 0.021353405534535796, '5. PI3Kα and PI3Kδ Inhibitors in Clinical Development for the Treatment of Lymphoma': 0.06406021660360739, 'Materials and methods/design': 0.0026691756918169746}\n",
      "\n",
      "{'results': 100.0}\n",
      "{'Results': 80.12408838576249, 'RESULTS': 19.832371829759442, 'results': 0.043539784478066834}\n",
      "\n",
      "{'': 100.0}\n",
      "{'table-wrap': 100.0}\n",
      "\n",
      "{'': 100.0}\n",
      "{'ref-list': 100.0}\n",
      "\n",
      "{'methods': 99.91103202846975, '': 0.0889679715302491}\n",
      "{'METHODS': 19.24673784104389, 'Methods': 80.62722419928826, 'METHODS.': 0.01482799525504152, 'methods': 0.022241992882562275, 'B. Methods': 0.01482799525504152, 'Methods-': 0.02965599051008304, 'II. Methods': 0.01482799525504152, 'II. METHODS': 0.01482799525504152, 'General Methods': 0.01482799525504152}\n",
      "\n",
      "{'background': 99.8215082552432, '': 0.178491744756805}\n",
      "{'INTRODUCTION': 14.123159303882197, 'Introduction': 85.6760374832664, 'INTRODUCTION:': 0.011155734047300312, 'introduction': 0.022311468094600623, 'Introduction2': 0.13386880856760375, 'Introduction:': 0.03346720214190094}\n",
      "\n",
      "{'conclusions': 99.92743105950653, '': 0.07256894049346879}\n",
      "{'Discussion': 81.54934687953556, 'DISCUSSION': 18.269230769230766, 'discussion': 0.10885341074020319, 'Discussion.': 0.018142235123367198, 'Discussion:': 0.054426705370101594}\n",
      "\n",
      "{'': 97.06681486970483, 'background': 0.9015684821538842, 'methods': 1.5684821538841547, 'conclusions': 0.37668272199580094, 'results': 0.04940101272076078, 'objective': 0.037050759540570584}\n",
      "{'article-meta': 49.194145979992584, 'TTVR': 0.006175126590095097, 'T-cell-related immunotherapies in colorectal cancer': 0.061751265900950966, 'CLINICAL TRIAL REGISTRATION': 0.17907867111275783, 'ETHICAL APPROVAL': 0.030875632950475483, 'Eosionophilic Esophagitis': 0.02470050636038039, 'Hypereosinophilic Syndrome': 0.07410151908114117, 'Therapeutic Targeting of “Poly‐depolyploidization”': 0.018525379770285292, '2. Materials and Methods': 7.978263554402865, '资料与方法': 0.012350253180190195, '4. Mitophagy as a Target for the Treatment of MASLD and Liver Fibrosis': 0.006175126590095097, 'Figures and Tables': 0.04940101272076078, 'Vaccines for schistosomiasis': 0.012350253180190195, '2. Method and Materials': 0.012350253180190195, 'BPD Compass: A Customizable Treatment for BPD Based on Personality Profiles': 0.012350253180190195, 'Clinical Trial Registration Number': 0.006175126590095097, 'Clinical Trial Registration': 0.06792639249104607, 'HCC risk scores based on clinical variables': 0.02470050636038039, 'HCC EARLY DETECTION SCORES AND BIOMARKERS': 0.012350253180190195, 'Key Summary': 0.006175126590095097, 'Key Summary Points': 0.018525379770285292, 'Trispecific Antibodies': 0.006175126590095097, 'Extended Half-Life Mutations': 0.02470050636038039, '2. Considerations and Available Data about New β-Lactam Agents': 0.012350253180190195, 'Ethical Approval': 0.09880202544152156, '3. Resistance': 0.012350253180190195, 'DATA STATEMENT': 0.006175126590095097, 'Ethics Approval and Informed Consent': 0.04940101272076078, '3. Influence of the Immune Microenvironment on Pediatric Tumor Biology': 0.02470050636038039, 'Examples for efforts and challenges to provide evidence based care Allogeneic HCT for Myelodysplastic Syndrome': 0.006175126590095097, 'Optimizing anticancer therapy by targeting RNA modifications': 0.012350253180190195, 'Strategies to balance efficacy and toxicity': 0.037050759540570584, '2. Modalities in Radiotherapy of Non-Small Cell Lung Cancer (NSCLC)': 0.018525379770285292, '5. Anti-CD79b Antibody–Drug Conjugate Polatuzumab': 0.012350253180190195, '9. BCL-2 Inhibitors': 0.018525379770285292, '10. BTK Inhibitors': 0.04940101272076078, 'Emerging Targeted (Inhaled) Therapies for Asthma': 0.02470050636038039, '5. Improving Patient Selection': 0.018525379770285292, 'BETTER ALTERNATIVES TO STRATIFIED PERMUTED BLOCK DESIGN AND MINIMIZATION': 0.012350253180190195, '2. Epidemiology of Arterial Thrombosis in Cancer': 0.012350253180190195, 'Gene Delivery Vectors for HF': 0.02470050636038039, 'Central Nervous System': 0.018525379770285292, 'PHARMACOLOGICAL THERAPIES TAGETING METABOLISM': 0.08645177226133136, '8. Iron–Phosphorus Homeostasis in Plants': 0.02470050636038039, '2. Latest in Diagnosis: From X-rays to Artificial Intelligence-Based Techniques': 0.012350253180190195, 'The evolving role of radiation therapy': 0.012350253180190195, 'Regulatory Insights': 0.006175126590095097, '6. Recent Clinical Trials with Anti-CD47 Antibody Magrolimab in Human Adult and Pediatric Cancers': 0.02470050636038039, 'Genetic Polymorphisms and the Response to Antiplatelet Therapies': 0.006175126590095097, '5. Limitations and Challenges': 0.02470050636038039, '11. IL-2': 0.012350253180190195, '14. IL-12': 0.012350253180190195, '8. Targeting Inhibition of ATRA Synthesis to Treat Cancer': 0.02470050636038039, '2. Molecular Mechanisms of Recurrence': 0.02470050636038039, '4. Evolving Treatment Paradigms for Recurrent Glioblastoma': 0.02470050636038039, '10. The circRNAs in EC': 0.02470050636038039, 'TARGETING THE APOPTOSIS PATHWAY': 0.02470050636038039, '3. Registration and Dissemination': 0.012350253180190195, 'FGFR': 0.012350253180190195, '7 Possible new indications for microtubule stabilizers': 0.012350253180190195, '8. Future Directions and Conclusions': 0.037050759540570584, '6. CBD Potential in Stroke': 0.012350253180190195, '3. Structure and Function of circRNAs': 0.012350253180190195, '4. Patients and Methods': 0.02470050636038039, '4. Clinical Trials and Approved Drugs': 0.04940101272076078, '4. Biosensor Systems for Cell Monitoring': 0.04940101272076078, 'Extended Data Figure Legends': 0.006175126590095097, 'Allosteric modulators of GPCRs': 0.006175126590095097, '3. Asymptomatic Severe Aortic Stenosis': 0.04940101272076078, '4. Older Patients': 0.037050759540570584, 'HISTIOCYTIC DISORDERS': 0.02470050636038039, '2. Materials and methods': 0.6483882919599852, '2. Early-Stage Disease Challenges': 0.07410151908114117, 'CHARACTERISTICS OF STUDIES': 0.012350253180190195, 'Significance of molecular crosstalk': 0.012350253180190195, '3. Anti-resistance drugs': 0.012350253180190195, '4. Anti-Virulence Drugs': 0.02470050636038039, '6. Alternative Treatments for Bacterial Infections': 0.02470050636038039, 'Breaking Bad Addictions - Targeting eIF4F': 0.02470050636038039, '2. The Applications of Stable Isotope Tracing in Cancer Research': 0.04940101272076078, 'Th2 cytokines (IL-5, IL-13, and IL-4)': 0.006175126590095097, 'Mast Cells': 0.012350253180190195, '3.0 Adenosinergic drugs': 0.04940101272076078, '4. The Role of Left Ventricular Unloading Systems during ECLS': 0.02470050636038039, '2 MATERIALS METHODS': 0.012350253180190195, '4. Neuro-Oncology': 0.037050759540570584, 'Star⋆Methods': 0.02470050636038039, '3. Limitations of G4-Based Antitumoral Therapies': 0.02470050636038039, '2. Advancements in Antibacterial Prodrug Applications': 0.02470050636038039, '2. Protein Prenylation': 0.012350253180190195, '2. Green-Nanotechnology': 0.012350253180190195, '3. Experimental Evidence for DCA Activity in Cancer': 0.02470050636038039, '3. Subsets of Breast Cancer Brain Metastases': 1.654933926145486, '6. Clinical Trials of Resveratrol and Quercetin in Colon Cancer': 0.037050759540570584, '5. Drug delivery systems intended to target brain metastases': 0.04940101272076078, '4. Mechanisms underlying fast/rapid onset antidepressants actions': 0.04940101272076078, 'Gene therapy for X-linked RP': 0.037050759540570584, 'Subunit NR2B-specific NMDA receptor antagonists': 0.02470050636038039, 'NMDA Receptor Glycine Site Partial Agonists': 0.012350253180190195, 'Other lncRNAs related to ovarian cancer etiology': 0.012350253180190195, 'Clinical applications of autophagy inhibition': 0.006175126590095097, 'OTHER CNS Disease Considerations': 0.012350253180190195, 'DNA‐PKCS INHIBITORS AND THEIR THERAPEUTIC POTENTIAL': 0.02470050636038039, 'Synthetic Molecules for Precise Regulation of Cellular Immunotherapies': 0.04940101272076078, 'Therapeutic strategies targeting SWI/SNF-deficient neoplasms': 0.006175126590095097, 'Normothermic Intraperitoneal Chemotherapy (NIPEC)': 0.037050759540570584, 'Autophagy': 0.012350253180190195, 'The possible impact of PTCy dose on the GVT effect': 0.06792639249104607, 'New strategies for enhancing the GVT effect in PTCy-based allo-HCT': 0.04322588613066568, 'Observations': 0.3458070890453254, 'Ethical approval': 0.09880202544152156, 'PATIENT CONSENT STATEMENT': 0.006175126590095097, 'GLYX-13': 0.006175126590095097, 'Scopolamine': 0.006175126590095097, '3. Pharmacodynamics and pharmacokinetics': 0.006175126590095097, '4. Clinical trials of ramucirumab': 0.012350253180190195, 'Clinical trial registration': 0.10497715203161666, 'Ependymoma': 0.012350253180190195, 'Diffuse Intrinsic Pontine Glioma': 0.07410151908114117, 'Discovery of antiseizure and disease-modifying treatments': 0.037050759540570584, 'To the Editor:': 0.018525379770285292, '7 Clinical trials': 0.061751265900950966, '2 讨论': 0.012350253180190195, 'Treatment strategy for NRG1 fusion-positive NSCLC': 0.012350253180190195, 'Future prospects and outlook': 0.006175126590095097, 'sub-article': 0.012350253180190195, 'Neurorehabilitation for Intracerebral Hemorrhage': 0.02470050636038039, 'Regulatory approvals': 0.006175126590095097, '4. Clinical Trials': 0.04940101272076078, 'Seizures': 0.006175126590095097, 'Neuropsychiatric disease': 0.02470050636038039, 'Preexisting Minor Resistant Subpopulation': 0.012350253180190195, 'Ethics approval and consent to participate': 0.07410151908114117, 'Promoting ferroptosis as a novel leukemia treatment strategy': 0.037050759540570584, '5. The Potential Use of Nucleocapsid as Vaccine Antigen': 0.02470050636038039, '6. Nucleocapsid and Other Antigens as Target for SARS-COV-2 Vaccines': 0.012350253180190195, 'Activation of': 0.02470050636038039, 'The pipeline to design new regimens': 0.018525379770285292, 'WHAT SHOULD CLINICIANS AND RESEARCHERS DO?': 0.012350253180190195, 'First-line therapy': 0.3458070890453254, 'Second-line therapy': 0.07410151908114117, 'Comparison of the outcomes of approved small molecule TKIs for aHCC': 0.012350253180190195, '7. Toxicity': 0.012350253180190195, '3. G-PROTEIN COUPLED RECEPTORS (GPCRs)': 0.02470050636038039, 'Antisense Therapy to Treat Spinal Muscular Atrophy': 0.006175126590095097, 'Consent to participate': 0.006175126590095097, 'Targeting adenosine receptors': 0.02470050636038039, 'Sources of Funding': 0.037050759540570584, 'Oversight and monitoring': 0.08645177226133136, 'Possible mechanisms for lymphopenia in SARS-CoV-2 patients': 0.02470050636038039, '4. Non-Ketamine Glutamate Modulators for Depression': 0.12350253180190193, 'Lessons from the clinical trial with': 0.006175126590095097, '6. Consequences of LINE1 activation on spermatogenesis': 0.02470050636038039, '3. Targeted therapies – Receptor Tyrosine Kinases': 0.037050759540570584, 'DCB use in ISR lesions of the SFA': 0.018525379770285292, 'POST-TRAUMATIC STRESS DISORDER (PTSD)': 0.006175126590095097, 'Successful Models With Nurses as CCL Leaders': 0.02470050636038039, 'Autologous hematopoietic stem cell transplant': 0.012350253180190195, 'Ethics Approval and Consent to Participate': 0.061751265900950966, 'Perioperative immunotherapy': 0.037050759540570584, 'PATIENTS and METHODS': 0.006175126590095097, 'Transgene delivery systems': 0.02470050636038039, '4 circRNAs in infection-associated lung injury': 0.018525379770285292, '5 circRNAs in inhalation lung injury': 0.012350253180190195, 'BENEFITS BEYOND DIABETES': 0.061751265900950966, 'Patients and methods': 0.2346548104236137, 'Commentary': 0.030875632950475483, 'Obeticholic acid': 0.006175126590095097, 'Informed consent statement': 0.006175126590095097, 'Mismatch repair pathway in the pathogenesis of colorectal carcinoma and response to immunotherapy': 0.012350253180190195, 'Immunomodulatory agents': 0.012350253180190195, 'RESISTANCE': 0.07410151908114117, 'GLP-1 Agonists': 0.006175126590095097, 'Other Pharmacologic Options': 0.006175126590095097, 'Metabolic and Bariatric Surgery': 0.012350253180190195, 'Transparency, Rigor, and Reproducibility Summary': 0.012350253180190195, 'CAD in Patients With ESRD': 0.012350253180190195, 'PATIENTS AND METHODS': 0.09262689885142646, 'STATE-OF-THE-ART LEFT MAIN PERCUTANEOUS CORONARY INTERVENTION': 0.037050759540570584, 'Ethics and consent': 0.018525379770285292, 'PICO Questions and Recommendations': 0.012350253180190195, 'POTENTIAL STRATEGIES FOR TOLERIZATION IN NMO': 0.012350253180190195, 'Funding': 0.2223045572434235, 'Sample size': 0.012350253180190195, '3 NHP study achievements and translational impediments': 0.006175126590095097, 'BEYOND SORAFENIB: OTHER PHARMACOLOGIC APPROACHES TO THE MANAGEMENT OF ADVANCED HCC': 0.012350253180190195, 'BEST SUPPORTIVE CARE': 0.006175126590095097, '8. Future Therapies': 0.012350253180190195, 'CLINICAL TRIALS AND FUTURE PROSPECTS': 0.018525379770285292, 'INFLAMMATION AND OXIDATIVE STRESS IN CLD AND UNDERLYING MOLECULAR MECHANISMS': 0.012350253180190195, '3. Patients and Methods': 0.14820303816228234, 'Applications of transdermal functional nano-systems for treating skin diseases': 0.012350253180190195, 'No.14v node dissection for distal local advanced GC': 0.006175126590095097, '4. PPARγ': 0.012350253180190195, 'Non-coding RNAs': 0.006175126590095097, 'Patients and Methods': 0.14202791157218725, 'Clinical Trials in Humans': 0.04940101272076078, 'Pharmacological Therapy': 0.02470050636038039, 'Kidney transplantation': 0.012350253180190195, 'Second-generation EGFR/HER-TKIs': 0.02470050636038039, 'DNA Level Changes': 0.04940101272076078, 'Third-generation EGFR/HER-TKIs': 0.012350253180190195, 'Methods and basic clinical information': 0.02470050636038039, '5. Poxvirus Vectors': 0.02470050636038039, '7. NIAID-Sponsored DNA vaccines (VRC-EBODNA023-00-VP, VRCEBODNA012-00-VP, and VRCMARDNA025-00-VP)': 0.006175126590095097, '8. Inovio-developed DNA Vaccines (INO-4201, INO-4202, and INO-4212)': 0.006175126590095097, 'Ethics Approval and Consent': 0.006175126590095097, 'Corneal endothelium': 0.012350253180190195, 'Trial registration': 0.06792639249104607, 'Use of eculizumab in patients with kidney disease': 0.012350253180190195, 'Novel Modulators of the NO-NOsGC-cGMP pathway': 0.04940101272076078, 'Immunomodulatory agents in sepsis (summarized in': 0.037050759540570584, 'Comparing the basics of PBT with EBRT': 0.012350253180190195, 'Local therapy of the axilla': 0.012350253180190195, 'Case study': 0.012350253180190195, '3 Data Description': 0.012350253180190195, 'Pharmacology': 0.012350253180190195, 'Conclusion and future directions': 0.018525379770285292, 'Materials': 0.04940101272076078, '7 Discussion—limitations of current studies, main challenges and solutions': 0.006175126590095097, '2.1 MATERIALS AND METHODS': 0.04940101272076078, 'Considerations for antigen-specific immunotherapy in T1D': 0.02470050636038039, 'DNA': 0.012350253180190195, '2. Molecular Level': 0.012350253180190195, 'Treatment of SSADHD': 0.006175126590095097, '1. Biogenesis and action mechanisms of circRNA': 0.02470050636038039, '6. mRNA/saRNA approach for protein replacement purposes': 0.02470050636038039, 'Case Example: The Syncope Risk Stratification (SRS) Study': 0.012350253180190195, 'Power calculation': 0.012350253180190195, 'Treatments': 0.13585278498209213, '3. Benefits and efficacy of neoadjuvant immunotherapy': 0.02470050636038039, '7. Other concerns regarding neoadjuvant immunotherapy': 0.012350253180190195, 'Clinical Demonstration': 0.006175126590095097, 'Radiation therapy': 0.061751265900950966, 'Neuroendocrine prostate cancer': 0.006175126590095097, 'Statistical tests': 0.012350253180190195, 'Genomic-based approaches to guide ARTA in localized disease treated by surgery or primary radiotherapy': 0.012350253180190195, 'Computational identification and characterization of regulatory elements': 0.012350253180190195, 'Management of refractory EoE': 0.006175126590095097, 'Enhancing allogeneic NK cell responses': 0.012350253180190195, 'B-VSTs for acute, lethal virus infections': 0.006175126590095097, 'B-VSTs to treat virus-associated malignancies outside the transplant setting': 0.012350253180190195, 'Improving the efficacy of B-VSTs': 0.012350253180190195, '1. Epidemiology and etiologies of SCD in the young': 0.02470050636038039, '4. Injectable Hydrogels': 0.04940101272076078, 'Five-year view': 0.02470050636038039, 'INFECTIOUS LUNG INJURY': 0.012350253180190195, 'APPROACH TO PATIENTS WITH PULMONARY DYSFUNCTION': 0.012350253180190195, 'AF prevention trials': 0.02470050636038039, 'EVIDENCE SUMMARY AND CONCLUSIONS': 0.012350253180190195, 'Experimental': 0.037050759540570584, '5.0 Monoclonal Antibodies': 0.037050759540570584, '6.0 Cytokine Therapy': 0.02470050636038039, 'Antiangiogenic agents': 0.037050759540570584, '1 资料与方法': 0.02470050636038039, '2 MPM的表观遗传学靶向研究进展': 0.012350253180190195, '3 MPM的信号通路蛋白靶向研究进展': 0.006175126590095097, '4 MPM的临床试验研究进展': 0.012350253180190195, 'Development of Allosteric Modifiers of Haemoglobin to Treat Sickle Cell Disease': 0.012350253180190195, '3 围手术期辅助EGFR-TKIs靶向治疗方案问题探讨': 0.04322588613066568, 'Pharmacologic approach to therapy': 0.02470050636038039, 'Trial Registration': 0.030875632950475483, 'CLINICAL TRANSLATION': 0.04940101272076078, '5 Therapeutic potential of the pharmacological modulation of autophagy': 0.006175126590095097, '5 Treatment of MASLD-HCC': 0.012350253180190195, 'The biologic function of CDK7': 0.09880202544152156, '2.0 Methods': 0.04940101272076078, '3. Immune Checkpoint Inhibitors for Advanced, Unresectable, or Recurrent TETs': 0.02470050636038039, '7. Discussion': 0.012350253180190195, '2. ER Stress in Multiple Sclerosis': 0.006175126590095097, 'Clinical translation and challenge': 0.02470050636038039, 'Toxicity': 0.012350253180190195, '3. Toxicity and Challenges for Potential Clinical Trials': 0.006175126590095097, 'CADI-05': 0.006175126590095097, 'Electromotive drug administration of mitomycin C': 0.006175126590095097, '7. Clinical implications and perspectives': 0.02470050636038039, '7. MBL Concentration vs. Bacterial Disease Protection': 0.006175126590095097, '2. Treatment of Metastatic HER2-Positive Gastric Cancer': 0.02470050636038039, '6. Perioperative Treatment of HER2 Gastric Cancer': 0.018525379770285292, '6. Development of Human Agonistic CD40 Antibodies for Clinical Use': 0.27170556996418427, '7. Treatment': 0.012350253180190195, '8. Future Directions': 0.037050759540570584, '4. circRNA-Extracellular Vesicles': 0.11115227862171174, 'Preliminary clinical data and published results': 0.037050759540570584, 'Key ongoing clinical trials': 0.20995430406323332, '2. Mesothelin': 0.08645177226133136, '5. CDKN2A': 0.006175126590095097, 'PREVENTION OF A FIRST EPISODE OF OHE': 0.012350253180190195, 'PREVENTION OF OHE IN SPECIAL POPULATIONS': 0.012350253180190195, '4. Adjuvant Systemic Therapy': 0.037050759540570584, '8. Clinical Trials': 0.012350253180190195, 'Commentary main text': 0.012350253180190195, 'Study protocol': 0.030875632950475483, '4. Clinical Trials with Mitochondria/ROS-Targeted Drugs': 0.02470050636038039, 'Structural, functional, and expression characteristics of': 0.006175126590095097, '3. Skin Substitutes—Characteristics and Clinical Application': 0.02470050636038039, 'Clinical trials numbers': 0.012350253180190195, '4. Translation of Non-Coding RNA-Targeted Therapies through Trials and Approval for Clinical Use': 0.08645177226133136, '5. Development of microRNA-Based Cardiovascular Therapeutic Approaches in Clinical Trials': 0.02470050636038039, 'The role of the immunotherapy in the mCRC management': 0.07410151908114117, '6. Targeting LPA for Cancer Treatment': 0.012350253180190195, '5. Perspectives in Clinical Research': 0.02470050636038039, '3. HER2 Inhibition in Advanced GEA': 0.02470050636038039, '4. HER2 Inhibition in Locally Advanced GEA': 0.012350253180190195, 'Trial conduct and registrations': 0.012350253180190195, '7. Discovery Approaches for Bifunctional Degraders': 0.04940101272076078, 'Recent Clinical Studies on Cardioprotection and Their Possible Implications for Practice': 0.037050759540570584, '3. Translational Research Informing the Path to the Clinic': 0.018525379770285292, '5. Evidence Regarding Different Antiplatelet Agents': 0.012350253180190195, 'Materials and equipment': 0.006175126590095097, '5. GLP-1 Receptor Agonists in Parkinson’s Disease Treatment': 0.12350253180190193, '3. Autoimmune Diseases': 0.012350253180190195, '6. BRCA Mutations': 0.012350253180190195, '7. p16 (MST1 or CDKN2A) Mutations': 0.02470050636038039, 'Ethical considerations': 0.018525379770285292, 'Aim': 0.006175126590095097, '4. Targeting GAGs in Cancer—New Prospective': 0.012350253180190195, '1.2 Methods': 0.012350253180190195, 'Future Outlook': 0.02470050636038039, '11. Delivery Route for Efficient Treatment against SARS-CoV-2': 0.006175126590095097, 'Comments and discussion': 0.012350253180190195, 'Outcome measures': 0.037050759540570584, '3. Folic Acid—Targeted Nanoparticles': 0.037050759540570584, '4. GLP-1 in MASLD and MASH: Randomized Clinical Trials': 0.07410151908114117, '4. Implication for Clinical Applications of Microbial Metabolites in CRC': 0.012350253180190195, 'TAXANES: THE CORNERSTONE FOR CHEMOTHERAPY FOR CRPC': 0.02470050636038039, 'Modulating Haemoglobin F and S Expression': 0.012350253180190195, '3. Tyrosine Kinase Inhibitors in AdvSM and Challenges for Response Criteria': 0.02470050636038039, '3. The Other Anti-Gag Compounds': 0.02470050636038039, 'DEVELOPMENT OF RADIOTHERAPY TECHNIQUES FOR BR': 0.012350253180190195, 'Management of Persistent Agitated Delirium': 0.02470050636038039, '5. Active Trials: Adult Early Stage HL': 0.018525379770285292, '6. Active Trials: Adult Advanced Stage HL': 0.02470050636038039, '4. Non/Delayed Unions': 0.012350253180190195, '5. Cartilage Repair': 0.030875632950475483, '7. Osteogenesis Imperfecta (OI)': 0.012350253180190195, 'Allergen-specific Therapies': 0.037050759540570584, '3 Antiangiogenic therapy': 0.037050759540570584, 'TRIALS WITH MODERN APBI TECHNIQUES': 0.02470050636038039, '4. Targeting Microbiota to Counteract Respiratory Infections': 0.012350253180190195, '14. Proton Therapy in Anal Cancer': 0.012350253180190195, 'Development of the Integrated Care Case Practice': 0.012350253180190195, 'Path to the Clinic: Progress and Challenges': 0.04940101272076078, 'STEP 7: EVALUATE THE INTERVENTION': 0.012350253180190195, '3. Early Stages': 0.012350253180190195, '7. Current Clinical Trials for SCA3': 0.061751265900950966, 'MONOTHERAPIES USING IMMUNE CHECKPOINT INHIBITORS FOR HCC': 0.012350253180190195, 'CURRENT STATUS OF IMMUNE CHECK-POINT INHIBITORS FOR HEPATOCELLULAR CARCINOMA: ADVANCEMENT OF COMBINED REGIMENS': 0.037050759540570584, 'Phage display derived antibodies in clinical development': 0.037050759540570584, 'STRA TEGIES FOR TARG ETING IMMUNO - SUPPRESSIVE CELLS (': 0.012350253180190195, 'Therapeutic Use of Native Natriuretic Peptides: A Focus on Heart Failure': 0.012350253180190195, 'Designer Natriuretic Peptides: For Cardiovascular Disease': 0.02470050636038039, 'Familial Cardiomyopathies': 0.02470050636038039, 'Genetic Approaches to Therapy: Pharmacogenetics and Future Approaches': 0.02470050636038039, '2. Aldehyde Dehydrogenases': 0.04940101272076078, 'Results.': 0.02470050636038039, 'Materials and Methods.': 0.0030875632950475487, 'Clinical findings regarding preventive or relief effects of probiotics against influenza or upper respiratory tract infections': 0.012350253180190195, '3. Clinically Approved Representative Small-Molecule TKIs of EGFR': 0.012350253180190195, 'Treatment of metabolic dysfunction in HIV': 0.02470050636038039, 'OPTIMIZING AND MAXIMIZING CURRENT BIOLOGIC AGENTS': 0.037050759540570584, 'Specific Antisense Therapy to Lower Lp(a)': 0.012350253180190195, 'Funding sources': 0.018525379770285292, '2. Safety and efficacy of antihyperglycemic agents in youth': 0.04940101272076078, '4. Melatonin as an Antihypertensive': 0.006175126590095097, '5. Future Directions in the Initial Management of Patients with DLBCL': 0.02470050636038039, '7. Elderly and Frail Patients with DLBCL': 0.018525379770285292, '2. Materials & Methods': 0.02470050636038039, '2. Risk Stratification': 0.05557613931085587, 'MDM2/X inhibitors': 0.006175126590095097, '4. Progress toward Clinical PTT Applications': 0.04940101272076078, '4. Microglia-Targeting Therapeutic Interventions in CNS Disorders': 0.012350253180190195, '2. Methods and Population': 0.006175126590095097, 'Overview of qHPV vaccine LTFU data': 0.02470050636038039, 'Role of early Abiraterone/Enzalutamide': 0.012350253180190195, 'Advances in Radiation therapy': 0.02470050636038039, '5. Clinical Production of mRNA for Electroporation': 0.037050759540570584, '6. Clinical Application of mRNA Electroporation in Cell-Based Immunotherapies': 0.02470050636038039, '4. Known X-Linked Developmental and Epileptic Encephalopathies': 0.02470050636038039, 'Data From Randomized Trials': 0.012350253180190195, '3. Human Clinical Trials:': 0.006175126590095097, '2. General Alterations of the Immune System in the Context of Monoclonal Gammopathies': 0.02470050636038039, 'Serine/glycine and one-carbon metabolism': 0.02470050636038039, 'PHARMACOLOGICAL MANAGEMENT': 0.006175126590095097, '7. Decliners and interventions': 0.02470050636038039, 'Combining molecular approaches with histopathology': 0.012350253180190195, 'Family Support and Transition Planning': 0.006175126590095097, '6. Vedolizumab': 0.012350253180190195, '8. Therapeutic Potential of Targeting GPER': 0.006175126590095097, 'Clinical classification of LCH': 0.012350253180190195, 'New therapeutic approaches and tentative targets emerging from the (recent) insights into the LCH biology': 0.02470050636038039, 'Clinical trials registration': 0.006175126590095097, 'CURRENT CLINICAL DEVELOPMENT OF COMPOUNDS PROMOTING HGF/MET FOR ALZHEIMER’S DISEASE': 0.012350253180190195, 'INVARIANT NATURAL KILLER T CELL (iNKT) TARGETED THERAPIES': 0.012350253180190195, 'CURRENT STATE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH SCD': 0.04940101272076078, 'CORD BLOOD EXPANSION STRATEGIES': 0.012350253180190195, 'DISEASE MODIFYING THERAPIES VERSUS HEMATOPOIETIC STEM CELL TRANSPLANT': 0.006175126590095097, 'Quinone Derivatives': 0.006175126590095097, '2. Micro RNA Signatures of Lung Cancer': 0.018525379770285292, 'Clinical Experience With Antiangiogenic Agents In Glioblastoma': 0.02470050636038039, 'Enzalutamide': 0.02470050636038039, 'Key Points': 0.030875632950475483, 'Clinical Trial Approval': 0.006175126590095097, '2. The Evolution of Translational Precision Medicine Research': 0.006175126590095097, '2. Gene Expression Profiling': 0.02470050636038039, 'Sources of Big Data and Access Considerations': 0.012350253180190195, 'Common mechanisms and therapeutic opportunities': 0.012350253180190195, 'Persisting oncogenic addiction to the EGFR pathway beyond progression': 0.02470050636038039, 'Third-generation EGFR TKIS': 0.018525379770285292, 'Immunotherapy and EGFR TKIs': 0.037050759540570584, 'Mechanisms of acquired resistance to EGFR-TKIs in NSCLC': 0.012350253180190195, '2. Therapeutic Management of Rectal Cancer': 0.012350253180190195, 'Glycaemic Control in Cardiovascular Risk Reduction: An Actively Evolving Paradigm': 0.006175126590095097, 'Data acquisition and performance': 0.02470050636038039, '6. Translational Research': 0.006175126590095097, '2. Fungal–Metal Interactions': 0.02470050636038039, '5. Clinical studies to target microglia activation with immune-modulating drugs': 0.037050759540570584, '2. The Metabolomics of TET Family of Genes': 0.02470050636038039, '5. Clinical perspectives': 0.006175126590095097, '5. Nicotinamide: Pleyotropic Activity and Therapeutic Avenues': 0.012350253180190195, 'TARGETING IRON AS THERAPY IN AKI': 0.12350253180190193, '7. RIPK1 and AD': 0.006175126590095097, 'Funding Sources': 0.018525379770285292, 'Clinical Trial Data': 0.09880202544152156, '4. Patients on Dialysis': 0.018525379770285292, 'CURRENT LIMITATIONS AND PERSPECTIVES': 0.012350253180190195, 'glossary': 0.0030875632950475487, 'Enveloped virus-like particle vaccines': 0.006175126590095097, 'Neoadjuvant immunotherapy with chemotherapy': 0.030875632950475483, 'ADVANCES IN CANCER TREATMENT': 0.04940101272076078, 'Randomised trials since 2017': 0.012350253180190195, '5. Alzheimer’s Disease': 0.037050759540570584, 'Transformation of GVHD prophylaxis by posttransplant cyclophosphamide': 0.006175126590095097, 'Inactivation of GVHD-causing T cells by costimulatory blockade': 0.006175126590095097, 'Chronic GVHD therapies achieve FDA approval at last': 0.006175126590095097, 'Nivolumab (BMS-936558/MDX-1105)': 0.006175126590095097, 'Durvalumab (MEDI-4736)': 0.012350253180190195, 'Atezolizumab (MPDL-3280A)': 0.006175126590095097, 'Therapeutic development for SARS-CoV-2': 0.030875632950475483, 'Intersection of circRNAs and Ferroptosis': 0.07410151908114117, 'Trial registration number': 0.030875632950475483, '8. Outlook: Treatment of Melanoma Brain Metastases (MBM)': 0.037050759540570584, 'Therapies in the Development Pipeline': 0.14820303816228234, 'Brain Metastases': 0.012350253180190195, '4. Contribution to Pathophysiology in Dercum’s and Roch-Leri Diseases': 0.006175126590095097, 'Novel antibody therapeutics targeting mesothlin as cancer drugs in development': 0.02470050636038039, 'Melanoma Management: What is New Under the Sun?': 0.02470050636038039, 'Pathogenesis of Stasis Dermatitis': 0.02470050636038039, '3. Toxicity': 0.012350253180190195, '4. Biological Activities of 1,3-Cyclohexadien-1-Carboxaldehyde': 0.006175126590095097, '6. ACE2 Associations with COVID-19 Infection and Lung Function': 0.018525379770285292, '5. TMR as a Prevention or Treatment for Neuromas': 0.012350253180190195, 'DYSREGULATED lncRNAs IN OC': 0.061751265900950966, 'Trial details': 0.006175126590095097, 'Secukinumab for AS': 0.012350253180190195, 'Distal Symmetric Polyneuropathy': 0.02470050636038039, 'PRELIMINARY EXPERIENCE': 0.006175126590095097, '7. Expert opinion': 0.012350253180190195, 'BASIC SCIENCE': 0.04940101272076078, '8. Adxbladder': 0.037050759540570584, '2. Rationale for Inhaled Antibiotics in CF': 0.006175126590095097, 'Is this the dawn of a new surgery-free era?': 0.08027664567123625, '5. LncRNAs in Cancer Hallmark': 0.006175126590095097, '4. Fenamates and Cognitive Impairment': 0.012350253180190195, 'The trials evidence base': 0.018525379770285292, 'CLINICAL TRIAL REGISTRATION NUMBER': 0.006175126590095097, '4. ENaC': 0.061751265900950966, 'CircRNAs and their roles in regulating TC hallmarks': 0.012350253180190195, 'Ethical Consideration': 0.012350253180190195, 'Targeting PTK7 in cancer': 0.08645177226133136, '3. Approvals and data and safety monitoring': 0.02470050636038039, '4. Window of Opportunity to Achieve Synergy between Radiotherapy and Immunotherapy': 0.006175126590095097, '7. Charged Particle Radiation in Combination with Immunotherapy': 0.06792639249104607, 'ACUTE MANAGEMENT': 0.04940101272076078, 'DRUGS TARGETING': 0.012350253180190195, '2. Characterization of CircRNAs and RPBs': 0.02470050636038039, 'Potential of TBV candidates': 0.006175126590095097, 'Pathophysiology of SCD': 0.02470050636038039, '4 Clinical perspectives': 0.04322588613066568, 'Antitubercular Agents Regulating Mycolylarabinogalactan Peptidoglycan (mAGP) Assembly': 0.02470050636038039, 'Antitubercular Agents Regulating Mycobacterial Respiratory System': 0.012350253180190195, 'Conclusion & Future Directions': 0.006175126590095097, 'Mechanisms of ICI Resistance in HCC and Treatment Strategies': 0.012350253180190195, 'Risk of reporting biases in syntheses': 0.02470050636038039, 'Mitochondrial pathways and ROS': 0.012350253180190195, 'ETHICS STATEMENT AND CONSENT TO PARTICIPATE': 0.006175126590095097, 'First Translation: from Genes to Targetable Pathways': 0.012350253180190195, 'Second Translation: from Targetable Pathways to Candidate Drugs': 0.037050759540570584, 'Diffuse Oligodendroglial Tumors': 0.012350253180190195, 'Corticotropin-Releasing Factor': 0.006175126590095097, 'Anti-IL-4/13 therapy as a potential treatment for BP': 0.08645177226133136, 'Physical disability': 0.02470050636038039, 'Navigating Biological Complexity in Precision Oncology': 0.02470050636038039, 'Data and Knowledge Sharing': 0.012350253180190195, 'Host Transcriptional Signatures for Predicting Progression to Active TB': 0.012350253180190195, 'Recombinant TRAIL': 0.037050759540570584, 'Clinical application': 0.061751265900950966, '3. DISCOVERY AND DEVELOPMENT OF BRD4 INHIBITORS': 0.04940101272076078, 'The role of microRNAs in the development of SLE': 0.030875632950475483, 'The role of LncRNAs in the progression of SLE': 0.006175126590095097, 'Recommendations': 0.018525379770285292, 'Focus on PDE5 Inhibitors\\\\nagainst Neurodegeneration': 0.012350253180190195, 'Further analysis of the PROMAGEN study': 0.006175126590095097, 'PRECLINICAL AND CLINICAL STUDIES: PROGRESS AND OBSTACLES': 0.037050759540570584, 'Gene Therapy Approaches for Charcot-Marie-Tooth Neuropathy Type 1A': 0.04940101272076078, 'Critical Summary of the Proposed Charcot-Marie-Tooth Neuropathy Type 1A Gene Therapy Approaches': 0.012350253180190195, '7. Prognostic Value, Therapeutic Implications, and Future Perspective': 0.012350253180190195, 'Translation regulation and cell invasion': 0.006175126590095097, 'Trikafta propels a new era in CFTR research': 0.006175126590095097, '5. Alternative Vaccination Strategies Based on Vectors': 0.02470050636038039, 'Multispecific engagers binding T cells in cancer immunotherapy': 0.012350253180190195, 'Extending T-cell engagers to infectious diseases': 0.012350253180190195, 'Multispecific engagers binding myeloid cells in cancer and infectious diseases': 0.061751265900950966, 'II. lncRNAs in breast cancer – early evidence of dysregulation and function': 0.02470050636038039, 'Outcomes, Milestones and Goals': 0.012350253180190195, 'MICRORNA – IN THE GENOME': 0.006175126590095097, 'Asundexian': 0.012350253180190195, 'Other Small Molecule FXIa Inhibitors under Investigation': 0.012350253180190195, 'Cellular pathology and therapeutic approaches': 0.012350253180190195, 'Therapeutic Genetic Material Other Than DNA: RNA Addition and Repair': 0.018525379770285292, 'Therapeutic Delivery Vectors': 0.02470050636038039, 'Presentations at CANNeCTIN annual meetings': 0.006175126590095097, 'Cell-based vaccines': 0.012350253180190195, 'Modulating Th1/Th2 Imbalance': 0.012350253180190195, 'A Computer‐Age Tool to Help Authors in the Field of Carbon Allotropes': 0.006175126590095097, 'Funding acknowledgement': 0.006175126590095097, 'Extended Data': 0.012350253180190195, 'Current Challenges and Opportunities for Antibody-Based Therapeutics': 0.012350253180190195, 'New treatment venues: exploiting the linked triad of cellular volume, ECM and [Cl': 0.02470050636038039, 'Clinical Trials of ER Modulation in Bladder Cancer': 0.018525379770285292, 'Oral prostanoids in clinical use: beraprost and treprostinil': 0.012350253180190195, 'Treatment for scabies': 0.012350253180190195, 'Novel therapeutic avenues in polycythemia vera': 0.037050759540570584, 'Clinical Evidence': 0.061751265900950966, 'Natural product scaffolds that inhibit the 20S proteasome': 0.012350253180190195, 'SAIA-TB impact assessment': 0.012350253180190195, 'BCL-2': 0.006175126590095097, 'Menin': 0.012350253180190195, 'TRIAL REGISTRATION': 0.05557613931085587, '2. - Materials and Methods': 0.02470050636038039, 'DIGOXIN IN STEATOHEPATITIS': 0.05557613931085587, 'DIGOXIN IN CANCER': 0.02470050636038039, 'DIGOXIN IN VIRAL INFECTION': 0.012350253180190195, 'CLINICAL STUDIES IN PDT': 0.09262689885142646, 'Immunology': 0.04940101272076078, 'Data Sharing Statement': 0.006175126590095097, 'PSA-TRICOM': 0.030875632950475483, 'Ipilimumab': 0.09262689885142646, 'Current Status of Phage Therapy as a Biomedical Tool': 0.006175126590095097, 'Effects of ESAT-6 on mycobacterial virulence: modulating host cell response': 0.012350253180190195, 'Structural Intervention': 0.030875632950475483, 'Atherosclerosis': 0.05557613931085587, 'Assays Measuring Neutralizing and Total Anti-AAV Antibody Levels': 0.018525379770285292, 'Antiplatelet therapy': 0.012350253180190195, 'Percutaneous Coronary Intervention': 0.07410151908114117, 'Drug-Eluting Balloons': 0.02470050636038039, 'Effects on CV Outcomes': 0.018525379770285292, 'Amino Acid PET Including Fluciclovine': 0.006175126590095097, 'DATA ANALYSIS': 0.012350253180190195, '5: Monoclonal antibodies (mAbs)': 0.012350253180190195, 'Trial rationale': 0.006175126590095097, 'Hallmarks of pathophysiology of pulmonary arterial hypertension': 0.012350253180190195, 'The BCL-2 family, mechanism of action of BH3-mimetics and BH3 profiling': 0.02470050636038039, 'BIOLOGICAL MECHANISMS OF THE': 0.012350253180190195, 'Novel therapeutic targets for CRPC variants': 0.037050759540570584, '4. Dendritic Cell generation': 0.012350253180190195, '8. Vaccines target DCs': 0.012350253180190195, 'APC’s Neuroprotective Activities and Reduction of tPA-induced Bleeding': 0.012350253180190195, 'CD47 and immune surveillance during normal and malignant hematopoiesis': 0.02470050636038039, 'Future directions and limitations': 0.006175126590095097, 'ECM stiffness': 0.006175126590095097, 'Therapeutic targets and opportunities': 0.012350253180190195, '8 Clinical trials': 0.006175126590095097, '4. Clinical Targeting of IGF1R in RMS: Evidence and Trends': 0.006175126590095097, \"4. Rituximab's Applications in Hematological Malignancies\": 0.012350253180190195, '7. Other mAbs for NHL': 0.006175126590095097, 'Phytoremediation of metals': 0.018525379770285292, '8 Advancements in future therapeutic strategies': 0.006175126590095097, 'Pharmacological targeting of LPL': 0.04940101272076078, 'TARGETING DNA-PKcs AS A CANCER THERAPY': 0.012350253180190195, 'Targeting ribosome biogenesis for cancer therapeutics': 0.018525379770285292, 'Clinical role of HER2-directed therapies in the management of gastric and esophageal adenocarcinoma': 0.012350253180190195, 'Possible Scenarios on Using ACE2-Based Treatments for COVID-19': 0.006175126590095097, 'Directions for future research': 0.030875632950475483, 'AIRWAY REMODELING': 0.04940101272076078, 'The Future of Immunotherapies in HCC Beyond ICI': 0.037050759540570584, 'Anti-CD20 mAbs and immunoconjugates': 0.012350253180190195, 'Family Critical Time Intervention': 0.006175126590095097, 'Challenges in radiotherapy': 0.012350253180190195, 'ATRA neurotoxicity': 0.012350253180190195, 'Acute coronary syndromes and myocardial revascularization': 0.012350253180190195, 'Targeting the epithelium and epithelial cytokines to modify airway remodelling': 0.012350253180190195, 'FURTHER POTENTIAL TREATMENTS FOR OBESITY AND T2DM': 0.006175126590095097, 'Ongoing NRG-1 clinical trials for heart failure': 0.02470050636038039, 'Modulation of genomic maintenance through inhibition of KYN signaling as a potential anti-cancer treatment in gliomas': 0.012350253180190195, '7. Zonisamide and methylprednisolone': 0.012350253180190195, 'PATHOPHYSIOLOGY': 0.012350253180190195, 'Therapeutic Targets: Clinical Evidences': 0.08645177226133136, 'PATIENTS AND MATERIALS': 0.02470050636038039, 'Ethical approval, research governance and data access': 0.006175126590095097, 'Sonotheranostics': 0.006175126590095097, 'Conclusion and future perspective of optical devices with AI for soil-transmitted helminth and': 0.006175126590095097, 'Intention-to-Treat Efficacy Analysis': 0.02470050636038039, 'TARGET ANTIGENS': 0.02470050636038039, 'A ROLE FOR GLP-1 IN THE PHARMACOTHERAPY OF CLINICAL OBESITY': 0.037050759540570584, 'Cell-Based Therapies Using Polyclonal Tregs': 0.02470050636038039, 'Novel Methods to Promote Immune Regulation': 0.012350253180190195, 'TARGETING METABOLIC PATHWAYS': 0.09880202544152156, 'OXIDATIVE STRESS AND INFLAMMATION': 0.1605532913424725, 'The structure of FOXP3 bound to T': 0.006175126590095097, 'Bapineuzumab and Solanezumab - the first Anti-Amyloid Beta Monoclonal Antibodies': 0.04322588613066568, \"Preventive Clinical Trials Targeting the Presymptomatic Alzheimer's Disease Stage – focus on Solanezumab, Gantenerumab, and Crenezumab\": 0.006175126590095097, 'Inhibiting the Viral Proteases': 0.12350253180190193, 'FUNDING': 0.012350253180190195, 'Targeting the gut microbiota for inhibiting CRC metastasis: clinical approaches for prevention, treatment, and prognostic evaluation': 0.030875632950475483, 'Clinical implementation of': 0.012350253180190195, 'Supramolecular Drug Delivery Systems': 0.04940101272076078, 'Future Directions for Supramolecular Drug Delivery Systems': 0.012350253180190195, 'Second-generation BTK inhibitor binding mechanisms': 0.018525379770285292, 'CLINICAL IMPLICATIONS OF THE STEP PROGRAMME': 0.012350253180190195, '2. MATERIALS AND METHODS': 0.037050759540570584, 'Targeting Autophagy in Neurological Diseases': 0.04322588613066568, 'Radiation therapy for BM': 0.006175126590095097, 'Upcoming clinical trials investigating BRAFi ± MEKi or radiotherapy for MBM': 0.037050759540570584, '3. Hereditary papillary renal carcinoma: Type 1 papillary renal carcinoma': 0.012350253180190195, '4. Birt-Hogg-Dubé syndrome: Hybrid oncocytic and chromophobe renal carcinoma': 0.012350253180190195, '5. Hereditary leiomyomatosis and renal cell carcinoma: Type 2 papillary renal carcinoma': 0.02470050636038039, 'Evidences for SCS Effectiveness in FBSS': 0.006175126590095097, 'CLINICAL TRIALS REGISTRATION': 0.018525379770285292, 'Dissemination': 0.012350253180190195, '3. Non-pharmacological rhythm-control therapies': 0.012350253180190195, 'Statistical Analysis': 0.006175126590095097, 'Biogenesis, Properties, and Functions of circRNAs': 0.012350253180190195, 'Comment': 0.037050759540570584, 'circRNAs and Human Diseases': 0.018525379770285292, 'NICOTINAMIDE AND HYPOPHOSPHATEMIA: FROM TOXICITY MONITORING TO THERAPEUTIC INTERVENTION': 0.006175126590095097, 'CHALLENGES FOR BIOSIMILAR ADOPTION': 0.012350253180190195, 'Building on Our Past Legacy and Present Strengths': 0.012350253180190195, 'Integrating FFR and coronary flow reserve into management of CAD': 0.006175126590095097, 'miRNAs as prognostic markers and therapeutic targets in thyroid cancer': 0.012350253180190195, 'QOL instrument adjuncts': 0.006175126590095097, '2.0 MATERIALS AND METHODS': 0.012350253180190195, 'LAAO: past and present': 0.012350253180190195, 'Efficacy data for LAAO': 0.06792639249104607, 'CLINICAL TRIALS REGISTRATION NUMBERS': 0.006175126590095097, 'Probiotics': 0.006175126590095097, 'CLINICAL TRIAL NUMBER': 0.02470050636038039, '7. FUTURE DIRECTIONS': 0.012350253180190195, 'Multi-cancer Early Detection in the Preclinical Period': 0.030875632950475483, 'Conclusion and Future Directions': 0.006175126590095097, '4. Pharmacokinetics of polymyxins': 0.012350253180190195, 'Palliative treatment regimens': 0.061751265900950966, 'COMMENTARY': 0.04322588613066568, '2. Materials and Method': 0.012350253180190195, 'EECV2 Collaborative Group': 0.012350253180190195, '2. Materials and method': 0.012350253180190195, 'BTK inhibition': 0.006175126590095097, 'Human and Animal Rights and Informed Consent': 0.018525379770285292, 'Effect of Antihypertensive Therapies on HFpEF Pathophysiology and Outcomes': 0.04940101272076078, 'Non-pharmacological treatment in elderly HF patients': 0.037050759540570584, 'Crosstalk and Combination Therapies': 0.02470050636038039, 'Anti-Podocyte Antibodies in the Pathogenesis of MN': 0.012350253180190195, 'Anti-Podocyte Antibodies and Response to Treatment': 0.006175126590095097, 'OMICs-based diagnostic and prognostic lung cancer biomarkers in advanced clinical development': 0.012350253180190195, 'How to Use the Anti-Inflammatory Properties of the Vagus Nerve for Therapeutic Purposes?': 0.02470050636038039, 'Adjuvant Treatment in Endometrial Cancer': 0.012350253180190195, 'COMMENT': 0.037050759540570584, 'THERAPEUTIC CLINICAL TRIALS OF REGIONAL THERAPY FOR ADVANCED EXTREMITY MELANOMA': 0.012350253180190195, 'Transparency statements Study registration': 0.012350253180190195, 'CASE STUDIES': 0.012350253180190195, 'Intratumoural distinctions inform intertumoural heterogeneity': 0.012350253180190195, 'Outcomes': 0.02470050636038039, 'Canagliflozin/Metformin FDC Place in Therapy': 0.018525379770285292, 'Clinical Trials in Integrin Targeting': 0.006175126590095097, 'Pre-registered Clinical Trial Number': 0.018525379770285292, 'Phase III trials of nintedanib in NSCLC': 0.006175126590095097, 'Targeted treatment of mutated': 0.037050759540570584, 'Anti-PD-1 drugs': 0.09880202544152156, 'Other Drugs Under Investigation': 0.012350253180190195, 'To the editors': 0.006175126590095097, 'ETHICS APPROVAL AND CONSENT TO PARTICIPATE': 0.012350253180190195, 'Clinical trial registry number and website': 0.006175126590095097, 'DIRECTIONS FOR FUTURE RESEARCH': 0.012350253180190195, '7. Update on treatment approaches': 0.012350253180190195, 'Pharmacologic profiles': 0.012350253180190195, 'The types and effects of conduction abnormalities after TAVR': 0.061751265900950966, '11. EICOSANOID-BASED CARDIOVASCULAR THERAPEUTICS': 0.02470050636038039, 'CLINICAL TRIALS REGISTRY': 0.006175126590095097, '2 Diagnosis and Staging': 0.02470050636038039, '3 Imaging-Based Prognostic Markers': 0.02470050636038039, '4 Imaging-Based Assays of Predictive Biomarkers': 0.02470050636038039, '7 Imaging-based Trial Endpoints': 0.012350253180190195, 'Clinical perspective': 0.037050759540570584, 'ETHICS APPROVAL AND PARTICIPANTS′ CONSENT': 0.006175126590095097, '4. Nutritional Approaches for Suppression of Obesity-Association Inflammation': 0.02470050636038039, 'VI. Modulators of Alternative Splicing': 0.061751265900950966, 'DIFFERENTIATED THYROID CARCINOMA': 0.02470050636038039, 'Protocol': 0.006175126590095097, 'Allogeneic cell therapy': 0.012350253180190195, 'DATA: DESCRIPTIVE STATISTICS': 0.006175126590095097, 'OVERVIEW OF THIS CCR FOCUS': 0.012350253180190195, 'Ethical Considerations': 0.006175126590095097, 'III. CORNEAL SUBBASAL NERVE PLEXUS': 0.04940101272076078, 'POLYCLONAL ANTIBODIES': 0.006175126590095097, 'Peripartum cardiomyopathy': 0.006175126590095097, '3. Peripheral Blood Monitoring': 0.02470050636038039, 'Obesity': 0.04940101272076078, 'Radiolabeled compounds for thyroid cancers': 0.006175126590095097, 'The role of the Tspan protein family in cancer treatment': 0.012350253180190195, 'Subtopic 4: Treatment of ICU SCD': 0.02470050636038039, '2. Application of MSCs in Autoimmune Diseases': 0.012350253180190195, 'Transcription through the nucleosome': 0.012350253180190195, 'Clinical research progress of histotripsy': 0.037050759540570584, 'Sphingolipids': 0.04940101272076078, 'COPD': 0.012350253180190195, 'Part 5: ncRNAs as Biomarkers and Therapeutic Targets': 0.012350253180190195, 'LCH as consequence of misguided myeloid differentiation': 0.012350253180190195, 'Applications': 0.04940101272076078, 'CCR7 as a Novel Therapeutic Target in CLL': 0.012350253180190195, 'Practical Guidance for NMD Patients in the Covid-19 Pandemic': 0.012350253180190195, 'Ethical Approval and Clinical Trial Registration': 0.006175126590095097, 'Target Antigen in OS': 0.012350253180190195, 'PITFALLS FOR CLINICAL IMPLEMENTATION': 0.012350253180190195, 'Patient Selection – New Tumor Subsets Based on Molecular Classification': 0.006175126590095097, '3. GUARDIAN Study and the Systemic Gaps Experienced': 0.006175126590095097, 'Clinical observations': 0.05557613931085587, 'Immunity and PDAC': 0.012350253180190195, 'ETHICAL CONCERNS': 0.006175126590095097, 'Avenues of intervention': 0.04940101272076078, '5-FU TDM with Capecitabine': 0.006175126590095097, 'Clinical Trials of Cell Therapies in COPD Subjects': 0.037050759540570584, 'Drug Therapies to Regenerate the Damaged Lung in COPD': 0.006175126590095097, 'Novel immunotherapy targets characterized by scRNA-seq': 0.012350253180190195, 'THERAPEUTIC OPPORTUNITIES AND CHALLENGES IN TARGETING MICROGLIA/MACROPHAGES IN STROKE': 0.02470050636038039, 'Reconstitution of NPC symmetric core protomers': 0.006175126590095097, 'Pharmacological treatment of obesity': 0.018525379770285292, '4. Classification Experiments': 0.02470050636038039, 'Analysis': 0.006175126590095097, '6. Translational link to the clinic': 0.006175126590095097, 'Antithrombotic therapy after LAAO': 0.04322588613066568, 'Transthyretin expression silencer': 0.006175126590095097, 'Second-generation small-interfering RNA agents': 0.006175126590095097, 'Transthyretin stabilizer drugs': 0.012350253180190195, 'Anti PCSK9 therapies: alirocumab, evolocumab, and inclisiran': 0.08027664567123625, 'Other renal denervation systems': 0.006175126590095097, 'Existing capabilities and unmet needs': 0.018525379770285292, 'Resistance to PARP Inhibition': 0.006175126590095097, 'Receptor crosstalk shapes B cell activation': 0.04940101272076078, 'THERAPIES TARGETING MITOCHONDRIAL FUNCTION IN AGE-RELATED NAFLD': 0.012350253180190195, 'The Skin': 0.012350253180190195, '10. Ag-Specific Cell Therapies': 0.006175126590095097, 'Data Description': 0.012350253180190195, 'NEUROMUSCULAR disorders RELATED TO ABNORMAL AUTOPHAGY INDUCTION': 0.012350253180190195, 'Summary and future directions': 0.02470050636038039, 'ANALYSIS': 0.006175126590095097, '7 Therapeutic targeting of tumor ECM': 0.018525379770285292, '6 Considerations for clinical trials of radiation therapy with STING agonists': 0.018525379770285292, 'Autophagy and cGAS-STING signaling in cancer': 0.04940101272076078, '4 Mitochondria-mediated ferroptosis in malaria': 0.02470050636038039, 'Strengths and limitations': 0.006175126590095097, 'Dear Editor': 0.012350253180190195, 'Summary and conclusion': 0.012350253180190195, 'CodeBreaK 200 (NCT04303780) (Confirmatory Randomized Phase III Trial of Sotorasib versus Docetaxel)': 0.006175126590095097, 'Sotorasib is the First but Not the Only Covalent': 0.030875632950475483, 'Pharmacological therapies for brain aging': 0.02470050636038039, 'Diabetic therapeutics for brain aging': 0.012350253180190195, 'The role of AFP in the TME of HCC': 0.061751265900950966, 'The role of AFP in the diagnosis and treatment of HCC': 0.006175126590095097, '2. The DIAN-TU Alzheimer’s Disease Prevention Trial Platform': 0.006175126590095097, 'Clinical Development of CSF1R Inhibitors': 0.04322588613066568, 'Methodik': 0.012350253180190195, '5. ApoE-targeted therapy for AD': 0.04940101272076078, 'Rare Mutation Types of EGFR': 0.012350253180190195, '6. Ethics and informed consent': 0.006175126590095097, 'SUMMARY AND FUTURE DIRECTIONS': 0.04940101272076078, 'CLINICAL TRIALS DATA': 0.012350253180190195, 'PROSPECTS AND CHALLENGES FOR CLINICAL TRANSLATION': 0.02470050636038039, 'Blood alternatives': 0.012350253180190195, 'Therapeutic Interventions in the Diabetic Brain': 0.04940101272076078, 'Others': 0.006175126590095097, 'Trial designs for intratumour heterogeneity': 0.02470050636038039, 'An example of intratumour heterogeneity in the clinic': 0.012350253180190195, 'LOOKING FOR HIGH RISK PATIENTS: EVIDENCE FROM CLINICAL TRIALS': 0.012350253180190195, 'COMMENTS': 0.018525379770285292, 'Hepatectomy': 0.037050759540570584, 'DETAILS CONCERNING SEMAGLUTIDE’S PHARMACOLOGIC PROPERTIES FAVORING DR SAFETY': 0.018525379770285292, 'Human studies': 0.018525379770285292, 'Ways to overcome limitations and future direction': 0.04322588613066568, 'First approvals granted during 2016': 0.006175126590095097, 'Regulatory actions: Projections for 2017': 0.08645177226133136, 'To the Editor,': 0.018525379770285292, 'Management of primary uveal melanoma': 0.012350253180190195, 'Metastatic uveal melanoma therapies': 0.006175126590095097, 'Short-term management': 0.037050759540570584, 'Long-term management': 0.02470050636038039, 'Patiromer': 0.012350253180190195, 'DEVELOPMENT OF BETTER PREDICTION AND EVALUATION MODELS': 0.006175126590095097, '4. Clinical application of CD40 agonists to cancer therapy': 0.037050759540570584, 'Underlying mechanisms of long COVID': 0.012350253180190195, 'MCT1': 0.006175126590095097, 'MCT8 and MCT10': 0.006175126590095097, 'CURRENTLY AVAILABLE AND EMERGING TREATMENT OPTIONS': 0.037050759540570584, 'Performance benchmarks': 0.006175126590095097, 'NOVEL AGENTS FOR PV/ET TREATMENT': 0.02470050636038039, 'list': 0.0030875632950475487, 'CRS': 0.006175126590095097, 'CLINICAL DATA OF ASCIMINIB': 0.012350253180190195, 'Menin Mechanisms and Metastases': 0.012350253180190195, 'GLP-1RA and renal outcomes': 0.012350253180190195, '2. METHODS AND MATERIALS': 0.012350253180190195, 'Where translation begins: Novel pathophysiological insights': 0.02470050636038039, 'Purpose of the study': 0.012350253180190195, 'AUTOPHAGY': 0.018525379770285292, 'Objectives': 0.012350253180190195, 'GENERATION OF CART CELLS': 0.012350253180190195, 'LIMITATIONS TO CART CELL THERAPY': 0.012350253180190195, 'IMPROVING CART CELL THERAPY': 0.037050759540570584, 'ALTERNATIVE MINIMALLY INVASIVE TREATMENT OPTIONS': 0.012350253180190195, 'Recent AAV treatment advances': 0.012350253180190195, 'Current treatment of AAV': 0.02470050636038039, 'THERAPEUTIC EFFICACY OF KINASE INHIBITOR THERAPY IN HISTIOCYTOSES': 0.04940101272076078, '3. Beyond rational drug design: responsible drug diffusion': 0.012350253180190195, 'Treatment strategies beyond progression': 0.006175126590095097, 'Additional third-generation EGFR inhibitors': 0.02470050636038039, 'ERBB2 gene mutation or amplification': 0.061751265900950966, 'Current evidence of MET-selective TKIs': 0.02470050636038039, 'Human translation': 0.02470050636038039, 'Is PICS the Cause of Morbidity Associated with Chronic Critical Illness?': 0.006175126590095097, 'Acknowledgements and Funding': 0.018525379770285292, 'Developmental Therapeutics in PV and ET': 0.037050759540570584, 'History of quinacrine': 0.018525379770285292, 'Microglia targeting for treating cerebrovascular diseases': 0.012350253180190195, 'Ethical Approval Statement': 0.006175126590095097, 'Basic principles of clinical trials': 0.012350253180190195, '5. Vector/OV-Induced Immunity': 0.012350253180190195, '2. Methods and Materials': 0.018525379770285292, 'Vector delivery systems': 0.018525379770285292, 'Protein-based vaccines': 0.018525379770285292, '5. In Vivo Applications of ECM Hydrogels': 0.012350253180190195, 'DISTURBANCE OF LOCAL CELLULAR COMPONENTS TO BE RESPONSIBLE FOR THE DENDRITE PATHOLOGY IN NEURODEGENERATIVE DISEASES': 0.012350253180190195, 'TRAIL-MEDIATED SIGNALING NETWORK': 0.012350253180190195, 'Systematic Treatment': 0.061751265900950966, 'HYDROGEL INJECTIONS': 0.012350253180190195, 'SENOLYTIC THERAPIES': 0.012350253180190195, 'Targeting receptors and/or channels': 0.006175126590095097, 'Clinical profile of canagliflozin': 0.04940101272076078, '4.0 The Philosophy of Cancer Immunotherapy': 0.02470050636038039, 'Present state and prospective outlook': 0.012350253180190195, '3. Immune Response to SARS-CoV-2 Vaccines': 0.012350253180190195, 'IMMUNE CHECKPOINT INHIBITION IN ENDOMETRIAL CANCER': 0.012350253180190195, 'Arteritis-Prone Mouse Models for Modification to Produce LVV Models': 0.006175126590095097, 'Factors to consider for interpretation of the PreSERVE-AMI trial results': 0.037050759540570584, 'EL ESTUDIO': 0.006175126590095097, 'Convection-Enhanced Delivery': 0.037050759540570584, 'Neutralizing Antibodies': 0.012350253180190195, 'GLUTAMATERGIC SIGNALING AND DEPRESSION': 0.006175126590095097, 'Potential Unfavorable Effect of Twice-weekly Dialysis': 0.012350253180190195, 'Therapeutic Gene Expression': 0.006175126590095097, 'Implementation of MS-Based Proteomics in Clinical Settings': 0.018525379770285292, 'Regional treatments': 0.006175126590095097, 'Trial registration and date of first participant randomisation': 0.006175126590095097, 'NANOMATERIALS IN VENOM RESEARCH': 0.04940101272076078, 'PCSK9 INHIBITION STRATEGIES': 0.11115227862171174, 'CLINICAL USE OF PCSK9 INHIBITORS': 0.012350253180190195, 'Third-generation TKIs': 0.2223045572434235, 'Results:': 0.012350253180190195, 'Daily Symptom Burden of COPD': 0.006175126590095097, 'LAMA/LABA or LABA/ICS?': 0.006175126590095097, 'Clinical Trials of Obinutuzumab in B-cell NHL': 0.02470050636038039, 'Clinical Trials of Obinutuzumab in CLL': 0.037050759540570584, 'Shorter Duration of Infusion': 0.006175126590095097, 'Huntington’s Disease': 0.012350253180190195, 'Surgical Considerations for Arteriovenous Access': 0.012350253180190195, 'Patient population and methods': 0.02470050636038039, '7. ncRNA-Based Therapeutic Approaches': 0.006175126590095097, 'Chemoprevention: Using Drugs and Nutrients to Decrease Cancer Risk': 0.037050759540570584, 'Immunoprevention: Vaccines': 0.006175126590095097, \"3. GLP-1, Neuroprotection, and Alzheimer's Disease\": 0.012350253180190195, 'The functions of circRNAs in NPC': 0.012350253180190195, 'Regulation of proliferation': 0.018525379770285292, 'Regulation of apoptosis': 0.02470050636038039, 'Regulation of migration, invasion and metastasis': 0.012350253180190195, 'NEOADJUVANT AND ADJUVANT THERAPY': 0.037050759540570584, 'Letter to the Editor': 0.02470050636038039, '3. Current Results of Immune Therapies in Biliary Tract Cancers': 0.02470050636038039, '4. The Future of Immune Therapies in Biliary Tract Cancers': 0.02470050636038039, 'Kawakinra trial (Europe)': 0.006175126590095097, 'ANAKID Trial (USA)': 0.006175126590095097, '3. Therapeutic uses of DCA': 0.02470050636038039, 'Direct Targeting of Mesenchymalized Tumor Cells': 0.012350253180190195, 'Immunological Targeting of Mesenchymalized Tumor Cells': 0.037050759540570584, 'Impact on relatives and caregivers': 0.006175126590095097, '3. Regulatory Affairs and Data and Safety Monitoring': 0.012350253180190195, '3. HER1 Imaging': 0.037050759540570584, '4. HER2 Imaging': 0.04940101272076078, '4. Treatment': 0.012350253180190195, '4. Targeting Metabolic Adaptation': 0.012350253180190195, 'Ethical and governance approval': 0.006175126590095097, '3. Improving Receptor Specificity of the Apoptosis-Inducing Ligands': 0.04940101272076078, 'Figures, Scheme and Tables': 0.006175126590095097, '6. RNA-Based Therapeutics': 0.006175126590095097, 'Patient-focused perspectives': 0.012350253180190195, '6. Therapeutic Targeting of Noncoding RNAs': 0.061751265900950966, 'THROMBOCYTOPENIA-ASSOCIATED MULTIPLE ORGAN FAILURE': 0.02470050636038039, 'Apoptosis': 0.018525379770285292, 'Alternative forms of cell death': 0.012350253180190195, 'E': 0.006175126590095097, 'CLINICAL TRIAL EVIDENCE FOR THE EFFICACY OF RENAL DENERVATION': 0.02470050636038039, 'CircRNAs-mediated autophagy modulation and their impact on cancer therapeutic resistance': 0.006175126590095097, 'PROTAC-enhanced ACT': 0.02470050636038039, '4. Isoform-Specific Inhibitors': 0.7286649376312214, 'Convection-enhanced delivery of the tumor-targeted immunotoxin': 0.012350253180190195, 'Current status of glucocorticoids in sepsis treatment': 0.012350253180190195, 'The burning need for disease-modification trials': 0.006175126590095097, 'Expert commentary': 0.02470050636038039, '5. SOD as a Pharmacological Agent': 0.037050759540570584, '3. Using the Framework to Critically Evaluate a Model Agent: Temsirolimus': 0.012350253180190195, '6. MEK Inhibitors in Combination with Type 1 Insulin-Like Growth Factor Receptor Inhibitors': 0.012350253180190195, 'Treatment options for patients with APDS': 0.02470050636038039, 'Reinvigoration/tumour ratio affects clinical outcome': 0.006175126590095097, 'GLP-1R agonists': 0.04940101272076078, 'Immunoprevention': 0.018525379770285292, '4. Namodenoson for the Treatment of MASLD/MASH': 0.012350253180190195, 'Power calculations': 0.006175126590095097, '3. Potential Mechanisms of Metformin on the Gut Microbiome': 0.012350253180190195, '4. Glomerular Disease': 0.02470050636038039, '5. Kidney Transplantation': 0.012350253180190195, '6. Genetic Kidney Disease': 0.04940101272076078, 'Source of Funding': 0.006175126590095097, 'CALR-mutated MPNs provide novel therapeutic targets': 0.006175126590095097, '2. Targeted Axillary Dissection: More Questions Open Than Answered': 0.037050759540570584, 'AUTHORS’ CONCLUSIONS': 0.012350253180190195, '4 ncRNA modification': 0.08645177226133136, 'Atezolizumab': 0.08645177226133136, 'PreHomeCare study': 0.012350253180190195, '6. 5-HT1D Agonists–Ditans': 0.19760405088304311, '6. Lessons from the Use of PPAR': 0.006175126590095097, 'Implementation in atherosclerotic cardiovascular disease risk profiling': 0.012350253180190195, 'The Diabetes Prevention – Immune Tolerance (DiAPREV-IT) studies': 0.02470050636038039, '3. Colorectal Cancer Treatment': 0.012350253180190195, 'Initial Therapy': 0.02470050636038039, 'Subsequent Therapy': 0.006175126590095097, '8. Anti-TSLP Therapy, Anti-OX40': 0.012350253180190195, '7. Clinical Pharmacology of Casimersen': 0.012350253180190195, '8. Efficacy of Casimersen': 0.006175126590095097, 'Hypertrophic Cardiomyopathy': 0.030875632950475483, 'Lamin Mutations Dilated Cardiomyopathy': 0.006175126590095097, '2. Therapeutic Approach to AKI in Kidney Transplant': 0.04940101272076078, '4. Preclinical Studies and Clinical Trials': 0.02470050636038039, 'Trials registration': 0.006175126590095097, 'Progress to Date': 0.006175126590095097, 'Overview of Pediatric DOAC Programs': 0.037050759540570584, 'Adjuvant and neoadjuvant chemotherapy': 0.006175126590095097, 'NOVEL APPROACHES TO THE TREATMENT OF ACUTE NEUROMYELITIS OPTICA LESIONS': 0.018525379770285292, 'Program descriptions, data, and methods': 0.012350253180190195, '3. Clinical Application of BEN as Pre-Transplant Conditioning': 0.006175126590095097, '5. Clinical Application of BEN Post-Transplant': 0.018525379770285292, 'Lung Cancer': 0.012350253180190195, '4. The Potential Use of c-BIF as Biomarkers and Treatment for Cancer Immunotherapies': 0.02470050636038039, '7. Immune Regulators in Clinical Trials: The Translational Significance in Cancer-Associated Thrombosis': 0.012350253180190195, '4. Design and Development of RGD-Based Integrin Ligands for Biomedical Applications and Translation': 0.012350253180190195, '5. Integrin Targeted Molecular Imaging and Radiotherapy': 0.02470050636038039, 'Future Directions and Conclusions': 0.030875632950475483, '3. Re-Engineering Proteins for Drug Repurposing Using Nemvaleukin Alfa as a Case Study': 0.006175126590095097, '6. Integrin Targeting in Non-Cancer Diseases': 0.037050759540570584, '4. The Versatile Use of Anti-VEGF Agents to Enhance Immunotherapies': 0.02470050636038039, 'The arsenic era': 0.006175126590095097, '3. Basal Weekly Insulin': 0.006175126590095097, '4. Circulating Tumour DNA (ctDNA) in the Neoadjuvant and Pre-Cystectomy Setting': 0.006175126590095097, '5. Circulating Tumour DNA (ctDNA) in the Post-Cystectomy and Adjuvant Setting': 0.006175126590095097, 'Part 2. The Use of BTM in Clinical Practice: Potential, Problems, and Pitfalls': 0.02470050636038039, \"Authors' conclusions\": 0.037050759540570584, 'Opportunities for translation': 0.006175126590095097, '7. Increased Brain Glucose Uptake and Brain Insulin Resistance, Two Sides of the Same Coin?': 0.006175126590095097, '5. Gastroprotective Activity of Dietary Polyphenols and Their Bioactive Metabolites through Modulating GM': 0.02470050636038039, 'DISEASE MODIFYING THERAPIES': 0.012350253180190195, '7. Tumor-Infiltrating Neutrophils—A Double Edged Sword in CRC': 0.012350253180190195, '8. Therapies Targeting Neutrophils in CRC': 0.07410151908114117, 'Annealing of single-stranded DNA': 0.006175126590095097, '3. TCEs in the Treatment of Hematological Malignancies': 0.24700506360380386, 'EDITORIAL': 0.006175126590095097, 'Experimental\\\\nSection': 0.012350253180190195, 'Application of metabolomics in MS therapeutics': 0.006175126590095097, 'Factor IXa (FIXa) Aptamer': 0.018525379770285292, '3. BCG, Immune Checkpoints, and Immune Checkpoint Inhibitors (ICI)': 0.04940101272076078, '5. BCG and Chemokines Attracting Effector versus Suppressive Populations of Immune Cells: Rationale for Modulating PGE2 Production and Signaling': 0.006175126590095097, '5. Therapeutic Opportunities': 0.006175126590095097, 'Remdesivir': 0.006175126590095097, 'APN01': 0.006175126590095097, 'Camostat Mesylate': 0.012350253180190195, 'SELECT – Assessing the Cardiovascular Benefit of Subcutaneous Semaglutide in Patients With Overweight or Obesity': 0.006175126590095097, 'PIONEER 6 – Establishing the Cardiovascular Safety of Oral Semaglutide': 0.006175126590095097, 'Future Clinical Trials Examining Semaglutide Effects on Cardiovascular Disease': 0.012350253180190195, 'Intervention': 0.037050759540570584, '3. Exploiting Vulnerabilities Stemming from RB1 Deficiency-Associated Mechanisms for Targeted Therapy': 0.012350253180190195, 'Safety of quercetin use in diseases': 0.018525379770285292, '2. Eosinophilic Esophagitis (EoE)': 0.037050759540570584, 'THE STUDY': 0.012350253180190195, 'Epilepsy': 0.012350253180190195, 'Fragile X Syndrome': 0.006175126590095097, 'Premenstrual Mood Disorder': 0.006175126590095097, 'Alzheimer’s Disease': 0.006175126590095097, 'Traumatic Brain Injury': 0.018525379770285292, 'Smoking Cessation': 0.012350253180190195, '3. Target Antigens': 0.012350253180190195, 'RADIATION THERAPY': 0.006175126590095097, '2. Treatment Options Available for Cutaneous Melanoma and Their Efficacy': 0.012350253180190195, 'EXPERIMENTAL MODEL AND SUBJECT DETAILS': 0.012350253180190195, 'RE-IRRADIATION AS SALVAGE TREATMENT': 0.006175126590095097, 'Nodal irradiation and hypofractionation': 0.006175126590095097, 'Precision surgical treatment of gastric cancer': 0.012350253180190195, '9. Exploration of new therapeutic strategies': 0.012350253180190195, 'DNA-Protein interactions': 0.006175126590095097, '2. Sphingosine-1-phosphate (S1P) receptor (S1PR) modulators for treatment of multiple sclerosis': 0.012350253180190195, '3. S1P as a possible therapeutic target for other autoimmune conditions': 0.04940101272076078, '4. LOADING MECHANISMS': 0.02470050636038039, 'Impact of Pharmacological Treatment': 0.006175126590095097, 'INSIGHTS FROM RANDOMIZED CONTROLLED TRIALS OF CALORIE RESTRICTION': 0.012350253180190195, '3. Targeting histones and their role in epileptogenesis': 0.04940101272076078, 'PDT and PTT Biological Interplay': 0.012350253180190195, 'The PRINT protocol': 0.012350253180190195, 'New paths to forge': 0.012350253180190195, '8. Guidelines and Clinical Trials Focusing on Pharmacogenomics/Pharmacogenetics in β-Thalassemia and SCD': 0.006175126590095097, 'Current Therapeutics for Huntington’s Disease': 0.006175126590095097, 'ETHICS AND CONSENT TO PARTICIPATE': 0.006175126590095097, 'Chimeric Antigen Receptor-Modified T-cells': 0.02470050636038039, 'Declaration of patient consent': 0.006175126590095097, 'Moving Forward: PDT as Non-Ionizing Radiotherapy': 0.012350253180190195, 'Human Trials': 0.02470050636038039, 'Assessment for Phenotypic Characterization': 0.006175126590095097, 'Hemodynamic Support with Vasopressors/Inopressors': 0.006175126590095097, 'Efficacy testing': 0.02470050636038039, 'Design of the GUIDED-HF Study': 0.006175126590095097, '2. The ETS Family': 0.02470050636038039, 'Modulation of seizures by Sig1R ligands': 0.04940101272076078, 'Evidence from clinical studies': 0.04322588613066568, '1. Saracatinib: An Overview': 0.012350253180190195, 'Step-by-step method details': 0.02470050636038039, 'Basic Protocol 2: Establishing and Running of Percoll Gradients': 0.02470050636038039, '1. Andexanet alfa': 0.02470050636038039, 'ANDEXANET ALFA': 0.02470050636038039, 'Role of Oxidative Stress in the Cardiovascular Effects of Air Pollution and Smoking': 0.012350253180190195, 'Bromodomains & bromodomain-containing proteins: structure, inhibition by chemical probes & emerging role as drug targets': 0.11115227862171174, 'PROs in “Survivorship” and Maintenance Treatment': 0.006175126590095097, 'PROs in Palliative Chemotherapy': 0.006175126590095097, 'Article Information': 0.012350253180190195, '4. Other Treatments': 0.012350253180190195, 'Ischaemic post-conditioning': 0.006175126590095097, 'Nitric oxide and nitrite': 0.006175126590095097, 'Optimizing approaches to cardioprotection': 0.012350253180190195, '4. GABAergic Inhibition in Autistic Patients': 0.02470050636038039, 'Target Antigens': 0.006175126590095097, 'CAR/BiKE/TriKE for NK cell activation': 0.012350253180190195, 'Relamorelin': 0.006175126590095097, 'Other Ghrelin Receptor Agonists': 0.04940101272076078, 'MANAGEMENT OF RECURRENT GLIOMAS': 0.006175126590095097, 'Ongoing Nivolumab-Related Trials of Preoperative Therapy': 0.037050759540570584, '5. Percutaneous Coronary Intervention for in-Stent Restenosis': 0.012350253180190195, 'Therapeutic targeting of AOC3 in DR': 0.012350253180190195, 'Canagliflozin safety profile': 0.037050759540570584, 'TKIs': 0.012350253180190195, 'Drugs that target other pathways': 0.012350253180190195, 'TREATMENT OPTIONS OF GERD IN PATIENTS AFTER LSG: THE PRESENT AND FUTURE PERSPECTIVES': 0.006175126590095097, 'RIBOSOME BIOGENESIS': 0.012350253180190195, 'Practical Considerations': 0.02470050636038039, 'Preclinical studies and clinical trials in lung cancer': 0.018525379770285292, 'Gas Plasma Technology and Decontamination': 0.012350253180190195, 'Antiangiogenetic agents': 0.02470050636038039, 'Newer-generation transcatheter aortic valves': 0.04940101272076078, 'Post-Injury Fibrinolysis': 0.006175126590095097, 'Histone-based regulatory mechanisms associated with schizophrenia exert significant effects on cognition and behavior in the preclinical model': 0.006175126590095097, 'Supercharging SERPINs': 0.02470050636038039, 'Optimal Management of Sepsis in Cancer Patients': 0.02470050636038039, 'Antibodies-based immunotherapies: latest advancements': 0.006175126590095097, '2. Clinical Data Elicit the Need for New Preclinical Models of Thyroid Cancer': 0.04940101272076078, 'Serp-1: A Virus-Derived Coagulation Regulator and Therapeutic Immune Modulator': 0.006175126590095097, 'Fibrinolysis and Serpins in SARS-CoV-2 Infection and the COVID-19 Pandemic': 0.018525379770285292, 'FOR ZIKA AND FOR MANY FUTURE EMERGING INFECTIONS, EVEN MANY OPPONENTS OF PLACEBO-CONTROLLED TREATMENT TRIALS COULD SUPPORT VACCINE IRCTS': 0.02470050636038039, 'Glycemic Control': 0.006175126590095097, 'CLINICAL CONSIDERATIONS AND RECOMMENDATIONS': 0.012350253180190195, 'IMMUNOTHERAPY EDITING IMMUNE SYSTEM BY REENGINEERING T-CELLS': 0.012350253180190195, 'Relapsed/Refractory Setting': 0.037050759540570584, 'Native CDVs for brain-targeted drug delivery': 0.030875632950475483, 'Inhibition of NRF2 activity': 0.012350253180190195, '7 Case study': 0.006175126590095097, 'III. Pharmacology': 0.012350253180190195, 'A decade of ERA clinical application': 0.006175126590095097, 'The Future of Tailored CRC Treatment': 0.012350253180190195, '2. Methods and materials': 0.012350253180190195, 'Mechanism of action and preclinical studies of daratumumab': 0.006175126590095097, 'Efficacy and safety of daratumumab': 0.012350253180190195, 'Acute Respiratory Distress Syndrome': 0.02470050636038039, 'Discussion and Perspectives': 0.030875632950475483, 'Pharmacological Modulators of PAR1': 0.012350253180190195, 'Indications for PAR1 modulation': 0.02470050636038039, 'Clinical targeted therapy': 0.11115227862171174, 'NEWER TARGETS TO TREAT COGNITIVE DISORDERS AND DEMENTIA': 0.037050759540570584, '8 | CLINICAL TRIALS OF HELMINTHIC THERAPY FOR IMMUNE-MEDIATED DISEASE': 0.018525379770285292, '5. Clinical Implications of Platelet Hyper-Reactivity in Diabetes': 0.012350253180190195, 'EPO-AKI': 0.006175126590095097, 'High morbidity and mortality in HFpEF including SCD': 0.012350253180190195, 'Strategy Reducing the Radiation-Related Toxicities': 0.006175126590095097, 'Ethical approval and patient consent': 0.006175126590095097, 'Hematologic-Related Prognostic Parameters': 0.012350253180190195, 'Baroreflex activation therapy': 0.02470050636038039, 'Central iliac arteriovenous anastomosis': 0.012350253180190195, 'Carotid body ablation': 0.012350253180190195, 'Experimental Procedures and Human Subjects': 0.006175126590095097, '12. Lipid mRNA-Based Nanovaccines': 0.02470050636038039, '13. Dendritic Cell mRNA-Based Vaccines': 0.018525379770285292, '3. Clinical Studies in Human Subjects': 0.012350253180190195, 'Clinical evidence': 0.02470050636038039, 'Correlation between circRNAs and carcinomas': 0.012350253180190195, 'Tim-3 as an LSC Marker in AML': 0.012350253180190195, 'Tim-3 as a Therapeutic Target': 0.037050759540570584, '4. Electroporation as a Method for pDNA Delivery': 0.012350253180190195, '8. Pipeline of Vaccines and New Therapeutics': 0.018525379770285292, 'Precision Medicine in Gastric Cancer': 0.006175126590095097, 'Data sources': 0.02470050636038039, 'Ethical approval and consent to participate': 0.006175126590095097, 'CONTEMPORARY LANDSCAPE OF INTRATUMORAL IMMUNOTHERAPIES': 0.037050759540570584, 'FUTURE DIRECTIONS FOR INTRATUMORAL IMMUNOTHERAPY': 0.012350253180190195, 'TRAIL-Sensitizing Agents': 0.012350253180190195, 'Nucleotide-Based Therapies': 0.006175126590095097, '9. Circulating Tumor DNA (ctDNA)': 0.012350253180190195, 'Consent': 0.012350253180190195, 'Methods for colorectal cancer screening': 0.012350253180190195, 'Future prospects of CRC screening': 0.012350253180190195, 'Efficacy Data': 0.6916141780906508, 'TARGETING THE CDK4/6-RB PATHWAY IN CANCER': 0.006175126590095097, '2. Timing of ART Initiation in SIV-Infected Macaques': 0.012350253180190195, '4. Several Ways to Improve PROTACs’ Oral Bioavailability': 0.006175126590095097, '5. Recent Advancements in Orally Bioavailable PROTACs': 0.012350253180190195, 'OTHER DRUGS': 0.012350253180190195, 'THERAPIES/CLINICAL TRIALS UNDER INVESTIGATION': 0.14202791157218725, 'Strategies for Clinical ZIKV Vaccine Development': 0.037050759540570584, 'The advent of rituximab biosimilars: where are we now?': 0.02470050636038039, 'Are there opportunities for microbiota-focused preventative and\\\\nadjunct-therapeutic strategies?': 0.006175126590095097, 'Future therapies for CHC in children': 0.030875632950475483, 'THE DIVISION OF DLBCL INTO SEPARATE ENTITIES': 0.030875632950475483, '5. Role of Nanoparticles in Curcumin Delivery': 0.012350253180190195, '6. Clinical Translation and Future Perspectives': 0.012350253180190195, 'Place of Relugolix in the Management of Advanced Prostate Cancer': 0.006175126590095097, '8. Melatonin and Retinal Ischemia': 0.006175126590095097, 'CURRENT SPINAL AGENTS': 0.09880202544152156, 'CSC AGENTS IN CLINICAL DEVELOPMENT FOR GASTRIC CANCER': 0.04940101272076078, 'Systematic reviews and meta‐analyses of randomized controlled trials': 0.006175126590095097, '5. PRE Is a Druggable Target for HBV Therapy': 0.006175126590095097, 'STING in cancer immunotherapy': 0.012350253180190195, 'Application of': 0.012350253180190195, 'Intervention Design': 0.04940101272076078, '2. Conjugate Meningococcal Vaccines Developed by GSK Biologicals': 0.012350253180190195, '2.0 Method': 0.006175126590095097, 'Randomized efficacy trials': 0.012350253180190195, '6. The potency of CYP1B1 inhibitors as clinical therapeutic agents': 0.006175126590095097, '7. Clinical Candidates': 0.07410151908114117, 'Transparency Statement': 0.012350253180190195, 'Parathyroid allotransplantation': 0.006175126590095097, 'Senotherapeutics': 0.012350253180190195, 'IGNITE PHARMACOGENETICS WORKING GROUP': 0.012350253180190195, 'Inherited peripheral neuropathies (IPNs)': 0.04940101272076078, '7. Five Year View': 0.006175126590095097, 'Data sharing statement': 0.012350253180190195, 'Therapeutic Use of Native NPs: A Focus on HF': 0.012350253180190195, 'Designer NPs: For CV Disease': 0.02470050636038039, 'The role of the IL-23 pathway in immune-mediated inflammatory diseases': 0.02470050636038039, 'Frontiers for exploration in therapeutic intervention through IL-23 inhibition': 0.012350253180190195, 'Description of species': 0.02470050636038039, 'Immunostimulants': 0.006175126590095097, 'Clinical Trials Using Pluripotent Stem Cell-derived Retinal Pigment Epithelial': 0.012350253180190195, 'The First Clinical Trial': 0.006175126590095097, 'Results from clinical trials of mRNA-COVID-19 vaccines': 0.037050759540570584, 'Splenomegaly': 0.012350253180190195, 'Opportunities for combining OVs with ACTs': 0.04940101272076078, 'Research Perspectives in Hemorrhage-expansion and Imaging': 0.018525379770285292, 'Experimental Therapies for SI-AKI: Blood Purification Approaches': 0.006175126590095097, 'What We Know So Far—the Evidence-Based vNOTES Hysterectomy': 0.012350253180190195, 'Challenges in clinical translation of cell therapies': 0.012350253180190195, '3 MicroRNAs: future biomarker for ovarian cancer management': 0.061751265900950966, 'Therapeutic NPs in Management of Glioma/GBM': 0.012350253180190195, 'Trial registry number': 0.030875632950475483, 'Women and asymptomatic carotid disease': 0.006175126590095097, 'Is It Worthwhile to Treat ID in HF?': 0.012350253180190195, 'Airway clearance': 0.02470050636038039, 'Motixafortide HSPC mobilization in healthy volunteers': 0.006175126590095097, 'Motixafortide plus G-CSF HSPC mobilization for auto-HCT': 0.018525379770285292, 'Motixafortide HSPC mobilization for allo-HCT': 0.012350253180190195, 'Measures': 0.012350253180190195, '2. PROTEIN METHYLTRANSFERASES': 0.02470050636038039, 'Therapeutic targeting of the key drivers of type 2 inflammation in CRSwNP': 0.018525379770285292, 'BCL2 inhibitors': 0.012350253180190195, 'Immunomodulatory drugs': 0.012350253180190195, 'Antibody therapies': 0.012350253180190195, 'Nivolumab in combination': 0.030875632950475483, 'Ethics, consent, and permissions': 0.006175126590095097, '2. Patients and materials': 0.012350253180190195, 'VEINSTEP Study': 0.012350253180190195, 'Psychological and behavioural factors influencing consumer beliefs and consumption of LCS beverages': 0.012350253180190195, 'Limiting Dietary Phosphorus Intake': 0.006175126590095097, 'MDM2 and MDM4 therapies': 0.012350253180190195, 'Defining Clinical and Translational Research': 0.012350253180190195, 'Study population': 0.006175126590095097, 'Ethical approval code and trial registration': 0.006175126590095097, 'Basic Science': 0.02470050636038039, 'Therapy Based on Isolated Mitochondria': 0.006175126590095097, 'Immunoinformatics and Genomics': 0.006175126590095097, 'Ethics approval, trial registration, and consent to participate': 0.012350253180190195, 'CLINICAL SAFETY DATA': 0.24700506360380386, 'Luspatercept for β-Thalassemia': 0.030875632950475483, 'Therapeutic vaccines for EBV': 0.02470050636038039, 'Inhibitors of cyclin-dependent kinase 4/6': 0.018525379770285292, 'Human': 0.006175126590095097, 'Rationale and Objectives of the': 0.012350253180190195, 'INTRODUCTION: SHPT FROM THE GUIDELINE PERSPECTIVE': 0.012350253180190195, 'Inhibitors of protein arginine methyltransferases': 0.006175126590095097, 'CLINICAL TRIALS RELATED TO ICD': 0.018525379770285292, 'Study Rationale': 0.006175126590095097, 'DISEASES ASSOCIATED WITH UNPRODUCTIVE SPLICING AND NMD': 0.012350253180190195, 'GACI': 0.012350253180190195, 'BENCH TO BEDSIDE': 0.018525379770285292, 'Bromodomain inhibitors': 0.29640607632456467, 'The Need for New Treatments': 0.012350253180190195, '3. Gene editing technology': 0.04940101272076078, 'Degenerative pathomechanisms in IBM': 0.012350253180190195, 'Toxicity considerations': 0.02470050636038039, 'The glucometabolic approach': 0.012350253180190195, 'Clinical efficacy of osimertinib in NSCLC': 0.018525379770285292, 'Efficacy of osimertinib in': 0.006175126590095097, 'Monoclonal gammopathy: the importance of early detection and intervention': 0.018525379770285292, 'Biomarkers and Related Molecular Mechanisms Associated With Abscopal Effect': 0.02470050636038039, '3 CHALLENGES TO HCMV VACCINE DEVELOPMENT': 0.006175126590095097, 'Role of TDP-43': 0.02470050636038039, 'Demographic characterestics of the included studies': 0.012350253180190195, 'NEW REGIMENS': 0.018525379770285292, 'Clinical development of Zymogen-like FXa': 0.006175126590095097, 'Future Clinical Assessment -Intracerebral Hemorrhage': 0.006175126590095097, 'Clinical Trials and Patents': 0.012350253180190195, 'Technical considerations': 0.02470050636038039, 'Clinical outcomes': 0.006175126590095097, 'Pharmacological Treatments': 0.012350253180190195, '4. Intervention': 0.012350253180190195, 'Utility of Oncotype DX in patients with positive nodal disease': 0.006175126590095097, 'Risk Stratification in Clinical Practice; Triaging Upfront': 0.006175126590095097, 'Trials in the first-line setting for advanced cHL': 0.006175126590095097, 'Trials in the relapsed/refractory setting': 0.006175126590095097, 'T cell responses independently of CD28/TCR engagement': 0.012350253180190195, 'Tumor Microenvironment of the Childhood Brain': 0.030875632950475483, 'A Clinical Conundrum and a Way Forward': 0.012350253180190195, 'SORAFENIB AND OTHER CHEMOTHERAPEUTIC DRUGS': 0.012350253180190195, 'FIRST (ENHANCE T CELL ACTIVATION)': 0.04940101272076078, '3. Biomarker screening for early gastric cancer': 0.02470050636038039, 'Trial international registration': 0.006175126590095097, 'Taxonomic account': 0.07410151908114117, 'Future perspectives of TNF-α/TRAIL therapy and clinical application of agents targeting the sphingolipid pathway': 0.08027664567123625, 'Myocardial Fat': 0.012350253180190195, 'In vivo AMPK activation, ATP depletion, and 8-Cl-ATP accumulation': 0.006175126590095097, '8-Cl-Ado-dependent autophagy induction in vivo': 0.006175126590095097, '5. Sialic Acids on': 0.006175126590095097, '7. Differential Distribution of Sialic Acids on Promastigotes of Virulent and Avirulent': 0.006175126590095097, 'The 2000s to the Present: Mechanisms and a Return to Treatment': 0.02470050636038039, 'Deep Mutagenesis-Guided Immunogen Engineering': 0.006175126590095097, 'Deep Mutagenesis of Host Receptors: Implications of Human Polymorphisms and Engineered Receptors as Therapeutics': 0.006175126590095097, '1. Methods': 0.012350253180190195, 'Switching and alternation of biosimilars': 0.006175126590095097, 'Financial support': 0.006175126590095097, 'CLINICAL USE OF VIRTUAL BRAIN TWINS': 0.012350253180190195, 'FDA Accepted Personalized Medicine Therapy in Colon Cancer': 0.02470050636038039, 'TARGETTING LYMPHOCYTE TRAFFICKING: OTHER SMALL MOLECULES FOR CROHN’S DISEASE': 0.012350253180190195, 'Dissemination of Information': 0.006175126590095097, 'Targeting IDH1 Mutants in AML: Ivosidenib': 0.012350253180190195, 'Targeting IDH2 Mutants in AML: Enasidenib': 0.07410151908114117, 'Enasidenib and Ivosidenib as Part of Multi-Agents Regimens': 0.02470050636038039, 'Methods to target splicing in cancer': 0.012350253180190195, 'CircRNAs in regulating response to cancer immunotherapy': 0.037050759540570584, 'KIDNEY AND HEART PROTECTION WITH INCRETIN THERAPIES': 0.018525379770285292, 'PROGNOSIS': 0.061751265900950966, 'When should fibrinogen concentrate or prothrombin complex concentrate be given?': 0.02470050636038039, 'Colorectal cancer': 0.012350253180190195, 'Hepatocellular carcinoma': 0.02470050636038039, 'Gastric cancer': 0.030875632950475483, 'Current factors available and extended half-life (EHL) factor development': 0.006175126590095097, 'The Role of Medical Therapy in Degenerative Aortic Stenosis': 0.006175126590095097, 'Pharmacokinetics and Pharmacodynamics of the Novel, pH Neutral Furosemide Formulation': 0.006175126590095097, 'Paradigm Shift in HF Care': 0.018525379770285292, 'Prevention of HTRs in high-risk patients (recommendation 3)': 0.012350253180190195, 'Transfusion management during pregnancy (recommendation 8)': 0.006175126590095097, '7. Nrf2 Inhibitors in the Treatment of Chemoresistant Tumors': 0.012350253180190195, '5. Future Prospects of Radiotherapy with Other Radiosensitizing Agents': 0.02470050636038039, 'Autophagy modulating drugs': 0.012350253180190195, 'Molecular Mechanism of Sphingosine Kinases': 0.012350253180190195, '2. Overview of Microtubules and Tubulin Isotypes': 0.012350253180190195, '4.5 Treatment': 0.04940101272076078, 'Clinical trial identifier': 0.006175126590095097, '7. Genomic trials': 0.030875632950475483, 'AKI Alert Challenges': 0.006175126590095097, 'Inhibitors of Lp(a)': 0.012350253180190195, 'BIOMARKERS FOR CAD': 0.012350253180190195, '6. PVR and Cancer': 0.006175126590095097, 'Clinical definition of renal recovery': 0.02470050636038039, '4. Current Promising Antibiotics in Treating CRE Infections': 0.05557613931085587, 'Effects of Canagliflozin Treatment on Cardiovascular Risk Factors': 0.02470050636038039, 'NONCONVENTIONAL IMMUNOSUPPRESSANTS': 0.037050759540570584, '1. Comparisons of acute treatments for pulmonary exacerbations': 0.012350253180190195, '8. NON-CODING RNAS AS POTENTIAL BIOMARKERS AND THERAPEUTIC TARGETS': 0.006175126590095097, 'Current Therapeutic Approaches in Mitochondrial Disease Treatment': 0.012350253180190195, 'Future Therapeutic Approaches in Mitochondrial Disease Treatment': 0.012350253180190195, 'Chemistry and preclinical data': 0.04940101272076078, 'STUDY POPULATION AND METHODS': 0.012350253180190195, 'Clinical trial registration number': 0.006175126590095097, 'GRANTS': 0.006175126590095097, '7. Therapy for Conjunctivitis Associated with SARS-CoV-2': 0.012350253180190195, 'Targeting lncRNAs to diagnose and treat lipid metabolism-related diseases': 0.02470050636038039, '6. Therapeutic Targeting of rRNA Synthesis to Treat Breast Cancer': 0.02470050636038039, 'Prenatal diagnostic testing': 0.006175126590095097, 'TREATMENT OF CHILDHOOD OBESITY': 0.012350253180190195, 'CYTOREDUCTIVE NEPHRECTOMY': 0.006175126590095097, 'Model of care': 0.012350253180190195, 'Radionuclide Preparation and Administration': 0.06792639249104607, '4. Personalized Medicine and Clinical Trials Based on Phages (Determining the Safety of Phage Therapy)': 0.012350253180190195, 'Targeting Enzymes Involved in the Ubiquitin Cascade': 0.006175126590095097, 'Clinical Evidence That MnDPDP Protects Against Oxidative Stress and CIPN': 0.006175126590095097, 'Clinical applications': 0.04940101272076078, 'Targeting inflammasome activation in SSRA': 0.012350253180190195, 'THERAPEUTICS PRODUCTS WITH P53 STATUS AS A TARGET': 0.07410151908114117, 'Trial information': 0.02470050636038039, 'HYPERTROPHIC CARDIOMYOPATHY': 0.037050759540570584, 'Patient education and QOL support for patients with gastrointestinal cancer receiving immunotherapy': 0.07410151908114117, 'TARGETS INVOLVED IN APOPTOSIS': 0.006175126590095097, 'SURFACE PROTEIN TARGETING': 0.030875632950475483, 'TARGETED PROTEIN DEGRADATION': 0.012350253180190195, 'Other rare gene aberrations in lung cancer': 0.06792639249104607, 'ADAPTED STRATEGIES IN NAT': 0.012350253180190195, 'INCORPORATING ADDITIONAL AGENTS INTO NAT REGIMENS': 0.037050759540570584, '4. Self-Expanding Metal Stents': 0.012350253180190195, '3. The Different Roles Played by HSPs in OS and Their Therapeutic Benefits': 0.02470050636038039, '5. The Preclinical and Clinical Advantages of Inhibiting HSPs in OS': 0.006175126590095097, 'Acknowledgements and funding': 0.006175126590095097, 'Statements of ethical approval': 0.006175126590095097, '2. Treatment of PDAC': 0.02470050636038039, 'Possible Application of Anti-histamine Drugs in Irritable Bowel Syndrome': 0.006175126590095097, '4. Human Translation': 0.02470050636038039, 'Th17/IL-23 Inhibition': 0.006175126590095097, 'Th2 Antagonism': 0.012350253180190195, 'Advances in Interventional Cardiology': 0.012350253180190195, 'Antiplatelet Therapy': 0.02470050636038039, '11. Five-Year View': 0.006175126590095097, 'Long-Term Side Effects': 0.037050759540570584, 'THERAPEUTIC STRATEGIES IN HF': 0.037050759540570584, 'Targeting IDH1 - ivosidenib': 0.037050759540570584, 'Targeting IDH1 - olutasidenib': 0.006175126590095097, 'Targeting IDH2 – enasidenib': 0.02470050636038039, '7. Targeting C5aR': 0.018525379770285292, 'Accomplishments': 0.012350253180190195, 'Medical Management in Early Childhood': 0.006175126590095097, 'Antibodies targeting PCSK9': 0.02470050636038039, 'Clinical Studies of Canagliflozin Versus Sitagliptin': 0.012350253180190195, 'Clinical Studies of Canagliflozin in Combination With Incretin-Based Therapies': 0.012350253180190195, 'Considerations for Use of Canagliflozin and Incretin-Based Therapies in Clinical Practice': 0.012350253180190195, 'Management of Mild Asthma': 0.02470050636038039, 'BEYOND GLYCEMIC CONTROL: THE USE OF ORAL HYPERGLYCEMIC AGENTS': 0.037050759540570584, 'Maintenance BCG': 0.012350253180190195, 'Development of long-acting glucagon receptor mono-agonists': 0.012350253180190195, 'Potential clinical applications of hemoperfusion and ongoing trials': 0.012350253180190195, 'Viral infections, including severe acute respiratory syndrome coronavirus 2': 0.02470050636038039, 'BASIC PROTOCOL 3 – Organ recovery and bacterial enumeration': 0.012350253180190195, 'Future directions and conclusion': 0.006175126590095097, 'Efficacy of ramucirumab in NSCLC clinical trials': 0.012350253180190195, 'Structural commentary': 0.006175126590095097, '13. Metformin': 0.006175126590095097, '2. Clinical staging and initial management impact': 0.012350253180190195, 'Successful Target Identification and Translation': 0.061751265900950966, 'Conclusion and Future Direction': 0.006175126590095097, 'Other functional indexes to assess coronary stenosis in ACS': 0.02470050636038039, '2. RUXOLITINIB': 0.006175126590095097, 'Contrast agents for ocular imaging': 0.037050759540570584, 'Available studies on the CatLet or Hexu angiographic scoring system and its future study directions': 0.018525379770285292, 'Future in RB': 0.006175126590095097, '11. Potential Non-Genetic Modifiers of Response to HEMT': 0.006175126590095097, '10. Candidates for Cellular Therapy': 0.012350253180190195, 'Role of metabolic dysregulation and epigenetic alteration in tumor microenvironment-mediated immune tolerance': 0.02470050636038039, '4. Prevention': 0.02470050636038039, '3. Neuroendocrine Prostate Cancer (NEPC)': 0.037050759540570584, '4. Prostate-Specific Antigen (PSA)-Null and NE-Null Double-Negative CRPC (DNPC)': 0.037050759540570584, 'Clinical trials of gene-editing-based therapeutics': 0.006175126590095097, 'LIMITATIONS AND CHALLENGES OF': 0.012350253180190195, '5. Reovirus': 0.02470050636038039, 'Clinical risk assessment': 0.012350253180190195, 'Temozolomide Concurrent With Radiotherapy': 0.006175126590095097, '6. Therapeutic Potential of the Inflammasomes in Cancer Immunotherapy': 0.04322588613066568, '5. Lipid-Based Nanoparticles for Vaccines': 0.14820303816228234, 'ISAACC Cohort': 0.006175126590095097, 'Targets': 0.012350253180190195, '8. Cyclin-Dependent Kinase Inhibitors': 0.04940101272076078, 'MRAs in CKD and DKD': 0.02470050636038039, 'Clinical Implications for Use of MRAs in DKD': 0.006175126590095097, 'The potential role of immunotherapy in STS': 0.012350253180190195, 'Treatment considerations in germline': 0.04940101272076078, '6. Investigation of therapeutic interventions for treating the NCLs using canine models': 0.006175126590095097, '3. CoQ': 0.012350253180190195, '6. Von Willebrand Factor Aptamers': 0.037050759540570584, '4 CVOTs of GLP-1RAs': 0.05557613931085587, '1. Cancer Chemoimmunotherapy': 0.09880202544152156, '3. Existing treatment': 0.04940101272076078, '3. Toward Remyelination and Repair in Multiple Sclerosis (MS)': 0.07410151908114117, 'NIH trial registration': 0.012350253180190195, 'Clinical Evaluations of DP and CRTH2 Antagonism': 0.04940101272076078, '5. Preclinical and Clinical Evidence of Targeting Chemokines': 0.012350253180190195, '2. Secreted Proteins': 0.02470050636038039, 'Cell-Based Therapy': 0.02470050636038039, 'Protein Therapy': 0.006175126590095097, 'Disease-Modifying or Symptomatic Control Treatments': 0.012350253180190195, '4. What Are the Potential Alternatives?': 0.006175126590095097, 'RITs targeting hematologic malignancies': 0.012350253180190195, 'What cautions need to be borne in mind when considering using nintedanib?': 0.012350253180190195, 'Key messages regarding feasibility': 0.006175126590095097, '2. Known RNA-Targeting Splicing Modifiers for the Treatment of Human Diseases\\\\n': 0.012350253180190195, 'lncRNAs as biomarkers in disorders of the CNS: Diagnostic relevance': 0.012350253180190195, 'Translation of biomaterials to the clinic; clinical trials': 0.02470050636038039, 'THE NEED FOR ICG IN TRAUMA SURGERY': 0.012350253180190195, '10. Pharmacological Strategies': 0.012350253180190195, 'Secondary prevention': 0.012350253180190195, 'Immune checkpoint inhibitors and EGFR-TKIs': 0.02470050636038039, '2. Circulating Tumor DNA (ctDNA)': 0.037050759540570584, '6. From Bench to Clinic. The “Clinic” Side: Clinical Trials of NPs for Oral Diseases': 0.006175126590095097, 'Reported improvements of CAR-T/CAR-NK cell production with Nanoplasmid vectors': 0.006175126590095097, 'Barriers to clinical adoption': 0.037050759540570584, 'Efectos del tratamiento de la fibrilación auricular en el desarrollo de deterioro cognitivo': 0.012350253180190195, 'GDY and its history': 0.02470050636038039, '4. Other TKIs Studied in Thyroid Cancer': 0.037050759540570584, 'Ethical Approval:': 0.006175126590095097, '2) Selective hormone receptor degraders': 0.006175126590095097, 'Analysis and sample size': 0.012350253180190195, 'MATHERIALS AND METHODS': 0.012350253180190195, 'Data collection': 0.012350253180190195, 'N‐regulated phytohormones biosynthesis and transport': 0.012350253180190195, 'Ethical approval statement': 0.006175126590095097, 'Overcoming limitations of clopidogrel': 0.012350253180190195, 'Exploring newer antiplatelet strategies (': 0.037050759540570584, 'EMPAGLIFLOZIN PHASE 3 CLINICAL TRIALS': 0.09880202544152156, 'ONGOING EMPAGLIFLOZIN PHASE 3 TRIALS': 0.012350253180190195, 'Future Directions and Uses for Empagliflozin and SGLT2 Inhibitors': 0.006175126590095097, '4. Pharmacology and Clinical Applications': 0.02470050636038039, '6. Alternative Administration Schemes': 0.02470050636038039, 'STATUS OF CLINICAL TRIALS INVOLVING ANTI-IGFS AND IGF-1R MABS': 0.012350253180190195, 'THERAPEUTIC STRATEGIES FOR IGF-1R NETWORK': 0.030875632950475483, 'Cardiotoxicity': 0.012350253180190195, '9. S1P-Blocking Antibodies': 0.006175126590095097, '6. Clinical Trials with CBD': 0.006175126590095097, '7. Efficacy': 0.012350253180190195, 'Clinical relevance of lncRNAs in OC': 0.006175126590095097, 'mRNA vaccine development for COVID-19': 0.012350253180190195, 'Therapeutic Polyclonal Antibodies': 0.012350253180190195, 'How to use this article': 0.06792639249104607, 'Middle meningeal artery embolization': 0.012350253180190195, 'Treg Cells in Clinical Applications': 0.04940101272076078, 'Future directions and conclusions': 0.012350253180190195, 'Platelet Inhibitors and Cardiac Surgery': 0.04940101272076078, 'Core news': 0.037050759540570584, '6. From Bench to Bedside': 0.006175126590095097, 'Current evidence base for clinical application': 0.02470050636038039, 'Pharmacological Treatment': 0.02470050636038039, 'Clinical Roles of the Autophagic Organelles in DDRs': 0.02470050636038039, 'BCR-ABL inhibitors': 0.012350253180190195, 'Role of the Funding Source': 0.006175126590095097, 'Expansion': 0.006175126590095097, '3. EGFR Targeted Therapies': 0.037050759540570584, '7. Myeloproliferative Neoplasms': 0.006175126590095097, '2. Antibodies Neutralizing the Anthrax Toxins': 0.061751265900950966, '3. Integration of Intra-Tumor Heterogeneity into Multi-Layered Personalized Cancer Therapy': 0.02470050636038039, 'Progressive multifocal leukoencephalopathy': 0.02470050636038039, 'Alzheimer’s Disease Biomarkers in or at High Risk of Diabetes': 0.006175126590095097, 'THE EFFECTIVE AND POTENTIAL THERAPEUTIC TARGETS OF RAAS': 0.02470050636038039, 'Pre-registered clinical trial number': 0.012350253180190195, 'Current therapeutics strategies targeting the neuroglia interaction': 0.04940101272076078, '7. Therapeutic Options': 0.012350253180190195, 'EGFR': 0.012350253180190195, 'RET': 0.006175126590095097, '4. Oncolytic properties of vesicular stomatitis virus (VSV)': 0.006175126590095097, '7. Targeting Mitochondria in NAFLD–HCC: New Challenges for a Bright Future': 0.012350253180190195, 'PARP inhibitor resistance': 0.04322588613066568, 'The Pharmacological Profile of E4': 0.08645177226133136, '6. Muscular Laminopathies': 0.012350253180190195, '4. Adjuvant Systemic Treatment': 0.02470050636038039, 'Niraparib in ovarian cancer treatment': 0.02470050636038039, 'Clinical stage I patients': 0.037050759540570584, 'Probiotic efficacy: a closer look': 0.061751265900950966, 'Ethical Clearance': 0.006175126590095097, 'Primary Data of EMPOWER-Lung 1 and -Lung 3': 0.006175126590095097, '4. Polycystins and cell survival and apoptotic pathway signaling': 0.012350253180190195, '3. NANOTHERAPEUTIC SYSTEMS FOR LOCAL TREATMENT': 0.037050759540570584, 'CircRNAs in diagnosis and prognosis of human cancers': 0.02470050636038039, 'Contemporary management of ANOCA/INOCA': 0.012350253180190195, 'Novel invasive therapies for INOCA': 0.012350253180190195, 'Characteristics of AIIRD-MAS': 0.012350253180190195, 'Progressions in treatment': 0.012350253180190195, '2. Incidence and Risk Factors for Venous or Arterial Thrombosis in Immune Mediated Hemolysis': 0.006175126590095097, '9. Treatment Targeting Splicing': 0.037050759540570584, 'Techniques for Reducing Contrast Volume Administration': 0.02470050636038039, \"The Proposal: To Provide Information on All Site Principal Investigators' Recruitment Performance\": 0.04322588613066568, 'Radiotherapy target volumes based on relapse patterns': 0.006175126590095097, '4. RSV Disease Activity across Tropical South America': 0.02470050636038039, 'Pegcetacoplan': 0.006175126590095097, 'Danicopan\\u2009+\\u2009eculizumab': 0.006175126590095097, 'Iptacopan\\u2009+\\u2009eculizumab': 0.006175126590095097, '7. Induced Pluripotent Stem Cells': 0.006175126590095097, 'CONVERSION SURGERY AND CHEMOTHERAPY FOR TREATING UNRESECTABLE NON-METASTATIC TUMORS': 0.006175126590095097, '7. Highlighting Current Trials and Future Trials': 0.006175126590095097, 'Optimal Current Use of Novel Agents in Myeloma': 0.012350253180190195, 'Case studies and context': 0.012350253180190195, 'Postural Tachycardia Syndrome': 0.07410151908114117, 'Diagnosis of GHD': 0.012350253180190195, '3. Stage-Dependent Therapeutic Regimes': 0.012350253180190195, '3. Practical Applications': 0.006175126590095097, '4. Gene Editing': 0.012350253180190195, '4. Early Detection of PDAC': 0.02470050636038039, '9. Therapeutic Targeting of Claudins': 0.012350253180190195, '5. Outcome Measures': 0.02470050636038039, 'Idursulfase post-approval programs': 0.02470050636038039, 'CURRENT TREATMENT OPTIONS FOR LIVER FIBROSIS': 0.04940101272076078, '2. Antibody formation against secreted gene products such as factor IX': 0.012350253180190195, 'CANCERS OF THE HEPATOBILIARY TRACT': 0.012350253180190195, 'COLORECTAL ADENOCARCINOMAS': 0.006175126590095097, '2. Axillary Surgery in the Upfront Surgery Setting': 0.012350253180190195, 'Criticism of the PARADIGM-HF trial': 0.006175126590095097, '4. Pharmacological Treatment and Prevention': 0.006175126590095097, 'TARGETS FOR NEUROPROTECTION IN THE PICU': 0.012350253180190195, 'Wnt/β-catenin signaling pathway in EC': 0.012350253180190195, 'Genetic Cardiomyopathies': 0.012350253180190195, 'Targeting SHP2 in Hematological Malignancy': 0.012350253180190195, 'Future developments in metformin research': 0.006175126590095097, 'Gene-editing to improve ACT': 0.012350253180190195, '4. Basal Cell Carcinoma': 0.006175126590095097, '3. Formation of oxo-ETEs': 0.02470050636038039, 'APPLICATION OF ZINC FINGER PROTEINS IN BIOMEDICAL RESEARCH': 0.02470050636038039, 'Prevention of cutaneous squamous cell carcinoma in organ transplant recipients': 0.02470050636038039, 'Modifying sun-protection behaviour in organ transplant recipients': 0.02470050636038039, '7. Discussion and Future Directions': 0.02470050636038039, '1. Cyclin Dependent Kinase 4/6 (CDK4/6) inhibition': 0.04940101272076078, 'Microtubule inhibitors': 0.04940101272076078, 'GASTRIC ADENOCARCINOMA': 0.02470050636038039, 'Existing and Emerging Therapies': 0.04322588613066568, 'Lessons from clinical trials': 0.19142892429294803, 'Setting up an international registry': 0.006175126590095097, 'Therapies Targeting Epicardial Fat': 0.02470050636038039, 'Other New Generation Balloon-expandable THV Under Investigation': 0.006175126590095097, '6. TREATMENT OF CATASTROPHIC APS': 0.006175126590095097, 'circRNA and CVDs': 0.012350253180190195, 'Therapeutic Uses of Metformin': 0.02470050636038039, 'CBT in the Next Thirty Years': 0.02470050636038039, 'Immunomodulators': 0.012350253180190195, 'Management of early stage disease': 0.012350253180190195, 'Biotherapeutics for HES': 0.02470050636038039, 'Biotherapeutics on the horizon': 0.037050759540570584, '5. Combinational Treatment of OVs with Immunotherapies': 0.02470050636038039, '6. Overcoming Limitations and Obstacles of OV Therapy': 0.02470050636038039, 'Niraparib Clinical Trials and Safety Summary': 0.030875632950475483, 'Addition of Non-globin Genetic Elements': 0.037050759540570584, 'Clinical trials number': 0.012350253180190195, 'Cancer Chemotherapeutic Agents Derived from Bacteria and Fungi': 0.037050759540570584, 'Sickle Cell Disease': 0.02470050636038039, 'ETHICAL APPROVAL AND INFORMED CONSENT': 0.006175126590095097, 'Nutrient-/Energy-Sensing Mechanisms Implicated in Dietary Preconditioning': 0.012350253180190195, 'Intact apoptotic pathway': 0.012350253180190195, 'The Intervention Development Process and Outcome: Three Phases': 0.012350253180190195, 'Efficacy of Balloon Pulmonary Angioplasty': 0.02470050636038039, '5.0. Methods of CO Administration': 0.012350253180190195, 'Apoptosis Inhibitors': 0.061751265900950966, 'Putative roles of miRNAs as a regulator of different cellular biological events in CaP radioresistance': 0.037050759540570584, 'miRNAs as biomarkers or therapeutic targets for CaP RT': 0.012350253180190195, 'The Current Application of Biomarkers in Sepsis-Associated AKI': 0.012350253180190195, 'Prevention and therapy of purine-related diseases by dietary and herbal interventions': 0.006175126590095097, 'Bruton’s Tyrosine Kinase as a Validated Molecular Target in Cancer Cells': 0.030875632950475483, 'Coumarins as a New Class of Bruton’s Tyrosine Kinase Inhibitors': 0.006175126590095097, 'Prevention trials': 0.012350253180190195, 'ALTERNATIVE TREATMENTS': 0.012350253180190195, 'TREATMENTS UNDER INVESTIGATION': 0.018525379770285292, 'CLINICAL TRIALS WITH ABS AND LIGANDS': 0.05557613931085587, 'Population and methods': 0.012350253180190195, 'Pharmacological Therapies': 0.012350253180190195, 'Potential sources of NK cells for CAR engineering': 0.02470050636038039, 'Preclinical studies of CAR‐engineered NK cells': 0.012350253180190195, 'Support': 0.006175126590095097, 'Paraspeckle formation': 0.012350253180190195, '3. Liquid Metal Cleanliness Online Analyzing System': 0.012350253180190195, '4 Treatment of HCV Genotype 3 Infection': 0.012350253180190195, 'Diseases and therapeutic applications of CSF1R inhibition': 0.012350253180190195, 'Therapeutic agents for treating hematopoietic malignancies by inhibiting the activity of PcG proteins': 0.12350253180190193, '4.': 0.012350253180190195, 'Preclinical and clinical experience with ribociclib in individual indications': 0.02470050636038039, 'Ribociclib in perspective': 0.018525379770285292, '2.0 Materials and Methods': 0.012350253180190195, '5-HTP has shown promising antidepressant effects, but poor pharmacokinetics limits the therapeutic potential': 0.012350253180190195, 'In mouse models, 5-HTP SR transforms the therapeutic potential of 5-HTP': 0.012350253180190195, '3. Methods—Generating Synthetic 3D\\xa0Targets': 0.012350253180190195, '1.3 Study Rationale and Hypotheses': 0.006175126590095097, '3. Emerging Trends in Treatment of BM': 0.012350253180190195, 'Percutaneous Treatment': 0.012350253180190195, 'Right Tests': 0.02470050636038039, 'Right Treatments': 0.037050759540570584, 'TO THE EDITOR:': 0.006175126590095097, 'Studies in patients': 0.006175126590095097, 'THE FUTURE: INTEGRATING RADIOTHERAPY AND IMMUNOTHERAPY IN THE CLINICAL SETTING': 0.006175126590095097, 'CANCER TREATMENT BY DEVELOPING AUTOPHAGY INHIBITORS': 0.13585278498209213, 'Pharmacologic Treatments': 0.02470050636038039, '1. Hematological Malignancies': 0.006175126590095097, '5. Therapeutic Options': 0.061751265900950966, 'Expanding on the Concept of Pseudoprogression – “Delayed Responses After Confirmed Progression (DR)” and Response After Clinical Deterioration': 0.02470050636038039, 'Expanding Clinical Boundaries - Activity in Advanced, Fungating, Disfiguring Disease and Good Tolerance Despite Multiple Comorbidities': 0.006175126590095097, 'Immunogenicity': 0.012350253180190195, 'Clinical Evidence of Corneal Neuroregeneration': 0.018525379770285292, 'Additional Experimental Approaches to Promote Metabolism': 0.006175126590095097, 'Other means of posttranscriptional regulation of the haemostatic system': 0.012350253180190195, 'ACTIVATION OF p73 BY UNCOUPLING OF NEGATIVE REGULATORS': 0.012350253180190195, 'OTHER MOLECULES THAT DIRECTLY OR INDIRECTLY PROMOTE p73 EXPRESSION AND FUNCTIONS': 0.02470050636038039, 'LYMPHOPENIA AND LYMPHOCYTE DYSFUNCTION': 0.012350253180190195, 'STRESS ERYTHROPOIESIS AND ANEMIA': 0.006175126590095097, 'Prostate Tumor Microenvironment Composition': 0.02470050636038039, 'Dermatological Diseases': 0.012350253180190195, 'Hematological and Immunological System Diseases': 0.04322588613066568, 'Latest monoclonal antibodies against RSV': 0.006175126590095097, 'CHALLENGES FACING ZFN-BASED GENE EDITING BEFORE ROUTINE TRANSLATION TO CLINIC': 0.006175126590095097, 'Progress and challenges of MARTs inhibitors': 0.006175126590095097, 'Largest U.S. Patient Samples': 0.018525379770285292, '8. Autophagy Inhibitor/Activator and Liver Diseases': 0.012350253180190195, 'Long-Term Studies': 0.012350253180190195, '4. Expert Commentary': 0.012350253180190195, 'Peripheral Artery Disease Treatments': 0.006175126590095097, '6. Mesenchymal Progenitors and Clinical Application': 0.037050759540570584, '5. Antiangiogenic Agents': 0.006175126590095097, 'NATURAL PROMOTERS': 0.04940101272076078, 'The Study': 0.006175126590095097, '5. Potential therapies for β thalassemia': 0.02470050636038039, '6. Trial Registry Number': 0.006175126590095097, 'Cell-based therapy': 0.012350253180190195, 'Diffuse intrinsic pontine glioma': 0.012350253180190195, 'LATER DAYS OF AITD GENE DISCOVERY AND REFINING ASSOCIATION SIGNALS': 0.012350253180190195, 'Veliparib': 0.006175126590095097, 'RNA HEXAMER NANOSTRUCTURE CONSTRUCTED USING VERSATILE RNA MOTIFS': 0.012350253180190195, 'Pharmacologic interventions for severe and/or refractory toxicities': 0.07410151908114117, 'Pulmonary Microvasculopathy in CTEPH': 0.012350253180190195, 'Patient and Caregiver’s Perspectives': 0.006175126590095097, 'Clinical translation of': 0.018525379770285292, '5.0 GUCY2C Agonists for Colorectal Cancer Prevention': 0.012350253180190195, '6.0 GUCY2C-Targeted Immunotherapies for Metastatic Colorectal Cancer': 0.012350253180190195, 'Pharmacological Treatments in Acute and Chronic Conditions': 0.037050759540570584, 'Clinical Pharmacological Trials and Future Prospects': 0.04940101272076078, 'Investigational Drugs Targeting Cartilage Metabolism': 0.061751265900950966, 'Preclinical Testing': 0.09880202544152156, 'TriKE': 0.012350253180190195, 'The future direction of TriKEs': 0.006175126590095097, 'Therapies for GO': 0.006175126590095097, 'MULTI-PARAMETRIC MAGNETIC RESONANCE IMAGING': 0.037050759540570584, 'Harnessing the p53 Network': 0.012350253180190195, 'Physiological Assessment of Left Main Lesions': 0.006175126590095097, 'Cohort description': 0.012350253180190195, 'Special Patient Populations': 0.006175126590095097, 'Molecular strategies for the therapeutic approach to Alzheimer’s disease': 0.037050759540570584, 'Sources of funding': 0.006175126590095097, 'Local control': 0.02470050636038039, 'Other strategies to deliver drugs to the CNS': 0.012350253180190195, 'Targeted inhibitors of SARS-CoV-2 main protease': 0.04940101272076078, '2. Anti-PEG Abs in the clinic': 0.012350253180190195, 'DELIRIUM': 0.030875632950475483}\n",
      "\n",
      "{'methods': 99.86426874787921, '': 0.1357312521208008}\n",
      "{'Materials and methods': 39.56565999321344, 'MATERIALS AND METHODS': 26.348829317950457, 'Materials and Methods': 33.4916864608076, 'MATERIALS and METHODS': 0.3223617237869019, 'Materials And Methods': 0.10179843909060061, 'MATERIALS AND\\xa0METHODS': 0.0339328130302002, 'MATERIALS AND METHODs': 0.0339328130302002, '\\ufeffMaterials and methods': 0.10179843909060061}\n",
      "\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "\n",
    "model = \"angleloss\"\n",
    "n_neighbors = 5000\n",
    "total_datapoints = f'{300000}'\n",
    "file_name = f\"clustering/{model}/clustering_labels_{n_neighbors}_{total_datapoints}.xlsx\"\n",
    "\n",
    "df = pd.read_excel(file_name)\n",
    "\n",
    "from collections import Counter\n",
    "\n",
    "for column in df.columns:\n",
    "    cluster_content = df[column].dropna().tolist()\n",
    "    mapping_section = [anonymous_mapping_dict[x.lower()] for x in cluster_content]\n",
    "    \n",
    "    counter = Counter(mapping_section)\n",
    "    total = sum(counter.values())\n",
    "    percentage = {key: (value / total) * 100 for key, value in counter.items()}\n",
    "    print(percentage)\n",
    "\n",
    "    counter = Counter(cluster_content)\n",
    "    total = sum(counter.values())\n",
    "    percentage = {key: (value / total) * 100 for key, value in counter.items()}\n",
    "    print(percentage)\n",
    "    print()\n",
    "\n",
    "        "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Adjusted Rand Index (ARI): 0.4149572782083435\n"
     ]
    }
   ],
   "source": [
    "from sklearn.metrics import adjusted_rand_score\n",
    "true_labels = []\n",
    "pred_labels = [] \n",
    "for i, column in enumerate(df.columns):\n",
    "    \n",
    "    cluster_content = df[column].dropna().tolist()\n",
    "    mapping_section = [section_name_to_label[anonymous_mapping_dict[x.lower()]] for x in cluster_content]\n",
    "\n",
    "    true_labels += mapping_section\n",
    "    pred_labels += [i] * len(cluster_content)\n",
    "\n",
    "\n",
    "ari_score = adjusted_rand_score(true_labels, pred_labels)\n",
    "print(\"Adjusted Rand Index (ARI):\", ari_score)\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.21"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
